<SEC-DOCUMENT>0001104659-20-092375.txt : 20200810
<SEC-HEADER>0001104659-20-092375.hdr.sgml : 20200810
<ACCEPTANCE-DATETIME>20200810070407
ACCESSION NUMBER:		0001104659-20-092375
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200810
DATE AS OF CHANGE:		20200810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		201087036

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20200630x10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7401.38943 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/10/2020 9:59:09 AM -->
      <!-- iXBRL Library version: 1.0.7401.38955 -->
      <!-- iXBRL Service Job ID: f973d40b-85c8-42bd-b93e-19920035f813 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:plx="http://www.protalix.com/20200630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityCentralIndexKey" id="Tc_ckVCq6MfJUie7H_8uVpt2Q_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:CurrentFiscalYearEndDate" id="Tc_IW2DNjztgEK6TAjae8vSVA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:DocumentFiscalYearFocus" id="Tc_s35AJIzc3UawdPSXsEOiyw_4_1">2020</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:DocumentFiscalPeriodFocus" id="Tc_Y1o2mvNPzU6u6MJltG02dg_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:AmendmentFlag" id="Narr_e5I4_87RqEuawUA5JIlxig">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew" decimals="-5" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" id="Hidden_1glMU2yQtkCyCKsj6VV7zw">25000000</ix:nonFraction><ix:nonNumeric contextRef="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gS8uxFBdfkSX_TQFGXUbNg" name="us-gaap:StockholdersEquityReverseStockSplit" id="Hidden_aWG3j73WyUuWsRh-fIJdNA">1-for-10</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gS8uxFBdfkSX_TQFGXUbNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-19</xbrli:startDate><xbrli:endDate>2019-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0C6K83V4j0Kphnkf8n9mcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IjoXygzFWkGqMriuJJW-Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NOmRUBGMQ0qHujxUMsdUWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6VRfrb4a006C6zwz8zQtcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_w3xlUNxxE0W57aWLj2hlhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fUF3B9mz-0uCzmKZ02-ItQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kfGHTqSzx06Mpo3yF5o4OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bQ8d5NSZLk-awmHoE9teAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D91DMekLyUi786I0a96WxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VL6BuAeE9k-1CymbZrfhIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2iGT9UYX20ufEOy7uLUIZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_vbRY0t2qH0qlCvQizNy7Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7lZ2PehKpES7w0uB9Q2kTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YVr3HQawREa2lJZHx3PH6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LXVbu_pYy0S9ohnZflii4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fnM9Fs8xWUimFQZTDbqXWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_00e2daMkjkeossE65QH8wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uG2XyhIdEaKWq0i_Og6tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Joi_qhyS7EefeW8MDTljgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_QmGZUi6OjUqO1LnkJZCRXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ubU6rEERnEi4sCmFzEPs9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_yM7VN6n3HEqpoGO7RPojOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_b4IHEMa-EkOw9g0xX9vuVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_plx_PfizerMember_MzTzy7EFIEmRNIq4UP5v3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_country_BR_TrfPY3So-kuw0KkLJAQz4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_ObY9WS7lOkC896sj2TQd1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_leyen5aCU02wk6AuAeZjWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_mjHtdYriEEG-CXeWej1g7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CnxupLEavEiCHMgWdkLIPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_plx_PfizerMember_w1KRKtpN60Coy6CM1mW_ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_country_BR_yD1PqwkIzUCdzznvt7waSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2020_To_3_18_2020_twsaV_MqKEyUfAkshadSOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-18</xbrli:startDate><xbrli:endDate>2020-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCX0MKCM4Ee34kOUnZ6BZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__6LA1s6dWU-YSFkzfQtBfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PQTvkYR-K0GQcvIHSBU09A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NWcLSQS2Y0abZ9Z36xlHpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_pL8I8jq_hEi_gqPwIAohXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_-Vqrm9TF40e2UHLfW2k7NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_R_GVwE60AEeYABBHU95XbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_2BE4yI-8FUy-wuebFU1qwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YozhTzDOZUqiiF9r9XEkGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qGcyw11XhEi9-0J_8vb26A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_U3lSq0ip90Kl1sHOY8UG4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZxLgitN4OEGYDuBZoHnVXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_RRB1BC9l90W_DnZi--Mbqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q_06E9Fbq02P0s8c6weMJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_WY_KFkHtI06S0Nse9YgtVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_RgcHJTMxiESAmSco2vlgwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vmg-JoGYmU-PSD4wN2qEbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DJm4hQ_X0kWnko7Ett0rIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyryerKYm0ufav34CwRxYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_srt_ProductOrServiceAxis_plx_BioManguinhosAlfataligliceraseMember_-6BPcOpQpkGF-ZjY7GtFWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:BioManguinhosAlfataligliceraseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_hPUJj7qNDUCmWCpyRrXLFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-18</xbrli:startDate><xbrli:endDate>2020-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-05</xbrli:startDate><xbrli:endDate>2020-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Sxo21H1-MUWD7YwWykIU8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_WPrxp0I9xU2_fyXrH5jLVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GM0kOY_mhEaJYH7pGa-SUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cV4rpMaJSkOSIB3MCn8lXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_16_2020_To_3_16_2020_oczPe0ei5ku15xZwnsPhTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7Z6yJiZE0GhfmBPrBAtlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_7CpUJdJGtEWp1gkOo1-Dkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RbVve-0-m0yDA75z_FJzKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2020_HtHclQDk4kyUNEXyTR4Guw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1968c8fb_87b3_4d8d_b438_3c94e3ed9235"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:DocumentType" id="Narr_yTOFm2dzeUeSj-6VKJmmmA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:DocumentQuarterlyReport" id="Narr_jtf_MlgNlUmCEIrxVyb0EA"><b style="font-family:'Times New Roman';font-weight:bold;">&#8999;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:DocumentPeriodEndDate" id="Narr_XX6pRXZVEE-UkF39ds4erg"><b style="font-size:8pt;font-weight:bold;">June 30, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:DocumentTransitionReport" id="Narr_iEjsTr3hGEmdkkH2PMce8g"><b style="font-family:'Times New Roman';font-weight:bold;">&#9723;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityFileNumber" id="Narr_Qo8RYBBcMUuHEA73j7qw2g"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityRegistrantName" id="Narr_nNKQhe0ed0e7xyO7Joqckg"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_48903b1d_c102_4243_9161_24f709ce23ac"></a><a id="Tc_QYVODvv-wkKLDpgrAkixUQ_1_1"></a><a id="Tc_MhEBoz4uuUKdRYCI-8XkTg_2_0"></a><a id="Tc_EmvtQttvG0KhEF3P_AibBw_2_1"></a><a id="Tc_XkO-yFHCxUmSEi3o2dw-CQ_4_0"></a><a id="Tc_mq-y5moS9k-iC25cPOBB5Q_5_0"></a><a id="Tc_2_LJS9xqNEG0x2FHvNIqbQ_5_1"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityIncorporationStateCountryCode" id="Tc_WpGeGCjHiEarHfUt-wm6BQ_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityTaxIdentificationNumber" id="Narr_djvWS5VQ5kCiTQ619cXbsg"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityAddressAddressLine1" id="Narr__u9jdLXT7069IKv_c4tfow"><b style="font-size:8pt;font-weight:bold;">2 Snunit Street</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityAddressAddressLine2" id="Narr_1arZNpZpgkai-RnpkSDKiQ"><b style="font-size:8pt;font-weight:bold;">Science Park</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityAddressAddressLine3" id="Narr_rigEptziSUuDBq4mCnWlwA"><b style="font-size:8pt;font-weight:bold;">POB 455</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityAddressCityOrTown" id="Narr_nw0JFT4AP02p9HyuEcm7fg"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Carmiel</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">, </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityAddressCountry" id="Narr_K2wMeFoHuU6LrkK-O4U3cQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Israel</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityAddressPostalZipCode" id="Tc_9Gztz08mkUGjqkOi3Ngx_Q_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">2161401</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">+</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:CityAreaCode" id="Narr_jHNG9jBEIEW9BoleMtL-IQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">972-4</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">-</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:LocalPhoneNumber" id="Narr_TxLfrsEcSkOUyuwcvJE8nA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">988-9488</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_dkXZWP31tUGpAoaD_DD4rQ_1_0"></a><a id="Tc_Ulfpc4_T0EmuwIMQYF4I9w_1_2"></a><a id="Tc_ypKBuKboxU2Z0lR7uFhDpQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:30.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:Security12bTitle" id="Tc_eC6Fis5PREen6_VfFSKfLg_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.87%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:TradingSymbol" id="Tc_SHaf4MX4yE6rXS4TVyEQSw_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.94%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:SecurityExchangeName" id="Tc_hBYj_iMxS02ZJCTCwoa0Lg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityCurrentReportingStatus" id="Narr_M2AhJtotDEGPIuDZiTJzLw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityInteractiveDataCurrent" id="Narr_IPhSHfZAWEqybvqIvU2N2A"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_xYWy9fQJ-EKmIZmPs-MudQ_1_0"></a><a id="Tc_wFFug0MRvE2NvA51n0NWdg_1_1"></a><a id="Tc_il644uRiW0esqRkAzb7Vew_1_3"></a><a id="Tc_5sTgfA9d906IgRp8p0RsSA_2_0"></a><a id="Tc_BZGM4VA7s0-cEhCt4FFQbg_2_1"></a><a id="Tc_z_2fpBdjpkaGi9rDbZk5ag_2_2"></a><a id="Tc_DM-MsyXo602w96Ag3NskEA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityFilerCategory" id="Tc_02zBJzqH6EeXGxw6UHYp-Q_1_2"><span style="font-size:8pt;">Accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Emoji';">&#9746;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntitySmallBusiness" id="Tc__3m25o93yEqeQyyKsQh1fA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityEmergingGrowthCompany" id="Tc_mRzKk3ZZuEy0LaTPzg46Eg_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="dei:EntityShellCompany" id="Narr_44myAHaO9UyJCMRS7lTU8w"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On August&#160;1, 2020, approximately <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_8_1_2020_HtHclQDk4kyUNEXyTR4Guw" decimals="0" name="dei:EntityCommonStockSharesOutstanding" id="Narr_nsHPCTqGRUWPRcu1NywwGA">32,442,636</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3dad011b_0c99_47ca_bc29_95c056dd5438"></a></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets (Unaudited) &#8211;As of June&#160;30, 2020 and December&#160;31, 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations (Unaudited) &#8211;For the Six and Three Months Ended June&#160;30, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Changes in Capital Deficiency (Unaudited) &#8211; For the Six and Three Months Ended June&#160;30, 2020 and 2019</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211;For the Six Months Ended June&#160;30, 2020 and 2019</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_c882c677_016d_4bd3_b00a_98b59271fdd2"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_kWT8nLbxIEiG_MSEZ6RueA_1_2"></a><a id="Tc_3vLRTZE-HE6qoZJyDtWCEw_1_5"></a><a id="Tc_PQ2oaGKsV0GS_8uD5SQ-Kw_3_0"></a><a id="Tc_MVz2OdnliEa-3A015TWb0Q_5_0"></a><a id="Tc_UOygtUIsnEOjykOZoIUX3w_6_0"></a><a id="Tc_XNdv4gIjTEews9v4N8sMDw_6_2"></a><a id="Tc_HXaNTUGuE0ypne_UcPiCIA_6_5"></a><a id="Tc_2ShtdS-L4EakoC0DVfzzSw_7_0"></a><a id="Tc_Gs-8lUPOuEG48D6zDGqYSQ_8_0"></a><a id="Tc_W1qFDRYT-E6lFrFlE3xONQ_9_0"></a><a id="Tc_ozxVc8q9V0SNqgcA0l8zvA_10_0"></a><a id="Tc_qfE0WKLX8kmExU7xWWN2Uw_11_0"></a><a id="Tc_JVzDp4h7f0msGxdUb9GQ8A_11_2"></a><a id="Tc_Kg0ba9TerUGEpwtTXjc77w_11_5"></a><a id="Tc_7GlPef42hEG5IsjC-OITQQ_13_0"></a><a id="Tc_Et8Lysz3xUayQt7STp2nYg_14_0"></a><a id="Tc_KXd9wQL0TkeDEHLVQvdqyA_14_2"></a><a id="Tc_mKwANhFl7kiu41ytK20xpg_15_0"></a><a id="Tc_wgBKVp9NBUefg2fqhR8WJQ_15_5"></a><a id="Tc_-dJGsf_B8k-I0mD5Cmf-7w_16_0"></a><a id="Tc_ZOenJDMbIEG2jQeteFEnFw_17_0"></a><a id="Tc_hHqJSg8Yzkml2LgEyr8Asg_18_0"></a><a id="Tc_ZW3UZdU1f0OZQxWXb9bYHA_18_2"></a><a id="Tc_uNmJ-KSNOUevH4nd5W-TEA_18_5"></a><a id="Tc_JkqBFpD2Y0yePxGWPa_W2A_19_0"></a><a id="Tc_0PgwKAX1YkaGkC2TgGl27A_19_2"></a><a id="Tc_B10do8Uoxkm2TQVhiBPBVA_19_5"></a><a id="Tc_aHwpaLBhkE-ABxWDJuziag_21_0"></a><a id="Tc_5BqaqvlAw02FWEGo6__WiQ_23_0"></a><a id="Tc_v_vWGhGJ-Eq_bsEipjMfAA_24_0"></a><a id="Tc_b11zlxwS0k2C9fsFMN-JPw_25_0"></a><a id="Tc__UajjHJbu0Ox30hF6enzDA_25_2"></a><a id="Tc__myXlbej_EKhf56j5nox1A_25_5"></a><a id="Tc_ZrK91m_yzEKZm2G2D8nplw_26_0"></a><a id="Tc_1jMTDaWxLka72JbhWuf6Jg_27_0"></a><a id="Tc_GZj12B5JwUSJPJGut6xBMg_28_0"></a><a id="Tc_EBu7z5Gsvka70LL7CQLJsw_29_0"></a><a id="Tc_D0yocOX4RkqFO0GdMN11vw_30_0"></a><a id="Tc_8yofvVE2jkKiGwoav1qRUw_30_2"></a><a id="Tc_Qv4yaUZlUUKTKsmogSzB7g_30_5"></a><a id="Tc_YM3wO8Rzy0-Jc0zW8FDF7w_32_0"></a><a id="Tc_GEOGXBvyf02tG8dmDXimTA_33_0"></a><a id="Tc_vp1wo4qxJkqa2o3tH68qoA_33_2"></a><a id="Tc_fk66IeWPwE--OKxU9nO0rw_33_5"></a><a id="Tc_cd3Nw3qp3UuiobIA67Dhkg_34_0"></a><a id="Tc_U9_teQ-yBEmqBcsWDgMrbg_35_0"></a><a id="Tc_09ElHVYOuUOgs5adK_BUVA_36_0"></a><a id="Tc_9lFC96LtfEuwdqENI0omUQ_37_0"></a><a id="Tc_lWaf8ctMgEaK_qWif-KI0A_38_0"></a><a id="Tc_WdwO8_YmAEu74wTge3qlzw_38_2"></a><a id="Tc_Vy6Q1PveXUq27I1vYQMAnw_38_5"></a><a id="Tc_1VVOeppNoE69rTVnfxrcNg_39_0"></a><a id="Tc_hBLCcwHS20e-fZRwkTbqLA_39_2"></a><a id="Tc_wyiPuJ3E-06assNr4fJS3g_39_5"></a><a id="Tc_PeY-n-OOPkiaRwzNagJVhA_41_0"></a><a id="Tc_c7EZ60xXpUObqGkOtvtdfQ_43_0"></a><a id="Tc_UQqtDjw3D020k4NTf0Aq9A_44_0"></a><a id="Tc_35qoq_wgXUm8ogHvM1H33g_44_2"></a><a id="Tc_C0ZPVGaIOEOI_T-fzWzcYg_44_5"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HLe6VB0I80-ExV6HzL5qQw_6_3">4,843</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1XQvvLNfuEuRuM9e619WBw_6_6">17,792</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_sns04n-0i0q0svPk5b4S8Q_7_3">30,147</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_a4_6hr48ak-ZTeUUCllTOw_8_3">5,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_FUo9PXa7D02KcGIKJY1pmw_8_6">4,700</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_pYg_HspKi0qFSL18naOJ6A_9_3">2,893</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_maxEuA-3a0iSMNesIdc9Pw_9_6">1,832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_qCZihxhwGEq20FyYCkZeeg_10_3">11,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_cB1BsAOarE-YBTJ7duKu2Q_10_6">8,155</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_RPGKz27qeEGg_YAANEH7mA_11_3">54,210</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_MulEmMgllUS3Wxcik0hZxw_11_6">32,479</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Long-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndOtherNoncurrentAssets" scale="3" id="Tc_Twe2v9UBH06PDE_8XTs_tg_14_3">5,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Funds in respect of employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_7A5AvHxMo0KK3pD1zyuamA_15_3">2,005</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_rsOhk65AekStjf6MzSi-kw_15_6">1,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_wWSrBkX_GkiwoMVOKEnqVQ_16_3">4,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_psdI0O9UV0q_tfEwx9u67w_16_6">5,273</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_JI0N8pN-Uk6JBTQuG4YBWQ_17_3">5,677</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_mBxLrphYBUa8P7Di39BPBA_17_6">5,677</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_-EpAQJTUjEWjTIdI2Af8OA_18_3">17,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_aetSJ4uhyE236YW6_SmVxQ_18_6">12,913</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Yyl-hlGf-E-6_x_yJwPkjw_19_3">71,710</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_rDaq0_GzRka6v4nmyaX8rg_19_6">45,392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES NET OF CAPITAL DEFICIENCY</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_d51aL7pjpUqItBWvjLhnMQ_25_3">6,707</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_AUpJou5aFUGcFwGev6t1mQ_25_6">6,495</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_NL5Hp1H0yUCJHmgyJ20LTQ_26_3">11,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_iKtL5NKdM0mqGMrg2bSnfg_26_6">11,905</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_53khd3VOc0OnHy-WMMjTYA_27_3">1,145</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_Ea_tvjO4DEyRs1b0afl5rA_27_6">1,139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_WIH9TIFAS0CRChqKcdd5wg_28_3">18,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_lNJFrIVf8EKXJvRDWzrXYw_28_6">16,335</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Promissory note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_EZ4no7Z9wUGbyyzBwEcUxw_29_3">4,301</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_lVLPjwAco02eV-r0c26HHQ_29_6">4,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_gcSMAAwNrkKq4uDDgAsIRw_30_3">42,415</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_UX-C_LM6J0K-EIxoQ6D9XA_30_6">40,175</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_bgUrse6cgkWLDzyzQY2X-A_33_3">52,622</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_wX3k0Z09Akaeq21FN7qb0Q_33_6">50,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_SzreveLBAEGTiNT4v3cPHg_34_3">4,122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_pHf77p3HEEi4sStu4Md-7Q_34_6">16,980</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_RtR8QQEDPke_PR1KUIEN0A_35_3">2,665</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_Viix6tMjh0K5Q1X7EnpFxQ_35_6">2,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_fd8f_e291UCYv7ehHcNt9w_36_3">4,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_c7EQkeY1sE6yeA-YXXwAlQ_36_6">4,528</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_L56IHoulxUy9F8h2zxBFnA_37_3">124</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc__vl_dOiCfUy040txldTjmA_37_6">509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_emT3w-MErkueD9OJrlCv3g_38_3">64,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_KjIXEmY6NEC86LGJM9ZY5w_38_6">75,539</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_zLkDqLJJMEO6qJP5JwoM7w_39_3">106,474</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_6wcrO9Y57U2Zj8lifs_bew_39_6">115,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CAPITAL DEFICIENCY</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IVlIE1xqNE2q7K54C3lGkQ_43_3">34,764</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BvlPfORoY0Oj5mB_d0TCgQ_43_6">70,322</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities net of capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_2balJo3F10iXiuReHfzVXQ_44_3">71,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_i33o0Ij0Vkmq6Ep7oysaUA_44_6">45,392</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_b9de7fa0_0798_4353_b7f3_181f7139a027"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_YYO3OKWyN0GsJSne_vm63w_1_2"></a><a id="Tc_2rvNDmet2kOGCM3mGTQDJg_1_8"></a><a id="Tc_sanzJzKqjkKo5oJc7pvIZw_2_2"></a><a id="Tc_IoLs_Q3j8U-QzDcyf-9DsA_2_5"></a><a id="Tc_KSl7qdM_Gkiw1P6cC2W2Xg_2_8"></a><a id="Tc_9uBBfaLV1k6-RDIKf-vAxA_2_11"></a><a id="Tc_3VctYmz3YEeHvqb4xGfyfw_3_0"></a><a id="Tc_vTAeBrWv4kST6V6yUeFt9Q_3_2"></a><a id="Tc_kxxwOWVD_EqPvHoULPM8mA_3_5"></a><a id="Tc_0XRnhpmR7EKsf_GgBAoUaA_3_8"></a><a id="Tc_u03Pj65hrEeUQNvRzWXnNg_3_11"></a><a id="Tc_cuBQv5Z6bUSxCeXzB82D3g_4_0"></a><a id="Tc_ZnbGvp4G0keys0_b5jTnDg_5_0"></a><a id="Tc_5OFXOkQFKEWGXELgX49R2w_6_0"></a><a id="Tc_DwaDuaTC-Ea5wyPAxlMVcw_7_0"></a><a id="Tc_xgzvh3BCUk-l8mwlt5ZKzA_8_0"></a><a id="Tc_lNX1XmdUw0Gwbz_Ogfl6-w_9_0"></a><a id="Tc_d2UyFka0tEmUTViuGWaZEg_10_0"></a><a id="Tc_1G-zlo6WfEyiWdOB7A5GCQ_11_0"></a><a id="Tc_CerTMkuC3kuVJq6ZfKtwUA_12_0"></a><a id="Tc_8HhlBtSek0WAhfsGUBzNMw_13_0"></a><a id="Tc_pNbdCyNbnU-C5SytOeu6Fg_13_2"></a><a id="Tc_EkvOPd0TkUeLPPX-WPPrOw_13_5"></a><a id="Tc_momMDZ0KMESZd_SIgcCwEg_13_8"></a><a id="Tc_pKgzdokD10yrhqVOW0uRmA_13_11"></a><a id="Tc_RwfGx6g4_kiXklFzPS1QLQ_14_0"></a><a id="Tc_1ZvAzZ44b0euhfPe6mkSTg_14_2"></a><a id="Tc_atfASZjIiUu49XOCj-ulyA_14_5"></a><a id="Tc_C81Bj5oL4ECRyeeZIBdn4g_14_8"></a><a id="Tc_YoyfLzAISECik3fR4rbssA_14_11"></a><a id="Tc_t2O6Vd8s1UqH2Y3MgFeMuQ_15_0"></a><a id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"></a><a id="Tc_TdImY1-FSEG3VFt3BnxqSQ_16_0"></a><a id="Tc_OmT1jGyskE6Ngm4XWHEcnw_16_2"></a><a id="Tc_kooZa9BcFE2L5l_SLYHYyQ_16_5"></a><a id="Tc_wsjkog6WpkGtTVxIo_UAFw_16_8"></a><a id="Tc_I6Jx7GP1gUap0Wwd3wCKIw_16_11"></a><a id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"></a><a id="Tc_mcpL1HN-EE-dBizv1COhOQ_17_0"></a><a id="Tc_ETlKCfHcxUSGqdhW6_CYfQ_17_2"></a><a id="Tc_6_kvVbh_M0OYlG8tpcdS5w_17_5"></a><a id="Tc_FWIq5kY_VEOjmS4VAEGA4g_17_8"></a><a id="Tc_TzOkW1MRmEKdWrvA7fFtmg_17_11"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues from selling goods</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_yM7VN6n3HEqpoGO7RPojOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_o1FoUtK_zU6X8L5e7iX1bw_3_3">8,679</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_mjHtdYriEEG-CXeWej1g7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_0TjI7N8e30qSytmN7MheBA_3_6">6,960</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_QmGZUi6OjUqO1LnkJZCRXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_O9UFqPrWrk2eRloN0sh84A_3_9">3,648</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_ObY9WS7lOkC896sj2TQd1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_xBxk0zZ0n0yLGLa_EvLl5g_3_12">3,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues from license and R&amp;D services</b></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_b4IHEMa-EkOw9g0xX9vuVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Y0omcKFFQEyaC_XHRuG0Jw_4_3">23,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CnxupLEavEiCHMgWdkLIPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_cvbjjOueD066ceZ_j_DtEQ_4_6">15,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ubU6rEERnEi4sCmFzEPs9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_YH9BVnBxykGciXVWgCKgTQ_4_9">7,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_leyen5aCU02wk6AuAeZjWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_zrbEweIGKkCCkqZ4W-w8iA_4_12">8,817</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6N0wQeMDM0WIsVnSYoPI7A_5_3">32,613</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_uC8yQPJceUOFhaGWSON05Q_5_6">22,686</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ZobAhpgXrE2U-66sHqDogA_5_9">10,967</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_cj3P5JbnEUe_e4I9WodCJw_5_12">12,247</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost of goods sold</b></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_qawOWwvI4UmeWjc3dPqUeQ_6_3">5,253</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_DjRQEoCaqkOTz8nvL23dsQ_6_6">4,740</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_R1MiKoO_0USYxioUGUBvLA_6_9">1,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_3EQdXqrjPE2wXD47URaNdg_6_12">2,695</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and development expenses, net (1)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_SGr6NUUCe0C5Bk_s1pDMng_7_3">19,526</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_J4RETHFjp0638EmprGXqgw_7_6">25,021</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Ui5GxFKS9E2x7Ltt3u8Mbw_7_9">9,186</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_iv2_bzm7606avIFAv9jEDA_7_12">13,323</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Selling, general and administrative expenses (2)</b></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_u36KAAK2xkWqrWosBzYeJQ_8_3">5,381</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_hnMVfBeSmU-kdjccWs-nQA_8_6">4,298</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_HBLGVjxUYE2z0u3vuDZE6w_8_9">2,194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_YGB6guIBwUuiEMPH4WOchQ_8_12">2,068</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating income (loss)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_EvrV1osUa0W9m_OSLRlgLg_9_3">2,453</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_qUjlTwUbmkmHG15LqpieZg_9_6">11,373</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_EO2r1jaGsEO2ThEpyxQe0A_9_9">2,240</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_-XULAD_Fb0eEguoHuhEF0w_9_12">5,839</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial expenses</b></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_K3htR1Tj4kGXDUXasHn7Vw_10_3">5,177</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_2m2s41B_mkSNCBBTOq6iPw_10_6">3,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_usK05MoeAUmWhvJHW_BOtA_10_9">1,948</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_EoIlOpahxESlhyZX_YeFEw_10_12">1,907</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial income</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_4aENFiYp-06VYdMOY3BldQ_11_3">241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_F7-meTDb3kyonkGqVtP0Ew_11_6">193</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_sSJ56NB4706Msj1hp-xnJQ_11_9">38</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_hRatgfPYzEuoCHY9IT6dSQ_11_12">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial expenses, net</b></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_cNekAXYebUq1zUVMvO5Ltg_12_3">4,936</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_mhLNqWfi1EWHwubpDRYZYw_12_6">3,634</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_9j5VLCb1qU2S6-RHPL9JcQ_12_9">1,910</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_M1CB2gj0dk2HXUvqFXCP1w_12_12">1,904</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_TfR3DfBK90K7L7vfSMMTDQ_13_3">2,483</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bQd0Zc0XPU61H_x0JM0jNw_13_6">15,007</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s3IHY2E84Uqh-GJUtgmJtQ_13_9">4,150</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wSh9Fcb1EkW7AX2S6BGjPw_13_12">7,743</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss per share of common stock - basic and diluted</b></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_y6-tCtrsEEuVu9S8AAoY9w_14_3">0.12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_RIDnrCEqf0G4xMZrMNSKHA_14_6">1.01</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_e4c4FW7Eukmtglu5BFNk4A_14_9">0.13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_dPghKo-SskCahhJRwTxjcw_14_12">0.52</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average number of shares of common stock used in computing loss per share &#8211; basic and diluted</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_GHidFxu9A0mogDg8Y3BIZQ_15_3">19,923,935</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_cLSLtadXOEqTSHM2_23nFQ_15_6">14,838,213</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_nrO4cQMnRUqj3HT3V9Urcw_15_9">32,442,636</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_tIbwDqO1E0WdJ0F2soZB-Q_15_12">14,838,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"><b style="font-weight:bold;">(1) Includes share-based compensation</b></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZxLgitN4OEGYDuBZoHnVXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_EeE-6K-_SESW5-xiJhQxfg_16_3">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_RgcHJTMxiESAmSco2vlgwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_kqv6uzIi1Ey5FprxClxd7A_16_6">316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qGcyw11XhEi9-0J_8vb26A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_WlSMvUVBHEycYD-zq58bQw_16_9">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q_06E9Fbq02P0s8c6weMJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_WegpFSIS406CMoEwVP6qJA_16_12">138</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"><b style="font-weight:bold;">(2) Includes share-based compensation</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_U3lSq0ip90Kl1sHOY8UG4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_K5U7vCuU0kyZZtRTXa6SHQ_17_3">625</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_WY_KFkHtI06S0Nse9YgtVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wxqwnlxsWE6oQjwmxUjyNA_17_6">87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YozhTzDOZUqiiF9r9XEkGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iiLvmh8awkCekx-T4BcjYw_17_9">272</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_RRB1BC9l90W_DnZi--Mbqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_HcH8PP-tXESuCn7gBm6Npg_17_12">25</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4186801a_4d48_4136_96ef_30b3253d9899"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAPITAL DEFICIENCY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_GCnKJQr_DUKWHy7x3jGGcg_1_7"></a><a id="Tc_Ew9zdwFELEKaX_iWLqCcOA_2_2"></a><a id="Tc_0ZsEWwaPFUWJMNZhuo5Qgg_2_4"></a><a id="Tc_DTmSvgvNgkuzGn22uKZM5A_2_7"></a><a id="Tc_Fr0AvuavfE2tBltkrro-3w_2_10"></a><a id="Tc_LRfwYLWNoUyk3CTQ-FVmVw_3_2"></a><a id="Tc_mMFUCId3a0iCuj9Lpn0VDQ_3_4"></a><a id="Tc_tVvVfi6rAUqocKk8SM-s_Q_3_7"></a><a id="Tc_-r1hiohOikqaaRF2OYhhQQ_3_10"></a><a id="Tc_PlXG5YY-bk-6prcADk_1lA_3_13"></a><a id="Tc_uLUwg2wktUKWHbUcsUhklw_4_2"></a><a id="Tc_etm2Aavm8kqnHRDIIIMkaQ_5_2"></a><a id="Tc_PYFfUwXPnEytyXkUy8pUcQ_5_4"></a><a id="Tc_1R5g4NAD6028eEGrLvOHkQ_6_0"></a><a id="Tc_lW2H4cjGoEeI7qBW1x-UlQ_6_4"></a><a id="Tc_3EGEE5DN4UCJ7PqYUvu46A_6_7"></a><a id="Tc_eN_A_adZzkO4XqBlyBQtig_6_10"></a><a id="Tc_grKmm0ECO0KK8zLNQoieQA_6_13"></a><a id="Tc_zUzrI5HbkU2DhB3W6AcHGg_7_0"></a><a id="Tc_OffDhGr6aESQRc0O5bgL1g_8_0"></a><a id="Tc_ZMiSyC_Iskm9YhYwwWML6A_9_0"></a><a id="Tc_AfRsvXhPT0We17QJMvAakw_10_0"></a><a id="Tc_YCZjqTY7qUuDZr2AQhRAeg_10_4"></a><a id="Tc_LLOa6B-V4kCsH1vMDRJSpA_10_7"></a><a id="Tc_cBoQ9I-fmk-dJponSUtmcQ_10_10"></a><a id="Tc_adFAhg1fk0ap3b4zsHiPVg_10_13"></a><a id="Tc_A68Z5YDm7EWMH-nZHrg7Og_11_0"></a><a id="Tc_Eq8MBs2Hn0i5hIfqVRvmGg_11_4"></a><a id="Tc_rRZHYiVYlUmpp4xo4d4XGQ_11_7"></a><a id="Tc_uozPWcL9vU2IsH3NOnPguw_11_10"></a><a id="Tc_mRMWl4-sh0ixMHjBSRRohg_11_13"></a><a id="Tc_4QL3bbnNck2NBac_A46UYg_12_0"></a><a id="Tc_6oiDV27ayEOsBUNrUjenPg_13_0"></a><a id="Tc_aF89wIYohk6RpRKQDFKzQQ_14_0"></a><a id="Tc_sImpyEmnbEGlPiIn2gXIdg_15_0"></a><a id="Tc_bH0_CfDesEm7sCqC5D7uUw_16_0"></a><a id="Tc_ZDNyypxSZEeY-Cfmo_lyUw_17_0"></a><a id="Tc_Ehx_O7lbcUKQu0jvrokcdg_17_4"></a><a id="Tc_ceqeslFkVEKU0gSx4HYNjA_17_7"></a><a id="Tc_r8utrekEhEa9wN568L_ESw_17_10"></a><a id="Tc_KatTexQLRkOyBadIL_oHvA_17_13"></a><a id="Tc_Kw2F5MVEP0mg90RFhXz31w_18_0"></a><a id="Tc_uEG-9nrYgEmPVKv-nxfSvA_18_4"></a><a id="Tc_77jTVIBGn0eS2CkW0nO0nQ_18_7"></a><a id="Tc_ANmGdkpaK0it13UbyvAffg_18_10"></a><a id="Tc_eh7i7RKlYk6u-Rt8_iHp9Q_18_13"></a><a id="Tc_l1pUpihFk0S-EOKQqkMJ7g_19_0"></a><a id="Tc_UjNsctg1E0mxdeDLGaZyoA_20_0"></a><a id="Tc_baFObi-lE0WzppjAtHxRWw_21_0"></a><a id="Tc_PPFq-GrJTEGbUlPYNlbU5w_22_0"></a><a id="Tc_Kj4l5tK4t0Sveu0-FC4axw_22_4"></a><a id="Tc_ih-waV05tUmuM8y_-GD65g_22_7"></a><a id="Tc_9MSi1jxO20GlA2-5-rxD1g_22_10"></a><a id="Tc_7_ud6PyEMUeLqcOq5DJvgA_22_13"></a><a id="Tc_2IMHEkaT30qnPmMSdcOCYQ_23_0"></a><a id="Tc__r8lX_l5Ekq0PtnHdFNBfQ_23_4"></a><a id="Tc_RnEXxRGymUaRb8FEk7MtIA_23_7"></a><a id="Tc_OESrBNsHHkuEAxFGsxGJ8A_23_10"></a><a id="Tc_QwkL98BpykKAfQXcQ2zWmg_23_13"></a><a id="Tc_1edtIEcAE0m4PspvG5Bejg_24_0"></a><a id="Tc_YvhE48uhFEm3hM49XGp-Ww_25_0"></a><a id="Tc_qgHcTixFI0S3zNO001aI4g_26_0"></a><a id="Tc_M1-O1fNBA0KhhXSHi_3oxg_27_0"></a><a id="Tc_QAElJiiL2EqGHaO6hNLLdw_27_4"></a><a id="Tc_R_MXx-E4D02rVJq2A_r4wg_27_7"></a><a id="Tc_yTPZRcCi50mXDBPt_dNKXw_27_10"></a><a id="Tc_6e4Gpn0I20uBTEo0a9eo4Q_27_13"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uG2XyhIdEaKWq0i_Og6tQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_BgiW9FPxW02DMAsP901yug_6_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uG2XyhIdEaKWq0i_Og6tQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KUU4hrParUaoU0Wq1RRk7g_6_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YVr3HQawREa2lJZHx3PH6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_d7T3QGvRukiHq-ANJbXeLg_6_8">269,657</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7lZ2PehKpES7w0uB9Q2kTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LGPgncN4CE2n788r7qQ7ow_6_11">322,553</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2018_2BE4yI-8FUy-wuebFU1qwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_47XLLqBXv0GBmRpSoFtP2w_6_14">52,881</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2019:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyryerKYm0ufav34CwRxYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_96gQSeEnPEqYQelUAJwD0w_8_8">403</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Dc6M3fyNeEeMgj_jxwO1vg_8_14">403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NWcLSQS2Y0abZ9Z36xlHpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9Xj8gESXSE2V-evOIvOKhg_9_11">15,007</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_KSnK6CzLQUmjV4J-pPMMZA_9_14">15,007</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_iVEqitVQvU-5xqMr6waasw_10_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Bw6jItEYrEGBajt1KyHECQ_10_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D91DMekLyUi786I0a96WxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YYXHzjDNQ0a7pLFh8hpocg_10_8">270,060</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bQ8d5NSZLk-awmHoE9teAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_3RXcmxP1nUmK6PWJdlNFeg_10_11">337,560</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EqsXr3UvTEasUY6X4cSkLQ_10_14">67,485</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fnM9Fs8xWUimFQZTDbqXWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_P3QDfTMfWES1L14xViYFdA_11_2">14,838,213</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fnM9Fs8xWUimFQZTDbqXWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XIUxTxopgUmZDm90nm6Fww_11_5">15</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kfGHTqSzx06Mpo3yF5o4OA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_p2w2gYmyD0C4y0w4uuWzlQ_11_8">270,492</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fUF3B9mz-0uCzmKZ02-ItQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_94ZAyNZQqUyp-12bhM_pTg_11_11">340,829</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IFq764MHV0u11oAuPWiUMg_11_14">70,322</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2020:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and warrants, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7Z6yJiZE0GhfmBPrBAtlw" decimals="0" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" scale="0" id="Tc_Fr4gczi0IE-okyUw_-7bWg_13_2">17,604,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7Z6yJiZE0GhfmBPrBAtlw" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_9PKwc6sAFkGX_OgtorTdCA_13_5">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_AeHDbaI_C0yQqIAZf5DtHg_13_8">41,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_CutGlNx2kEGpsToJgXdv6A_13_14">41,343</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Note receivable from issuance of common stock and warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ReceivablesFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_aWo5wtU1SEeGDhhJLmey4w_14_8">4,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:ReceivablesFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_k7qKh4y1QEGwWG6OMym3sA_14_14">4,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Vd3I9AOjS02Css7Kl_gqZQ_15_8">698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_G0A71PSnqE6oj4GgFEP9uA_15_14">698</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__6LA1s6dWU-YSFkzfQtBfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6wm3BA8XFU6_vLD4nrZJ7Q_16_11">2,483</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_kDwYs7wD00G4Agw82wLqYw_16_14">2,483</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_6v7CAO-TVUO21ZSLi16FLg_17_2">32,442,636</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wImdQ_0N4UCC936Iyj7U1g_17_5">33</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IjoXygzFWkGqMriuJJW-Lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hJ2aDGIj6kKbGiVlVetQFw_17_8">308,515</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0C6K83V4j0Kphnkf8n9mcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_-y7Y5-JJ2U2hzGgePlrz3A_17_11">343,312</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FwxZAx_42ESRwHSvVnzODg_17_14">34,764</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_00e2daMkjkeossE65QH8wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_wQKrDYKrC0iNFY-QHlvcXw_18_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_00e2daMkjkeossE65QH8wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1F2yuJcyw0yeEC3lN0Wjaw_18_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2iGT9UYX20ufEOy7uLUIZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QPurUBqOOU6JEc2IK9H9vg_18_8">269,947</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VL6BuAeE9k-1CymbZrfhIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_UvQF1fMGKEyUqJHdJQNZpQ_18_11">329,817</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2019_vbRY0t2qH0qlCvQizNy7Ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2zKrSw_U5Uy--o2-Fgu-zg_18_14">59,855</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June 30, 2019:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DJm4hQ_X0kWnko7Ett0rIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_36EBWWpygkuxICNztiVqeQ_20_8">113</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kmg5NzlAZEe7AuL1UOEZUg_20_14">113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PQTvkYR-K0GQcvIHSBU09A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NwgoiTTEXEKXRalqnu-6oA_21_11">7,743</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Njdz7aaXTUKMgRrrnCnLIw_21_14">7,743</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_TnOmOEnIYk2Rn7q7Xnj0iw_22_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_R1XQ_7FUPUW9do7dqfJyoA_22_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D91DMekLyUi786I0a96WxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6ZcDOPZQgEugMMNHhB7ZHQ_22_8">270,060</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bQ8d5NSZLk-awmHoE9teAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_118WhVkm_k2ZMTrZRl0xkw_22_11">337,560</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rTBv8CoxL0Gau0FZUW5O6w_22_14">67,485</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:middle;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LXVbu_pYy0S9ohnZflii4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Cw2t2AjstEiMdHc8f0LPHg_23_2">32,442,636</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LXVbu_pYy0S9ohnZflii4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lUxM971TukSaJ0aTRbqP1A_23_5">33</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6VRfrb4a006C6zwz8zQtcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_omJLh2NONUKbK2pbvyX8RQ_23_8">308,248</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NOmRUBGMQ0qHujxUMsdUWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_R5D1WW2p30iUg2PfxdFDCg_23_11">339,162</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_3_31_2020_w3xlUNxxE0W57aWLj2hlhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_cimR9YQPLE6OhvNNeZiuZg_23_14">30,881</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Changes during the three-month period ended  June 30, 2020:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vmg-JoGYmU-PSD4wN2qEbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_E4c2LbxMQkSfpG5IxIY5Bg_25_8">267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_b3wufFFusUmFpwToW1lXiQ_25_14">267</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCX0MKCM4Ee34kOUnZ6BZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JcL8_fQ_JUaHw1uM3HvZlw_26_11">4,150</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_w-szCl4iBEGBpU26DArnTQ_26_14">4,150</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_rAT4sKTVtEmVf-XqUEgE6g_27_2">32,442,636</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_w9aQCs2sIk2QK2sdhauECA_27_5">33</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IjoXygzFWkGqMriuJJW-Lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6PZba7x_NUKzTaQOY81Yqg_27_8">308,515</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0C6K83V4j0Kphnkf8n9mcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xk5xFwB0_kWepYmJ4xRavA_27_11">343,312</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_s-Qy9Ou8NU6C8w-gWALIYw_27_14">34,764</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;Common Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_7WjgQ-TVBkmyWYIerFFV1A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_fOLVMAYkF0mcU_7lXGa2Eg">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of June 30, 2020 and 2019 - <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3oLcKUew1EufuoV8mFPLjQ">120,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_G9gi4DchuE-QN00BRHu2bA">350,000,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5a09774a_7eae_401f_9a0a_2228f3521968"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_RK4312jLs0C20L7DBYWrvQ_1_2"></a><a id="Tc_4bAWTIxUm0OC2b2tcNtAVQ_2_2"></a><a id="Tc__Iku-3UqMEWsuPEXrqqU4A_2_5"></a><a id="Tc_2UeDALrBhES6CnnZZA1NTA_3_0"></a><a id="Tc_ajvKcafEt0K_tiKc_CIwYg_4_0"></a><a id="Tc_b3zv3ipa-UKIooZ0x-dyOw_4_2"></a><a id="Tc_K4eVdvWtAUuZKUtZqoxuNg_4_5"></a><a id="Tc_89h8OZ7L40OXlQU1tUi2Nw_5_0"></a><a id="Tc_Cp9e0JPHkUi2AG0HcDgTBw_6_0"></a><a id="Tc_X1t7YFAwIUO8Vf6kxteqGw_7_0"></a><a id="Tc_WQYsUTixhkyUSVCbg04YvQ_8_0"></a><a id="Tc_3krje0EKqk6c6ymhlIZHGQ_9_0"></a><a id="Tc_SrGgsO_8HkWzq4aO-Lm_2Q_10_0"></a><a id="Tc_w5nx_R5RukugDcnUtkc6UQ_10_6"></a><a id="Tc_jKsrwg-FKE6ZuLaZyvE8cQ_11_0"></a><a id="Tc__2SNErPmSkytC0Kfo0nd4w_12_0"></a><a id="Tc_nnIFxprYbkCwM0nwyqr2cA_13_0"></a><a id="Tc_shETJ7VaRkOmWnIkgfHmJQ_14_0"></a><a id="Tc_U4KYOMJUxU-m88Vzfov9HQ_15_0"></a><a id="Tc_UyvtVPmpmkyE9iwGaRexxA_16_0"></a><a id="Tc_MWvhZjrKtU64nBuie-gj5w_17_0"></a><a id="Tc_NDMKJPYrUUS_fW1remFs-Q_18_0"></a><a id="Tc_8G-onMBLikqiE5WgnloHdw_19_0"></a><a id="Tc_2oXkAH8dM0WAJEl7K7UbRA_19_2"></a><a id="Tc_suVn0sHjBUWJpfbaBYzrVg_19_5"></a><a id="Tc_Of7U0UaaKECKObxAV5GPtw_21_0"></a><a id="Tc_q8TP7tEjh0-9G65n9qekOw_22_0"></a><a id="Tc_gs4Jdj7vAUWc3EnbHP4qBw_22_2"></a><a id="Tc_EhIc_Bwbt0Sc8EG2__3pKA_22_5"></a><a id="Tc_WxnclVc0K0mtYkhsh1jt-w_22_6"></a><a id="Tc_sXBwS-XzF0GZn3LvM0Rn4A_23_0"></a><a id="Tc_Ft6N5bI53kaO9f-SzLkwJA_24_0"></a><a id="Tc_iIaKquv-_02XjFY404ouWw_24_3"></a><a id="Tc_MJHmEDpdLESSEtjDoTXXJg_25_0"></a><a id="Tc_Ky2dXEMKg02EmOcQ0sCsgQ_26_0"></a><a id="Tc_8ZZZfVRs-ECTMN1usy1nKg_26_2"></a><a id="Tc_jIE3EFFEmUe9XICAynwdwg_26_5"></a><a id="Tc_SZPDk7u590WvI1avYn-lEw_28_0"></a><a id="Tc_wfeOyUpYF06nNNyvPV6atQ_29_0"></a><a id="Tc_LayBDWBddE-tnoFQA1KpWw_29_2"></a><a id="Tc_Y77XeS0yTUyK7Ky4prOIXQ_29_5"></a><a id="Tc_v2KlZIuNiUiQlW11-bzdNQ_29_6"></a><a id="Tc_g1kc9zEHLEmi4jmJtBZxSw_30_0"></a><a id="Tc_k89NSiSMJEO9NYLc4n4kyw_30_2"></a><a id="Tc_No5UI_aRZEetuvworRk8Rw_30_5"></a><a id="Tc_ouxiQ8aQjk2kfVQtlqwPTg_30_6"></a><a id="Tc_FeLAYiRy_0W5Uxheb3VJMQ_31_0"></a><a id="Tc_4OKRBBVSS0SQz_Pp-VhwRg_31_2"></a><a id="Tc_IwTnt_FkUUawO8UgGh1zRA_31_5"></a><a id="Tc_Dm0wrxBMGEmKk9b9zL6sMA_32_0"></a><a id="Tc_lqrCK6PMi0G_ruhxL-Hzkw_33_0"></a><a id="Tc_ugTlgZiqdEu_k_rLd-oQ0g_34_0"></a><a id="Tc_UpEpIwXPHUaA2pOt-BUjow_34_2"></a><a id="Tc_4tOwSS6pO0CYZpRonEKtLg_34_5"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_I209uJsesEK-jHJXsse3eA_4_3">2,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VTa-f4iBdEi8O0Ts31sYvw_4_6">15,007</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Gyk9angNAUC-WaDJ73CIlg_6_3">698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_m2JkcPSRFUKMRMYk8sNI3A_6_6">403</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_QSYnTIsTHEy2f10owrXmiQ_7_3">710</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_Cs-BPTrZrUKRquR3x3RTlA_7_6">784</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial expenses (income), net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_ZZVpRTiPA0y5FcNS06PdBQ_8_3">250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_OhbQwFiqNU-As3iQVW1kBw_8_6">150</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_S9jAnfeSh0yheFJsR12gTQ_9_3">107</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_m8ICoPeJakKHpbyXG1b50g_9_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_kOmAz5MbVkWlIC7F-1fQKA_10_3">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_DuaA9HhTXkW7w8CKns3Wug_11_3">1,665</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_WBV2PPergkaOm-im1aETLw_11_6">1,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability (including non-current portion)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_g25DZ9MMYk6WEpXPMMhBIQ_13_3">10,841</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_srlGELsm9Uuqb_WCVZEf0A_13_6">442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_sYf-45RStEuprHFPN-_nRQ_14_3">1,621</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_LKQKAckbtkaJkGlWqSTzsw_14_6">2,811</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_FcWLD6iPy0C4J4STr_BQfg_15_3">27</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_GWKlcFpF_E-qbgfO17OfWg_15_6">69</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_vGv0r1nkkE61hQmDxowiIg_16_3">2,910</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_D8NS9gz2M0iirNIj9jvzEw_16_6">1,571</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts payable and accruals</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_SjhVd2Qxx0mwJC5kRHysFw_17_3">309</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_VanhuKtuB0GkMPp34on9Tw_17_6">1,471</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Increase (decrease) in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_9yS2S62DfE-5gAzCfxPixA_18_3">385</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_wPId99l0o0Wuu6Ssy-1Fdw_18_6">56</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_JxJW3bLFrEa2fCOGrCViMA_19_3">14,952</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_a-B6vefCmkuhFcc4oP-uKQ_19_6">12,446</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Increase in bank deposits (including long-term deposits)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_huetaFbNQk6_WKPH5r7BkA_22_3">35,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_dxpx6ERDQUmPj0iUKAdUAA_23_3">278</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_MGjcBoqX_0KkDBRefdjMtg_23_6">207</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Increase in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInRestrictedCash" scale="3" id="Tc_4rYibeOzg0uZc1JVuIyK4w_24_6">236</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_WRSb7Ko9ZUeLxZtb6QxKXg_25_3">69</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_uK7AaIGLFEuR6TbuIo8Ueg_25_6">23</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_WdXNlKRIvkCWpTpMQGMI5Q_26_3">35,347</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_FO1EE_s3XkaoK_v9D00W2w_26_6">466</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net of issuance cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_5MDwYu0LKkSTNd2NHOuTGg_29_3">37,343</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_D4wrQplwE0el0GhLmDhGWQ_30_3">37,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_VYmcDKYeskqPHpuaiVag_A_31_3">7</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_DVFJP75FMUSzrtakkHaP5A_31_6">200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DECREASE IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_N1QB8kqJ6Uu_Aqv8dTKSgQ_32_3">12,949</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_OhPYqok_CUqO5pD0RTSP-w_32_6">12,712</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc__-hQD-kbKUKST433ykfKeQ_33_3">17,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2018_2BE4yI-8FUy-wuebFU1qwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_N0yQOpNBCk-KGqFIeK-zdg_33_6">37,808</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gT_XeOYvnUObnO8dPwZwWA_34_3">4,843</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_C5l1J4pg3USXg21aIhxnHA_34_6">25,096</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_3gJY0Bu27EO_L7sKqWDh2Q_1_2"></a><a id="Tc_MZO6xR0wPkiF9wlD0YRIzA_2_2"></a><a id="Tc_Ehwvy4oRvEClifaB-X9WWw_2_5"></a><a id="Tc_SLX8B96GF0WHu5RN5EpLGA_3_0"></a><a id="Tc_f_bA5PryHEaQ_Ju0xlF_Jg_4_0"></a><a id="Tc_OyXtjbK69Uy-cnGBozMQAQ_4_2"></a><a id="Tc_nhAGsRK6zUaaNTXvPrHV0w_4_5"></a><a id="Tc_daVVyaS2tUGarMSJefGBfA_5_0"></a><a id="Tc_5PxyTG5Ay068E7UvEPabOg_5_2"></a><a id="Tc_a7py6pq4eUCsiqmyVXDAKg_6_0"></a><a id="Tc_bJBGBRUIjkmV7CTSJc7X8g_6_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_MnHmRvjDh0Sd5er98y0iYQ_4_3">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_HGp_arIGW0q2awzjo8fWdg_4_6">329</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_fs8BfyLriEaEjoHchMH1Bw_5_3">362</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Note receivable from issuance of common stock and warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="-3" format="ixt:numdotdecimal" name="plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_zS5GpQDv5ky064h-c_ETXA_6_3">4,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_yrhMO_LrFEyPapvu5P3OrQ" continuedAt="Tb_yrhMO_LrFEyPapvu5P3OrQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_zk6-HKcyXkGgdP0dT-mliQ" continuedAt="Tb_zk6-HKcyXkGgdP0dT-mliQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Protalix BioTherapeutics,&#160;Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix&#160;Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">OPRX-106, the Company&#8217;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&#8217;s development and commercialization partner (&#8220;Chiesi&#8221;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease under the FDA&#8217;s Accelerated Approval pathway. On July 28, 2020, the FDA informed Chiesi that the BLA had been filed for review and that the FDA was working on the 74-day letter. In addition, the FDA informed Chiesi that no &#8220;Refuse To File&#8221; will be issued for the PRX-102 BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On March 18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_x3F3deHGHUqKzmrxcoI6dA">17,604,423</ix:nonFraction> unregistered shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_6zLx54aA3Eu7TV98_Zk6sA">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), at a purchase price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA" decimals="3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues" scale="0" id="Narr_FM6EtmD9lkK811nEHH8_Ww">2.485</ix:nonFraction> and warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_2fFDA5s3MUSkcTvdFoOEmw">17,604,423</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_dOQ0bAvn-km3qOCqQy-bOA">2.36</ix:nonFraction> per share. The warrants are exercisable commencing <ix:nonNumeric contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA" format="ixt-sec:durwordsen" name="plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" id="Narr_-e5-iVuh9ES5BDDsoq5otg"><span style="white-space:pre-wrap;">six months</span></ix:nonNumeric><span style="white-space:pre-wrap;"> following their issuance for a period of </span><ix:nonNumeric contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_W5fmk2qCMkuxnS0MXVIjgA"><span style="white-space:pre-wrap;">five years</span></ix:nonNumeric><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The net proceeds committed to the Company from the private placement were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_3_18_2020_To_3_18_2020_twsaV_MqKEyUfAkshadSOQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_NyopeK6Wg0-f4LGS2iR-Ig">41.3</ix:nonFraction> million, after deducting advisory fees and other estimated offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">In July 2020, the Company collected total proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_7_1_2020_To_7_31_2020_hPUJj7qNDUCmWCpyRrXLFQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndCollectionOfReceivables" scale="6" id="Narr_YsfEHp7db063bXmJM5CQpw">4.6</ix:nonFraction> million from accounts receivable outstanding at June 30, 2020; approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_7_1_2020_To_7_31_2020_hPUJj7qNDUCmWCpyRrXLFQ" decimals="-5" format="ixt:numdotdecimal" name="plx:TotalProceedsFromAccountsReceivableOutstandingChiesi" scale="6" id="Narr_9F323QsRQEaSNYmDTykneQ">1.6</ix:nonFraction> million in connection with its collaboration with Chiesi and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_7_1_2020_To_7_31_2020_srt_ProductOrServiceAxis_plx_BioManguinhosAlfataligliceraseMember_-6BPcOpQpkGF-ZjY7GtFWA" decimals="-5" format="ixt:numdotdecimal" name="plx:TotalProceedsFromAccountsReceivableOutstandingFiocruz" scale="6" id="Narr_28Jm5uZBBkSGpvYqlsmvtQ">3.0</ix:nonFraction> million from sales of BioManguinhos alfataliglicerase to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;).</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yrhMO_LrFEyPapvu5P3OrQ_cont1" continuedAt="Tb_yrhMO_LrFEyPapvu5P3OrQ_cont2"><ix:continuation id="Tb_zk6-HKcyXkGgdP0dT-mliQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&#160;the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_Hww1lG__8keU_ftcNTlqfQ">25.0</ix:nonFraction>&#160;<span style="-sec-ix-hidden:Hidden_1glMU2yQtkCyCKsj6VV7zw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">million</span></span> in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_7vx4TvIuQEaMAfDzR1PAmw">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_Wt6APVWKL06LMai4qWq0mQ">10.0</ix:nonFraction>&#160;million per&#160;year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_VLfEkt_aeUi1jbLCPXZ9Gg">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_iUkPD3sv4kyJXIqXBiifqA">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_33heOCz9Kku3UZySwet47w">7.5</ix:nonFraction>&#160;million per&#160;<span style="white-space:pre-wrap;">year, and to receive  additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_xXRJtjaqI0itpx_7cJMP4g">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GM0kOY_mhEaJYH7pGa-SUg" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_vCa3xoe1CU6Y3v2bviDKPA">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cV4rpMaJSkOSIB3MCn8lXw" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_DOHjea3cFUK1DbcvC7rafA">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Sxo21H1-MUWD7YwWykIU8Q" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_GvZtySasHkipJIHAXgXfZw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_WPrxp0I9xU2_fyXrH5jLVA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_9Rihp4q_wkGGY5JejMCSQA">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#8220;Pfizer Agreement&#8221;). In October&#160;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_7CpUJdJGtEWp1gkOo1-Dkg" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_PH3Rzv_Gg0mLFqo6KblN7g">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_ScJ2WMKRL0mRVJFmBEecwg" continuedAt="Tb_ScJ2WMKRL0mRVJFmBEecwg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&#160;year.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yrhMO_LrFEyPapvu5P3OrQ_cont2" continuedAt="Tb_yrhMO_LrFEyPapvu5P3OrQ_cont3"><ix:continuation id="Tb_ScJ2WMKRL0mRVJFmBEecwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_7cmmcAUhNkSCflGe9zDEtw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The calculation of diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_a6pqRSj9lkuDGUop-GhCOw">7,812,543</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_MGTQypRsiUOR7nHay4lkuw">18,445,764</ix:nonFraction> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the six months ended June 30, 2019 and 2020, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_poagBYGCwkuZFiAnzuTYvQ">7,805,142</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_0x4LkikptkyHioPAsB1pdA">25,997,289</ix:nonFraction> shares of Common Stock for the three months ended June 30, 2019 and 2020, respectively, because their effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#8217;s reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_aWG3j73WyUuWsRh-fIJdNA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one</span></span>-for-ten, effective as of December 19, 2019.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_9TNA6kp_T0W8_0pU_UuFGg" continuedAt="Tb_9TNA6kp_T0W8_0pU_UuFGg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2) the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yrhMO_LrFEyPapvu5P3OrQ_cont3"><ix:continuation id="Tb_9TNA6kp_T0W8_0pU_UuFGg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_ZA-J0t5TB0-gl3sM848Cag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">e.</b><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_5b31fb9c_2090_4681_83b1_6f700ccf3b30"></a><a id="Tc_fyIDq9gE2kyNFFNbnB0sig_1_2"></a><a id="Tc_uVxww47810qW8I5JW928sA_1_5"></a><a id="Tc_13ia4leH4UerU7XYEzpauw_2_0"></a><a id="Tc_OwFd4PQH80m-1iJo-h0OKA_2_2"></a><a id="Tc_imtDaRUziUOQRFgxv9jx8w_2_5"></a><a id="Tc_BEo4EagkrUKcKA9RC5G2tA_3_0"></a><a id="Tc_jCXDz5GJIUS4Ih_7GLmlAQ_3_2"></a><a id="Tc_iq7RDLM7TUCRGOhOUHmBuw_3_5"></a><a id="Tc_yLVxpMtkF0u9dI8w7Lp1OA_4_0"></a><a id="Tc_wzHtLt1A3US2hnieHj-cmA_5_0"></a><a id="Tc_TUkj-jIEWUinteu1bkJslA_6_0"></a><a id="Tc_d3lqitv7dUyOyW82cdQToQ_6_2"></a><a id="Tc_2yVvbyvsI063AJvknlJI7A_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_JOZuFmGdxkyQTDpWJ1NC6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_82QTYnFHsUG-9knzOPy7kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Inventories at June 30, 2020 and December&#160;31, 2019 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_-2lRnp42nU6F3wE3MX2S3Q_3_3">3,902</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_L2pko-4eQU-JOT2_PyWP8Q_3_6">3,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_lqW08dZew0ycVyGtpTpOzA_4_3">560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_yNiDTfxuK0S5EHvzdxYPLg_4_6">552</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_hek_wMxb7k-7898tCy4qiw_5_3">6,603</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_ecGbIEPNs0OiPQAUoelcHg_5_6">3,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_9QXdcoXSVUmaDebvg2K8Mw_6_3">11,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_IJFOCpssuESi401n3fLDTQ_6_6">8,155</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_jMiD2EFpnUaWVJtwnnBzCA" continuedAt="Tb_jMiD2EFpnUaWVJtwnnBzCA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d002d227_bf39_47c7_97b0_43f3ca0805ef"></a><a id="Tc__UPM6sZn6kG5Us1_i7kdWQ_1_2"></a><a id="Tc_3YFIEujafUS8KyHhJWftWQ_2_0"></a><a id="Tc_cgdU_e69PkqDhvKOhkJx-A_3_0"></a><a id="Tc_kXGI3vglSUa_Y69uBp_f7g_4_0"></a><a id="Tc_6puQurkhzUuhKUF6NPbT5g_4_3"></a><a id="Tc_RlxqsXdnSEWSl1Qj8cueZg_5_0"></a><a id="Tc_78xg5W1RXUOc6GA2RIAGow_5_3"></a><a id="Tc_mj97pw5yx061o4ZPvKwMrQ_6_0"></a><a id="Tc_E8shvVMWaUu9OzJE4Uw-Og_6_3"></a><ix:continuation id="Tb_jMiD2EFpnUaWVJtwnnBzCA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">As of June 30, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_R_GVwE60AEeYABBHU95XbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_JvxT1sySYEGghxr7IaKFNA">57.9</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_-Vqrm9TF40e2UHLfW2k7NA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_vcbdxbT0EUaT2nbQZLkNYQ">7.50</ix:nonFraction>% convertible promissory notes due November 2021 (the &#8220;2021 Notes&#8221;) as of June 30, 2020 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_R_GVwE60AEeYABBHU95XbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_WvBLZQZDIkak4YDtclE9Ew">62.2</ix:nonFraction>&#160;million based on a Level 3 measurement.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_pL8I8jq_hEi_gqPwIAohXw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_IoYL9kE8vE2Y7zrvXaK01w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June 30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Joi_qhyS7EefeW8MDTljgw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_QOGcGRlKmkitBcJ7rDPgeg_2_2">3.79</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg" format="ixt-sec:duryear" name="plx:FairValueAssumptionsTerm" id="Tc_XtrCszAw-UqzXrAl4lRgXQ_3_2"> 1.38</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg" decimals="4" format="ixt:numdotdecimal" name="plx:FairValueAssumptionsRiskFreeInterestRates" scale="-2" id="Tc_YDl92K5T9kaRI_bFeHJlvQ_4_2">0.16</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg" decimals="4" format="ixt:numdotdecimal" name="plx:FairValueAssumptionsExpectedVolatilityRates" scale="-2" id="Tc_YnOcKylfAEqvuizGpIW-9w_5_2">107.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg" decimals="4" format="ixt:numdotdecimal" name="plx:FairValueAssumptionsExpectedDividendRates" scale="-2" id="Tc_500Mv8Jx-ky4kEFSgmnYDQ_6_2">12.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_37bdf232_f28d_4755_b2b5_4a1dbd36dd54"></a><a id="Tc_qmc7caIVlEy1ZSZBbCKTSg_1_2"></a><a id="Tc_YPJwjwNjD0C95Gg1alsHxA_2_0"></a><a id="Tc_8CXLJG2_AEC0uZVVMK4D1A_2_2"></a><a id="Tc_LmMH0CFbJEGuSoxUf0ynwA_2_5"></a><a id="Tc_v1pCHzmJdU6e2hbOGY6BHg_3_0"></a><a id="Tc_K-QJBUg_50KxAL_9lyQ59w_3_2"></a><a id="Tc_G-F8GcpaGES-JYYk0XjFcA_3_5"></a><a id="Tc_EQHZVmHNR0ivRyWPF-AJ5A_4_0"></a><a id="Tc_pR4ag-M5Xkm_rUvzYKxyAw_4_2"></a><a id="Tc_asvF2yCznUOJRK7ewXERkg_4_5"></a><a id="Tc_EUjplw4ElEy_Rf6gXx5tGA_5_0"></a><a id="Tc_9Jx4J_lIDEyZdlfdz8ToUA_5_2"></a><a id="Tc_QkKLzPZ6BEegEphBOjPGQw_5_5"></a><a id="Tc_n3ecwtnph0ar5qBBNtgLew_6_0"></a><a id="Tc_vuxL3A4PVUaqyXpi5I5uEA_6_2"></a><a id="Tc_Hm0OX0V1wkeEjvP6IeceTg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="plx:RevenueDisclosureTextBlock" id="Tb_VdPnePiut0azwhOTtEdG8w" continuedAt="Tb_VdPnePiut0azwhOTtEdG8w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="plx:SupplementaryIncomeStatementInformationTableTextBlock" id="Tb__R5cjI0fTUOQ02GwdQnpvw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_plx_PfizerMember_MzTzy7EFIEmRNIq4UP5v3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_oVqk338hA0KBtLJtmzoF4Q_3_3">2,679</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_plx_PfizerMember_w1KRKtpN60Coy6CM1mW_ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_1TMfvn_JDEq-Wmd00iW3mg_3_6">2,735</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_country_BR_TrfPY3So-kuw0KkLJAQz4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_g4MqE1y02ECQdsGhbdxQyw_4_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_country_BR_yD1PqwkIzUCdzznvt7waSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_psqc0bd1iUaE8WrUclMtxQ_4_6">4,225</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_yM7VN6n3HEqpoGO7RPojOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bO44unSX6kmWi-_K4bFS4w_5_3">8,679</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_mjHtdYriEEG-CXeWej1g7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6o3dcnZpN02rrXi62ycaxQ_5_6">6,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_b4IHEMa-EkOw9g0xX9vuVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_eNdTzr3Y-UCaAcuv9UKIhQ_6_3">23,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CnxupLEavEiCHMgWdkLIPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_TnUCritni0Kkhomi17Pf6Q_6_6">15,726</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_VdPnePiut0azwhOTtEdG8w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">During the six months ended June 30, 2020, the Company recorded revenue in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RbVve-0-m0yDA75z_FJzKw" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInEstimateOfTotalCostsExpectedToBeIncurred" scale="6" id="Narr_zZrzFtov30iybxPtwKPFJA">6.7</ix:nonFraction> million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On March 16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) to evaluate the production of a novel complex protein utilizing ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, the Company&#8217;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="Duration_3_16_2020_To_3_16_2020_oczPe0ei5ku15xZwnsPhTQ" decimals="-5" format="ixt:numdotdecimal" name="plx:NonRefundablePayment" scale="6" id="Narr_H-7Wvbn2tUuHa0dRx8bA2g">1.0</ix:nonFraction> million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_a8t9JYdSIEWR3SoTtSCAYg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On June 17, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr__c6YMLwRVU-d3r21YwLmew">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_eWvZzfcB90yR9VEImfcXig">196,995</ix:nonFraction> shares of Common Stock to the Company&#8217;s Sr. Vice President and Chief Development Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_mC4FH-KumEyvo2MsZfKf6w">3.59</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uWSrdCLBrUaAShjPco6ZJA">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_FEm2AzXTREuT3fVspTit-w">16</ix:nonFraction> equal quarterly increments. Vesting of the options granted to the Sr. Vice President and Chief Development Officer are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President and Chief Development Officer to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_cPupUzcWHEC0NJnIRA4t7g">0.5</ix:nonFraction> million based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_QV6Qrw8k9EudKYwFX7sP2A">3.59</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_N-VRNeK28Uuzy9SWI84Z4A">0</ix:nonFraction>% for all years; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_0mNT8fMjV0a3g89n2TadfA">80.43</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_fCZHI5xLmkCaRRH2yEs9sw">0.59</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_cPzeGgypskWle0GlzCMNvg">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On June 17, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_dsd66gD5bk6TZV6stjhsrg">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_brz9SFQf_EO_V78osa0FPg">760,311</ix:nonFraction> shares of Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Plan. The options granted have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_rU1LxlxB5EWJZfedJxX5Gw">3.66</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_kehIwRs3EUiX7uI5fTBJNQ">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_3IvkRzgK3EKBna7rzzcUsA">16</ix:nonFraction> equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_aNRIAdljqU2znHzOXHqvAQ">1.9</ix:nonFraction> million based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_LhOgxXeqZUGtvZK6wrj7aQ">3.66</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_9CgSoOQgiUSfgJSlIEGYsw">0</ix:nonFraction>% for all years; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_xsWFaRsX1kiQvWG6avCZhg">80.49</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_hrIGzFrImEmxZyh2by8taQ">0.45</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_4vS6TTljGEa9PllyEveycQ">six years</ix:nonNumeric>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_ey-Fhz3sOkiXLWa270xwLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July 5, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_9TudnAcswkuevEObysHXhQ">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_1YIw3wS2t0u20xbeF6_Exg">129,771</ix:nonFraction> shares of Common Stock to the Company&#8217;s new Vice President, Research and Development under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_gpcAcjjO7UKz3rwKCFUq5w">3.73</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_-e5WpTQo9UGnVV8vh9SIWw">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_IVGvtkUWBUaKkUd5KdR4KQ">16</ix:nonFraction> equal quarterly increments. Vesting of the options granted to the Vice President, Research and Development is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg" contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_Efa-smEr0UOlmwTcK36ZgA">329,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA" contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_5bBYTTIWRE6BXAsxd6hd1w">3.73</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_8QPUgARR0kOSia7npedpLA">0</ix:nonFraction>% for all years; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_lRDnD4b6N0WeotpJ6bQryw">80.60</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_CA1FJJG8z0OqY72CpudFuA">0.395</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_0i2sP1AnyUe2txsYbn7nKg">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In accordance with ASC 855 &#8220;Subsequent Events&#8221; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_01bf7475_0f8a_409d_b931_f35f29e5e711"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2019. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors including those set forth under &#8220;Risk Factors&#8221; in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2019, and in our Quarterly Report on Form</i>&#160;<i style="font-style:italic;">10-Q for the quarter ended March</i>&#160;<i style="font-style:italic;">31, 2020.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the risk that the FDA will not accept our application for Accelerated Approval of PRX-102 with the data generated to date or will request additional data or other conditions of the submission, or that the FDA, the European Medicines Agency, or the EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient funding to finance our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks relating to our evaluation and pursuit of strategic alternatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks related to our ability to regain compliance with the continued listing standards of the NYSE American LLC, or the NYSE American, or to otherwise maintain compliance with its continued listing standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks relating to our ability to manage our relationship with our collaborators, distributors or partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks relating to our ability to make required payments under our outstanding convertible notes or any other indebtedness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks relating to the compliance by Fiocruz, an arm of the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks relating to our ability to execute a license agreement with SarcoMed USA Inc., or SarcoMed, with terms and conditions acceptable to us, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our dependence on performance by third-party providers of services and supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the impact of development of competing therapies and/or technologies by other companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks related to our supply of drug product to Pfizer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks related to our expectations with respect to the potential commercial value of our product and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">potential product liability risks, and risks of securing adequate levels of related insurance coverage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On June&#160;8, 2020, we announced the appointment of Yael Hayon, Ph.D. to serve as our new Vice President, Research and Development, effective July&#160;5, 2020. Yoseph Shaaltiel, Ph.D. retired from his position as our Executive Vice President, Research and Development, effective June&#160;15, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On June&#160;8, 2020, we announced the promotion of Einat Brill Almon, Ph.D. to Sr. Vice President and Chief Development Officer. Dr. Almon first joined Protalix Ltd. in December 2004, originally as a Senior Director and later as Vice President, and became our Senior Vice President, Product Development in 2006.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On July 23, 2020, we announced that we had entered into a non-binding term sheet with SarcoMed. The arrangement, if consummated, would relate to the development and commercialization of PRX-110 for the treatment of Pulmonary Sarcoidosis and related diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On July 28, 2020, the FDA informed Chiesi that the BLA for PRX-102 for the treatment of adult patients with Fabry disease that had been submitted on May 27, 2020 had been filed for review and that the FDA was working on the 74-day letter. In addition, the FDA informed Chiesi that no &#8220;Refuse To File&#8221; will be issued for the PRX-102 BLA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we disclosed last quarter, we continue to actively advance all our clinical programs. We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, our clinical trials have not been materially adversely affected by COVID-19. In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March 18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make further adjustments in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In response to the spread of COVID-19, and with local directives issued in response thereof, we restructured the work day within our facilities to consist of two shifts thereby reducing the number of employees present in the facilities at any time and facilitating their ability to practice social distancing. Employees that were able to work from home were instructed to do so. Such efforts resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:271.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2020, after local directives allowed more flexibility with respect to social interactions, we returned to a regular work day. However, as the pandemic&#8217;s effect locally has continued to change, and local Israeli directives have evolved to address the changing effects, we have decided to restore the two-shift work day schedule and to again encourage employees that are able to work from home to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic on our business and our clinical trials as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our trials, expected timelines and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell cultures in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; the potential for oral delivery of proteins; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages Versus Mammalian Cell Production</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="plx-20200630x10q005.jpg" alt="Graphic" style="display:inline-block;height:271.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:540pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:363.3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20200630x10q006.jpg" alt="Graphic" style="display:inline-block;height:363.3pt;width:540pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-102 is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein under development for the treatment of Fabry disease. Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack the lysosomal enzyme, &#945;-galactosidase-A leading to the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>) in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time and, as a result, Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> accumulates, primarily in the blood and in the blood vessel walls. The accumulation leads to a narrowing of the blood vessels, which in turn leads to decreased blood flow and tissue nourishment. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease was approximately $1.7&#160;billion in 2019 (Global Data) and continues to grow at a CAGR of approximately 10% (Data Bridge Market Research).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On May 28, 2020, we, together with Chiesi, announced the submission on May 27, 2020 of a BLA to the FDA for PRX-102 for the treatment of adult patients with Fabry disease under the FDA&#8217;s Accelerated Approval pathway. The BLA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study succeeding the phase I/II clinical trial, interim clinical data from our <i style="font-style:italic;">BRIDGE </i>Study and safety data from our on-going clinical studies of PRX-102, including extension studies. On July 28, 2020, the FDA informed Chiesi that the BLA had been filed for review and that it was working on the 74-day letter. In addition, the FDA informed Chiesi that no &#8220;Refuse to File&#8221; will be issued for the BLA. Upon the BLA approval, if approved, we will be eligible to receive a milestone payment from Chiesi.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2017, the European Commission granted Orphan Drug Designation for PRX-102 for the treatment of Fabry disease. Orphan Drug Designation for PRX-102 qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time PRX-102 is approved for marketing in the European Union, if at all, we expect that PRX-102 will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January 2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our phase&#160;III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> Studies. In 2015, we completed a phase&#160;I/II clinical trial of PRX-102. Patients that completed the phase&#160;I/II clinical trial were offered the opportunity to continue PRX-102 treatment as part of a long-term extension study. In the phase III clinical program, we are studying two alternative dosing regimens for PRX-102; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of Fabry patients. Enrolment has been completed in each of the <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIGHT</i> Studies. Topline results from the <i style="font-style:italic;">BRIDGE</i> study were released in May 2020. The last patient/last visit in the <i style="font-style:italic;">BRIGHT</i> study was in July 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BALANCE </i>Study, is a 24-month, randomized, double blind, active control study of PRX-102 in Fabry patients with impaired renal function. We have completed enrollment of 78 patients in the trial, which is designed to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) on renal function in Fabry patients with progressing kidney disease previously treated with Fabrazyme infused once every two weeks. Patients previously treated with Fabrazyme for approximately one year and on a stable dose for at least six months were screened and then randomized on a 2:1 ratio to 1&#160;mg/kg of PRX-102 or 1&#160;mg/kg of Fabrazyme. Randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &lt;&#160;or&#160;&#8805;&#160;1&#160;g/g by spot urine sample. The study was designed such that no more than 50% of the patients enrolled in the study would be female. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The primary endpoint for the <i style="font-style:italic;">BALANCE </i>Study is the comparison in the annualized rate of decline of eGFR slope between Fabrazyme and PRX-102. eGFR is considered a clinically valuable, reliable and accepted test to measure the level of kidney function and stage of kidney disease. Additional parameters being evaluated include: cardiac assessment, lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>(a biomarker for monitoring Fabry patients status), pain, quality of life, immunogenicity, Fabry clinical events, pharmacokinetics and other parameters. The study also evaluates the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We intend to conduct an interim analysis when the last enrolled patient reaches 12 months of treatment to test for non-inferiority to support anticipated regulatory filings with the EMA. Notwithstanding the interim analysis, patients enrolled in the <i style="font-style:italic;">BALANCE</i> Study will continue to be treated for a total of 24 months, at which point the data will be analyzed to test for superiority in a final analysis of the study data. This final analysis will be used to support converting the accelerated approval into a traditional approval, if the May 2020 PRX-102 BLA submission results in an approval from the FDA under the Accelerated Approval pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> Study is an open label, switch-over study designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 infused every two weeks, in up to 22 Fabry patients. The trial, which has been completed, enrolled patients previously treated with agalsidase alfa (Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) for at least two years and on a stable dose for at least six months. Patients were screened and evaluated over three months while continuing Replagal treatment. Following the screening period, each patient was enrolled and switched from Replagal treatment to receive intravenous (IV) infusions of PRX-102 1&#160;mg/kg every two weeks for 12 months. Topline results from the study were released in May 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Topline results of the data generated in the <i style="font-style:italic;">BRIDGE</i> Study showed significant improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate (eGFR slope) and an amelioration of the course of disease in both male and female patients who were switched from Replagal to PRX-102. Consistent with previously announced interim data, PRX-102 was found to be well tolerated, with all adverse events being transient in nature without sequelae. Twenty-two patients were enrolled in the study; two of those patients withdrew early from the study due to hypersensitivity reaction, and 20 of the patients successfully completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on Replagal to -1.16 mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.67&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from 5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to 0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Baseline characteristics of the patients, ranging from ages 24 to 60 years, were as follows: mean eGFR 75.87 in males and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females; mean residual leucocytes enzymatic activity was 4.8% of lab normal mean in males and 27.9% in females; and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> mean levels were 49.7&#160;nM and 13.8&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Data from the interim analysis of the <i style="font-style:italic;">BRIDGE</i> Study was included in the PRX-102 BLA submission to the FDA under the Accelerated Approval pathway, and we anticipate that the final analysis will be used to support a Marketing Authorization Application (MAA) with the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The phase&#160;III <i style="font-style:italic;">BRIGHT</i> clinical trial of PRX-102 for the treatment of Fabry disease, or the<i style="font-style:italic;"> BRIGHT</i> Study, which was completed in July 2020, is a 12-month, open-label switch-over study designed to assess the safety, efficacy and pharmacokinetics (PK) of PRX-102 via intravenous (IV) infusions of 2&#160;mg/kg administered every 4 weeks in up to 30 patients with Fabry disease, previously treated with an ERT (Fabrazyme or Replagal). The rationale for this open-label switch-over study is based on the enhanced pharmacokinetic (PK) profile of PRX-102. Phase 1/2 study measurements and PK projection modelling data suggest that PRX-102 2.0&#160;mg/kg every 4&#160;weeks may be beneficial in patients with mild to moderate Fabry disease. This treatment dose and regimen is aimed to serve as a maintenance program for Fabry patients without severe clinical symptoms and with relatively slow disease progression, with the potential to delay the risk of developing disease complications. To determine eligibility for participation in the study<i style="font-style:italic;">,</i> candidates were screened to identify and select Fabry patients without severe clinical symptoms and with relatively slow disease progression whom, according to the evaluation of the treating physician, were candidates for the new regimen. Patients who matched the criteria were enrolled in the study and switched from their current treatment of intravenous (IV) infusions every 2&#160;weeks to 2&#160;mg/kg of PRX-102 every 4&#160;weeks for 12&#160;months. Enrollment in the <i style="font-style:italic;">BRIGHT</i> study was completed in June 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patients participating in the study are evaluated for various disease-related clinical symptoms and biomarkers, including their kidney disease rate of deterioration, while being treated with the 4-week dosing regimen as measured by eGFR. In addition, participating patients are evaluated to assess the safety and tolerability of PRX-102. This study analysis is descriptive in nature. In February 2019, we announced preliminary PK data from the <i style="font-style:italic;">BRIGHT</i> study. The results demonstrate that PRX-102 was present and remained active in the plasma over the 4-week infusion intervals. The mean concentration of PRX-102 at day 28 was 138&#160;ng/mL. In comparison, published data on Fabrazyme (1&#160;mg/kg every 2 weeks) shows a mean concentration of 20&#160;ng/mL at 10 hours post infusion. In addition, the area under the curve (AUC) for PRX-102 was measured to be approximately 2,000,000&#160;ng&#160;hr/mL over 28 days. Based on published data, the AUC of Fabrazyme is approximately 10,000&#160;ng&#160;hr/mL. A preliminary safety analysis of 19 patients enrolled in the <i style="font-style:italic;">BRIGHT</i> study was also conducted, and indicated that PRX-102 is well tolerated. To date, substantially all of the patients who completed the study opted, with the advice of the treating physician, to continue treatment under the 4-week dosing regimen in a long-term extension study. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase III clinical trials of PRX-102 as many of the patients were already treated in home care settings. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our clinical development activities for PRX-102 were initiated with a phase I/II clinical trial; a worldwide, multi-center, first-in-human, open-label, dose-ranging study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and efficacy parameters of PRX-102 administered by IV infusion every other week for 12 weeks to adult na&#239;ve symptomatic Fabry disease patients. Baseline values for renal Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions assessed by Barisoni lipid inclusion scoring system (BLISS), plasma Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> and supportive clinical data were collected at the start of treatment. The phase&#160;I/II clinical trial was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received intravenous (IV) infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, up to 60-month extension study under which all patients receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE </i>Study and <i style="font-style:italic;">BRIDGE</i> Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805; 50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Data was recorded at 24 months from 11 patients who completed 12 months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who could not continue to participate in a clinical study due to personal reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Results have shown that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGRF levels of 108.02 and 107.20 at baseline and 24 months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index (MSSI), a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed anti-drug antibodies (ADA), of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45.0&#160;million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15% - 35% (ex-US) and 15% - 40% (US).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;23, 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Gaucher disease is a $1.5&#160;billion global annual therapeutic market that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs. We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain distribution rights to Elelyso in Brazil (marketed as alfataliglicerase) through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH. In 2019, we generated $9.1&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Tulinercept (OPRX-106)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Tulinercept is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc), for inhibiting TNF alpha. It is in development for oral administration. When administered orally and while passing through the digestive tract, the plant cells function as a natural delivery vehicle, having the unique attribute of a cellulose cell wall, which makes them resistant to degradation compared to proteins produced via mammalian cell expression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Through oral administration, tulinercept is designed to work locally in the gut, thereby avoiding the systemic exposure that occurs when TNF alpha inhibitors are administered by injection or intravenous infusion. Oral administration may potentially lead to a safer to use anti-TNF and may potentially reduce the safety concerns associated with currently approved therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">OPRX-106 may also be less immunogenic which can potentially result in longer-term efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our oral delivery mechanism can potentially prove to be a safer and more convenient method of protein administration and could be applied to additional proteins in certain indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Alidornase alfa is our proprietary chemically-modified plant cell-expressed recombinant form of human deoxyribonuclease I (DNase I), administered through inhalation. In cystic fibrosis (CF) patients, the accumulation of thick sputum in the lungs exposes them to recurrent infections and compromises lung function. DNase I therapy, or dornase alfa, is generally recommended for CF&#160;patients as a mucus thinning agent (mucolytic) to help with clearance from the airways to improve lung function and reduce exacerbations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">However, DNase I activity is compromised by actin, a globular multi-functional protein, found in high concentration in the sputum of CF patients, that is a potent inhibitor of DNase I. As such, we believe that actin may decrease the enzyme&#8217;s DNA degradation activity and potentially interfere with the effectiveness of inhaled DNase I in the lungs of CF&#160;patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to reduce the actin-DNase I interaction and the subsequent inhibition of DNase I activity by actin, we developed alidornase alfa by chemically modifying the enzyme forming an actin inhibition resistant DNase I. This novel treatment candidate may result in improved lung function and decreased incidence of recurrent infections in patients. Thus, we believe there is the potential that our form of the enzyme will demonstrate significantly enhanced efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 23, 2020, we announced that we had entered into a non-binding term sheet with SarcoMed. The arrangement, if consummated, would relate to the development and commercialization of alidornase alfa for the treatment of Pulmonary Sarcoidosis and related diseases. On July 21, 2020, the FDA granted Orphan Drug Designation for alidornase alfa for the treatment of Sarcoidosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-115</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout. The Uricase enzyme converts uric acid to allantoin, which is easily eliminated through urine. We use our proprietary plant-based system to express an optimized recombinant enzyme under development for the potential treatment of Gout which is designed to have an improved half-life, reduced immunogenicity and better efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of June&#160;30, 2020, we hold a broad portfolio of over 85 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 40 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development. As disclosed above, we have entered into a non-binding term sheet with SarcoMed. The arrangement, if consummated, would relate to the development and commercialization of alidornase alfa for the treatment of Pulmonary Sarcoidosis and related diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended June</span>&#160;<span style="font-style:italic;font-weight:bold;">30, 2020 compared to the three months ended June</span>&#160;<span style="font-style:italic;font-weight:bold;">30, 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded revenues from selling goods of $3.6&#160;million during the three months ended June&#160;30, 2020, an increase of $0.2&#160;million, or 6%, compared to revenues of $3.4&#160;million for the three months ended June&#160;30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded revenues from license and R&amp;D services of $7.3&#160;million for the three months ended June&#160;30, 2020, a decrease of $1.5&#160;million, or 17%, compared to revenues of $8.8&#160;million for the three months ended June&#160;30, 2019. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The decrease is primarily due to the completion of two out of the three phase III clinical trials of PRX-102 as well as lower costs related to the <i style="font-style:italic;">BALANCE</i> Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold was $1.8&#160;million for the three months ended June&#160;30, 2020, a decrease of $0.9&#160;million, or 32%, from cost of goods sold of $2.7&#160;million for the three months ended June&#160;30, 2019. The decrease is primarily due to a change in the cost structure as well as lower royalties paid to the Israeli Innovation Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $9.2&#160;million for the three months ended June&#160;30, 2020, a decrease of $4.1&#160;million, or 31%, compared to $13.3&#160;million of research and development expenses for the three months ended June&#160;30, 2019. The decrease is primarily due to the completion of two out of the three phase III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> Study as well as a decrease in costs related to manufacturing of our drug in development as some of the manufactured drug product and related costs have been recorded as inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative expenses were $2.2 million for the three months ended June 30, 2020, an increase of $0.1 million, or 6%, compared to $2.1 million for the three months ended June 30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial expenses net were $1.9 million for the three months ended June 30, 2020 and for the three months ended June 30, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Six months ended June 30, 2020 compared to the six months ended June 30, 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded revenues from selling goods of $8.7 million during the six months ended June 30, 2020, an increase of $1.7 million, or 25%, compared to revenues of $7.0 million for the six months ended June 30, 2019. The increase resulted primarily from an increase of $1.8 million in sales of drug product to Brazil, which was partially offset by a decrease of $0.1 million in sales of drug substance to Pfizer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded revenues from license and R&amp;D services of $23.9 million for the six months ended June 30, 2020, an increase of $8.2 million, or 52%, compared to revenues of $15.7 million for the six months ended June 30, 2019. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The increase is primarily due to revenues recognized in connection with an updated costs estimation throughout the trials until completion in the amount of $6.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold was $5.3 million for the six months ended June 30, 2020, an increase of $0.6 million, or 11%, from cost of goods sold of $4.7 million for the six months ended June 30, 2019. The increase is primarily due to an increase in sales of goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $19.5 million for the six months ended June 30, 2020, a decrease of $5.5 million, or 22%, compared to $25 million of research and development expenses for the six months ended June 30, 2019. The decrease is primarily due to the completion of two out of the three phase III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> Study as well as a decrease in costs related to manufacturing of our drug in development as some of the manufactured drug product and related costs have been recorded as inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative expenses were $5.4 million for the six months ended June 30, 2020, an increase of $1.1 million, or 25%, compared to $4.3 million for the six months ended June 30, 2019. The increase resulted primarily from a $0.8 million increase in compensation related costs and a $0.3 million increase in professional fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial expenses net were $4.9 million for the six months ended June 30, 2020, an increase of $1.3 million, or 36%, compared to financial expenses net of $3.6 million for the six months ended June 30, 2019. The increase resulted primarily from expenses related to our outstanding convertible notes equal to $1.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our sources of liquidity include our cash balances. At June 30, 2020, we had $4.8 million in cash and cash equivalents and $35.2 million in bank deposits (both short and long term). We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2020, we completed a private placement of common stock and warrants with committed net proceeds of approximately $41.3 million. In connection with the offering, we issued 17,604,423 unregistered shares of our common stock at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of common stock at an exercise price of $2.36 per share.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operations was $15.0 million for the six months ended June 30, 2020. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the six months ended June 30, 2020 of $2.5 million was increased by a $10.8 million decrease in contracts liability, a $1.6 million increase in accounts receivable and other assets and a $2.9 million increase in inventories, partially offset by an increase of $0.3 million in accounts payable and accruals, and $1.7 million amortization of debt issuance costs and debt discount. Net cash used in investing activities for the six months ended June 30, 2020 was $35.3 million and consisted primarily of an increase in bank deposits. Net cash provided by financing activities was $37.3 million resulting from our issuance of common stock and warrants on March 18, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operations was $12.4 million for the six months ended June 30, 2019. The net loss for the six months ended June 30, 2019 of $15 million was increased by a $2.8 million increase in accounts receivable, but was partially offset by an increase of $1.5 million in accounts payable and accruals and by a decrease in inventories of $1.6 million. Net cash used in investing activities for the six months ended June 30, 2019 was $0.5 million and consisted primarily of purchases of property and equipment, and an increase in restricted deposit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Future Funding Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. We currently have outstanding $57.9&#160;million aggregate principal amount of our 2021 Notes that are secured with a perfected lien on all of our assets. Under the terms of the indenture governing the 2021 Notes, we are required to maintain a minimum cash balance of at least $7.5<span style="font-family:'28mugxoulnobhnx';">&#160;</span>million. As previously disclosed, we have received a deficiency letter from the NYSE American stating that we are not in compliance with the continued listing standards as set forth in Section 1003(a)(i) <span style="font-family:'28mugxoulnobhnx';">&#8211;</span> (iii) of the NYSE American Company Guide as we have reported a stockholders<span style="font-family:'28mugxoulnobhnx';">&#8217;</span> equity deficiency as of June<span style="font-family:'28mugxoulnobhnx';">&#160;</span>30, 2019 and net losses in our five most recent fiscal years ended December<span style="font-family:'28mugxoulnobhnx';">&#160;</span>31, 2018. The letter has no immediate effect on the listing of our common stock on the NYSE American. Our common stock will trade on the NYSE American while we regain compliance with the continued listing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant expenditures in the near future, including significant research and development expenses related primarily to the clinical trials of PRX-102. Our material cash needs for the next 24 months will include, among other expenses, (i) costs of preclinical and clinical trials, (ii) employee salaries, (iii) payments for rent and operation of our manufacturing facilities, (iv) fees to our consultants and legal advisors, patents and fees for service providers in connection with our research and development efforts and (v) payment of principal and interest on our outstanding convertible promissory notes and other debt. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12 months from the date that the financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be required to raise additional capital in the future in order to develop and commercialize our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to maintain the listing of our common stock with the NYSE American;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our efforts, combined with those of Chiesi, to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of commercialization activities, including product marketing, sales and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress and results of our clinical trials, particularly our clinical trials of PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">conversions of our 2021 Notes from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing and outcome of regulatory review of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. Currently, we do not expect the COVID-19 pandemic to have an adverse effect on our ability to raise capital if and to the extent we deem necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the six months ended June&#160;30, 2020 and June&#160;30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of June&#160;30, 2020 and June&#160;30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3e9dee42_0f55_421b_ab67_6501db00f32c"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the dollar. Most of our revenues and approximately 50% of our expenses and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 40% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S. dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.509</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.620</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.565</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.466</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.456</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fc0e321b_cd80_40df_a2cd_cbe62e3d8357"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended June&#160;30, 2020 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0c22db0f_214d_41ab_b347_fa2d5f9ec7c4"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9854dd9c_6a98_4910_9557_1773a225dcf8"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There have been no material changes to the risk factors previously disclosed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 and in our Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a62926db_c20b_432a_9ad1_ac23b7d75e02"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no unregistered sales of equity securities during the three months ended June<b style="font-weight:bold;">&#160;</b>30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cc04a25c_4b1a_4551_891e_89d7b482ec6f"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_08b705b2_1fb4_4d49_bf82_1ed43c4c8401"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_562d3a0e_b25f_4c64_a371_a338f3432e89"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_39255e09_64e2_4a6c_91e8_f4e6945731fe"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:9.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">333-48677</p></td><td style="vertical-align:top;width:9.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December 19, 2019</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.15pt;"><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Indenture, dated as of December&#160;7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Supplemental Indenture, dated as of July</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;25, 2017</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Supplemental Indenture, dated as of November&#160;27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;1, 2017</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="plx-20200630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended &amp; Restated Protalix BioTherapeutics, Inc. 2006 Employee Stock Incentive Plan, as amended</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.2</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920070904/tm2022015d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement with Yael Hayon, Ph.D., dated June&#160;7, 2020</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">10.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">June&#160;7, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.3</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920070904/tm2022015d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Employment Agreement with Einat Brill Almon, Ph.D., dated June&#160;7, 2020</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">10.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">June&#160;7, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="plx-20200630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="plx-20200630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="plx-20200630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a href="plx-20200630xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL INSTANCE FILE</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL SHEMA FILE</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL CALCULATION FILE</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL DEFINITION FILE</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL LABEL FILE</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">XBRL PRESENTATION FILE</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_28e16703_f027_4348_a50a_3961557dad77"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;10, 2020</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;10, 2020</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>plx-20200630xex4d8.htm
<DESCRIPTION>EXHIBIT 4.8
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/10/2020 09:58:41 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit 4.8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(EXECUTIVE OFFICERS)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">This Option Agreement is made as of _______ __, ____ (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), by and between <b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b>, a corporation incorporated under the laws of the State of Delaware (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;), and the following employee of the Corporation (the &#8220;<b style="font-weight:bold;">Optionee</b>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">NAME: </b><br><b style="font-weight:bold;">ID:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WHEREAS, </b>the Corporation maintains the Amended and Restated Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as may be amended from time to time, a copy of which is has been provided to the Optionee with this Agreement and forms an integral part hereof (the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WHEREAS, </b>the Corporation has determined that the Optionee be granted an option under the Plan to purchase shares of the Corporation&#8217;s common stock, par value US$ 0.001 per share (the &#8220;<b style="font-weight:bold;">Shares</b>&#8221;), and the Optionee has agreed to such grant, subject to all the terms and conditions as set forth in the Plan and as provided herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, it is agreed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">PREAMBLE AND DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Preamble to this Agreement constitutes an integral part hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unless otherwise defined herein, capitalized terms used herein shall have the meaning ascribed to them in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">GRANT OF OPTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation hereby grants to the Optionee the number of Options set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> hereto, each Option exercisable into 1 (one) Share, against payment of the Purchase Price specified in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b>, subject to the terms and conditions set forth in the Plan and the terms and conditions set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Optionee is aware that the Corporation intends to issue additional shares and to grant additional Options and other equity awards in the future to various entities and individuals, as the Corporation in its sole discretion shall determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">2.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All Trustee 102 Options will be held in trust by a Trustee appointed by the Corporation in its sole discretion and approved pursuant to Section 102 of the Tax Ordinance and the rules, regulations, orders and procedures promulgated thereunder (&#8220;<b style="font-weight:bold;">Section 102</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">2.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to Trustee 102 Options, the Optionee hereby acknowledges that he/she is familiar with the provisions of Section 102, including without limitation the type of Options granted hereunder and the tax implications applicable to such grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">2.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trustee 102 Options, which shall be granted under the Plan and/or any Shares allocated or issued upon exercise of such Trustee 102 Options and/or other shares received subsequently following any changes in capitalization as specified in Section 10 of the Plan, shall be allocated or issued to the Trustee and held for the benefit of the Optionee for such period of time as required by Section 102 (the &#8220;<b style="font-weight:bold;">Holding Period</b><font style="white-space:pre-wrap;">&#8221;).  If the requirements for Trustee 102 Options are not met for any reason whatsoever, the Trustee 102 Options may be treated as Non-Trustee 102 Options, all in accordance with the provisions of Section 102.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">2.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">With respect to any Trustee 102 Option, subject to the provisions of Section 102, an Optionee shall not sell or release from trust any Trustee 102 Option or Shares received upon the exercise of a Trustee 102 Option and/or any right deriving from or in connection therewith, including, without limitation, in accordance with Section 10 of the Plan or any bonus shares or stock dividends issued in connection therewith, until the later of (i) the lapse of the Holding Period required under Section 102, and (ii) the Vesting Dates pursuant hereto and provided further that the Optionee has deposited with the Trustee the funds which, in the Trustee&#8217;s discretion, is sufficient and necessary for the discharge of such Optionee&#8217;s tax obligations with respect to such Options and/or Shares.  Notwithstanding the above, if any such sale or release occurs during the Holding Period, the sanctions under Section 102 shall apply to and any expenses and/or tax consequences therefrom shall be borne solely by the Optionee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">PERIOD OF OPTION; VESTING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">3.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The term of this Option Agreement shall commence on the Date of Grant as set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> hereto and terminate on the earlier of the Expiration Date (as defined in Section 5.1 below), or the time at which the Option expires or terminates pursuant to the terms of the Plan or pursuant to the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">3.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the provisions of the Plan, Options shall vest and become exercisable according to the Vesting Dates set forth in Section 20(d) of the Plan, unless agreed otherwise as set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> (the &#8220;<b style="font-weight:bold;">Vesting Dates</b>&#8221;), subject to Continuous Service of the Optionee on each applicable Vesting Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">METHOD AND CONDITIONS OF EXERCISE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms of the this Agreement, the Plan and the Tax Ordinance, Options may be exercised by the Optionee by giving a written notice to the Corporation, in such form and method as may be determined by the Corporation (the &#8220;<b style="font-weight:bold;">Exercise Notice</b><font style="white-space:pre-wrap;">&#8221;), which exercise shall be effected following receipt of such notice by the Corporation at its principal office, accompanied by payment of the Purchase Price in full in any of the means (or combination of means) allowed pursuant to the Plan.  The notice shall specify the number of Shares with respect to which the Options are being exercised.  In addition to the foregoing, the Corporation may have in place, from time to time, a system whereby the Optionee can exercise his/her Options directly on-line through the Trustee.  In such cases, direct exercise by the Optionee through any such system shall be deemed the delivery of an Exercise Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">4.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Options may be exercised by the Optionee in whole at any time or in part from time to time, prior to the Expiration Date, to the extent that the Options become vested and exercisable in accordance with <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that such exercise is subject to the requirements of Section 102, Sections 4.4, 4.5 and the Optionee&#8217;s Continuous Service at all times during the period beginning on the Date of Grant and ending upon the date of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">4.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The Corporation shall, following receipt of an Exercise Notice, take all reasonably necessary steps to forthwith comply therewith, and issue the Shares to the Trustee to be held by the Trustee in accordance with the provisions of Section 20 of the Plan.  Subject to the terms hereof, the Trustee will transfer the Shares to the Optionee upon demand, but in case of Shares received in connection with the exercise of 102 Options, not prior to the end of the Holding Period, and in any event subject to the provisions of Section 102.  If the Corporation is required to take any action with respect to the Shares before the issuance thereof, the issuance shall be delayed until all actions required have been taken.  The Optionee agrees and acknowledges that the Options and/or Shares will not be transferred and released from the trust without deduction of applicable taxes at source or the deposit with the Trustee of funds which, in the Trustee&#8217;s opinion, are sufficient and necessary for the discharge of the such Optionee&#8217;s tax obligations with respect to the Options and/or Shares, and the Optionee authorizes the Trustee to execute any agreement with the Corporation in connection therewith. The Optionee hereby releases the Corporation and the Trustee from any liability in respect of any action or decision executed in pursuant to the Plan and this Agreement, or any Option or Share granted to him thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">4.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">Subject to the provisions of Section 4.5 below, upon any termination or expiration of Optionee&#8217;s Continuous Service, all Options granted to the Optionee will immediately expire such that the unvested portion of the Options will not vest, and the vested portion of the Options shall no longer be exercisable.  A notice of termination of Continuous Service shall be deemed to constitute termination of employment or service unless such notice specifies a later day on which employment or notice is to terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">4.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein above, an Option may be exercised after the date of termination of Optionee&#8217;s Continuous Service during an additional period of time beyond the date of such termination, but (a) only with respect to the number of Options already vested at the time of such termination according to the Vesting Dates (the &#8220;<b style="font-weight:bold;">Qualified Options</b>&#8221;), and (b) in no event after the Expiration Date of such Option, if: (i) termination is for reason other than Cause, Disability or death, any Qualified Option still in force and unexpired may be exercised within a period of twelve (12) months from the date of such termination; (ii) termination is the result of Disability or death of the Optionee, in which event any Qualified Option still in force and unexpired may be exercised within a period of twelve (12) months from the date of termination; (iii) within a period of twelve (12) months from the date of termination as set forth in Section 6 below; (iv) within fourteen (14) days from the date of termination for Cause; or (v) if prior to the date of such termination, the Administrator has authorized an extension of the terms of all or part of the Options beyond the date of such termination, then for a period not to exceed the period during which the Options by their terms would otherwise have been exercisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">4.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to Non-Trustee 102 Options, if the Optionee ceases to be employed by the Corporation, the Optionee shall extend to the Corporation a security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">4.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No fractional shares shall be issued upon the exercise hereof and any fractional shares, if any, shall be rounded to the lowest whole number.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">TERMINATION OF OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Except as otherwise stated in this Agreement, the Options, to the extent not previously exercised and paid for, shall terminate forthwith upon the earlier of: (i) the expiration date set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> hereto; (ii) the expiration of 10 years from the Date of Grant, and (iii) the expiration of any extended period in any of the events set forth in Section 4.5 above (and any such earlier date shall be referred to as the &#8220;<b style="font-weight:bold;">Expiration Date</b>&#8221;), and the right to acquire the Shares underlying the Options shall terminate, all interests and rights of the Optionee in and to the same shall ipso facto expire, and, in the event that in connection therewith any Options are still held by the Trustee as aforesaid, the trust with respect thereto shall ipso facto expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">CORPORATE TRANSACTIONS AND CHANGE OF CONTROL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Notwithstanding anything herein or in the Plan to the contrary, in the event of a Corporate Transaction or Change in Control, all of the Shares underlying the Options shall vest automatically and immediately.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-2-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">RIGHTS PRIOR TO EXERCISE OF OPTION; LIMITATIONS AFTER PURCHASE OF SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the provisions of Section 7.2 below, the Optionee shall not have any of the rights or privileges of a stockholder of the Corporation in respect of any Shares purchasable upon the exercise of any Option unless and until, following exercise and discharge by the Optionee of all its obligations in connection therewith (including the payment of applicable aggregate Purchase Price for the Shares issued upon exercise of the Options and any applicable taxes), the Optionee is registered as holder of such Shares in the Corporation&#8217;s register of stockholders and in case of Options and Shares held by the Trustee, subject always to the provisions of Section 20 of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Option granted hereunder, whether fully paid or not, may be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Optionee, only by the Optionee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any such action made directly or indirectly, for an immediate validation or for a future one, shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As long as the Shares are held by the Trustee in favor of the Optionee, all rights the latter possesses over the Shares shall be personal, and may not be transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shares issued to the Optionee shall be subject to such restrictions as required by any applicable securities law or the Corporation (including any lock up undertaking).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Until registered in the name of the Optionee, Shares eligible for voting shall be voted by an irrevocable proxy a copy of which is attached hereto as <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</b><font style="white-space:pre-wrap;">.  Those empowered under the Proxy shall be indemnified and held harmless by the Corporation against any cost or expense (including counsel fees) reasonably incurred by him/her, or any liability (including any sum paid in settlement of a claim with the approval of the Corporation) arising out of any act or omission to act in connection with the voting of such proxy unless arising out of such person&#8217;s own fraud, bad faith or gross negligence, to the extent permitted by applicable law.  Such indemnification shall be in addition to any rights of indemnification the person(s) may have as a director, officer or otherwise under the Corporation&#8217;s Certificate of Incorporation, any agreement, any vote of stockholders or directors, insurance policy or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The Optionee acknowledges that its right to sell Shares may be subject to some representations or undertakings on its part as well as other limitations, as set forth by the Corporation or, in the event the Corporation&#8217;s shares are registered for trading in any public market, by the Corporation or its underwriters.  In any such events, the Optionee will unconditionally agree to any such limitations as well as to make such representations, and perform such undertakings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Optionee shall not dispose of any Shares in transactions which violate, in the opinion of the Corporation, any applicable laws, rules and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Optionee agrees that the Corporation shall have the authority to endorse upon the certificate or certificates representing the Shares such legends referring to any applicable representations and undertakings of the Optionee as well as other applicable limitations and restrictions as it may deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">7.10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The Optionee agrees that he or she will not effect any sale or other disposition of Shares underlying the options granted to the Optionee under this Agreement, unless upon such sale or other disposition of Shares and after giving effect to the number of Shares so sold, the Optionee will retain, in the aggregate, a number of shares of common stock of the Corporation, including shares underlying outstanding stock options (provided that, as of the date of such sale, such options have an exercise price that is lower than the market price of the common stock on the date of sale), that have an aggregate market value, based on the market price of the Corporation&#8217;s common stock on the date of sale or other disposition, equal to not less than the annual base salary of the Optionee.  The restrictions set forth in this Section 7.10 shall terminate automatically, and cease to have any force or effect upon the earlier of a Change of Control or a Corporate Transaction, and the eighth anniversary of the Date of Grant.  The restrictions set forth in this Section 7.10 shall also terminate automatically, and cease to have any force or effect upon; if the Optionee ceases to perform Continuous Services.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">SHARES SUBJECT TO PLEDGE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Unless otherwise prohibited by law and notwithstanding anything to the contrary, if at the time at which any of the Options granted hereunder is exercised, Optionee is indebted to the Corporation (or any Related Entity) for any reason, then any Shares to be issued upon such exercise shall automatically be pledged against Optionee&#8217;s outstanding indebtedness, as deemed appropriate by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">GOVERNMENT REGULATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Plan, the grant and exercise of Options hereunder, and the obligation of the Corporation to sell and deliver Shares under such Options, shall be subject to all applicable laws, rules and regulations, whether of the State of Israel or of the United States or any other state having jurisdiction over the Corporation and the Optionee, including without limitation, the U.S. Securities Act of 1933 and the Israeli Securities Law and or any applicable securities law, and to such approvals by any governmental agencies or national securities exchanges as may be required.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-3-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">CONTINUOUS SERVICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="white-space:pre-wrap;">This Agreement, and the grant of Options set forth herein, shall not confer upon the Optionee any right with respect to the Optionee&#8217;s Continuous Service, nor shall it interfere in any way with his or her right or the right of the Corporation or any Related Entity to terminate the Optionee&#8217;s Continuous Service at any time, with or without cause, including but not limited to, Cause, and with or without notice.  The ability of the Corporation or any Related Entity to terminate the employment of the Optionee, who is employed at will, is in no way affected by its determination that the Grantee&#8217;s Continuous Service has been terminated for Cause for the purposes of this Agreement and the grant of Options set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">GOVERNING LAW &amp; JURISDICTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="white-space:pre-wrap;">This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws.  The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to this Agreement and/or the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">TAX CONSEQUENCES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">12.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">To the extent permitted by applicable law, any tax consequences arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act hereunder (whether taken by the Corporation, a Related Entity, the respective affiliates, the Trustee or the Optionee), shall be borne solely by the Optionee.  The Corporation, a Related Entity and/or the Trustee is authorized to withhold taxes according to the requirements under applicable laws, rules, and regulations, including withholding taxes at source.  Furthermore, the Optionee hereby agrees to indemnify the Corporation, any Related Entity and/or the Trustee and hold them harmless against and from any and all liability for or in connection with any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Optionee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">12.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The Optionee will not be entitled to receive from the Corporation, any Related Entity and/or the Trustee nor will the Trustee be required to release any Shares allocated or issued upon the exercise of Options prior to the full payment by the Optionee of the tax liabilities arising from the Options granted to him or her and/or the Shares issuable upon the exercise of such Options.  Neither the Corporation nor the Trustee shall be required to release any share certificate to the Optionee until all payments required to be made by the Optionee, in the Trustee&#8217;s opinion, have been fully satisfied.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">12.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation makes no representations or warranties regarding the tax treatment in connection with any aspect of the grant of any Option hereunder, including the exercise of the Option and the subsequent sale of Shares issued upon such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">12.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The receipt of the Options and the acquisition of the Shares to be issued upon the exercise of the Options may result in tax consequences. THE OPTIONEE IS ADVISED TO CONSULT A TAX ADVISER WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING OR EXERCISING THE OPTIONS OR DISPOSING OF THE SHARES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">DISCRETIONARY GRANT; NO WARRANTY AS TO FINANCIAL GAIN OR LOSS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">13.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The grant of Options under the Plan is made at the discretion of the Administrator.  The grant of an Option at a certain time does not in any way entitle the Optionee to any future Option grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">13.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation makes no express or implied promise or warranty as to the financial gain to be achieved or loss to be incurred through participation in the Plan and grant of Options hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 5pt 0pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">FAILURE TO ENFORCE NOT A WAIVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The failure of any party to enforce at any time any provision of this Agreement shall in no way be construed to be a waiver of such provision or of any other provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 5pt 0pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">PROVISIONS OF THE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">15.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without derogating from Section 15.3 below, the Options provided for herein are granted pursuant to the Plan, and said Options and this Agreement are in all respects governed by and subject to the terms and conditions of the Plan including all obligations on the Optionee, restrictions or limitations set forth therein with respect to the grant of Options or the Optionee&#8217;s eligibility to exercise such Options or receive or sell Shares covered thereby (or any other issue in connection with the foregoing) whether or not such obligations, restrictions or limitations are stipulated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">15.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without derogating from Section 15.3 below, any interpretation of this Agreement will be made in accordance with the Plan and in the event there is any contradiction between the provisions of this Agreement and the Plan, the provisions of the Plan will prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">15.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary (including the provisions of Sections 15.1 and 15.2): (a) <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> to this Agreement and Section 7 hereof will prevail over the terms of the Plan; and (b) any provisions of this Agreement imposing obligations on the Optionee, any restrictions or limitations with respect to the grant of Options hereunder or the Optionee&#8217;s eligibility to exercise such Options or receive or sell Shares covered thereby (or any other issue in connection with the foregoing), beyond the obligations,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:2pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-4-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">restrictions or limitations in connection therewith set forth in the Plan, shall be of full force and effect, be deemed additional to, and not substitutive for, the obligations, restrictions and limitations in connection therewith set forth in the Plan and shall not be derogated thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 8pt 0pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">BINDING EFFECT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">This Agreement shall be binding upon the heirs, executors, administrators, and successors of the parties hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 8pt 0pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">All notices or other communications given or made hereunder shall be in writing and shall be delivered or mailed by registered mail or delivered by facsimile with written confirmation of receipt, to the Optionee at his or her address included in the Corporation&#8217;s records and/or to the Corporation at the address below, or at such other place as the Corporation may designate by written notice to the Optionee:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c/o Protalix Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2 Snunit Street, Science Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">P.O. Box 455</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Carmiel 2161401, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Facsimile: 972-4-9889489<br>Attn: Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The Optionee is responsible for notifying the Corporation in writing of any change in the Optionee&#8217;s address, and the Corporation shall be deemed to have complied with any obligation to provide the Optionee with notice by sending such notice to the address indicated above or such changed address as to which it has been notified as specified herein, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 8pt 0pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">ENTIRE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="white-space:pre-wrap;">This Agreement and the Plan exclusively conclude all the terms of the Optionee&#8217;s Options, and annul and supersede any other agreement, arrangement or understanding, whether oral or in writing, relating to the grant of Options covered by this Agreement to the Optionee.  Any change of any kind to this Agreement will be valid only if made in writing and signed by both the Optionee and the Corporation&#8217;s authorized representative and has received the approval of the Administrator.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Corporation executed this Agreement as of the date first set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">The Optionee acknowledges receipt of a copy of the Plan and the Prospectus and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Agreement and the Plan (and the Prospectus) including all of the terms and provisions thereof.  The Optionee has reviewed the Plan, the Prospectus and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Agreement and the Plan (and the Prospectus).  The Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any question arising under the Plan or this Agreement.  The Optionee further agrees to notify the Corporation upon any change in the residence address indicated above.</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-5-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Terms of the Options</b></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name of the Optionee:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Designation:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">&#8999;</b><b style="font-weight:bold;">Trustee 102 Options (Capital Gains Options) / </b><b style="font-family:'Times New Roman';font-weight:bold;">&#9723;</b><b style="font-weight:bold;">Non-Trustee 102 Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aggregate Number of Options Granted:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date of Grant:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">_______ __, ____</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchase Price per Share:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Dates:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expiration Date:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">_______ __, ____</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;padding:0pt;" align="center"><tr><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NAME</b></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">DATE</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="direction:rtl;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PROXY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="direction:rtl;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">The undersigned hereby grants an irrevocable proxy to the Trustee under the Amended and Restated Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Plan</b><font style="font-size:12pt;">&#8221;), to vote all shares issued upon the exercise of Options by the undersigned at all meetings of the stockholders of Protalix Biotherapeutics, Inc. (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Corporation</b><font style="font-size:12pt;">&#8221;), and to sign all written resolutions of the stockholders of the Corporation on behalf of the undersigned, including the right to waive on behalf of the undersigned all minimum notice requirements for meetings of stockholders of the Corporation, and hereby authorize and grant a power of attorney to the Trustee as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Unless otherwise defined herein, capitalized terms used herein shall have the meaning ascribed to them in the Plan.  The undersigned hereby authorizes and grants power of attorney to the Trustee for as long as any Shares and/or Options which were allotted or granted on my behalf are held by the Trustee or registered in my name, or for as long as the certificates representing any shares are held by the Trustee, to exercise every right, power and authority with respect to the Shares and/or Options and to sign in my name and on my behalf any document (including any agreement, including a merger agreement of the Corporation or an agreement for the purchase or sale of assets or shares (including the shares of the Corporation held on my behalf) and any and all documentation accompanying any such agreements, such as, but not limited to, decisions, requests, instruments, receipts and the like), and any affidavit or approval with respect to the Shares and/or Options or to the rights which they represent in the Corporation in as much as the Trustee shall deem it necessary or desirable to do so.  In addition and without derogating from the generality of the foregoing, I hereby authorize and grant power of attorney to the Trustee to sign any document as aforesaid and any affidavit or approval and/or to make and execute any undertaking in my name and on my behalf if the Trustee shall, at its sole discretion, deem that the document, affidavit or approval is necessary or desirable for purposes of any placement of securities of the Corporation, whether private or public (including lock-up arrangements and undertakings), whether in Israel or abroad, for purposes of a merger of the Corporation with another entity, whether the Corporation is the surviving entity or not, for purposes of any reorganization or recapitalization of the Corporation or for purposes of any purchase or sale of assets or shares of the Corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">This Proxy and Power of Attorney shall be interpreted in the widest possible sense, in reliance upon the Plan and upon the goals and intentions thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">This proxy shall remain in effect until the earlier of the consummation of a Corporate Transaction or Change in Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="direction:rtl;font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="direction:rtl;font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="direction:rtl;font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NAME</b></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="direction:rtl;font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">DATE</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>3
<FILENAME>plx-20200630xex4d9.htm
<DESCRIPTION>EXHIBIT 4.9
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/10/2020 09:58:44 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit 4.9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(STANDARD)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;">This Option Agreement is made as of ________ ___, ______ (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), by and between <b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b>, a corporation incorporated under the laws of the State of Delaware (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;), and the following employee of the Corporation (the &#8220;<b style="font-weight:bold;">Optionee</b>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NAME:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">ID:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">WHEREAS, </b>the Corporation maintains the Amended and Restated Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as may be amended from time to time, a copy of which is has been provided to the Optionee with this Agreement and forms an integral part hereof (the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">WHEREAS, </b>the Corporation has determined that the Optionee be granted an option under the Plan to purchase shares of the Corporation&#8217;s common stock of the Corporation of par value US$ 0.001 each (the &#8220;<b style="font-weight:bold;">Shares</b>&#8221;), and the Optionee has agreed to such grant, subject to all the terms and conditions as set forth in the Plan and as provided herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, it is agreed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">PREAMBLE AND DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Preamble to this Agreement constitutes an integral part hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unless otherwise defined herein, capitalized terms used herein shall have the meaning ascribed to them in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">GRANT OF OPTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation hereby grants to the Optionee the number of Options set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> hereto, each Option exercisable into 1 (one) Share, against payment of the Purchase Price specified in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b>, subject to the terms and conditions set forth in the Plan and the terms and conditions set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Optionee is aware that the Corporation intends to issue additional shares and to grant additional Options and other equity awards in the future to various entities and individuals, as the Corporation in its sole discretion shall determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">2.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All Trustee 102 Options will be held in trust by a Trustee appointed by the Corporation in its sole discretion and approved pursuant to Section 102 of the Tax Ordinance and the rules, regulations, orders and procedures promulgated thereunder (&#8220;<b style="font-weight:bold;">Section 102</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">2.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to Trustee 102 Options, the Optionee hereby acknowledges that he/she is familiar with the provisions of Section 102, including without limitation the type of Options granted hereunder and the tax implications applicable to such grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">2.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trustee 102 Options, which shall be granted under the Plan and/or any Shares allocated or issued upon exercise of such Trustee 102 Options and/or other shares received subsequently following any changes in capitalization as specified in Section 10 of the Plan, shall be allocated or issued to the Trustee and held for the benefit of the Optionee for such period of time as required by Section 102 (the &#8220;<b style="font-weight:bold;">Holding Period</b><font style="white-space:pre-wrap;">&#8221;).  If the requirements for Trustee 102 Options are not met for any reason whatsoever, the Trustee 102 Options may be treated as Non-Trustee 102 Options, all in accordance with the provisions of Section 102.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">2.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">With respect to any Trustee 102 Option, subject to the provisions of Section 102, an Optionee shall not sell or release from trust any Trustee 102 Option or Shares received upon the exercise of a Trustee 102 Option and/or any right deriving from or in connection therewith, including, without limitation, in accordance with Section 10 of the Plan or any bonus shares or stock dividends issued in connection therewith, until the later of (i) the lapse of the Holding Period required under Section 102, and (ii) the Vesting Dates pursuant hereto and provided further that the Optionee has deposited with the Trustee the funds which, in the Trustee&#8217;s discretion, is sufficient and necessary for the discharge of such Optionee&#8217;s tax obligations with respect to such Options and/or Shares.  Notwithstanding the above, if any such sale or release occurs during the Holding Period, the sanctions under Section 102 shall apply to and any expenses and/or tax consequences therefrom shall be borne solely by the Optionee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">PERIOD OF OPTION; VESTING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">3.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The term of this Option Agreement shall commence on the Date of Grant as set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> hereto and terminate on the earlier of the Expiration Date (as defined in Section 5.1 below), or the time at which the Option expires or terminates pursuant to the terms of the Plan or pursuant to the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">3.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the provisions of the Plan, Options shall vest and become exercisable according to the Vesting Dates set forth in Section 20(d) of the Plan, unless agreed otherwise as set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> (the &#8220;<b style="font-weight:bold;">Vesting Dates</b>&#8221;), subject to Continuous Service of the Optionee on each applicable Vesting Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:2pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 8pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">METHOD AND CONDITIONS OF EXERCISE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms of the this Agreement, the Plan and the Tax Ordinance, Options may be exercised by the Optionee by giving a written notice to the Corporation, in such form and method as may be determined by the Corporation (the &#8220;<b style="font-weight:bold;">Exercise Notice</b><font style="white-space:pre-wrap;">&#8221;), which exercise shall be effected following receipt of such notice by the Corporation at its principal office, accompanied by payment of the Purchase Price in full in any of the means (or combination of means) allowed pursuant to the Plan.  The notice shall specify the number of Shares with respect to which the Options are being exercised.  In addition to the foregoing, the Corporation may have in place, from time to time, a system whereby the Optionee can exercise his/her Options directly on-line through the Trustee.  In such cases, direct exercise by the Optionee through any such system shall be deemed the delivery of an Exercise Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">4.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Options may be exercised by the Optionee in whole at any time or in part from time to time, prior to the Expiration Date, to the extent that the Options become vested and exercisable in accordance with <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that such exercise is subject to the requirements of Section 102, Sections 4.4, 4.5 and the Optionee&#8217;s Continuous Service at all times during the period beginning on the Date of Grant and ending upon the date of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">4.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The Corporation shall, following receipt of an Exercise Notice, take all reasonably necessary steps to forthwith comply therewith, and issue the Shares to the Trustee to be held by the Trustee in accordance with the provisions of Section 20 of the Plan.  Subject to the terms hereof, the Trustee will transfer the Shares to the Optionee upon demand, but in case of Shares received in connection with the exercise of 102 Options, not prior to the end of the Holding Period, and in any event subject to the provisions of Section 102.  If the Corporation is required to take any action with respect to the Shares before the issuance thereof, the issuance shall be delayed until all actions required have been taken.  The Optionee agrees and acknowledges that the Options and/or Shares will not be transferred and released from the trust without deduction of applicable taxes at source or the deposit with the Trustee of funds which, in the Trustee&#8217;s opinion, are sufficient and necessary for the discharge of the such Optionee&#8217;s tax obligations with respect to the Options and/or Shares, and the Optionee authorizes the Trustee to execute any agreement with the Corporation in connection therewith. The Optionee hereby releases the Corporation and the Trustee from any liability in respect of any action or decision executed in pursuant to the Plan and this Agreement, or any Option or Share granted to him thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">4.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">Subject to the provisions of Section 4.5 below, upon any termination or expiration of Optionee&#8217;s Continuous Service, all Options granted to the Optionee will immediately expire such that the unvested portion of the Options will not vest, and the vested portion of the Options shall no longer be exercisable.  A notice of termination of Continuous Service shall be deemed to constitute termination of employment or service unless such notice specifies a later day on which employment or notice is to terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">4.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein above, an Option may be exercised after the date of termination of Optionee&#8217;s Continuous Service during an additional period of time beyond the date of such termination, but (a) only with respect to the number of Options already vested at the time of such termination according to the Vesting Dates (the &#8220;<b style="font-weight:bold;">Qualified Options</b>&#8221;), and (b) in no event after the Expiration Date of such Option, if: (i) termination is for reason other than Cause, Disability or death, any Qualified Option still in force and unexpired may be exercised within a period of twelve (12) months from the date of such termination; (ii) termination is the result of Disability or death of the Optionee, in which event any Qualified Option still in force and unexpired may be exercised within a period of twelve (12) months from the date of termination; (iii) within a period of twelve (12) months from the date of termination as set forth in Section 6 below; (iv) within fourteen (14) days from the date of termination for Cause; or (v) if prior to the date of such termination, the Administrator has authorized an extension of the terms of all or part of the Options beyond the date of such termination, then for a period not to exceed the period during which the Options by their terms would otherwise have been exercisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">4.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to Non-Trustee 102 Options, if the Optionee ceases to be employed by the Corporation, the Optionee shall extend to the Corporation a security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">4.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No fractional shares shall be issued upon the exercise hereof and any fractional shares, if any, shall be rounded to the lowest whole number.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 8pt 0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">TERMINATION OF OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Except as otherwise stated in this Agreement, the Options, to the extent not previously exercised and paid for, shall terminate forthwith upon the earlier of: (i) the expiration date set forth in <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> hereto; (ii) the expiration of 10 years from the Date of Grant, and (iii) the expiration of any extended period in any of the events set forth in Section 4.5 above (and any such earlier date shall be referred to as the &#8220;<b style="font-weight:bold;">Expiration Date</b>&#8221;), and the right to acquire the Shares underlying the Options shall terminate, all interests and rights of the Optionee in and to the same shall ipso facto expire, and, in the event that in connection therewith any Options are still held by the Trustee as aforesaid, the trust with respect thereto shall ipso facto expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 8pt 0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">CORPORATE TRANSACTIONS AND CHANGE OF CONTROL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Acceleration of the vesting periods of unexercised Options upon a Corporate Transaction or a Change in Control shall be governed under Section 11(b) of the Plan.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">RIGHTS PRIOR TO EXERCISE OF OPTION; LIMITATIONS AFTER PURCHASE OF SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the provisions of Section 7.2 below, the Optionee shall not have any of the rights or privileges of a stockholder of the Corporation in respect of any Shares purchasable upon the exercise of any Option unless and until, following exercise and discharge by the Optionee of all its obligations in connection therewith (including the payment of applicable aggregate Purchase Price for the Shares issued upon exercise of the Options and any applicable taxes), the Optionee is registered as holder of such Shares in the Corporation&#8217;s register of stockholders and in case of Options and Shares held by the Trustee, subject always to the provisions of Section 20 of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Option granted hereunder, whether fully paid or not, may be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Optionee, only by the Optionee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any such action made directly or indirectly, for an immediate validation or for a future one, shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As long as the Shares are held by the Trustee in favor of the Optionee, all rights the latter possesses over the Shares shall be personal, and may not be transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shares issued to the Optionee shall be subject to such restrictions as required by any applicable securities law or the Corporation (including any lock up undertaking).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Until registered in the name of the Optionee, Shares eligible for voting shall be voted by an irrevocable proxy a copy of which is attached hereto as <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</b><font style="white-space:pre-wrap;">.  Those empowered under the Proxy shall be indemnified and held harmless by the Corporation against any cost or expense (including counsel fees) reasonably incurred by him/her, or any liability (including any sum paid in settlement of a claim with the approval of the Corporation) arising out of any act or omission to act in connection with the voting of such proxy unless arising out of such person&#8217;s own fraud, bad faith or gross negligence, to the extent permitted by applicable law.  Such indemnification shall be in addition to any rights of indemnification the person(s) may have as a director, officer or otherwise under the Corporation&#8217;s Certificate of Incorporation, any agreement, any vote of stockholders or directors, insurance policy or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The Optionee acknowledges that its right to sell Shares may be subject to some representations or undertakings on its part as well as other limitations, as set forth by the Corporation or, in the event the Corporation&#8217;s shares are registered for trading in any public market, by the Corporation or its underwriters.  In any such events, the Optionee will unconditionally agree to any such limitations as well as to make such representations, and perform such undertakings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Optionee shall not dispose of any Shares in transactions which violate, in the opinion of the Corporation, any applicable laws, rules and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">7.9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Optionee agrees that the Corporation shall have the authority to endorse upon the certificate or certificates representing the Shares such legends referring to any applicable representations and undertakings of the Optionee as well as other applicable limitations and restrictions as it may deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">SHARES SUBJECT TO PLEDGE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;">Unless otherwise prohibited by law and notwithstanding anything to the contrary, if at the time at which any of the Options granted hereunder is exercised, Optionee is indebted to the Corporation (or any Related Entity) for any reason, then any Shares to be issued upon such exercise shall automatically be pledged against Optionee&#8217;s outstanding indebtedness, as deemed appropriate by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">GOVERNMENT REGULATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;">The Plan, the grant and exercise of Options hereunder, and the obligation of the Corporation to sell and deliver Shares under such Options, shall be subject to all applicable laws, rules and regulations, whether of the State of Israel or of the United States or any other state having jurisdiction over the Corporation and the Optionee, including without limitation, the U.S. Securities Act of 1933 and the Israeli Securities Law and or any applicable securities law, and to such approvals by any governmental agencies or national securities exchanges as may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">CONTINUOUS SERVICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><font style="white-space:pre-wrap;">This Agreement, and the grant of Options set forth herein, shall not confer upon the Optionee any right with respect to the Optionee&#8217;s Continuous Service, nor shall it interfere in any way with his or her right or the right of the Corporation or any Related Entity to terminate the Optionee&#8217;s Continuous Service at any time, with or without cause, including but not limited to, Cause, and with or without notice.  The ability of the Company or any Related Entity to terminate the employment of the Optionee, who is employed at will, is in no way affected by its determination that the Grantee&#8217;s Continuous Service has been terminated for Cause for the purposes of this Agreement and the grant of Options set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">GOVERNING LAW &amp; JURISDICTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><font style="white-space:pre-wrap;">This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws.  The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to this Agreement and/or the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">TAX CONSEQUENCES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;"><font style="direction:rtl;">12.1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">To the extent permitted by applicable law, any tax consequences arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act hereunder (whether taken by the Corporation, a Related Entity, the respective affiliates, the Trustee or the Optionee), shall be borne solely by the Optionee.  The Corporation, a Related Entity and/or the Trustee is authorized to withhold taxes according to the requirements under applicable laws, rules, and regulations, including withholding taxes at source.  Furthermore, the Optionee hereby agrees to indemnify the Corporation, any Related Entity and/or the Trustee and hold them harmless against and from any and all liability for or in connection with any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Optionee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">12.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The Optionee will not be entitled to receive from the Corporation, any Related Entity and/or the Trustee nor will the Trustee be required to release any Shares allocated or issued upon the exercise of Options prior to the full payment by the Optionee of the tax liabilities arising from the Options granted to him or her and/or the Shares issuable upon the exercise of such Options.  Neither the Corporation nor the Trustee shall be required to release any share certificate to the Optionee until all payments required to be made by the Optionee, in the Trustee&#8217;s opinion, have been fully satisfied.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">12.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation makes no representations or warranties regarding the tax treatment in connection with any aspect of the grant of any Option hereunder, including the exercise of the Option and the subsequent sale of Shares issued upon such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">12.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The receipt of the Options and the acquisition of the Shares to be issued upon the exercise of the Options may result in tax consequences. THE OPTIONEE IS ADVISED TO CONSULT A TAX ADVISER WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING OR EXERCISING THE OPTIONS OR DISPOSING OF THE SHARES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">DISCRETIONARY GRANT; NO WARRANTY AS TO FINANCIAL GAIN OR LOSS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">13.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">The grant of Options under the Plan is made at the discretion of the Administrator.  The grant of an Option at a certain time does not in any way entitle the Optionee to any future Option grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">13.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation makes no express or implied promise or warranty as to the financial gain to be achieved or loss to be incurred through participation in the Plan and grant of Options hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">FAILURE TO ENFORCE NOT A WAIVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">The failure of any party to enforce at any time any provision of this Agreement shall in no way be construed to be a waiver of such provision or of any other provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">PROVISIONS OF THE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">15.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without derogating from Section 15.3 below, the Options provided for herein are granted pursuant to the Plan, and said Options and this Agreement are in all respects governed by and subject to the terms and conditions of the Plan including all obligations on the Optionee, restrictions or limitations set forth therein with respect to the grant of Options or the Optionee&#8217;s eligibility to exercise such Options or receive or sell Shares covered thereby (or any other issue in connection with the foregoing) whether or not such obligations, restrictions or limitations are stipulated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">15.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without derogating from Section 15.3 below, any interpretation of this Agreement will be made in accordance with the Plan and in the event there is any contradiction between the provisions of this Agreement and the Plan, the provisions of the Plan will prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 7pt 0pt;">15.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary (including the provisions of Sections 15.1 and 15.2): (a) <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b> to this Agreement and Section 7 hereof will prevail over the terms of the Plan; and (b) any provisions of this Agreement imposing obligations on the Optionee, any restrictions or limitations with respect to the grant of Options hereunder or the Optionee&#8217;s eligibility to exercise such Options or receive or sell Shares covered thereby (or any other issue in connection with the foregoing), beyond the obligations, restrictions or limitations in connection therewith set forth in the Plan, shall be of full force and effect, be deemed additional to, and not substitutive for, the obligations, restrictions and limitations in connection therewith set forth in the Plan and shall not be derogated thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 7pt 0pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">BINDING EFFECT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">This Agreement shall be binding upon the heirs, executors, administrators, and successors of the parties hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 8pt 0pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All notices or other communications given or made hereunder shall be in writing and shall be delivered or mailed by registered mail or delivered by facsimile with written confirmation of receipt, to the Optionee at his or her address included in the Corporation&#8217;s records and/or to the Corporation at the address below, or at such other place as the Corporation may designate by written notice to the Optionee:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c/o Protalix Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2 Snunit St., Science Park P.O.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Box 455, Carmiel 2161401, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Facsimile: 972-4-9889489<br>Attn: Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Optionee is responsible for notifying the Corporation in writing of any change in the Optionee&#8217;s address, and the Corporation shall be deemed to have complied with any obligation to provide the Optionee with notice by sending such notice to the address indicated above or such changed address as to which it has been notified as specified herein, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">ENTIRE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">This Agreement and the Plan exclusively conclude all the terms of the Optionee&#8217;s Options, and annul and supersede any other agreement, arrangement or understanding, whether oral or in writing, relating to the grant of Options covered by this Agreement to the Optionee.  Any change of any kind to this Agreement will be valid only if made in writing and signed by both the Optionee and the Corporation&#8217;s authorized representative and has received the approval of the Administrator.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Corporation executed this Agreement as of the date first set forth above.</p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">The Optionee acknowledges receipt of a copy of the Plan and the Prospectus and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Agreement and the Plan (and the Prospectus) including all of the terms and provisions thereof.  The Optionee has reviewed the Plan, the Prospectus and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Agreement and the Plan (and the Prospectus).  The Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any question arising under the Plan or this Agreement.  The Optionee further agrees to notify the Corporation upon any change in the residence address indicated above.</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="direction:rtl;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Terms of the Options</b></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name of the Optionee:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Designation:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">&#8999;</b><b style="font-weight:bold;">Trustee 102 Options (Capital Gains Options) / </b><b style="font-family:'Times New Roman';font-weight:bold;">&#9723;</b><b style="font-weight:bold;">Non-Trustee 102 Options</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aggregate Number of Options Granted:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date of Grant:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">______ ___, ____</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchase Price per Share:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Dates:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Expiration Date:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">______ ___, ____</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:44.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="direction:rtl;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PROXY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">The undersigned hereby grants an irrevocable proxy to the Trustee under the Amended and Restated Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Plan</b><font style="font-size:12pt;">&#8221;), to vote all shares issued upon the exercise of Options by the undersigned at all meetings of the stockholders of Protalix BioTherapeutics, Inc. (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Corporation</b><font style="font-size:12pt;">&#8221;), and to sign all written resolutions of the stockholders of the Corporation on behalf of the undersigned, including the right to waive on behalf of the undersigned all minimum notice requirements for meetings of stockholders of the Corporation, and hereby authorize and grant a power of attorney to the Trustee as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Unless otherwise defined herein, capitalized terms used herein shall have the meaning ascribed to them in the Plan.  The undersigned hereby authorizes and grants power of attorney to the Trustee for as long as any Shares and/or Options which were allotted or granted on my behalf are held by the Trustee or registered in my name, or for as long as the certificates representing any shares are held by the Trustee, to exercise every right, power and authority with respect to the Shares and/or Options and to sign in my name and on my behalf any document (including any agreement, including a merger agreement of the Corporation or an agreement for the purchase or sale of assets or shares (including the shares of the Corporation held on my behalf) and any and all documentation accompanying any such agreements, such as, but not limited to, decisions, requests, instruments, receipts and the like), and any affidavit or approval with respect to the Shares and/or Options or to the rights which they represent in the Corporation in as much as the Trustee shall deem it necessary or desirable to do so.  In addition and without derogating from the generality of the foregoing, I hereby authorize and grant power of attorney to the Trustee to sign any document as aforesaid and any affidavit or approval and/or to make and execute any undertaking in my name and on my behalf if the Trustee shall, at its sole discretion, deem that the document, affidavit or approval is necessary or desirable for purposes of any placement of securities of the Corporation, whether private or public (including lock-up arrangements and undertakings), whether in Israel or abroad, for purposes of a merger of the Corporation with another entity, whether the Corporation is the surviving entity or not, for purposes of any reorganization or recapitalization of the Corporation or for purposes of any purchase or sale of assets or shares of the Corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">This Proxy and Power of Attorney shall be interpreted in the widest possible sense, in reliance upon the Plan and upon the goals and intentions thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">This proxy shall remain in effect until the earlier of the consummation of a Corporate Transaction or Change in Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:44.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">DATE</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>plx-20200630xex10d1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/10/2020 09:58:47 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(June 7, 2020)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Purposes of the Plan</u><font style="white-space:pre-wrap;">.  The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company&#8217;s business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="white-space:pre-wrap;">.  The following definitions shall apply as used herein and in the individual Award Agreements except as defined otherwise in an individual Award Agreement.  In the event a term is separately defined in an individual Award Agreement, such definition shall supercede the definition contained in this Section&#160;2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">3(I) Option</u>&#8221; means Award granted under Section 3(I).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">102 Option</u>&#8221; means Award granted under Section 102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Administrator</u>&#8221; means the Board or any of the Committees appointed to administer the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Affiliate</u>&#8221; and &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Associate</u>&#8221; shall have the respective meanings ascribed to such terms in Rule&#160;12b-2 promulgated under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Applicable Laws</u>&#8221; means the legal requirements relating to the Plan and the Awards under applicable provisions of federal securities laws, state corporate and securities laws, the Code, the rules of any applicable stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to Awards granted to residents therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Assumed</u>&#8221; means that pursuant to a Corporate Transaction either (i)&#160;the Award is expressly affirmed by the Company or (ii)&#160;the contractual obligations represented by the Award are expressly assumed (and not simply by operation of law) by the successor entity or its Parent in connection with the Corporate Transaction with appropriate adjustments to the number and type of securities of the successor entity or its Parent subject to the Award and the exercise or purchase price thereof which at least preserves the compensation element of the Award existing at the time of the Corporate Transaction as determined in accordance with the instruments evidencing the agreement to assume the Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Award</u>&#8221; means the grant of an Option, SAR, Dividend Equivalent Right, Restricted Stock, Restricted Stock Unit or other right or benefit under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Award Agreement</u>&#8221; means the written agreement evidencing the grant of an Award executed by the Company and the Grantee, including any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Board</u>&#8221; means the Board of Directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Cause</u>&#8221; means, with respect to the termination by the Company or a Related Entity of the Grantee&#39;s Continuous Service, that such termination is for &#8220;Cause&#8221; as such term (or word of like import) is expressly defined in a then-effective written agreement between the Grantee and the Company or such Related Entity, or in the absence of such then-effective written agreement and definition, is based on, in the determination of the Administrator, the Grantee&#8217;s: (i) performance of any act or failure to perform any act in bad faith which is materially detrimental to the Company or a Related Entity as reasonably determined in good faith by a unanimous decision of members of the Board entitled to vote thereon; (ii) dishonesty, intentional misconduct or material breach of any agreement with the Company or a Related Entity; (iii) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person; (iv) embezzlement of funds of the Company or a Related Entity; (v) ownership, direct or indirect (i.e., by means of a holding company or family member), of an interest in a person or entity (other than a minority interest in a publicly traded company) in competition with the products or services of the Company or a Related Entity, including those products or services contemplated in a plan adopted by the Board; (vi) any breach of the Grantee&#8217;s fiduciary duties or duties of care to the Company or a Related Entity (except for conduct taken in good faith); (vii) any material failure to carry out a reasonable and legitimate directive of the Board; or (viii) any material breach of an Employee&#39;s undertakings of confidentiality and non competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Change in Control</u>&#8221; means a change in ownership or control of the Company effected through either of the following transactions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the direct or indirect acquisition by any person or related group of persons (other than an acquisition from or by the Company or by a Company-sponsored employee benefit plan or by a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership (within the meaning of Rule&#160;13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Company&#8217;s stockholders which a majority of the Continuing Directors who are not Affiliates or Associates of the offeror do not recommend such stockholders accept, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a change in the composition of the Board over a period of twelve (12) months or less such that a majority of the Board members (rounded up to the next whole number) ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who are Continuing Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Committee</u>&#8221; means any committee composed of members of the Board appointed by the Board to administer the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Common Stock</u>&#8221; means the common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Company</u>&#8221; means Protalix BioTherapeutics, Inc., a Delaware corporation, or any successor entity that adopts the Plan in connection with a Corporate Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Consultant</u>&#8221; means any person (other than an Employee or a Director, solely with respect to rendering services in such person&#8217;s capacity as a Director) who is engaged by the Company or any Related Entity to render consulting or advisory services to the Company or such Related Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Continuing Directors</u>&#8221; means members of the Board who either (i)&#160;have been Board members continuously for a period of at least twelve (12) months or (ii)&#160;have been Board members for less than twelve (12) months and were elected or nominated for election as Board members by at least a majority of the Board members described in clause&#160;(i) who were still in office at the time such election or nomination was approved by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Continuous Service</u><font style="white-space:pre-wrap;">&#8221; means that the provision of services to the Company or a Related Entity in any capacity of Employee, Director or Consultant is not interrupted or terminated.  In jurisdictions requiring notice in advance of an effective termination as an Employee, Director or Consultant, Continuous Service shall be deemed terminated upon the actual cessation of providing services to the Company or a Related Entity notwithstanding any required notice period that must be fulfilled before a termination as an Employee, Director or Consultant can be effective under Applicable Laws.  A Grantee&#8217;s Continuous Service shall be deemed to have terminated either upon an actual termination of Continuous Service or upon the entity for which the Grantee provides services ceasing to be a Related Entity.  Continuous Service shall not be considered interrupted in the case of (i)&#160;any approved leave of absence, (ii)&#160;transfers among the Company, any Related Entity, or any successor, in any capacity of Employee, Director or Consultant, or (iii)&#160;</font><font style="white-space:pre-wrap;">any change in status as long as the individual remains in the service of the Company or a Related Entity in any capacity of Employee, Director or Consultant (except as otherwise provided in the Award Agreement).  An approved leave of absence shall include sick leave, military leave, or any other authorized personal leave.  For purposes of each Incentive Stock Option granted under the Plan, if such leave exceeds three (3) months, and reemployment upon expiration of such leave is not guaranteed by statute or contract, then the Incentive Stock Option shall be treated as a Non-Qualified Stock Option on the day three (3) months and one (1) day following the expiration of such three (3) month period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Corporate Transaction</u>&#8221; means any of the following transactions, provided, however, that the Administrator shall determine under parts (iv) and (v) whether multiple transactions are related, and its determination shall be final, binding and conclusive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state in which the Company is incorporated;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the sale, transfer or other disposition of all or substantially all of the assets of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the complete liquidation or dissolution of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A)&#160;the shares of Common Stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B)&#160;in which securities possessing more than forty percent (40%) of the total combined voting power of the Company&#8217;s outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;acquisition in a single or series of related transactions by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule&#160;13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities but excluding any such transaction or series of related transactions that the Administrator determines shall not be a Corporate Transaction (provided however that the Administrator shall have no discretion in connection with a Corporate Transaction for the purchase of all or substantially all of the shares of the Company unless the principal purpose of such transaction is to change the state in which the Company is incorporated).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Covered Employee</u>&#8221; means an Employee who is a &#8220;covered employee&#8221; under Section&#160;162(m)(3) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Director</u>&#8221; means a member of the Board or the board of directors of any Related Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Disability</u><font style="white-space:pre-wrap;">&#8221; means as defined under the long-term disability policy of the Company or the Related Entity to which the Grantee provides services regardless of whether the Grantee is covered by such policy.  If the Company or the Related Entity to which the Grantee provides service does not have a long-term disability plan in place, &#8220;Disability&#8221; means that a Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determinable physical or mental impairment for a period of not less than ninety (90) consecutive days.  A Grantee will not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Administrator in its discretion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Dividend Equivalent Right</u>&#8221; means a right entitling the Grantee to compensation measured by dividends paid with respect to Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Employee</u><font style="white-space:pre-wrap;">&#8221; means any person, including an Officer or Director, who is in the employ of the Company or any Related Entity, subject to the control and direction of the Company or any Related Entity as to both the work to be performed and the manner and method of performance.  The payment of a director&#8217;s fee by the Company or a Related Entity shall not be sufficient to constitute &#8220;employment&#8221; by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Fair Market Value</u>&#8221; means, as of any date, the value of Common Stock determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Common Stock is listed on one or more established stock exchanges or national market systems, including without limitation the American Stock Exchange, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on the principal exchange or system on which the Common Stock is listed (as determined by the Administrator) on the date of determination (or, if no closing sales price or closing bid was reported on that date, as applicable, on the last trading date such closing sales price or closing bid was reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Common Stock is regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized securities dealer, its Fair Market Value shall be the closing sales price for such stock as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, the Fair Market Value of a share of Common Stock shall be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no such prices were reported on that date, on the last date such prices were reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the absence of an established market for the Common Stock of the type described in (i) and (ii), above, the Fair Market Value thereof shall be determined by the Administrator in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Grantee</u>&#8221; means an Employee, Director or Consultant who receives an Award under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Incentive Stock Option</u>&#8221; means an Option intended to qualify as an incentive stock option within the meaning of Section&#160;422 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Israeli Employee</u>&#8221; means Employees, office holders of the Company or a Related Company (&#8220;Nosei Misra&#8221; - as such term is defined in the Israeli Companies Law 1999) and Directors (excluding those who are considered a &#8220;Controlling Shareholder&#8221; pursuant to Section 32(9) of the Tax Ordinance or otherwise excluded by the Tax Ordinance).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Israeli Grantee</u>&#8221; means Grantees who are residents of the State of Israel or those who are deemed to be residents of the State of Israel for the payment of tax (whether such grantee is entitled to the tax benefits under Section 102 or not).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">ITA</u>&#8221; means Israeli Tax Authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Non-Employee</u>&#8221; means Consultants or any other person who is not an Israeli Employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Non-Qualified Stock Option</u>&#8221; means an Option not intended to qualify as an Incentive Stock Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Non-Trustee 102 Option</u>&#8221; shall mean a 102 Option granted pursuant to Section 102(c) of the Tax Ordinance and not held in trust by the Trustee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Officer</u>&#8221; means a person who is an officer of the Company or a Related Entity within the meaning of Section&#160;16 of the Exchange Act and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Option</u>&#8221; means an option to purchase Shares pursuant to an Award Agreement granted under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Parent</u>&#8221; means a &#8220;parent corporation&#8221;, whether now or hereafter existing, as defined in Section&#160;424(e) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Performance-Based Compensation</u>&#8221; means compensation qualifying as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(mm)&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Plan</u>&#8221; means this Amended and Restated 2006 Stock Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Related Entity</u>&#8221; means any Parent or Subsidiary of the Company. With respect to Israeli Grantees of 102 Options, the definition shall further include any entity permitted under Section 102 (a) of the Tax Ordinance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(oo)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Replaced</u>&#8221; means that pursuant to a Corporate Transaction&#160;<font style="white-space:pre-wrap;">the Award is replaced with a comparable stock award or a cash incentive program of the Company, the successor entity (if applicable) or Parent of either of them which preserves the compensation element of such Award existing at the time of the Corporate Transaction and provides for subsequent payout in accordance with the same (or a more favorable) vesting schedule applicable to such Award.  The determination of Award comparability shall be made by the Administrator and its determination shall be final, binding and conclusive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(pp)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Restricted Stock</u>&#8221; means Shares issued under the Plan to the Grantee for such consideration, if any, and subject to such restrictions on transfer, rights of first refusal, repurchase provisions, forfeiture provisions, and other terms and conditions as established by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(qq)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Restricted Stock Units</u>&#8221; means an Award which may be earned in whole or in part upon the passage of time or the attainment of performance criteria established by the Administrator and which may be settled for cash, Shares or other securities or a combination of cash, Shares or other securities as established by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Rule&#160;16b-3</u>&#8221; means Rule&#160;16b-3 promulgated under the Exchange Act or any successor thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(ss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">SAR</u>&#8221; means a stock appreciation right entitling the Grantee to Shares or cash compensation, as established by the Administrator, measured by appreciation in the value of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(tt)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Section 3(I)</u>&#8221; means section 3(I) of the Tax Ordinance as may be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(uu)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Section 102</u>&#8221; means section 102 of the Tax Ordinance as may be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(vv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Share</u>&#8221; means a share of the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(ww)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Subsidiary</u>&#8221; means a &#8220;subsidiary corporation&#8221;, whether now or hereafter existing, as defined in Section&#160;424(f) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(xx)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Tax Ordinance</u>&#8221; means the Israeli Income Tax Ordinance [New Version], 1961 (including as amended pursuant to Amendment 132 thereto) and to the extent not specifically indicated hereunder also the rules, regulations and orders or procedures promulgated thereunder from time to time, as amended or replaced from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(yy)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Trustee</u>&#8221; means any individual appointed by the Company to serve as trustee and approved by the ITA, in accordance with the provisions of Section 102(a) of the Tax Ordinance and the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(zz)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Trustee 102 Option</u>&#8221; means a 102 Option granted pursuant to Section&#160;102(b) of the Tax Ordinance and held in trust by the Trustee for the benefit of an Israeli Grantee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Stock Subject to the Plan</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">Subject to the provisions of Section &#8206;10, below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive Stock Options) under the Plan is 5,725,171 Shares.  Notwithstanding the foregoing, any Shares issued from and after November 10, 2014 in connection with Awards other than Options and SARs shall be counted against the limit set forth herein as one and one-half (1.5) Shares for every one (1) Share issued in connection with such Award (and shall be counted as one and one-half (1.5) Shares for every one (1) Share returned or deemed not have been issued from the Plan pursuant to Section 3(b) below in connection with Awards other than Options and SARs).  The Shares to be issued pursuant to Awards may be authorized, but unissued, or reacquired Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">Any Shares covered by an Award (or portion of an Award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) shall be deemed not to have been issued for purposes of determining the maximum aggregate number of Shares which may be issued under the Plan.  Shares that actually have been issued under the Plan pursuant to an Award shall not be returned to the Plan and shall not become available for future issuance under the Plan, except that if unvested Shares are forfeited, or repurchased by the Company at the lower of their original purchase price or their Fair Market Value at the time of repurchase, such Shares shall become available for future grant under the Plan.  Notwithstanding anything to the contrary contained herein: (i) Shares tendered or withheld in payment of an Option exercise price shall not be returned to the Plan and shall not become available for future issuance under the Plan; (ii) Shares withheld by the Company to satisfy any tax withholding obligation shall not be returned to the Plan and shall not become available for future issuance under the Plan; and (iii) all Shares covered by the portion of an SAR that is exercised (whether or not Shares are actually issued to the Grantee upon exercise of the SAR) shall be considered issued pursuant to the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Administration of the Plan</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Plan Administrator</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Administration with Respect to Directors and Officers</u><font style="white-space:pre-wrap;">.  With respect to grants of Awards to Directors or Employees who are also Officers or Directors of the Company, the Plan shall be administered by (A)&#160;the Board or (B)&#160;a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws and to permit such grants and related transactions under the Plan to be exempt from</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Section&#160;16(b) of the Exchange Act in accordance with Rule&#160;<font style="white-space:pre-wrap;">16b-3.  Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Administration With Respect to Consultants and Other Employees</u><font style="white-space:pre-wrap;">.  With respect to grants of Awards to Employees or Consultants who are neither Directors nor Officers of the Company, the Plan shall be administered by (A) the Board or (B) a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws.  Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board.  The Board may authorize one or more Officers to grant such Awards and may limit such authority as the Board determines from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Administration With Respect to Covered Employees</u><font style="white-space:pre-wrap;">.  Notwithstanding the foregoing, grants of Awards to any Covered Employee intended to qualify as Performance-Based Compensation shall be made only by a Committee (or subcommittee of a Committee) which is comprised solely of two or more Directors eligible to serve on a committee making Awards qualifying as Performance-Based Compensation.  In the case of such Awards granted to Covered Employees, references to the &#8220;Administrator&#8221; or to a &#8220;Committee&#8221; shall be deemed to be references to such Committee or subcommittee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Administration With Respect to Israeli Grantees</u><font style="white-space:pre-wrap;">.  With respect to grants of Awards to Israeli Grantees, the Plan shall be administered by (A) the Board or (B) a Committee or one or more Officers designated by the Board, which Committee or Officers shall be constituted or appointed in such a manner as to satisfy the ITA and the Applicable Laws applicable to Awards for Israeli Grantees.  Once appointed, such Committee or Officer shall continue to serve in its/his/her designated capacity until otherwise directed by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Administration Errors</u><font style="white-space:pre-wrap;">.  In the event an Award is granted in a manner inconsistent with the provisions of this subsection&#160;(a), such Award shall be presumptively valid as of its grant date to the extent permitted by the Applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Powers of the Administrator</u><font style="white-space:pre-wrap;">.  Subject to Applicable Laws and the provisions of the Plan (including any other powers given to the Administrator hereunder), and except as otherwise provided by the Board, the Administrator shall have the authority, in its discretion:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to select the Employees, Directors and Consultants to whom Awards may be granted from time to time hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine whether and to what extent Awards are granted hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine the number of Shares or the amount of other consideration to be covered by each Award granted hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to approve forms of Award Agreements for use under the Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine the terms and conditions of any Award granted hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to amend the terms of any outstanding Award granted under the Plan, provided that (A) any amendment that would adversely affect the Grantee&#8217;s rights under an outstanding Award shall not be made without the Grantee&#8217;s written consent, provided, however, that an amendment or modification that may cause an Incentive Stock Option to become a Non-Qualified Stock Option shall not be treated as adversely affecting the rights of the Grantee, (B)&#160;<font style="white-space:pre-wrap;">the reduction of the exercise price of any Option awarded under the Plan and the base appreciation amount of any SAR awarded under the Plan shall be subject to stockholder approval and (C) canceling an Option or SAR at a time when its exercise price or base appreciation amount (as applicable) exceeds the Fair Market Value of the underlying Shares, in exchange for another Option, SAR, Restricted Stock, or other Award or for cash shall be subject to stockholder approval, unless the cancellation and exchange occurs in connection with a Corporate Transaction.  Notwithstanding the foregoing, canceling an Option or SAR in exchange for another Option, SAR, Restricted Stock, or other Award or for cash with an exercise price, purchase price or base appreciation amount (as applicable) that is equal to or greater than the exercise price or base appreciation amount (as applicable) of the original Option or SAR shall not be subject to stockholder approval;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to construe and interpret the terms of the Plan and Awards, including without limitation, any notice of award or Award Agreement, granted pursuant to the Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(viii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;to grant Awards to Employees, Directors and Consultants employed outside the United States on such terms and conditions different from those specified in the Plan as may, in the judgment of the Administrator, be necessary or desirable to further the purpose of the Plan; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ix)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to designate Awards as 102 Options (whether through a trustee or not) or 3(I) Options subject to the limitations under the ITA or any other Applicable Law and to determine the type and route of the Trustee 102 Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to take such other action, not inconsistent with the terms of the Plan, as the Administrator deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">The express grant in the Plan of any specific power to the Administrator shall not be construed as limiting any power or authority of the Administrator; provided that the Administrator may not exercise any right or power reserved to the Board.  Any decision made, or action taken, by the Administrator or in connection with the administration of this Plan shall be final, conclusive and binding on all persons having an interest in the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Indemnification</u>. In addition to such other rights of indemnification as they may have as members of the Board or as Officers or Employees of the Company or a Related Entity, members of the Board and any Officers or Employees of the Company or a Related Entity to whom authority to act for the Board, the Administrator or the Company is delegated shall be defended and indemnified by the Company to the extent permitted by law on an after-tax basis against all reasonable expenses, including attorneys&#8217; fees, actually and necessarily incurred in connection with the defense of any claim, investigation, action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any Award granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by the Company) or paid by them in satisfaction of a judgment in any such claim, investigation, action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such claim, investigation, action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct; provided, however, that within thirty (30) days after the institution of such claim, investigation, action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at the Company&#8217;s expense to defend the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Eligibility</u><font style="white-space:pre-wrap;">.  Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants.  Incentive Stock Options may be granted only to Employees of the Company or a Parent or a Subsidiary of the Company.  An Employee, Director or Consultant who has been granted an Award may, if otherwise eligible, be granted additional Awards.  Awards may be granted to such Employees, Directors or Consultants who are residing in non-U.S. jurisdictions as the Administrator may determine from time to time, provided however that Awards to Israeli Grantees under Section 102 or Section 3(I) of the Tax Ordinance shall be subject to Section 20 below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.45pt;margin:0pt 0pt 10pt 0pt;">The Company does not warrant that the Plan will be recognized by the income tax authorities in any jurisdiction or that future changes will not be made to the provisions of applicable laws or rules or regulations which are promulgated from time to time thereunder, or that any exemption or benefit currently available, whether by the ITA pursuant to Section 102 or otherwise, will not be abolished.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Terms and Conditions of Awards</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Types of Awards</u>. The Administrator is authorized under the Plan to award any type of arrangement to an Employee, Director or Consultant that is not inconsistent with the provisions of the Plan and that by its terms involves or might involve the issuance of (i)&#160;Shares, (ii)&#160;cash or (iii)&#160;<font style="white-space:pre-wrap;">an Option, a SAR, or similar right with a fixed or variable price related to the Fair Market Value of the Shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions.  Such awards include, without limitation, Options, SARs, sales or bonuses of Restricted Stock, Restricted Stock Units or Dividend Equivalent Rights, and an Award may consist of one such security or benefit, or two (2)&#160;or more of them in any combination or alternative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Designation of Award</u><font style="white-space:pre-wrap;">.  Each Award shall be designated in the Award Agreement.  In the case of an Option, the Option shall be designated as either an Incentive Stock Option or a Non-Qualified Stock Option and with respect to Israeli Grantees may be further designated as 102 Options or 3(I) Options under the Tax Ordinance subject to the qualifications described in Section 20 below.  However, notwithstanding such designation, an Option will qualify as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section&#160;</font><font style="white-space:pre-wrap;">422(d) of the Code is not exceeded.  The $100,000 limitation of Section&#160;422(d) of the Code is calculated based on the aggregate Fair Market Value of the Shares subject to Options designated as Incentive Stock Options which become exercisable for</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">the first time by a Grantee during any calendar year (under all plans of the Company or any Parent or Subsidiary of the Company).  For purposes of this calculation, Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the Shares shall be determined as of the grant date of the relevant Option.  In the event that the Code or the regulations promulgated thereunder are amended after the date the Plan becomes effective to provide for a different limit on the Fair Market Value of Shares permitted to be subject to Incentive Stock Options, then such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Conditions of Award</u><font style="white-space:pre-wrap;">.  Subject to the terms of the Plan, the Administrator shall determine the provisions, terms, and conditions of each Award including, but not limited to, the Award vesting schedule, repurchase provisions, rights of first refusal, forfeiture provisions, form of payment (cash, Shares, or other consideration) upon settlement of the Award, payment contingencies, and satisfaction of any performance criteria.  The performance criteria established by the Administrator may be based on any one of, or combination of, the following: (i) increase in share price, (ii) earnings per share, (iii) total stockholder return, (iv) operating margin, (v) gross margin, (vi) return on equity, (vii) return on assets, (viii) return on investment, (ix) operating income, (x) net operating income, (xi) pre-tax profit, (xii) cash flow, (xiii) revenue, (xiv) expenses, (xv) earnings before interest, taxes and depreciation, (xvi) economic value added and (xvii) market share.  The performance criteria may be applicable to the Company, Related Entities and/or any individual business units of the Company or any Related Entity.  Partial achievement of the specified criteria may result in a payment or vesting corresponding to the degree of achievement as specified in the Award Agreement.  In addition, the performance criteria shall be calculated in accordance with generally accepted accounting principles, but excluding the effect (whether positive or negative) of any change in accounting standards and any extraordinary, unusual or nonrecurring item, as determined by the Administrator, occurring after the establishment of the performance criteria applicable to the Award intended to be performance-based compensation.  Each such adjustment, if any, shall be made solely for the purpose of providing a consistent basis from period to period for the calculation of performance criteria in order to prevent the dilution or enlargement of the Grantee&#8217;s rights with respect to an Award intended to be performance-based compensation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Acquisitions and Other Transactions</u><font style="white-space:pre-wrap;">.  The Administrator may issue Awards under the Plan in settlement, assumption or substitution for, outstanding awards or obligations to grant future awards in connection with the Company or a Related Entity acquiring another entity, an interest in another entity or an additional interest in a Related Entity whether by merger, stock purchase, asset purchase or other form of transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Deferral of Award Payment</u><font style="white-space:pre-wrap;">.  The Administrator may establish one or more programs under the Plan to permit selected Grantees the opportunity to elect to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other event that absent the election would entitle the Grantee to payment or receipt of Shares or other consideration under an Award.  The Administrator may establish the election procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts, Shares or other consideration so deferred, and such other terms, conditions, rules and procedures that the Administrator deems advisable for the administration of any such deferral program.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Separate Programs</u><font style="white-space:pre-wrap;">.  The Administrator may establish one or more separate programs under the Plan for the purpose of issuing particular forms of Awards to one or more classes of Grantees on such terms and conditions as determined by the Administrator from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Individual Limitations on Awards</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Individual Limit for Options and SARs</u><font style="white-space:pre-wrap;">.  The maximum number of Shares with respect to which Options and SARs may be granted to any Grantee in any calendar year shall be 5,725,171 Shares.  Shares which shall not count against the limit set forth in the previous sentence.  The foregoing limitations shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section&#160;</font><font style="white-space:pre-wrap;">&#8206;10, below.  To the extent required by Section&#160;</font><font style="white-space:pre-wrap;">162(m) of the Code or the regulations thereunder, in applying the foregoing limitations with respect to a Grantee, if any Option or SAR is canceled, the canceled Option or SAR shall continue to count against the maximum number of Shares with respect to which Options and SARs may be granted to the Grantee.  For this purpose, the repricing of an Option (or in the case of a SAR, the base amount on which the stock appreciation is calculated is reduced to reflect a reduction in the Fair Market Value of the Common Stock) shall be treated as the cancellation of the existing Option or SAR and the grant of a new Option or SAR.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Individual Limit for Restricted Stock and Restricted Stock Units</u><font style="white-space:pre-wrap;">.  For awards of Restricted Stock and Restricted Stock Units that are intended to be Performance-Based Compensation, the maximum</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">number of Shares with respect to which such Awards may be granted to any Grantee in any calendar year shall be 5,725,171 Shares.  The foregoing limitation shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section&#160;&#8206;10, below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Deferral</u>. If the vesting or receipt of Shares under an Award is deferred to a later date, any amount (whether denominated in Shares or cash) paid in addition to the original number of Shares subject to such Award will not be treated as an increase in the number of Shares subject to the Award if the additional amount is based either on a reasonable rate of interest or on one or more predetermined actual investments such that the amount payable by the Company at the later date will be based on the actual rate of return of a specific investment (including any decrease as well as any increase in the value of an investment).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Early Exercise</u><font style="white-space:pre-wrap;">.  The Award Agreement may, but need not, include a provision whereby the Grantee may elect at any time while an Employee, Director or Consultant to exercise any part or all of the Award prior to full vesting of the Award.  Any unvested Shares received pursuant to such exercise may be subject to a repurchase right in favor of the Company or a Related Entity or to any other restriction the Administrator determines to be appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Term of Award</u><font style="white-space:pre-wrap;">.  The term of each Award shall be the term stated in the Award Agreement, provided, however, that the term of an Award shall be no more than ten&#160;</font><font style="white-space:pre-wrap;">(10) years from the date of grant thereof.  However, in the case of an Incentive Stock Option granted to a Grantee who, at the time the Option is granted, owns stock representing more than ten&#160;percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the term of the Incentive Stock Option shall be five&#160;(5) years from the date of grant thereof or such shorter term as may be provided in the Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Transferability of Awards</u><font style="white-space:pre-wrap;">.  Incentive Stock Options or Options to Israeli Grantees may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Grantee, only by the Grantee.  Other Awards shall be transferable (i)&#160;by will and by the laws of descent and distribution and (ii)&#160;</font><font style="white-space:pre-wrap;">during the lifetime of the Grantee, to the extent and in the manner authorized by the Administrator but only to the extent such transfers are made to family members, to family trusts, to family controlled entities, to charitable organizations, and pursuant to domestic relations orders or agreements, in all cases without payment for such transfers to the Grantee.  Notwithstanding the foregoing, the Grantee may designate one or more beneficiaries of the Grantee&#8217;s Award in the event of the Grantee&#8217;s death on a beneficiary designation form provided by the Administrator.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Time of Granting Awards</u><font style="white-space:pre-wrap;">.  The date of grant of an Award shall for all purposes be the date on which the Administrator makes the determination to grant such Award, or such other date as is determined by the Administrator.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Award Exercise or Purchase Price, Consideration and Taxes</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Exercise or Purchase Price</u><font style="white-space:pre-wrap;">.  The exercise or purchase price, if any, for an Award shall be as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of an Incentive Stock Option:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(A)&#160;&#160;granted to an Employee who, at the time of the grant of such Incentive Stock Option owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the per Share exercise price shall be not less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(B)&#160;&#160;granted to any Employee other than an Employee described in the preceding paragraph, the per Share exercise price shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of a Non-Qualified Stock Option, the per Share exercise price shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of Awards intended to qualify as Performance-Based Compensation, the exercise or purchase price, if any, shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of SARs (other than with respect to Israeli Grantees), the base appreciation amount shall not be less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of other Awards, such price as is determined by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of this Section&#160;&#8206;7&#8206;(a), in the case of an Award issued pursuant to Section&#160;&#8206;6(d), above, the exercise or purchase price for the Award shall be determined in accordance with the provisions of the relevant instrument evidencing the agreement to issue such Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Consideration</u><font style="white-space:pre-wrap;">.  Subject to Applicable Laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award including the method of payment, shall be determined by the Administrator.  In addition to any other types of consideration the Administrator may determine, the Administrator is authorized to accept as consideration for Shares issued under the Plan the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;cash;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;check;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;surrender of Shares or delivery of a properly executed form of attestation of ownership of Shares as the Administrator may require which have a Fair Market Value on the date of surrender or attestation equal to the aggregate exercise price of the Shares as to which said Award shall be exercised;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;with respect to Options, payment through a broker-dealer sale and remittance procedure pursuant to which the Grantee (A) shall provide written instructions to a Company designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company sufficient funds to cover the aggregate exercise price payable for the purchased Shares and (B) shall provide written directives to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale transaction; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;with respect to Options, payment through a &#8220;net exercise&#8221; such that, without the payment of any funds, the Grantee may exercise the Option and receive the net number of Shares equal to (i)&#160;the number of Shares as to which the Option is being exercised, multiplied by (ii)&#160;a fraction, the numerator of which is the Fair Market Value per Share (on such date as is determined by the Administrator) less the Exercise Price per Share, and the denominator of which is such Fair Market Value per Share (the number of net Shares to be received shall be rounded down to the nearest whole number of Shares);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any combination of the foregoing methods of payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Administrator may at any time or from time to time, by adoption of or by amendment to the standard forms of Award Agreement described in Section&#160;4(b)(iv), or by other means, grant Awards which do not permit all of the foregoing forms of consideration to be used in payment for the Shares or which otherwise restrict one or more forms of consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Taxes</u><font style="white-space:pre-wrap;">.  No Shares shall be delivered under the Plan to any Grantee or other person until such Grantee or other person has made arrangements acceptable to the Administrator for the satisfaction of any non-U.S., federal, state, or local income and employment tax withholding obligations, including, without limitation, obligations incident to the receipt of Shares.  Upon exercise or vesting of an Award the Company shall withhold or collect from the Grantee an amount sufficient to satisfy such tax obligations, including, but not limited to, by surrender of the whole number of Shares covered by the Award sufficient to satisfy the minimum applicable tax withholding obligations incident to the exercise or vesting of an Award (reduced to the lowest whole number of Shares if such number of Shares withheld would result in withholding a fractional Share with any remaining tax withholding settled in cash).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Exercise of Award</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Procedure for Exercise; Rights as a Stockholder</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any Award granted hereunder shall be exercisable at such times and under such conditions as determined by the Administrator under the terms of the Plan and specified in the Award Agreement provided however that the standard vesting schedule for Israeli Grantees shall be as set forth in Section 20.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;An Award shall be deemed to be exercised when written notice of such exercise has been given to the Company in accordance with the terms of the Award by the person entitled to exercise the Award and full payment for the Shares with respect to which the Award is exercised has been made, including, to the extent selected, use of the broker-dealer sale and remittance procedure to pay the purchase price as provided in Section&#160;7(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Exercise of Award Following Termination of Continuous Service</u><font style="white-space:pre-wrap;">.  In the event of termination of a Grantee&#8217;s Continuous Service for any reason other than Cause, Disability or death, such Grantee may, but only within twelve&#160;</font><font style="white-space:pre-wrap;">(12) months from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator.  To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Exercise of Award Following Termination of Continuous Service for Cause</u><font style="white-space:pre-wrap;">.  In the event of termination of a Grantee&#8217;s Continuous Service for Cause, such Grantee may, but only within fourteen&#160;</font><font style="white-space:pre-wrap;">(14) days from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator.  To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Disability of Grantee</u><font style="white-space:pre-wrap;">.  In the event of termination of a Grantee&#8217;s Continuous Service as a result of his or her Disability, such Grantee may, but only within twelve&#160;</font><font style="white-space:pre-wrap;">(12) months from the date of such termination (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration date of the term of such Award as set forth in the Award Agreement), exercise the portion of the Grantee&#8217;s Award that was vested at the date of such termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator.  To the extent that the Grantee&#8217;s Award was unvested at the date of termination, or if Grantee does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Death of Grantee</u><font style="white-space:pre-wrap;">.  In the event of a termination of the Grantee&#8217;s Continuous Service as a result of his or her death, or in the event of the death of the Grantee during the post-termination exercise periods following the Grantee&#8217;s termination of Continuous Service specified in this Section 8, above, the Grantee&#8217;s estate or a person who acquired the right to exercise the Award by bequest or inheritance may exercise the portion of the Grantee&#8217;s Award that was vested as of the date of termination or such other portion of the Grantee&#8217;s Award as may be determined by the Administrator, within twelve (12) months from the date of death (or such longer or shorter period as specified in the Award Agreement but in no event later than the expiration of the term of such Award as set forth in the Award Agreement).  To the extent that, at the time of death, the Grantee&#8217;s Award was unvested, or if the Grantee&#8217;s estate or a person who acquired the right to exercise the Award by bequest or inheritance does not exercise the vested portion of the Grantee&#8217;s Award within the time specified herein, the Award shall terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The holder of an Option shall have none of the rights of a stockholder with respect to the Shares subject to the Option until such shares are transferred to the holder (or the Trustee, if applicable) upon the exercise of the Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Conditions Upon Issuance of Shares</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">If at any time the Administrator determines that the delivery of Shares pursuant to the exercise, vesting or any other provision of an Award is or may be unlawful under Applicable Laws, the vesting or right to exercise an Award or to otherwise receive Shares pursuant to the terms of an Award shall be suspended until the Administrator determines that such delivery is lawful and shall be further subject to the approval of counsel for the Company with respect to such compliance.  The Company shall have no obligation to effect any registration or qualification of the Shares under federal or state laws or other Applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">As a condition to the exercise of an Award, the Company may require the person exercising such Award make such representations and warranties  which, in the opinion of the Company, are required to ensure that such exercise, or a subsequent sale or disposition of any Shares obtained upon such exercise, does not contravene any Applicable Law, including inter alia, representations and warranties at the time of any such exercise that the Shares are</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="white-space:pre-wrap;">Unless otherwise set forth in an Award Agreement, Shares issued to a Grantee or the Trustee, as applicable, shall be subject to such restrictions as required by the appropriate securities&#8217; law and in the  event  that the  Company&#39;s shares  shall  be  registered  for  trading  in any  public  market, Grantee&#39;s  rights to sell the  Shares  may be  subject  to  certain limitations  (including a lock-up  period),  as will be requested by the Company or its  underwriters,  and the Grantee by executing an Award Agreement unconditionally agrees and accepts any such limitations and undertakes to further execute any agreement as may be requested by the Company or its underwriters from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Adjustments Upon Changes in Capitalization</u><font style="white-space:pre-wrap;">.  Subject to any required action by the stockholders of the Company, the number of Shares covered by each outstanding Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards have yet been granted or which have been returned to the Plan, the exercise or purchase price of each such outstanding Award, the maximum number of Shares with respect to which Awards may be granted to any Grantee in any calendar year, as well as any other terms that the Administrator determines require adjustment shall be proportionately adjusted for (i)&#160;any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Shares, or similar transaction affecting the Shares, (ii)&#160;</font><font style="white-space:pre-wrap;">any other increase or decrease in the number of issued Shares effected without receipt of consideration by the Company, or (iii) any other transaction with respect to Common Stock including a corporate merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or complete) or any similar transaction; provided, however that conversion of any convertible securities of the Company shall not be deemed to have been &#8220;effected without receipt of consideration.&#8221;  In the event of any distribution of cash or other assets to stockholders other than a normal cash dividend, the Administrator shall also make such adjustments as provided in this Section 10 or substitute, exchange or grant Awards to effect such adjustments (collectively &#8220;adjustments&#8221;).  Any such adjustments to outstanding Awards will be effected in a manner that precludes the enlargement of rights and benefits under such Awards. In connection with the foregoing adjustments, the Administrator may, in its discretion, prohibit the exercise of Awards or other issuance of Shares, cash or other consideration pursuant to Awards during certain periods of time.  Except as the Administrator determines, no issuance by the Company of shares of any class, or securities convertible into shares of any class, shall affect, and no adjustment by reason hereof shall be made with respect to, the number or price of Shares subject to an Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Corporate Transactions and Changes in Control</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Termination of Award to Extent Not Assumed in Corporate Transaction</u><font style="white-space:pre-wrap;">.  Effective upon the consummation of a Corporate Transaction, all outstanding Awards under the Plan shall terminate.  However, all such Awards shall not terminate to the extent they are Assumed in connection with the Corporate Transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Acceleration of Award Upon Corporate Transaction or Change in Control</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Corporate Transaction</u><font style="white-space:pre-wrap;">.  Except as provided otherwise in an individual Award Agreement, in the event of a Corporate Transaction and:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(A)&#160;&#160;for the portion of each Award that is Assumed or Replaced, then such Award (if Assumed), the replacement Award (if Replaced), or the cash incentive program (if Replaced) automatically shall become fully vested, exercisable and payable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares (or other consideration) at the time represented by such Assumed or Replaced portion of the Award, immediately upon termination of the Grantee&#8217;s Continuous Service if such Continuous Service is terminated by the successor company or the Company without Cause within twelve (12) months after the Corporate Transaction; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(B)&#160;&#160;&#160;for the portion of each Award that is neither Assumed nor Replaced, such portion of the Award shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares (or other consideration) at the time represented by such portion of the Award, immediately prior to the specified effective date of such Corporate Transaction, provided that the Grantee&#8217;s Continuous Service has not terminated prior to such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Change in Control</u><font style="white-space:pre-wrap;">.  Except as provided otherwise in an individual Award Agreement, following a Change in Control (other than a Change in Control which also is a Corporate Transaction) and upon the termination of the Continuous Service of a Grantee if such Continuous Service is terminated by the Company</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">or Related Entity without Cause within twelve (12) months after a Change in Control, each Award of such Grantee which is at the time outstanding under the Plan automatically shall become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value), immediately upon the termination of such Continuous Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Effect of Acceleration on Incentive Stock Options</u><font style="white-space:pre-wrap;">.  Any Incentive Stock Option accelerated under this Section&#160;&#8206;11 in connection with a Corporate Transaction or Change in Control shall remain exercisable as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section&#160;422(d) of the Code is not exceeded.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">12.&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Effective Date and Term of Plan</u><font style="white-space:pre-wrap;">.  The Plan shall become effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company.  It shall continue in effect until December 31, 2028 unless sooner terminated.  Subject to Section&#160;&#8206;17, below, and Applicable Laws, Awards may be granted under the Plan upon its becoming effective.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Amendment, Suspension or Termination of the Plan</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Board may at any time amend, suspend or terminate the Plan; provided, however, that no such amendment shall be made without the approval of the Company&#8217;s stockholders to the extent such approval is required by Applicable Laws, or if such amendment would lessen the stockholder approval requirements of Section&#160;4(b)(vi) or this Section 13(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Award may be granted during any suspension of the Plan or after termination of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No suspension or termination of the Plan (including termination of the Plan under Section&#160;&#8206;11, above) shall adversely affect any rights under Awards already granted to a Grantee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Reservation of Shares</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company, during the term of the Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">No Effect on Terms of Employment/Consulting Relationship</u><font style="white-space:pre-wrap;">.  The Plan shall not confer upon any Grantee any right with respect to the Grantee&#8217;s Continuous Service, nor shall it interfere in any way with his or her right or the right of the Company or any Related Entity to terminate the Grantee&#8217;s Continuous Service at any time, with or without cause, including but not limited to, Cause, and with or without notice.  The ability of the Company or any Related Entity to terminate the employment of a Grantee who is employed at will is in no way affected by its determination that the Grantee&#8217;s Continuous Service has been terminated for Cause for the purposes of this Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">No Effect on Retirement and Other Benefit Plans</u><font style="white-space:pre-wrap;">.  Except as specifically provided in a retirement or other benefit plan of the Company or a Related Entity, Awards shall not be deemed compensation for purposes of computing benefits or contributions under any retirement plan of the Company or a Related Entity, and shall not affect any benefits under any other benefit plan of any kind or any benefit plan subsequently instituted under which the availability or amount of benefits is related to level of compensation.  The Plan is not a &#8220;Pension Plan&#8221; or &#8220;Welfare Plan&#8221; under the Employee Retirement Income Security Act of 1974, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Stockholder Approval</u><font style="white-space:pre-wrap;">.  The grant of Incentive Stock Options under the Plan shall be subject to approval by the stockholders of the Company within twelve (12) months before or after the date the Plan is adopted excluding Incentive Stock Options issued in substitution for outstanding Incentive Stock Options pursuant to Section&#160;</font><font style="white-space:pre-wrap;">424(a) of the Code.  Such stockholder approval shall be obtained in the degree and manner required under Applicable Laws.  The Administrator may grant Incentive Stock Options under the Plan prior to approval by the stockholders, but until such approval is obtained, no such Incentive Stock Option shall be exercisable.  In the event that stockholder approval is not obtained within the twelve (12) month period provided above, all Incentive Stock Options previously granted under the Plan shall be exercisable as Non-Qualified Stock Options.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Unfunded Obligation</u><font style="white-space:pre-wrap;">.  Grantees shall have the status of general unsecured creditors of the Company.  Any amounts payable to Grantees pursuant to the Plan shall be unfunded and unsecured obligations for all purposes, including, without limitation, Title&#160;</font><font style="white-space:pre-wrap;">I of the Employee Retirement Income Security Act of 1974, as amended.  Neither the Company nor any Related Entity shall be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations.  The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder.  Any investments or the creation or maintenance of any trust or any Grantee account shall not create or constitute a trust or fiduciary relationship between the Administrator, the Company or any Related Entity and a Grantee, or otherwise create any vested or beneficial interest in any Grantee or the Grantee&#8217;s creditors in any assets of the Company or a Related Entity. The Grantees shall have no claim against the Company or any Related Entity for any changes in the value of any assets that may be invested or reinvested by the Company with respect to the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Construction</u><font style="white-space:pre-wrap;">.  Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan.  Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.  Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Israeli Grantees</u>. This Section shall apply only to Israeli Grantees and is intended to enable the Company to grant Awards under the Plan pursuant and subject to Section 102 and Section 3(I) of the Tax Ordinance. Accordingly, the Plan is designated to comply with the Tax Ordinance and the rules, regulations and orders or procedures promulgated thereunder from time to time, as amended or replaced from time to time and shall be submitted to the ITA as required thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In any case of contradiction, whether explicit or implied, between the provisions of this Section and the Plan, the provisions set out in this Section shall prevail unless the Administrator decides otherwise to ensure compliance with the Tax Ordinance and other Applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Eligibility</u>. 102 Options may be granted only to Israeli Employees. Non-Employees may only be granted 3(I) Options. The grant of an Award hereunder shall neither entitle the Grantee to participate nor disqualify the Israeli Grantee from participating in, any other grant of Awards pursuant to the Plan or any other option or stock plan of the Company or any Related Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Grant of Awards in Trust</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Grants Made Under Section 102</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:146.4pt;margin:0pt 0pt 10pt 0pt;">The Company may designate 102 Options as Trustee 102 Options or Non-Trustee 102 Options. The designation of Non-Trustee 102 Options and Trustee 102 Options shall be subject to the terms and conditions set forth in Section 102 of the Tax Ordinance and the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Grant of Trustee 102 Options</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(1) The grant of the Trustee 102 Options shall be made under the Plan and shall be conditional upon the approval of the Plan by the ITA. Trustee 102 Options may be granted at any time after the passage of thirty (30) days following the delivery by the Company to the ITA of a notice pertaining to the appointment of the Trustee and the adoption of the Plan, unless otherwise determined by the ITA. Options which shall be granted pursuant to Section 102 and/or any Shares issued upon exercise of such Options and/or other shares received subsequently following any realization of rights, shall be issued to the Trustee. Each Israeli Grantee in respect of whom a Trustee 102 Option is granted and held in trust by the Trustee shall be referred to as a &#8220;beneficial optionee&#8221; hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(2) Trustee 102 Option(s) may either be classified as Capital Gain Option(s) or Ordinary Income Option(s):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:170.1pt;margin:0pt 0pt 10pt 0pt;">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trustee 102 Option(s) elected and designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) shall be referred to herein as &#8220;Capital Gain Option(s)&#8221; or &#8220;CGO&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:170.1pt;margin:0pt 0pt 10pt 0pt;">(B)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trustee 102 Option(s) elected and designated by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) shall be referred to herein as &#8220;Ordinary Income Option(s)&#8221; or &#8220;OIO&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(3) The Company&#8217;s election of the type of Trustee 102 Options as CGO or OIO granted to Employees (the &#8220;Election&#8221;) shall be appropriately filed with the ITA 30 days before the date of grant of a Trustee 102 Option, unless otherwise determined by the ITA. Such Election shall become effective beginning the first date of grant of a Trustee 102 Option under this Plan and shall remain in effect until the end of the year following the year during which the Company first granted Trustee 102 Options. The Election shall obligate the Company to grant only the type of Trustee 102 Option it has elected, and shall apply to all Israeli Grantees who were granted Trustee 102 Options during the period indicated herein or therein, all in accordance with the provisions of Section 102(g) of the Tax Ordinance. Notwithstanding, such Election shall not prevent the Company from granting Non-Trustee 102 Options simultaneously.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(4) All Trustee 102 Options must be held in trust by and issued on the name of the Trustee, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(5) With respect to Trustee 102 Options, the provisions of the Plan and/or an Award Agreement shall be subject to the provisions of Section 102 and the ITA&#8217;s permit, and the said provisions and permit shall be deemed an integral part of this Section and of the Award Agreement for the respective Grantees thereof. Any provision of Section 102 and/or the said permit which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in the Plan or the Award Agreement, shall be considered binding upon the Company and the Israeli Grantee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Issuance to Trustee</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(1) All Trustee 102 Options granted under the Plan and/or any Shares allocated or issued upon exercise of such Trustee 102 Options and/or other and all rights deriving from or in connection therewith, including, without limitation, in accordance with Section 10 above or any bonus shares or stock dividends issued in connection therewith shall be granted by the Company to the Trustee, and the Trustee shall hold each such Trustee 102 Option and the Shares issued upon exercise thereof in trust for such period of time as required by Section 102 or any regulations, rules or orders or procedures promulgated thereunder (the &#8220;Holding Period&#8221;), for the benefit of the Grantees in respect of whom such Trustee 102 Option was granted. All certificates representing Shares issued to the Trustee under the Plan shall be deposited with the Trustee, and shall be held by the Trustee until such time that such Shares are released from the Trust as herein provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(2) In event the requirements for Trustee 102 Options are not met for any reason whatsoever, then the Trustee 102 Options may be treated as Non-Trustee 102 Options, all in accordance with the provisions of Section 102 and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">(3) With respect to any Trustee 102 Option, subject to the provisions of Section 102 and any rules or regulations or orders or procedures promulgated thereunder, an Israeli Grantee shall not be entitled to sell or release from Trust the Trustee 102 Option, the Shares received upon the exercise of such Option and/or any right deriving from or in connection therewith, including, without limitation, in accordance with Section 10 above or any bonus shares or stock dividends issued in connection therewith, until the later of: (i) the lapse of the Holding Period required under Section 102, and (ii) the vesting of such Options set forth in the respective Award Agreement (such later date being hereinafter referred to as the &#8220;Release Date&#8221;).  Notwithstanding the foregoing, if such sale or release occurs during the Holding period, the provisions of Section 102 and the rules or regulations promulgated thereunder shall apply and any expenses and/or tax consequences therefrom shall be borne by the Israeli Grantee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(4) Subject to the terms hereof, at any time after the Release Date with respect to any Trustee 102 Options or Shares the following shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:170.1pt;margin:0pt 0pt 10pt 0pt;">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trustee 102 Options granted, and/or Shares or rights issued to the Trustee shall continue to be held by the Trustee, on behalf of the beneficial optionee. From and after the Release Date, upon the written request of any beneficial optionee, the Trustee shall release from the Trust the Trustee 102 Options granted, and/or the Shares or rights issued, on behalf of such beneficial optionee, by executing and delivering to the Company such instrument(s) as the Company may require, giving due notice of such release to such beneficial optionee, provided, however, that the Trustee shall not so release any such Trustee 102 Options and/or Shares and/or rights to such beneficial optionee unless the latter, prior to, or concurrently with, such release, provides the Trustee with evidence, satisfactory in form and substance to the Trustee, that all taxes, if any, required to be paid upon such release have, in fact, been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:170.1pt;margin:0pt 0pt 10pt 0pt;">(B)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Alternatively, from and after the Release Date, upon the written instructions of the beneficial optionee to sell any Shares and rights issued upon exercise of Trustee 102 Options, the Trustee shall use its best efforts to effect such sale and shall transfer such Shares to the purchaser thereof concurrently with the receipt, or after having made suitable arrangements to secure the payment, of the purchase price in such transactions. The Trustee shall withhold from such proceeds any and all taxes required to be paid in respect of such sale, shall remit the amount so withheld to the appropriate tax authorities and shall pay the balance thereof directly to the beneficial optionee, reporting to such beneficial optionee and to the Company the amount so withheld and paid to said authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:170.1pt;margin:0pt 0pt 10pt 0pt;">(C)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, in the event the underwriters of securities of the Company impose restrictions on the transferability of the Shares during a lock-up period, the beneficial optionee shall not be entitled to release from Trust the Trustee 102 Options granted and/or the Shares issued and/or to instruct the Trustee to effect a sale of same, for as long as the restrictions are in effect. In the event the Trustee 102 Options granted and/or the Shares issued have been released from trust the restrictions imposed on the transferability of same shall nevertheless apply to said optionee&#8217;s Trustee 102 Options and/or Shares in the same manner. Consequently, the Israeli Grantee shall sign any documents required in order to effect the restrictions, for as long as the restrictions are in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:170.1pt;margin:0pt 0pt 10pt 0pt;">(D)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon receipt of the Award, the Israeli Grantee will sign an undertaking to release the Trustee from any liability in respect of any action or decision duly taken and bona fide executed in relation with the Plan, or any Option or Share or rights granted to same thereunder. The Trustee may establish additional terms and conditions in connection with Awards held in trust by the Trustee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Grant of Non-Trustee 102 Options</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(1) Awards granted pursuant to this subsection are intended to constitute Non-Trustee 102 Options and shall be subject to the general terms and conditions of the Plan and Section 20, except for provisions of the Plan applying to Trustee 102 Awards or Options under a different tax law or regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">(2) With respect to Non-Trustee 102 Options, if the Grantee ceases to be employed by or of service to the Company or a Related Company, the Grantee may be required to extend to the Company a security or guarantee for the payment of tax due at the time of sale of Shares or other rights, all in accordance with the provisions of Section 102 and the rules, regulation or orders promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Grants Made Under Section 3(I)</u><font style="white-space:pre-wrap;">. Awards granted pursuant to this subsection are intended to constitute 3(I) Options and shall be subject to the general terms and conditions of the Plan and Section 20 thereof, except for said provisions of the Plan applying to Awards under a different tax law or regulation. The Administrator may choose to deposit the Awards granted pursuant to Section 3(I) of the Tax Ordinance with a trustee. In such event, said trustee shall hold such Option in trust, until exercised by the Grantee, pursuant to the Company&#39;s instructions from time to time.  If determined by the Administrator, the trustee shall be responsible for withholding any taxes to which a Grantee become liable upon the exercise of Options.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Award Agreement</u>. Without derogating from the powers of the Administrator under the Plan, the Administrator shall adopt the form of Award Agreement for Israeli Grantees in form acceptable by the ITA and in compliance with the Tax Ordinance. The Award Agreement shall further indicate the type of Options (102, 3(I), Trustee, Non-Trustee etc.) granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">Vesting</u>. Without derogating from the terms of any Award Agreement or the discretionary authority of the Administrator, the standard vesting for Options to Israeli Grantees shall be as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Twenty five percent (25%) of the Options granted under each Award Agreement shall vest on the end of the first year of Continuous Service following the vesting commencement date determined by the Administrator and if not specified the date of the grant of an Option (the &#8220;First Anniversary&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The remaining 75% of the Options shall vest on a quarterly basis over a period of three years commencing as of the First Anniversary in twelve (12) equal portions subject to Continuous Service of the Grantee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to all Shares (in contrast to unexercised Options) allocated or issued upon the exercise of Options by the Israeli Grantee, the Grantee shall be entitled to receive dividends in accordance with the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">quantity of such Shares, subject however to any applicable taxation on distribution of dividends. Subject to the Tax Ordinance and any restrictions imposed by the Trustee or the ITA, during the period in which Shares are held by the Trustee on behalf of the Israeli Grantee, the cash dividends paid with respect thereto shall be paid directly to the Grantee after deduction of withholding tax applicable thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without derogating from anything in the Plan, to the extent permitted by Applicable Laws, any tax consequences, attributable to the Israeli Grantee, arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act (of the Company, a Related Company, the Trustee or the Grantee), hereunder, shall be borne solely by the Grantee. The Company and/or or a Related Company and/or the Trustee shall withhold taxes according to the requirements under the Applicable Laws, rules, and regulations, including withholding taxes at source. Furthermore, to the extent permitted by Applicable Law, the Grantee shall agree to indemnify the Company and/or a Related Company and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Grantee. The Administrator and/or the Trustee shall not be required to release any Share certificate to a Grantee until all required payments have been fully made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Plan, to the extent applicable to Israeli Grantees, shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to Israeli Grantees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>plx-20200630xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/10/2020 09:58:50 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 10, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>plx-20200630xex31d2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/10/2020 09:58:53 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 10, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>plx-20200630xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/10/2020 09:58:56 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 10, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>plx-20200630xex32d2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 8/10/2020 09:58:59 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 10, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2020 9:59:17 AM-->
<!--Modified on: 8/10/2020 9:59:17 AM-->
<schema xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:plx="http://www.protalix.com/20200630" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.protalix.com/20200630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" id="DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="Notes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_Notes2021Member" substitutionGroup="xbrli:item" />
  <element id="plx_SupplementaryIncomeStatementInformationTableTextBlock" name="SupplementaryIncomeStatementInformationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsTerm" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsRiskFreeInterestRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsRiskFreeInterestRates" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsExpectedVolatilityRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedVolatilityRates" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsExpectedDividendRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedDividendRates" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNoteMember" substitutionGroup="xbrli:item" />
  <element name="PfizerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_PfizerMember" substitutionGroup="xbrli:item" />
  <element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" name="UpfrontNonrefundableNonCreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ReceivablesFromSaleOfCommonStockAndWarrants" name="ReceivablesFromSaleOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" name="StockIssuedDuringPeriodIssuePricePerShareNewIssues" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" name="WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" name="TotalProceedsFromAccountsReceivableOutstandingFiocruz" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" name="TotalProceedsFromAccountsReceivableOutstandingChiesi" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" name="ChangeInEstimateOfTotalCostsExpectedToBeIncurred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_NonRefundablePayment" name="NonRefundablePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" name="SeniorVicePresidentAndChiefDevelopmentOfficerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_BioManguinhosAlfataligliceraseMember" name="BioManguinhosAlfataligliceraseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_VicePresidentResearchAndDevelopmentMember" name="VicePresidentResearchAndDevelopmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2020 9:59:17 AM-->
<!--Modified on: 8/10/2020 9:59:17 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637326503565428530" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637326503565428530" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637326503565428530" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637326503565428530" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637326503565428530" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637326503565428530" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637326503565428530" xlink:to="plx_ShortTermBankDeposits_637326503565428530" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637326503565438370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637326503565428530" xlink:to="us-gaap_AccountsReceivableNetCurrent_637326503565438370" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637326503565438370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637326503565428530" xlink:to="us-gaap_OtherAssetsCurrent_637326503565438370" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637326503565438370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637326503565428530" xlink:to="us-gaap_InventoryNet_637326503565438370" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637326503565438370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637326503565438370" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_637326503565438370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637326503565438370" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_637326503565438370" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637326503565438370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637326503565438370" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637326503565438370" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637326503565438370" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637326503565438370" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637326503565438370" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637326503565448300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637326503565438370" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637326503565448300" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637326503565448300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637326503565448300" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637326503565448300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637326503565448300" xlink:to="us-gaap_LiabilitiesNoncurrent_637326503565448300" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637326503565448300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637326503565448300" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637326503565448300" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637326503565448300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637326503565448300" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637326503565448300" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637326503565448300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637326503565448300" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637326503565448300" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637326503565458293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637326503565448300" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637326503565458293" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637326503565458293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637326503565448300" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637326503565458293" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637326503565458293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637326503565448300" xlink:to="us-gaap_LiabilitiesCurrent_637326503565458293" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637326503565458293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637326503565458293" xlink:to="us-gaap_AccountsPayableTradeCurrent_637326503565458293" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637326503565458293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637326503565458293" xlink:to="us-gaap_AccountsPayableOtherCurrent_637326503565458293" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637326503565458293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637326503565458293" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637326503565458293" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637326503565458293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637326503565458293" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637326503565458293" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637326503565468293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637326503565458293" xlink:to="us-gaap_NotesPayableCurrent_637326503565468293" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637326503565468293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637326503565468293" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637326503565468293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637326503565468293" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637326503565468293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637326503565468293" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637326503565468293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637326503565468293" xlink:to="us-gaap_OtherNonoperatingExpense_637326503565468293" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637326503565478593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637326503565468293" xlink:to="us-gaap_OtherNonoperatingIncome_637326503565478593" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637326503565478593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_NetIncomeLoss_637326503565478593" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637326503565478593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_ShareBasedCompensation_637326503565478593" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637326503565478593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_Depreciation_637326503565478593" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637326503565478593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637326503565478593" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637326503565478593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637326503565478593" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637326503565488321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637326503565488321" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637326503565488321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_AmortizationOfFinancingCosts_637326503565488321" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637326503565488321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637326503565488321" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637326503565488321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637326503565488321" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637326503565488321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637326503565488321" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637326503565488321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_IncreaseDecreaseInInventories_637326503565488321" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637326503565488321" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637326503565488321" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637326503565498305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503565478593" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637326503565498305" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503565498305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503565498305" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637326503565498305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503565498305" xlink:to="plx_IncreaseDecreaseInBankDeposits_637326503565498305" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637326503565498305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503565498305" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637326503565498305" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_637326503565498305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503565498305" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_637326503565498305" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637326503565498305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503565498305" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637326503565498305" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637326503565498305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637326503565498305" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637326503565508297" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637326503565498305" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637326503565508297" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637326503565508297" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637326503565508297" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637326503565508297" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637326503565508297" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637326503565508297" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637326503565508297" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637326503565508297" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637326503565508297" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2020 9:59:17 AM-->
<!--Modified on: 8/10/2020 9:59:17 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637326503565518804" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637326503565518804" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637326503565538238" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637326503565538238" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637326503565548241" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637326503565548241" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637326503565578240" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637326503565578240" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503565588304" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503565588304" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637326503565588304" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637326503565588304" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637326503565718250" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637326503565718250" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637326503565718250" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637326503565718250" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637326503565738249" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637326503565738249" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_BioManguinhosAlfataligliceraseMember" xlink:label="plx_BioManguinhosAlfataligliceraseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_BioManguinhosAlfataligliceraseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503565808253" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503565808253" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsExpectedDividendRates" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NonRefundablePayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503565848242" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503565848242" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637326503565858250" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_637326503565858250" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_VicePresidentResearchAndDevelopmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637326503565878243" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637326503565878243" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2020 9:59:17 AM-->
<!--Modified on: 8/10/2020 9:59:17 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" xml:lang="en-US">Long-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" xml:lang="en-US">Long-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License And Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses, net (1)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses (2)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Financial expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Financial income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial expenses, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Loss per share of common stock - Basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares of common stock used in computing loss per share - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Amount of receivables from sale of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Receivables From Sale of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses (income), net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (decrease) in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase in bank deposits (including long-term deposits)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants, Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note Receivable from Issuance of Common Stock and Warrants, Net of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2021Member" xlink:to="plx_Notes2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes 2021 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability component based on income approach</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental income statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Income Statement Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">B [R]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non-Creditable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Per share price at which the new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Issue Price Per Share, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Warrants And Rights, Commencement Period For Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants, commencement period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from private placement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" xml:lang="en-US">Proceeds from Sale and Collection of Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Chiesi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" xml:lang="en-US">Total Proceeds from Accounts Receivable Outstanding - Chiesi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Chiesi</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Fiocruz</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" xml:lang="en-US">Total Proceeds from Accounts Receivable Outstanding - Fiocruz</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Fiocruz</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price (USD)</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsTerm" xlink:to="plx_FairValueAssumptionsTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Fair Value Assumptions Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsRiskFreeInterestRates" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Fair Value Assumptions Risk Free Interest Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsExpectedVolatilityRates" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Fair Value Assumptions Expected Volatility Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsExpectedDividendRates" xlink:to="plx_FairValueAssumptionsExpectedDividendRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Fair Value Assumptions Expected Dividend Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNoteMember" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:to="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" xml:lang="en-US">The amount represents the revenue recognized due to a change in estimate of total costs expected to be incured.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" xml:lang="en-US">Change In Estimate Of Total Costs Expected To Be Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" xml:lang="en-US">Revenue recognized due to change in estimate of total costs expected to be incurred</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NonRefundablePayment" xlink:to="plx_NonRefundablePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Amount of non refundable payment not yet recognized to revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Non Refundable Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Non refundable payments not yet recognized to revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_BioManguinhosAlfataligliceraseMember" xlink:label="plx_BioManguinhosAlfataligliceraseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_BioManguinhosAlfataligliceraseMember" xlink:to="plx_BioManguinhosAlfataligliceraseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_BioManguinhosAlfataligliceraseMember_lbl" xml:lang="en-US">This member stands for the product, BioManguinhos alfataliglicerase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_BioManguinhosAlfataligliceraseMember_lbl" xml:lang="en-US">Bio Manguinhos Alfataliglicerase [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_BioManguinhosAlfataligliceraseMember_lbl" xml:lang="en-US">Bio Manguinhos Alfataliglicerase [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">This member stands for Senior Vice President and Chief Development Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">Senior Vice President And Chief Development Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">Sr. Vice President And Chief Development Officer [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Share Based Payment Arrangement Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Non-employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share Based Payment Arrangement Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Certain employees</label>
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VicePresidentResearchAndDevelopmentMember" xlink:to="plx_VicePresidentResearchAndDevelopmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">This member stands for vice president research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">New Vice President Research And Development [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2020 9:59:17 AM-->
<!--Modified on: 8/10/2020 9:59:17 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637326503565918246" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637326503565918246" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637326503565918246" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637326503565918246" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637326503565918246" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637326503565918246" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637326503565918246" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637326503565918246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637326503565918246" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637326503565928255" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637326503565928255" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3_637326503565928255" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637326503565928255" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry_637326503565928255" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637326503565928255" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637326503565928255" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637326503565928255" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637326503565928255" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637326503565928255" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637326503565928255" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637326503565928255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637326503565928255" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637326503565938246" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637326503565938246" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637326503565938246" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637326503565938246" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637326503565938246" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637326503565938246" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637326503565938246" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637326503565938246" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637326503565938246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637326503565938246" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637326503565948242" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637326503565948242" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637326503565948242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637326503565948242" xlink:to="us-gaap_AssetsCurrentAbstract_637326503565948242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637326503565948242" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637326503565948242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637326503565948242" xlink:to="plx_ShortTermBankDeposits_637326503565948242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637326503565948242" xlink:to="us-gaap_AccountsReceivableNetCurrent_637326503565948242" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637326503565948242" xlink:to="us-gaap_OtherAssetsCurrent_637326503565948242" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637326503565948242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637326503565948242" xlink:to="us-gaap_InventoryNet_637326503565948242" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637326503565948242" xlink:to="us-gaap_AssetsCurrent_637326503565958252" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637326503565948242" xlink:to="us-gaap_AssetsNoncurrentAbstract_637326503565958252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637326503565958252" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_637326503565958252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637326503565958252" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637326503565958252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637326503565958252" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637326503565958252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637326503565958252" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637326503565958252" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637326503565958252" xlink:to="us-gaap_AssetsNoncurrent_637326503565958252" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637326503565948242" xlink:to="us-gaap_Assets_637326503565958252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637326503565958252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637326503565958252" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637326503565958252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637326503565958252" xlink:to="us-gaap_AccountsPayableTradeCurrent_637326503565958252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637326503565958252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637326503565958252" xlink:to="us-gaap_AccountsPayableOtherCurrent_637326503565958252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637326503565958252" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637326503565968246" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637326503565958252" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637326503565968246" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637326503565958252" xlink:to="us-gaap_NotesPayableCurrent_637326503565968246" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637326503565958252" xlink:to="us-gaap_LiabilitiesCurrent_637326503565968246" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637326503565968246" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637326503565968246" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637326503565968246" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637326503565968246" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637326503565968246" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637326503565968246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637326503565968246" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637326503565968246" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637326503565978258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637326503565968246" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637326503565978258" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637326503565978258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637326503565968246" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637326503565978258" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637326503565978258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" xlink:to="us-gaap_LiabilitiesNoncurrent_637326503565978258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637326503565978258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" xlink:to="us-gaap_Liabilities_637326503565978258" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637326503565978258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" xlink:to="us-gaap_CommitmentsAndContingencies_637326503565978258" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637326503565978258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" xlink:to="us-gaap_StockholdersEquity_637326503565978258" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637326503565978258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637326503565958252" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637326503565978258" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637326503565988248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503565988248" xlink:to="srt_ProductOrServiceAxis_637326503565988248" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637326503565988248" xlink:to="srt_ProductsAndServicesDomain_637326503565988248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637326503565988248" xlink:to="us-gaap_ProductMember_637326503565988248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637326503565988248" xlink:to="us-gaap_LicenseAndServiceMember_637326503565988248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503565988248" xlink:to="us-gaap_StatementLineItems_637326503565988248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_Revenues_637326503565988248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_CostOfRevenue_637326503565988248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637326503565988248" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637326503565988248" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_OperatingIncomeLoss_637326503565988248" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_OtherNonoperatingExpense_637326503565988248" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_OtherNonoperatingIncome_637326503565988248" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637326503565988248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_NonoperatingIncomeExpense_637326503565988248" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_NetIncomeLoss_637326503565998252" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637326503565998252" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503565988248" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637326503565998252" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637326503565998252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503565998252" xlink:to="us-gaap_IncomeStatementLocationAxis_637326503565998252" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637326503565998252" xlink:to="us-gaap_IncomeStatementLocationDomain_637326503565998252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637326503565998252" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637326503565998252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637326503565998252" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637326503565998252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503565998252" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637326503565998252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637326503565998252" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637326503565998252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637326503565998252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637326503565998252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503565998252" xlink:to="us-gaap_StatementEquityComponentsAxis_637326503566008250" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637326503566008250" xlink:to="us-gaap_EquityComponentDomain_637326503566008250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637326503566008250" xlink:to="us-gaap_CommonStockMember_637326503566008250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637326503566008250" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637326503566008250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637326503566008250" xlink:to="us-gaap_RetainedEarningsMember_637326503566008250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503565998252" xlink:to="us-gaap_StatementLineItems_637326503566008250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="us-gaap_StockholdersEquity_637326503566008250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="us-gaap_SharesOutstanding_637326503566008250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637326503566008250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637326503566008250" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637326503566008250" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants_637326503566008250" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637326503566008250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="us-gaap_NetIncomeLoss_637326503566008250" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6373265035660082501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="us-gaap_StockholdersEquity_6373265035660082501" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6373265035660082501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566008250" xlink:to="us-gaap_SharesOutstanding_6373265035660082501" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637326503566018243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637326503566018243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_NetIncomeLoss_637326503566018243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_ShareBasedCompensation_637326503566018243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_Depreciation_637326503566018243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637326503566018243" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637326503566018243" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637326503566018243" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_AmortizationOfFinancingCosts_637326503566018243" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637326503566018243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637326503566018243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637326503566028252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637326503566028252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" xlink:to="us-gaap_IncreaseDecreaseInInventories_637326503566028252" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637326503566028252" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637326503566018243" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637326503566028252" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637326503566018243" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637326503566028252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637326503566028252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637326503566028252" xlink:to="plx_IncreaseDecreaseInBankDeposits_637326503566028252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637326503566028252" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637326503566028252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637326503566028252" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_637326503566028252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637326503566028252" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637326503566028252" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637326503566028252" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637326503566028252" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637326503566028252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637326503566028252" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637326503566038244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637326503566028252" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637326503566038244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637326503566038244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637326503566028252" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637326503566038244" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637326503566038244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637326503566038244" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637326503566038244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637326503566038244" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637326503566038244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637326503566038244" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6373265035660382441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6373265035660382441" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637326503566038244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637326503566038244" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637326503566038244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637326503566038244" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637326503566038244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637326503566048254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637326503566038244" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637326503566048254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637326503566048254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637326503566038244" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637326503566048254" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637326503566048254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637326503566048254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637326503566048254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637326503566048254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637326503566048254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637326503566048254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637326503566058259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637326503566058259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10601 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637326503566058259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637326503566058259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637326503566058259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637326503566058259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637326503566058259" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637326503566058259" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637326503566058259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637326503566058259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566068258" xlink:to="us-gaap_DebtInstrumentAxis_637326503566068258" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637326503566068258" xlink:to="us-gaap_DebtInstrumentNameDomain_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637326503566068258" xlink:to="plx_Notes2021Member_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566068258" xlink:to="us-gaap_StatementLineItems_637326503566068258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566068258" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637326503566068258" xlink:to="us-gaap_TypeOfArrangementAxis_637326503566068258" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637326503566068258" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566068258" xlink:to="plx_AmendedPfizerAgreementMember_637326503566068258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637326503566068258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566068258" xlink:to="plx_ChiesiUSAgreementMember_637326503566068258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566068258" xlink:to="plx_ChiesiExUSAgreementMember_637326503566078258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637326503566068258" xlink:to="dei_LegalEntityAxis_637326503566078258" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637326503566078258" xlink:to="dei_EntityDomain_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637326503566078258" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637326503566068258" xlink:to="srt_StatementGeographicalAxis_637326503566078258" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637326503566078258" xlink:to="srt_SegmentGeographicalDomain_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637326503566078258" xlink:to="country_BR_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637326503566068258" xlink:to="srt_RangeAxis_637326503566078258" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637326503566078258" xlink:to="srt_RangeMember_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637326503566078258" xlink:to="srt_MinimumMember_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637326503566078258" xlink:to="srt_MaximumMember_637326503566078258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637326503566068258" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637326503566078258" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637326503566078258" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637326503566078258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637326503566078258" xlink:to="us-gaap_PrivatePlacementMember_637326503566078258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637326503566068258" xlink:to="srt_ProductOrServiceAxis_637326503566088253" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637326503566088253" xlink:to="srt_ProductsAndServicesDomain_637326503566088253" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_BioManguinhosAlfataligliceraseMember" xlink:label="plx_BioManguinhosAlfataligliceraseMember_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637326503566088253" xlink:to="plx_BioManguinhosAlfataligliceraseMember_637326503566088253" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637326503566068258" xlink:to="plx_SignificantAccountingPoliciesLineItems_637326503566088253" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637326503566088253" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637326503566088253" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637326503566088253" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637326503566088253" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637326503566088253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637326503566088253" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637326503566098254" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637326503566098254" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_PaymentOnNetSalesPercentage_637326503566098254" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637326503566098254" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637326503566098254" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637326503566098254" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637326503566098254" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637326503566098254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637326503566098254" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637326503566108251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637326503566108251" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637326503566108251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637326503566108251" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_637326503566108251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_637326503566108251" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_637326503566108251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_637326503566108251" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_637326503566108251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_637326503566108251" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_637326503566108251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637326503566088253" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_637326503566108251" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637326503566118248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637326503566118248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637326503566118248" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637326503566118248" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_StatementTable_637326503566118248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566118248" xlink:to="us-gaap_DebtInstrumentAxis_637326503566118248" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637326503566118248" xlink:to="us-gaap_DebtInstrumentNameDomain_637326503566118248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637326503566118248" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637326503566118248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566118248" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637326503566118248" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637326503566118248" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503566118248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503566118248" xlink:to="us-gaap_FairValueInputsLevel3Member_637326503566118248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637326503566118248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566118248" xlink:to="us-gaap_StatementLineItems_637326503566118248" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566118248" xlink:to="us-gaap_SharePrice_637326503566128260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566118248" xlink:to="plx_FairValueAssumptionsTerm_637326503566128260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566118248" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates_637326503566128260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566118248" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates_637326503566128260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566118248" xlink:to="plx_FairValueAssumptionsExpectedDividendRates_637326503566128260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_StatementTable_637326503566128260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566128260" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637326503566128260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637326503566128260" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503566128260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637326503566128260" xlink:to="us-gaap_FairValueInputsLevel3Member_637326503566128260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566128260" xlink:to="us-gaap_DebtInstrumentAxis_637326503566128260" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637326503566128260" xlink:to="us-gaap_DebtInstrumentNameDomain_637326503566128260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_637326503566128260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637326503566128260" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_637326503566128260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566128260" xlink:to="us-gaap_StatementLineItems_637326503566138259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566138259" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637326503566138259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566138259" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637326503566138259" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566138259" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637326503566138259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637326503566138259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566138259" xlink:to="srt_ProductOrServiceAxis_637326503566138259" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637326503566138259" xlink:to="srt_ProductsAndServicesDomain_637326503566138259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637326503566138259" xlink:to="us-gaap_ProductMember_637326503566138259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637326503566138259" xlink:to="us-gaap_LicenseAndServiceMember_637326503566138259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566138259" xlink:to="us-gaap_TypeOfArrangementAxis_637326503566138259" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637326503566138259" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566138259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637326503566138259" xlink:to="plx_ChiesiUSAgreementMember_637326503566138259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637326503566138259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566138259" xlink:to="srt_StatementGeographicalAxis_637326503566138259" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637326503566138259" xlink:to="srt_SegmentGeographicalDomain_637326503566148260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637326503566148260" xlink:to="plx_PfizerMember_637326503566148260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637326503566148260" xlink:to="country_BR_637326503566148260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637326503566138259" xlink:to="us-gaap_StatementLineItems_637326503566148260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566148260" xlink:to="us-gaap_Revenues_637326503566148260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566148260" xlink:to="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_637326503566148260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637326503566148260" xlink:to="plx_NonRefundablePayment_637326503566148260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637326503566148260" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637326503566148260" xlink:to="srt_TitleOfIndividualAxis_637326503566148260" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637326503566148260" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503566148260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503566148260" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_637326503566148260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637326503566148260" xlink:to="us-gaap_GranteeStatusAxis_637326503566148260" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637326503566148260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637326503566148260" xlink:to="us-gaap_GranteeStatusDomain_637326503566148260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637326503566148260" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637326503566158257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637326503566148260" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637326503566158257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637326503566148260" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637326503566158257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637326503566158257" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637326503566158257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637326503566158257" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637326503566158257" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637326503566158257" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637326503566158257" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637326503566158257" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637326503566158257" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637326503566158257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637326503566158257" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637326503566158257" order="10" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637326503566168254" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637326503566168254" xlink:to="srt_TitleOfIndividualAxis_637326503566168254" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637326503566168254" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503566168254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637326503566168254" xlink:to="plx_VicePresidentResearchAndDevelopmentMember_637326503566168254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637326503566168254" xlink:to="us-gaap_SubsequentEventTypeAxis_637326503566168254" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637326503566168254" xlink:to="us-gaap_SubsequentEventTypeDomain_637326503566168254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637326503566168254" xlink:to="us-gaap_SubsequentEventMember_637326503566168254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637326503566168254" xlink:to="us-gaap_GranteeStatusAxis_637326503566168254" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637326503566168254" xlink:to="us-gaap_GranteeStatusDomain_637326503566168254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637326503566168254" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637326503566168254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637326503566168254" xlink:to="us-gaap_SubsequentEventLineItems_637326503566168254" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637326503566168254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637326503566168254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637326503566178264" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637326503566178264" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637326503566178264" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637326503566178264" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637326503566178264" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637326503566178264" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637326503566178264" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637326503566178264" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637326503566178264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637326503566168254" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637326503566178264" order="10" use="optional" priority="3" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>plx-20200630x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20200630x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (?!#@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M75_[,U"2"9G3?'+#T^E'H!LKJED]O).MRABC.';LIJQ%*DT2R1L&1AD$=Q7
M6G_(I:S_ -=_ZBNST/\ Y EG_P!<EH_X #KC6-/M)C%/=QQR#JI/-2VM_:7H
M)MKB.7'7:>E<7J<UA#XRF;48A)!Y8X*[N:?HHBE\32W.EP/%9+&=V1@$XH0,
M[FBN1TG6-<U27S!Y*VL,A$S;>2/;\*=#JVN:LEQ>:?Y$5K$Q"HXR7Q0!UE07
M%Y;VI03RK&7.U<]S7.R>*G/A]+N*)1=/)Y6T] WK69K)U82Z:-2:%PTH96C&
M"#Z&CK8#O**P[/5;B;Q)=6#[?)B0%<#FJ]GX@FSK$ER%,=FWR!1@GK_]:CS
MZ2FET5E5F4,W0$\FN6M;[Q)<VT6H1I;R02-D6X&#M^O_ ->JEZ=3?QI $:)9
M#'E W15[@^_6CK8.ESKTO+>2Y>V293,@RR#J*GKF+:^6+Q+J/F11 11;BZKA
MC^-01ZMK][9RZG;"W2U0DK$RY+ >]'0#KJ*Y2]\3W']G:==6<:[KB0HZ-ZC
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MJI:.R$M=6=78^(]'U*?R;34(99?[H."?IGK6I7,WW@C2;B>UGM4%A+ P(:W
M4MCL:H:SXCU-_$']BZ3/;6[0INEGN,8)]*5PMV.PN;F&SMWN+B18XD&6=N@J
ML^LZ<D5M(UW&$N3B$Y^_]*XJ?Q#<:SX*URWO5C%W: )(T7W6Y&"*S[__ ) ?
M@S_?7_V6B^OW?B.WZ_@>I%@JEB< #)-8Y\6:"&*G5+<$'!!-:=Q_QYR_]<S_
M "KQ_0KWPU;V=['K%GY]P96V$19./KVI.5G8$KJY[#;W,%W"LUO*DL;=&0Y!
MJ6O,?#MUJ&A^"M3U"%&C3S=ULLHSQGTK2LO$NO0:3-KNJQP"P,(:&)!AF<G
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MID-M';R#>J,-QY&2:UM,TRZM];U:YEC BN#^[.1S7044 <K8:-?0>&;^SDB
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MR-@@^M=_12Y1\QPEOX<U(^$]5B>SMX;N[ V0Q # !X!/YTV[\-ZI+I?AJ%(
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MN1?9X_0_G1]GC]#^=2T46"Y%]GC]#^='V>/T/YU+118+C$B5#E<_G61XI_Y
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M,<(';-=;X939:S9_OC^5 &Y1110 4444 %%%% !1110 4444 %%%% !1110
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MCK(T758]0\U0!O!+$^M:]>KAY\]/FN<56+C*S"BBBMC,**** "BBB@ HHHH
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MKE5V#:>@K'O+^RUG33!%\T3/M=3Z5Q4UE<&Z)8.9.O/-)9-?62SE4/S2 G-
M':?V%H6CVJ2Q6H60_P 2UU'A:]:\M)]QRL;A5^F*X/4KBY6SMFD'+KG%=5\/
MG9["\+?\]A_Z"* .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJU_<0VUH[SR+&N,98XJS7,^.?^1>;_KHM:4H\\U'N9UI\E-R70G1UD0.C!E(
MR".].JGI7_(*MO\ <%7*N2LVC*+O%,****104444 %%%% !1110 5X#XR/\
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MV<T]_#]X(M_V1>F>#19B.9N+=54B)MWK73Z#XKO=(L(K6."#RUZE@<FN>G+
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M6L[MHI_+"-TR<9H O7GB;QG=##64)B7G"MS6>OQ!URS)@N[1X4;AF1<XJQ+
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MR?Z'%_NBM>T^XWUH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8W\]E&1&[_O&Z#M@55M].NUU")Y(&50>2:T#J6H7VE>=%<2*\<C>8 V,C Y
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MQY+Y.!M//I7,>%UME%^;>X:8%SN9CGF@#YC\6(1XUO9U38OFL#SUYK/+,UY
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MI!'<@1[L[6'-7?%.G6MM;RPP*IB7!++_ !''-<]H&I6=M97$4\KH0^4],>E
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MI$(HE3& !@"M&%<$5#'#R,FKT2"F(M0CBI)#CO34&%H;WH B8<FF8J4K2!:
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M!I-TS_887C9UV\]J .F\'#0IO"]AOC(N& 0C%.UO6X?"&IBVM(@2W)RN:Q?
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MQ7(P>E<-J%Y&]S*TN[Y/EXH :C8YS@]^*GW_ ,0:LC[1ENA [9J7,A YZ]*
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M]115#P]_R+]C_P!<E_E16$U:31TP?-%,TZ***DH**** "BBB@ HHHH ****
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MYK^5'DQ_\\U_*GT4 ,\J/^XOY4>5'_<7\J?10 SRH_[B_E1Y4?\ <7\J?10
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M/R8O^>:_E3E14&%4#Z"G44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5S/CG_ )%YO^NBUTU5=0MH+NS>.>)9$QG##/-:4I<DU)]#.M!SIN*Z
MF!I7_(*MO]P5<IJ(L:!$4*JC  [4ZKD[MLRBK12"BBBD4%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7\Z9]D@_YY+1]D@_YY+0 _S8_P#GHOYT>;'_ ,]%_.F?9(/^>2T?9(/^>2T
M/\V/_GHOYT>;'_ST7\Z9]D@_YY+1]D@_YY+0 _S8_P#GHOYT>;'_ ,]%_.F?
M9(/^>2T?9(/^>2T /\V/_GHOYT>;'_ST7\Z9]D@_YY+1]D@_YY+0 _S8_P#G
MHOYT>;'_ ,]%_.F?9(/^>2T?9(/^>2T /\V/_GHOYT>;'_ST7\Z9]D@_YY+1
M]D@_YY+0 _S8_P#GHOYT>;'_ ,]%_.F?9(/^>2T?9(/^>2T /\V/_GHOYT>;
M'_ST7\Z9]D@_YY+1]D@_YY+0 _S8_P#GHOYT>;'_ ,]%_.F?9(/^>2T?9(/^
M>2T /\V/_GHOYT>;'_ST7\Z9]D@_YY+1]D@_YY+0 _S8_P#GHOYT>;'_ ,]%
M_.F?9(/^>2T?9(/^>2T /\V/_GHOYT>;'_ST7\Z9]D@_YY+1]D@_YY+0 _S8
M_P#GHOYT>;'_ ,]%_.F?9(/^>2T?9(/^>2T /\V/_GHOYT>;'_ST7\Z9]D@_
MYY+1]D@_YY+0 _S8_P#GHOYT>;'_ ,]%_.F?9(/^>2T?9(/^>2T /\V/_GHO
MYT>;'_ST7\Z9]D@_YY+1]D@_YY+0 _S8_P#GHOYT>;'_ ,]%_.F?9(/^>2T?
M9(/^>2T /\V/_GHOYT>;'_ST7\Z9]D@_YY+1]D@_YY+0 _S8_P#GHOYT>;'_
M ,]%_.F?9(/^>2T?9(/^>2T /\V/_GHOYT>;'_ST7\Z9]D@_YY+1]D@_YY+0
M _S8_P#GHOYT>;'_ ,]%_.F?9(/^>2T?9(/^>2T /\V/_GHOYT>;'_ST7\Z9
M]D@_YY+1]D@_YY+0 _S8_P"^OYT^H?LD'_/-:F P,"@ HHHH **** "BBB@
MK.UK38M4TYX)BP4?-\OM6C5+5+Z"PL7FN&VITSCO50OS+EW(J<KB^;8R[>%;
M:W2%,[4&!FI*9%*D\2RQG*L,@T\C(P:U=[ZF2M;03>O]X?G1O7^\/SIGDQ_W
M!1Y,?]P4AC]Z_P!X?G1O7^\/SIGDQ_W!1Y,?]P4 /WK_ 'A^=5A:VXOVO1CS
MFC$9.>P.?ZU-Y,?]P4>3'_<% #]Z_P!X?G1O7^\/SIGDQ_W!1Y,?]P4 0W-K
M;W;0M*03"^].>AJSO7^\/SIGDQ_W!1Y,?]P4 /WK_>'YT;U_O#\Z9Y,?]P4>
M3'_<% #]Z_WA^=&]?[P_.F>3'_<%'DQ_W!0 _>O]X?G1O7^\/SIGDQ_W!1Y,
M?]P4 /WK_>'YT;U_O#\Z9Y,?]P4>3'_<% #]Z_WA^=&]?[P_.F>3'_<%'DQ_
MW!0 _>O]X?G1O7^\/SIGDQ_W!1Y,?]P4 /WK_>'YT;U_O#\Z9Y,?]P4>3'_<
M% #]Z_WA^=&]?[P_.F>3'_<%'DQ_W!0 _>O]X?G1O7^\/SIGDQ_W!1Y,?]P4
M /WK_>'YT;U_O#\Z9Y,?]P4>3'_<% #]Z_WA^=&]?[P_.F>3'_<%'DQ_W!0!
M#-:V\]U!</@R0YV'/3-6=Z_WA^=,\F/^X*/)C_N"@!^]?[P_.C>O]X?G3/)C
M_N"CR8_[@H ?O7^\/SHWK_>'YTSR8_[@H\F/^X* '[U_O#\Z-Z_WA^=,\F/^
MX*/)C_N"@!^]?[P_.C>O]X?G3/)C_N"CR8_[@H ?O7^\/SHWK_>'YTSR8_[@
MH\F/^X* '[U_O#\Z-Z_WA^=,\F/^X*/)C_N"@!^]?[P_.C>O]X?G3/)C_N"C
MR8_[@H ?O7^\/SHWK_>'YTSR8_[@H\F/^X* '[U_O#\Z-Z_WA^=,\F/^X*/)
MC_N"@!^]?[P_.C>O]X?G3/)C_N"CR8_[@H ?O7^\/SHWK_>'YTSR8_[@H\F/
M^X* '[U_O#\Z-Z_WA^=,\F/^X*/)C_N"@!X8'H0:QO% +:*P ).\=*V%C5#E
M5 IZHKNJNH8;AP150ERR4NQ%2'/%Q[EKP^"- L@1@^4O\J*T54*H50 !T HK
M&3YFV=$(\L4A:YSQ1XST_P *-;K>QRN9P2OEC/2NCKEO%W@FV\7/;-<74L'D
M @; .<_7Z5#OT+5NIKZ#K5OX@TJ/4+576*0D ..>*TJRO#FAQ>'=&BTZ&5Y4
MC)(9^IS6K5.U]"5?J81O+N;4;R%;^"W2%PJJZC)X![TMIJLTEL3-*F5NA")4
M7*R#VIT>C17-[J+7ELK+*XV,>N-HZ572ROEM(;-X=PMKI"D@P-\8/7ZTET^0
MV::ZQ:M<>4/,^_LW[#MW>F:@M-6#;UG.Z0SM&BH.<"J/V*\2\S;6\L#F;<Q#
MYB89ZX]:+?2[JSO'OXXV:4SL'C)^\A[BA S>N;F*T@,TS;4'YD^E49=;A^QW
M,D22>=#&7\MTP?8X]*DU:VEN;:)H5W/%*LFPG[V.U49[:[OYKFY:V:'%H\*(
MQ&78TGL-%S3+J5M'%W=,[L5WG*8(&.@%32:C L,+AS^_&8\#/;.:DLXF33X(
MI%PPB56'X5D66F7,=Q.)5_=0(R6W/4-S_P#6IRW8EL6XM9@"0([22RRIN&R/
MJ,]?:GMK=FDFT^9M#;#($.T'TS5/2[&X@NK9Y(BH2VV$GL<]*HW=EJ5Q#*DD
M4[R>9N&' CQG/ HZ@;NGW<ES/>JY!6*8HF!VP*+G5K6UF:)_,9D&7V)D(/>H
M]+MY8);UI4*B2;<N>XP*KLEY97MZT-J9UN2&1@1A3C&#[<4 6YM8M(6"Y>0E
M0_[M=V%]339-:LT,84O(9$WJ(USD546*]LKN>7[+Y_VA%SY9 VL!C'/:DTO3
M;BTO87E08$)#$= 2<XH FGUQ ]D8$>2.X<J2%Y&.WUJ:36[.*1E;S-JML:0(
M=JGW-9R65W!%:.+=F,5R[L@(SM.>:JWMEJ5U;7$;PSM*SDJ%<"/&<].YQ0!M
M3:Y9P2RQN9"82!(53(7C.2?2GQ:M;7#O'&75@A=2R8##U'K5%["X:WU@>4=U
MP1Y8_O?*!_.I9;.<W5JZQ_*ELR,?0D#B@!Z:U;I%"LC22RR)O&R/EA]*F.L6
MGD12J7?S<A45<L<=>*HZ78W$%U;/+$5"6^PD]CGI5<6FH0QQ*(Y1%YDA<0D!
M^3QSZ4,"[=Z]&EI%-;H[[IQ$RE>5YY&/6IAJL,37+32DA)%14"?,"0#@>M9,
M>G7L=C+_ *.Y<7JSJA?)91COZU*]C>?;I+U8"=MRLJQDC+#8 ?Q%"_K\ _K\
MS3_MFS^SRS,701$!U9<,,^U26NIV]W,8D\Q7 W .N,CU%9%W97E\;JY-L8RZ
MHBQDC)P<DFM)K:7^VH)PG[M82I;T.: -&BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "N9\<_\ (O-_UT6NFK'\2Z9)JNDM;QNJ,"&R
M?:M:$E&I%LQQ$7*E)+>QG:5_R"K;_<%7*@LX#;6<4+$$HH!(J<\BKF[MM$05
MHI,Y*U^(.EW>KQZ<D4XE>3RP2.,UUM<79_#JSL]:CU-;V=G27S A QFNTJ5>
MVNY<K7TV,SQ!>SZ?HES<VNWSD'R;AD9K+_X2.:7P[]J0+'>1R)'-&1G:2<&M
M/Q#:S7FB3P0(7D;&%'?FL3Q!H-Y+Y%QIR9=S&MS%_> (Y^HI:W'H;-SXBL;2
M5HI#*[1@&5HXRRQ_4]JOO>0QV+WF_= L9DW+SE0,USOV?4=/;4H(K W*WA+)
M(& "DC&&SZ5HKITT'A-]/'SS"T:, =VVD4FW9L22NB-?$%O=-:/;O+'%++M!
M>+B0;2>#^'6IH?$5C<3B&/S?G)5)#&0CD>AJE+IMT;/08UAYMF7S1_=^0C^=
M9]KIFHPW\7V6TGM%$A,RF7="5_V0>E-[V#I<UM*UY9X8H[AB]U+(ZJD:] #C
M)]!6G?ZA;Z= )KAB 3M4*,ECZ 5R^D:)?:/=1WT<+LTTC+<1ELX4GAA6UKMI
M<3-975M%YKVLN\Q9QN!&./>B^B#J5=1\3PQZ)>W-HDOVF!<>6\>&0GH2/2KM
ME?/;: M[?22R;5WN3&%8#Z"L6^T[4=3CU:[-FT+S6RP10EAN;!SD]N]=1Y E
ML?(E7AH]K _2C6S#33^NQ4OM7M[>)5$I#RQ-(C!=V !G)J"/Q#:+)#;L999V
MC60E(^,'N?2LFPT74%M+\749,D<)MK49^\G//X\?E5K3-.O;:[EE,.T_8DC4
MMC&\#I1?^OO"W]?<78O$NGRW$<2^<!*VR.5HR$8^@-2Z)?37T-RTQ!,=P\:X
M&. <"N8_LS5YY+%IK>[:6&X5Y"\H\L#_ &5%=)H%I/:072SQE"]S(Z@]P3P:
M%_7X _Z_$+KQ%86ES) YE8Q$"5TC)6,GU-)<>)-/MYFC+2N$QYCQQEE3/J:H
M)%J>F3:A!!8?:!=3M+',2-HW=F'M40M=3L(M0LUL/M'VMBZRJP"C<,'/TI7=
MAV5S4N?$=A;3^2?-E?8),11EOE/>JY\21OJ]E;P1O);W$1D\P+46E:1<V5_)
MYB;D%FD0?U8=15.ST[4K)].E6T9F2*2-AD?(2<@GVI_U^8NAL1^)=/DN(XAY
MP65_+24QD(S>@-,E\5:9#+*CF8"&0Q2.(R51LXY-<\^F:O<_8C-;W;S0W*22
M%I0(P >=JBM"72;QM%U> 6Y,D]ZTB+Q\R[@<T:_U\AV7]?,TF\0VD]O=>2\D
M,D,>_,D6/E_O 'J*1_$UC;GRI#-)*L:N_EQ$\$=:J:MIEW<7MR\4)97L?*4@
MCEL]*?I^FW4-S>O)"0)+5(U/')"X(I7?]?,6G]?(OSZ_8PQP.IDF,Z[T2)"S
M%?7%4KCQ1%Y^FBTBDEBNI&1SLY7 Z?7-9PL=6A@L(C#<^0D.UUMG"N&SW/I4
M=AI6I64.GR-92,T%[*[IO!.ULX.3UZT^O]=P:T_KL;D6O6T-JTL\S2L;AXD5
M(_F)!Z #KCUIY\2:<MDUTSR*J.(W4H0RL>@(K%@TO4+.>&_6T,K0W4[&'(R5
M<\$4L^E:A>23WKVIC:>YB80D@D*O4FDF]!M+4Z"PUBUU&62*(2)+& 2DJ;3@
M]ZT*R8K29?$TUT8R(6MU0-[@]*UJI$L**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAJ^H2:98_:8E5
MF5@,-TJ_6+XJ_P"0(_\ OBM*23FDS*M)QIMHZS2[IK[3+>Y< -(@8@=**K^'
MO^1?L?\ KDO\J*YYJTFD=--MP39IU&\T4;8=U!]":DIK1HYRR GW%26,^U0?
M\]5_.C[5!_SU7\Z7R(O^>:_E1Y$7_/-?RH 3[5!_SU7\Z/M4'_/5?SI?(B_Y
MYK^5'D1?\\U_*@!/M4'_ #U7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'
M_/5?SH^U0?\ /5?SI?(B_P">:_E1Y$7_ #S7\J $^U0?\]5_.C[5!_SU7\Z7
MR(O^>:_E1Y$7_/-?RH 3[5!_SU7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/
MM4'_ #U7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'_/5?SH^U0?\ /5?S
MI?(B_P">:_E1Y$7_ #S7\J $^U0?\]5_.C[5!_SU7\Z7R(O^>:_E1Y$7_/-?
MRH 3[5!_SU7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'_ #U7\Z/M4'_/
M5?SI?(B_YYK^5'D1?\\U_*@!/M4'_/5?SH^U0?\ /5?SI?(B_P">:_E1Y$7_
M #S7\J $^U0?\]5_.C[5!_SU7\Z7R(O^>:_E1Y$7_/-?RH 3[5!_SU7\Z/M4
M'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'_ #U7\Z/M4'_/5?SI?(B_YYK^5'D1
M?\\U_*@!/M4'_/5?SH^U0?\ /5?SI?(B_P">:_E1Y$7_ #S7\J $^U0?\]5_
M.C[5!_SU7\Z7R(O^>:_E1Y$7_/-?RH 3[5!_SU7\Z/M4'_/5?SI?(B_YYK^5
M'D1?\\U_*@!/M4'_ #U7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'_/5?
MSH^U0?\ /5?SI?(B_P">:_E1Y$7_ #S7\J $^U0?\]5_.C[5!_SU7\Z7R(O^
M>:_E1Y$7_/-?RH 3[5!_SU7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'_
M #U7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'_/5?SH^U0?\ /5?SI?(B
M_P">:_E1Y$7_ #S7\J $^U0?\]5_.C[5!_SU7\Z7R(O^>:_E1Y$7_/-?RH 3
M[5!_SU7\Z/M4'_/5?SI?(B_YYK^5'D1?\\U_*@!/M4'_ #U7\Z/M4'_/5?SI
M?(B_YYK^5'D1?\\U_*@!/M4'_/5?SH^U0?\ /5?SI?(B_P">:_E1Y$7_ #S7
M\J $^U0?\]5_.C[5!_SU7\Z7R(O^>:_E1Y$7_/-?RH 3[5!_SU7\Z/M4'_/5
M?SI?(B_YYK^5'D1?\\U_*@!/M,'_ #U7\ZEZBH_)B_YYK^524 %%%% !1110
M 4444 %0W<B1VSL[!1CJ34U<UXX)'A]L$C]XM72ASS4>YG5GR0<NQ."& (.0
M>XI2<#)JGI7.EVW^X*N=:TDK.QG%W28SSH_[X_.CSH_[X_.E\M/[H_*CRT_N
MC\J0Q/.C_OC\Z/.C_OC\Z7RT_NC\J/+3^Z/RH 3SH_[X_.CSH_[X_.E\M/[H
M_*CRT_NC\J $\Z/^^/SH\Z/^^/SI?+3^Z/RH\M/[H_*@!/.C_OC\Z/.C_OC\
MZ7RT_NC\J/+3^Z/RH 3SH_[X_.CSH_[X_.E\M/[H_*CRT_NC\J $\Z/^^/SH
M\Z/^^/SI?+3^Z/RH\M/[H_*@!/.C_OC\Z/.C_OC\Z7RT_NC\J/+3^Z/RH 3S
MH_[X_.CSH_[X_.E\M/[H_*CRT_NC\J $\Z/^^/SH\Z/^^/SI?+3^Z/RH\M/[
MH_*@!/.C_OC\Z/.C_OC\Z7RT_NC\J/+3^Z/RH 3SH_[X_.CSH_[X_.E\M/[H
M_*CRT_NC\J $\Z/^^/SH\Z/^^/SI?+3^Z/RH\M/[H_*@!/.C_OC\Z/.C_OC\
MZ7RT_NC\J/+3^Z/RH 3SH_[X_.CSH_[X_.E\M/[H_*CRT_NC\J $\Z/^^/SH
M\Z/^^/SI?+3^Z/RH\M/[H_*@!/.C_OC\Z/.C_OC\Z7RT_NC\J/+3^Z/RH 3S
MH_[X_.CSH_[X_.E\M/[H_*CRT_NC\J $\Z/^^/SH\Z/^^/SI?+3^Z/RH\M/[
MH_*@!/.C_OC\Z/.C_OC\Z7RT_NC\J/+3^Z/RH 3SH_[X_.CSH_[X_.E\M/[H
M_*CRT_NC\J $\Z/^^/SH\Z/^^/SI?+3^Z/RH\M/[H_*@!/.C_OC\Z/.C_OC\
MZ7RT_NC\J/+3^Z/RH 3SH_[X_.CSH_[X_.E\M/[H_*CRT_NC\J $\Z/^^/SH
M\Z/^^/SI?+3^Z/RH\M/[H_*@!/.C_OC\Z/.C_OC\Z7RT_NC\J/+3^Z/RH 3S
MH_[X_.CSH_[X_.E\M/[H_*CRT_NC\J $\Z/^^/SH\Z/^^/SI?+3^Z/RH\M/[
MH_*@!/.C_OC\Z/.C_OC\Z7RT_NC\J/+3^Z/RH %=6.%8'Z4R>TAOD$%PFZ,L
M,BI JKT %5[[4(],MQ<RJS*K 87K3C=O3<F3BD^;8Z&W@CM;=((EVQH,*/04
M4VRNDO;.*YC!"2*& /6BL7>^IT1M96V)ZY/QEXVB\(O:K):M/YX8C!QC'_ZZ
MZRN?\2>#],\4M VH>;F$$+L;'6I=^A2MU+/AK7$\1:+%J*1&)9"1M)SC%:]9
MVB:-:Z#ID>GV>[R4)(W')YK1JG:^A*OU.<>\9]5O8IM3>W6)P$4>F!6@E_%9
M6UN9)GGBE8CSST![9JK]DO8-2O)DLX)XYG#*7?!' 'I4EU9W>HVD5I+#';PL
MV9=C9X'0#ZTEL/J2-K<8BA=8)6$SE8P.K8[_ $I_]M0+;R22(Z21L$,9ZY/2
MLR>.^M7TR$K&\L4K*A)X9<<9]#4EQHUS>1S3S",3O(KB/.5P.Q- %T:Y"(IV
MDB>-X4WE"021[4L>M1-)MEAEA#1F1&8?> ZU1.D7$EM=@6L$#R1;$56R3]35
MVYL)Y;BS>/8!%%(C;N>2 !QWZ4 +!JZW2\02HK1ET?J"/Z46&IQRHD;%\^2)
M=[_Q"J%MI-VEPKB*.W4(RNJ.2)"1QQVITVCW3:;91Q%5GB3RY#G^$]: +9UR
M(I%LA=WD!8("/N^M7;.\BO;<319QD@@]01VK*O-&;[7%/#!'.JQ",QNVW&.A
M!K0TRT:TL]CI&CDEBL8X% $,&LQW$RJD$AC9R@D'(S[^E06NL3'[:9[>0B.<
MQQA1DGIQ4"Z5>?;HY%BBA*R[GFC<C>N>FWWI9]-U'==)$$\J2Y\[A\%U(Y7V
MH_K\@+,NKJ]O<JR2P2PJ"1QG![BE?6TC>6-;>63R0"[+V&,YJ@-%N_\ 3"(H
MXQ-$JJH?."#W-7X=/G3^T,A?WZ )S_LXHZ ,;5ECOWD:0_91;+(![DU-#K4+
MNR2QO"0AD&[!RHZUGRZ%<3Q>6Q0?Z.B YS\P.?RJ:UTN=9_,-K;P%8F4$'<2
MQ'\J +=MK$=QAC!(D90NKGD$"EL]66\D15@D5'&4<\@_X5GVFE7D=TDBQ16R
MA&#A7W*Y(XX[4ZQTNZAOXI?*CMT7/F>6Y(?\.U'4#3OM12R>./8TDDF=J@XJ
ME<ZO-YMCY,#A9I"KJW!X'2I]6LY;KRMD$4RKG*N=I^H-4H],OHH;1OE=X9B^
MQGZ*1C&?:A RU)KT$;N?+<PQMM>48P#3[C68H9WB2)Y3& 9"I'RYYK+_ +"G
MC\V%;6WD5W+"5V.0"<\CO4MQHTJ7MQ+%;0SK-@C>Q&P@8_$4 7;2^-UJS+')
MNMS;JZCW)J6?4Q%?BT6!Y'VAB5Z 5#8:=+:7WF$((_(6/Y>.0<GBIA:2'6)+
MDX\IH0G7G- $/]O0;\^6_D[]GF\8STI;G6DMS(QMY6AB.'EQ@#_&LZ/0YXOW
M'V6W=?,SYS'G&<]/6FWNC7]S'=QLD<C2$^7*TAP!V&V@#7GU9(IVBB@DG9%#
M/L_A!Z55366.IRJT;+:K )-QXQ[THM+^TN9IK:.*3ST0,&;&Q@,?B*CFTN\E
MG?>R.LUN(GDS@AASG% %N'6$DDC62"6(2C,;-T:HEU^,P";[/*$9MB$X^9O2
MHQ9W]R]JERD4<=OSN5LESC ^E*--N%T6.V,4,CJV61SP1GU[&@#1L[S[6CDQ
M/$R'!5JC:5WUA858B..(NX]23@?R-0:/97%GYYE^2-V!2(/NV_C5BS@D2YNY
MY0 TLGR_[H&!_6@"M-J!M=5N!,Y\B.!7V^^:?'K"%RDL$D+;"ZA_X@*@O]*F
MO+NXD4JJO$JH2?X@<TDEE?WLJ/<QQ1"*-E4*V=S$8_"ET#J2P:Y',\.Z"6..
M;A)&Z$TUM?B4*XMY3"\@C67L23BFMID[6.GPD+F!LR<]L$<5E22S#3K6RC:"
M2(7"*KJWS, W]WM5=;!T-[6;R6RTR2>%=SC 'MS59]76VDE>99?E1"8_0DU<
MU6UDO-,F@BQYC ;<],@UF7&EWMS))*R(I<1<;LXVG)I=0+)UT!WC^QS^:B[B
MO^SZU-)K,"QP-&C2/,NY4'!Q2&RE.HW,^%V20"->>]9[:).$LY#%',\49C>-
MFP.O4&@"S+JOGM9- S(&N#'*IZC"GBDM]:58+51'-/),K,OJ<''-,BTF=5M6
M\J&,K<F5U0\ ;2/Q-+IVEW-M+8M(%Q#%(KX/<G(H_K\ +/\ ;<'V03;'WES&
M(N^X=JGLM0CO2Z!&22/[R-VK*GT2>1"Y2-W6Y:548\,I_E5[2K%[:2662"*$
MO@!4.3CW-"!E1K^8:[<><9([:V0,<'CIU-7(M81Y$62"6(2 F-FZ-@9J*XTN
M6YN-0R0J7$:JISW%1FSO[M[9;E(HTM\ME6R7.,#Z=:70"]IVHC48A*D#I&1E
M6;O5VJ>E6TEGI=O;RXWQH V#QFKE4P04444@"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *P/%]G/>Z&T5O&7?>#@>E;]1W'_'O)]*NG)PDI+H1
M4@IP<7U.<TZ-X=/@C<894 (JT>!116DG>[,HJR2.'LOB+#>:Y%I@LF5GE\O?
MN_6NXKEK;P%H]IJB:A'YWGI)Y@R_&:ZFDKVUW*E:^FQE^([J6ST&ZG@D,<B+
MD,.U9.GSB50\>ORW$HC+F+UX^E;.NV4NH:-<6L(4R2# W' J2.PCCL?+2&-9
M?*VY QSBIUU#L9%GXB\K3+(2J]S=S(7*J0.,]35L>)+3[-!<E'$,DIBD8_\
M+)O]K\:QO^$8NHA9SFV@N7CA\J2%WP.N00:L'0+N;24TUHK>"&XE+W7E'[J]
M=H]2?6G=AH7&UQ+K['+%YT<4MPT<;=I  >?IQ5/2/$S_ &*-KV"<J96C-P1\
MN=Q I\6C:BL.GVTGELEC<';)NY:/:0,CUYJ"'1]8;34TJ:.W6W\[>TJOD[=V
M<8]:%O\ UY!_7YEF#Q!]F:\^T%IF^TF.&->I&*U=,U:+4O-54:.:(X>-NHKG
MKGPO=22O/Y<4I6Y:18G; =2,=>QK7T+3);)KB66U@MS*1A(CG 'J>]$;]0E;
MH5)==N+37]2MS!-<Q0HCA4_@&W)-79/$4!6V^RPRW,EQ%YJHG4)ZFEBTZ=-6
MU6Y(7R[F-%CYYR%P<UF6.CZGI0L;BWCAFF2T%O-$SX'!R"#25_Z^8W;^OD76
M\46Y6W$5O-)+,S)Y0&&5EZ@TL.K2^9>&.WGG:.0*8L@;.,U4L=!O(=1M;R8Q
MEO.DEF"GA2PP /6FWVFZRC:A]A2,B[F!)\S:0F.<>]&O]?(-+EF'Q5#+ \C6
MDRD2^4BC!,C>@J1_$UO#:W4MQ;RPRVP4R1-UPQP"/6J9TS47M[3RK*"W>R??
M&GF[A)Q@YXXJ.]T34M32_N9TACGGCCBCB5\@!6R233U%H7)_$A$-P@LYHKA8
M#-$KX^<#O2VFOS'3+-Y+*:6YFCWE4Z8]<T[4M)N+O48Y4VB,6<D))/\ $V,?
MRK,.CZP\-DDT$<D4,7EM")RHR.C9[_2C7^OF&G]?(O-KIO)=,>U+QI+.T<J-
MUX'2M35-4BTN&-Y$9VD?8B+QDU@:;X>OK468D2)1#=/*P5N I'&*V==LIKVT
M1(H(9P'RT<O&X>Q[&C6P:7(SX@A2Q,\MO-')Y@B6$CYF8] /6A=?402M+97*
M31LJ^5MR6)Z8-9$/A[4H[82*422&Y$\%NTA90 ,$;O?-6;ZSU[4+=V?RHAYB
M$6Z/U4=<M[T:AH.O?$+2:??)'%):W<"!MKX/!/6IY?$D5NWE"&2=HT#3,A'R
M\5D+X;O]U^RV\,2W$*HB"0L00>Y-23^&[F.\GECL[:Z$ZCF5ROEG&/Q%+4>A
MTPOX7TTWT9WPB,R#'< 9JN=9A$6GR;&Q>MM3VX)Y_*G1:>4T,V'R(3"8_D&
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MLA<_:1:Q>=G._:,U:HHH **** "BBB@ IDES#:!99Y B!AEC3ZQ?%7_($?\
MWQ5TX\TE%]2*DW"#DNAVD,T<\*2Q,&1AE6'<45G^'O\ D7['_KDO\J*PDK2:
M.B$N:*9IT45#+%([Y69D&.@J2B:BJWV>;_GY?\J/L\W_ #\O^5 #I+.VEE$L
MD",XZ,1S2/8VLDAD>"-G/4D=:3[/-_S\O^5'V>;_ )^7_*@"N=)@;4&G>-&B
M\H1JA'3!JU)9V\JJLD*,%^Z".E-^SS?\_+_E1]GF_P"?E_RH =]BMO+:/R(]
MC')7'!-*EI;HJ*D* (=R@#H?6F?9YO\ GY?\J/L\W_/R_P"5 $-Y8&2WECM5
MCB:<XE8CJ#U_&K=O"EO;QPH,*BA147V>;_GY?\J/L\W_ #\O^5 #I;.VFD$D
ML".X[D4[[-#\_P"Z7]X,-QUJ/[/-_P _+_E1]GF_Y^7_ "H K+I$'V^6>2-&
MC9$54(^[C-6Y;.WF"B2%&"?=R.E-^SS?\_+_ )4?9YO^?E_RH >MI;IC;"@P
MVX8'0^M*]K!)OWQ(V_[V1UJ/[/-_S\O^5'V>;_GY?\J '+96R1[%@0+D-@#O
M0]E;22^:\",_]XCFF_9YO^?E_P J/L\W_/R_Y4 3"&,.[A%W. &..HI8XTBC
M"1J%4= .U0?9YO\ GY?\J/L\W_/R_P"5 %FBJWV>;_GY?\J/L\W_ #\O^5 %
MFBJWV>;_ )^7_*C[/-_S\O\ E0!9HJM]GF_Y^7_*C[/-_P _+_E0!9HJM]GF
M_P"?E_RH^SS?\_+_ )4 6:*K?9YO^?E_RH^SS?\ /R_Y4 6:*K?9YO\ GY?\
MJ/L\W_/R_P"5 %FBJWV>;_GY?\J/L\W_ #\O^5 %FBJWV>;_ )^7_*C[/-_S
M\O\ E0!9HJM]GF_Y^7_*C[/-_P _+_E0!9HJM]GF_P"?E_RH^SS?\_+_ )4
M6:*K?9YO^?E_RH^SS?\ /R_Y4 6:*K?9YO\ GY?\J/L\W_/R_P"5 %FBJWV>
M;_GY?\J/L\W_ #\O^5 %FBJWV>;_ )^7_*C[/-_S\O\ E0!9HJM]GF_Y^7_*
MC[/-_P _+_E0!9HJM]GF_P"?E_RH^SS?\_+_ )4 6:*K?9YO^?E_RH^SS?\
M/R_Y4 6:*K?9YO\ GY?\J/L\W_/R_P"5 %FBJWV>;_GY?\J/L\W_ #\O^5 %
MFBJWV>;_ )^7_*C[/-_S\O\ E0!9HJM]GF_Y^6_*K(X% !1110 4444 %%%%
M !45RJM;.& (QW%2UC>)]2ETO2&GA"EBP7GWJH1<I**(J24(N3V1&  ,#I15
M>RF:YLH9G #.H)Q4Y&00#BM6K.QDG=70M%1>4_\ SU:CRG_YZM2&5=8T\ZGI
MLEJ&"[R#D^QJ2#3;.WC9([:-0XP^%^]4WE/_ ,]6H\I_^>K4AC9+.VFMQ!)
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MJU'E/_SU:@"6BHO*?_GJU'E/_P ]6H EHJ+RG_YZM1Y3_P#/5J ):*B\I_\
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MT-5O,,T>F3WH5E6Y=1*RXW+@X)^M)#9TDUU''&S*RNR_PAQFI#-&NW>ZJ6Z
ML*Y@6\8T;49]@\TSN-W?&ZGYLQ/>?VD"7POE YR5Q_#[YH WH[Z"6]EM58&2
M, L,^M3O(D8S(ZJ/5CBL/3%@37;G";'>)"@?[V,<TZ^^SC70=0Q]G\C]UO\
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MM]ID_P"?:3\Z/M,G_/M)^= %FBJWVF3_ )]I/SH^TR?\^TGYT 6:*K?:9/\
MGVD_.C[3)_S[2?G0!9HJM]ID_P"?:3\Z/M,G_/M)^= %FBJWVF3_ )]I/SH^
MTR?\^TGYT 6:*K?:9/\ GVD_.C[3)_S[2?G0!9HJM]ID_P"?:3\Z/M,G_/M)
M^= %FBJWVF3_ )]I/SH^TR?\^TGYT 6:*K?:9/\ GVD_.C[3)_S[2?G0!9HJ
MM]ID_P"?:3\Z/M,G_/M)^= %FBJWVF3_ )]I/SH^TR?\^TGYT 6:*K?:9/\
MGVD_.C[3)_S[2?G0!9HJM]ID_P"?:3\Z/M,G_/M)^= %FBJWVF3_ )]I/SH^
MTR?\^TGYT 6:*K?:9/\ GVD_.C[3)_S[2?G0!9HJM]ID_P"?:3\Z/M,G_/M)
M^= %FBJWVF3_ )]I/SH^TR?\^TGYT 6:*K?:9/\ GVD_.C[3)_S[2?G0!9HJ
MM]ID_P"?:3\Z/M,G_/M)^= %FBJWVF3_ )]I/SH^TR?\^TGYT 6:*K?:9/\
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M=<;6[U5T^[U2TTV!(;E&>XOGBRZ?=&3FBX6.YHKD'U+7(TU'-S ?L!!)\O\
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M2=S9N%PWMQCBKE%'2P$4%NMO:I I)5%V@FJEMI,-J]LR.Q,"LJY[[CDUH44
M4/[)AW[M[9^T_:/^!8QCZ5&-$A#-^]DV&;S@O8'O6G10!D?\(_#Y8B^T2^4K
M[U3L#G-7[6S2U:9D))E?><^M6** ,]M(A:4R%VR;@7'_  (#&*G%E&+R:YR2
MTJ!&!Z8&?\:LT4 9L.B6L-A):#<4=MQ)/(/;\J6/254N9;B:4LFP;CT%:-%
M&;%HT:2B26:28A"B[^P-+:Z1':R6[B61_(5E3=Z'''Z5HT4 9YTF$VDEMO;;
M),9B>^=VZFRZ/&\TCQSRQ+*<R(AX8UI44 5(["**XDF4MEXQ'CV%0+H\2"UV
M2NIMR=I'<'J#6E10!0U2!Y$@N(ANDMY!( .XZ$?D:M)!")#,(E$C=6QS4M%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %0W-E#J$8MYP3&6&0#4U07=]%IT(N)L[%8 XJHWO[NY,N6SYMC?M;>.
MTMH[>(8CC4*H]J*2TN4O+2*XCSLD4,,T5@[WU.B-K*VQ-1112&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?K.EIJ^
MG/:NQ7/*GWK0HIQDXNZ)E%23B]CA$\':S&@1-30*.@&:O:7X9U.UOTENK\2P
MC.5&>:ZVBMY8JI)6=ON.>.#IQ::O]Y5^P0_[7YURMUX5UB6ZEDBU)5C9R57G
M@9KM**BG6E#8TJ4(5%:1Q,/A/64F1GU-2H8$CGD5U@L(L?Q?G5JBBI6E/<*=
M"%/X3E=7\-ZC=WQEL[X0P[0 ISUJA_PB.M_]!1?UKN:*N.)G%65ON(EA*<FV
M[_>9UEI8ALH(IW+RH@#L#U..M9^N:#=7JQ"QNO(*YW9)YKH:*SC4E&7,C65*
M,H\KV.&_X1'6_P#H*+^M;VC:+-9V9CO9_.DW$[@>U;=%7/$3FK,SIX:G!W7Y
MF1JND/=6#Q6DQBF)&')Z5SO_  B.M_\ 047]:[FBE"O."L@J8:%1W?YG-Z)X
M?O;*61KZ[\]6&% )XK6GTY'@D2-BKE2%.>AJ]14RJ2E+F9I"E&$>5'#'PCK>
M?^0HOZU;TSPQJEMJ$4UU?B6%<[D&>>*ZZBM'BJC5M/N,8X.FG=7^\J_8(?\
M:_.N6N_"NKS7DLD.HJD;,2JG/ KLZ*BG5E!W1K4H0J*TCB(_">M+*C-J:E0P
M)'/(KK%L(@H!+9QZU;HHJ5I3W%3H0I_"<MK'AS4+R]\VRO1#%M VG/6L_P#X
M1'6_^@HOZUW-%7'$SBK*WW$2PE.3N[_>9MCI?D6445Q(7E5<,P/4U1UO0KF]
MCB%C<^05/S$D\UT%%9JI)2YD:RI1E'D>QPW_  B.M_\ 047]:W=%T6>RM&CO
M;CSI"V0P/:MRBKGB)S5F9T\-3@^97^\R=4TA[K3Y(;64Q3-C:Y/3FN<_X1'6
M_P#H*+^M=S12A7G!60ZF&A4=W^9S6B>'KZRGD>^O!.C+A0,\&MB;3HWAD5"0
MQ4@'/0U=HJ95)2?,RX4HPCRHX8^$=;).-47'XU:T[PQJEO?Q2W.H"2%3\RC/
M-=?16CQ51JVGW&*P=-.^OWE7[!#_ +7YUR][X6U::\ED@U%4B9LJISP*[*BL
MX590=T:U*,*BLSAT\):TLBEM34@$$CFNM73X@@!+$@<\U;HIU*TI[BIT(4_A
M.7UGPY?WEXLEE>B&(( 5.>M9W_"(ZW_T%%_6NYHJXXF<596^XB6$IR?,[_>9
MFGZ4;>QBBN)#)*HPS ]:IZWH=S>PQ+8W/D,K$L2>HK?HK-5)*7,:NE%QY'L<
M-_PB.M_]!1?UK<T31+BRM9$OKCSY"^0P/08K=HJYXB<U9F=/"TX/F5_O,K4M
M):YL)(K64QS-]UB>E<W_ ,(CK?\ T%%_6NYHI0KS@K(=3#0J.[_,YG1?#M]9
M7+O?7@F0K@ 9X-;4FGQM&P4L&((!S5RBIG4E-W9<*481Y4<,?"6MEB1JBX_&
MK.G^%]5M[Z*6XU 21*<LHSS7845H\54:MI]QBL'33OK]Y5^P0_[7YUS%_P"%
M]6GO99;?41'$S953G@5V-%9PJR@[HUJ485%9G##PCK8(SJB_K77+I\04 EB0
M.>:MT4ZE:4]Q4Z$*=^4YC6O#M_>W2R6-Z(8PN"ISUK-_X1'6_P#H*+^M=S15
MQQ,XJRM]Q$\)3D^9W^\R].TEK>QBBN93),HPS ]:K:WH=Q>V\:6-QY#JV6)/
M45NT5FJDE+F-72BX<G0X;_A$=;_Z"B_K6WHFAW%E!(M]<^>Y;((/05O45<\1
M.:LS.&%IPES*_P!YEZCI1N+&2*VD,<K#Y6)Z5RTO@O5YTV2ZBCKUP<UWM%*G
F7G37NA5PU.H[R*FF6C6.F6]J[!FB0*2.AHJW163=W=FZ22LC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>plx-20200630x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20200630x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +7!#@# 2(  A$! Q$!_\0
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M '^7- '244@((!!R#WI: "BBB@ HHHH **** "BBL35?%FCZ+?QV5]<^7/(
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MKY06-MG"D=^E2F[.15EHCT?^U+36/#4U[9R"2&2%B#Z<=#7F?P;_ .0SJO\
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MJ^K?<FVB78R_$6F)K'A^]L7 _>1':3V8<C]:\$\&:1)JWBZTLI"6BMW+L.P
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M^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\
MA*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JT
MO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+
M_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-
M_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?
M]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^
M6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_
MPK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK
M8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\
MM/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/
M[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B
M_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E
M1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y
M:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?
MW%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%
M_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*
MB\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\
M>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P
M6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6G
MW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,
M?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_
M (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*
MM+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K
M2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O
M3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[T
MW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\
M?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?E
MO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\
M*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/
M^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\
MA*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JT
MO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+
M_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-
M_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?
M]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^
M6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_
MPK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK
M8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\
MM/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/
M[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B
M_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E
M1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y
M:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?
MW%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%
M_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*
MB\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\
M>P6GW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P
M6GW,?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6G
MW,?_ (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,
M?_A*M+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_
M (2K2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*
MM+_O3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K
M2_[TW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O
M3?\ ?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[T
MW_?EO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\
M?EO\*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?E
MO\*/^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\
M*/\ A*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/
M^$JTO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\
MA*M+_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\*/^$JT
MO^]-_P!^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_A*M+_O3?\ ?EO\*/\ A*M+
M_O3?]^6_PK8\M/[B_E1Y:?W%_*B\>P6GW,?_ (2K2_[TW_?EO\**V/+3^XOY
M447CV"T^XZBBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BL>YUJ:/49K.WL)+AH@I9E8 <C/>
MF_VOJ/\ T!IO^_B_XT[$<Z-JBL7^U]1_Z TW_?Q?\:/[7U'_ * TW_?Q?\:+
M!SHVJ*Q?[7U'_H#3?]_%_P :/[7U'_H#3?\ ?Q?\:+!SHVJ*Q?[7U'_H#3?]
M_%_QH_M?4?\ H#3?]_%_QHL'.C:HK%_M?4?^@--_W\7_ !H_M?4?^@--_P!_
M%_QHL'.C:HK%_M?4?^@--_W\7_&C^U]1_P"@--_W\7_&BP<Z-JBL7^U]1_Z
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M_?Q?\:/[7U'_ * TW_?Q?\:+!SHVJ*Q?[7U'_H#3?]_%_P :/[7U'_H#3?\
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M -_4_P :/[:U3_H!3_\ ?U/\:.1ASHWJ*P?[:U3_ * 4_P#W]3_&C^VM4_Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#)O\ _D8-(_WI/_0#5[6?^0+>_P#7
M%OY51O\ _D8-(_WI/_0#5[6?^0+>_P#7%OY52W1G_-_70AT;_D#VG_7,5>JC
MHW_('M/^N8J]2EN7'9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.?X9>A/L:YYT9Q.N&(A/R.FHH&" 000>A'>BL3<**** "BBB@ HHHH ****
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M*+AXF$7V%8]W;=GI5*:PU-1KK6J.DDTX:,@X+K@9P:ZVD!##(((]12YW>_\
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MWBRRD%T+R&>QEMD\R2.X4 [>Q&"<U%!XRM7FA$]C>VL$[;8IYD 1CV[Y'XT
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M "BBB@#'\-_ZS5?^OZ3^=;U8/AO_ %FJ_P#7])_.MZJGN13^$****DL****
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MVECE=+;[)XI\0W,J.(E"-D+U ';UKH[&\AU"RBN[<DQ2KN4D8.*EEC62-T/
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M^ON/1@01D'(HKD_!US;-)=VT+W<;J0QM;H'=']/:NLI@%%%%( HHHH ****
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MMI+>UNE2;4D?]^2S,,_>]J%K;Y?F#TO_ %T.PL/%%M>ZDMA):75K-(I>(3H
M) .N,&JFG>(;"R\.K>23W<R-.\:"7YY';<1@?YZ4FLQL?&GAYU0E56;) X'R
MUS5E;7$&A:3?FWD>*SOYWFC"\[2Q&<4?U^(?U^#.LC\3VUY'=6TT%W93I"9-
ML@ 8KZJ0:Q9?$EW;7/AR&RBO+BVN%9F+E2\ORG@D]QUJ_<:XNKBZCL;-G@6U
M??<.A4@XX45C*YL+3P=>SQ2B& .)"J$E<J0,BA;_ '?J#V^_]#LK#7;:^AO9
M-KQ&S=DF5^H*UCZEK+-IUCXAMA*D"2!9(V/WHR<9Q^M9'BB*YLM?>WLU/EZX
MJHV/X6!^8_E6UXLACLO!,EH@_A2) .YS@4NE_P"O,?6QU"L'0,#D$9%<[<>,
M;2.>98+.\NH8&*S3PH"BD=>_-;=G&T=A!$WWEC53]<5Q.C:G'X=TB[TF_MI_
MM:22;0L982[B<$'\:;T;$M4A_B_7);JWTJ+3Q=-;7DR[I;=@I<?W0<\&NQL4
M6UTR%29%5(P3YK98<=S7"QZ?=6>F>&8YHF#_ &_S&7&=@.3@UWMX\D=C.\*;
MY5C8HG]XXX%#T3!:M'/OXWLU3[0+&^:Q#;3=",;.N,]<X]ZZ1)4EA65#E&7<
M#ZBO)[^ZN+_PU,)KN_>\9?FLXXRJ(<\].U>FZ4<Z):]?]0O7Z4= ZF(OCFSD
M69XK"]EB@=DGD2,$1X./7GUXJW?^++&Q%D4CFN?MBEH1",EJY;0?$%K8Z'J=
MG);3-.US.(PD9(E)8XY_2IK'3;BRO/"T-Q&V^.-RW&=I/:A:V^0/2_S.@G\6
M01-%"EC>2WCIO-LB@L@_VN<"J>L>+ _A*]O],287$)\MT90'A;U8'_/-1/<K
MX?\ &-_=WT4AMKN-?+F1"P!'\-9<MM<ZAI/BO4HK:1(;S9Y"%<,P0#+8]Z6Z
MN-?$=&GBB.VTNR>YM;DWEPOR6Z@,[>_7&*)/$=I?:3J(=;NTGMX6:6,@+*HQ
MU4]/QKE]16.\N](U9C>+8+;F%WA!5HV'J.N*5+2VFM=<NK)+Z8?87C$\[$[^
M.@!IRV?S%'I\CI6\56FGQ:=:F*[N9;FU66+ #.X]_>M#1]>M]8,\:1303P'$
MD,RX9:YO387_ .$D\/,T;832 "2O0\5I:3&Z^.-9;80K)'@XX/%4]_O_ #%T
M^XZ8D*I9B%4#))Z 5YGXM\3G5)S9VC$6<9Y(_P"6A]?I6CXU\29W:79OQ_RV
M<'K[5PE:0AU9Q8BM?W(A1116IQA1110 58BL+N>/S(K69T_O*A(I=.MUNM2M
MH'^[)*JGZ$UU7B+7[W2M7-C8OY$%N  BC@\=Z3=K(N,4TV]D<:RLC%6!!'4$
M4E=[J&E6VL:AI4TB^6;N,F39QR!UJ@- TF[6^M;*6;[9:JS;F/#8ZBIY^Y;H
MN^AR04GH"<G%.DBDA;;+&R-UPPP:[348--C\,:841U=G^1AW.1G-.N=#AU#Q
M#)!=3R%4M0^[/-','L7^7XG#4Z..25]D:,[>BC)KK?[&T)M(_M-7N!#%)Y;K
MGES_ $J>#1(;'Q-9K9S2+%/"9%.>13YD+V3.*(*D@@@CJ#6CI^O:EID)BM;@
MK&3G:5##/XULZ7I6F:GJ$MM,+AKCS&W,I^4#/4U$NDZ0^NW%M&]Q-!$ORK&,
MEV[\T<RV!4Y+5,P;V^N=0N#/=2F20]S420RRMMCB=VQG"J2:[.7P]I]C?Z9<
M&.9(IWP8G.2#5LVUL_C&YCM'DB<0MOQTZ=J7,DM//\"O8R;]Y]OQ//J*Z6TT
M?3[?21J>JO(4ED*1I&<$X/6K \+VK:Q9QQRNUE=(70]Q3YD1[*5KG)45UKZ#
MI,]EJ M))OM%D"2S'AL5R5"DF*4''<****H@**** "MWQ=_R+^@?]>]85;OB
M[_D7] _Z]Z</C1I'X9''4445U&(4444 %%%% $L%K/=/LMX9)6]$4FB>VGMG
MV3PO$_HZD&NU-S)X=\$65Q882XNVR\H'(]JR;W6KOQ':65C<6ZM<>:%6Y(Y.
M>,5"DV]%H:N$4M7KN<W17<GPUH*ZB-%:>?\ M K_ *S/R[L=,56M?#6GV^D7
M5YJ;R@VT_EL(S]ZE[6(>QD<?17?R>%_#\-]91O)<%=00&%0?N<=2:I6?A:P!
MU8WDT@2Q? 9>I%'M8C]C(XY5+,%4$D\ #O3I(I(7*2QLCCJK#!%=>^B:>(M.
MU?2GD\DW*QNDAR0<UI:EH$6K^+M5GN2_V:U1&98_O,2HX%#JJ_W_ * J+:^[
M\;_Y'G=%==JGA[3[..RU!%G2RF?9)')PRU8U/PIINDZ=/J,MPTD$@'V50>6)
M'>CVL1>QE<XUH)4B65HG$;?=<J<'Z&F$$=01]:[JUM(#HWAU[N21X))F'E]@
M<\59U71](U3Q1=6:>9'<"(LH!P-P[4G5L[>OX#5%M73[?B>=T5T,NA0VGAB3
M4+HL+EIO+B7/IU-<]6BDGL9RBX[A1113)"BBB@!T<CQ2+)&Q5U.58'D&O7_!
MWBM-;M1;7+!;Z,8/_30>M>/5/9W<UC=1W,#E)$.016=2FIJQM2JNG*_0^A**
MQO#>O0Z_IBS*0)T&)4]#ZULUYS33LSU8R4E=!1112&%9.KZ##JLL,XN;BUN8
M<A)H&P0/3TK6HH P+?3;/PU;75]-+<W4LF/-E<;W;T&!6?X+T2."QO[J2!HQ
M?RNRQN,%8NP]N_YUUQ 88(!'O2@8&!0!RX\$VV%A?4;Y[)6W"U:0;/ITSC\:
MO3^'+>768=2CN)X9$C$;1H1MD7T((K:HH Y=O!%KB2&+4+Z&RD;<UHDF$.3D
MCID#\:TXM!M8-5BOXF=6BA\E8QC;C^=:M% &7::'!:-J#))(?MK%GSCY<C'%
M43X/M!I]E;0W=U#)9@K%<1L ^#U!XP?RKHJ* ,G2- @TF::X\^>YN9OOS3-E
MB/3BM:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH Q_#?^LU7_ *_I/YUO5@^&_P#6:K_U_2?SK>JI[D4_A"BBBI+"BBB@ HHH
MH **** ,2U_Y&?4_]R+_ -!K5K*M?^1GU/\ W(O_ $&M6FR(;?>%! (P1D44
M4BQ-H!R ,T;1@C P>O%+10 FU>.!QTXHP 2<#)ZTM% ";5V[=HQZ8I BCHH'
MX4ZB@!-HQC QZ8H*J1@@$>A%+10!5U"R%[I\MJLC0EQ@/'P5/K6!'X8O[FYM
M#JFI+/;VL@D1$BVEV'0L:ZFBCK</(0HK?>4'ZBC:N ,# ]J6B@!, D$@9%&U
M0,8&/3%+10 @10,!0!["@HI&"H(],4M% &&FASR^(!J5[=B:.'<+:$+@)GN?
M4U9U'2O[2O;-Y9/]'MW\PQX^\W:M.B@ II12<E03ZD4ZB@!" <9 XZ4M%% #
M?+3^XO/M2D?*0..,4M% &5H>BIH]G)!Y@E+S/+N*XQN.<5J8!(.!D4M% "%5
M;[R@_448&,8&/2EHH ;L7;MVC'IBE"J!@* /3%+10 FT9!P,C@<5SWBO7TT>
MS,,)'VR88&.JCUK8U&_ATRPENYS\J#@?WCV%>.ZE?S:G?RW4[99SGZ#TJX1N
M[G/B*O(K+<JN[.Y=B2Q.23WI***Z#S0HHHH **** 'Q2O!,DJ'#HP93[BNKG
MUG0-7:.ZU*WG2Z4 /Y>,/BN1HI-7*C)Q.UT[6QJWBVR\N/RK:%2L:>V*9<:S
MI6F3ZG):13?;9]T1#?=7GDBN0BFD@D$D3LCCHRG!IK,SL68DL3DD]ZEP1HJS
MMYG1MK-A<>'[2UG$HN;5LKM'!YJW_P )39?VQ-=^7+L>V\H# SFN0HIN*9*J
MR5OZV-M=7@'A:33-K^<T_F XXQ6D/$]F-4T^Y\N79;P>6PP,D^U<E11RK^ON
M!5)+^O.YV&G^(='MK*YC>.Z2:X8EY(P,X)Z5%IFLZ-ITUW%"MTL%Q&!YIQO5
MN:Y2BCE0_:RT\CJ[[Q)92P6$<"SDVLNXF0Y+#Z^M3?\ "1:7#K\FI1+.1-$5
M<$#@GTKCJ*.5![:7Y?@=)::SIUSI"Z9JB2[(I"\4D?49[&K'_"46JZQ9R)#(
MME:H41?XC[UR=%'*A*K)(Z"QURWMAJX=)#]L5A'@=,YZUS]%%-*Q,I-[A111
M3)"BBB@ K=\7?\B_H'_7O6%6[XN_Y%_0/^O>G#XT:1^&1QU%%%=1B%%%% !1
M110!T^E^(K+^R!I6L6SS6R-NC:,_,M+JGB6T\JRM=(M/)M[602@O]YF'K7+T
M5/(KW-/:2M8[D^)=!;41K1M[C^T O^KXV;L=:RY_$D5SX=N[.5'^TSW'FY ^
M4#-<U14JG%#=:3.LN?$UG-J&B3K'+ML8U60$#)(]*V]*U&SOK+Q%>RQN;65]
MQ7HV#7G%2QW,\43Q1RNL;_>4' /UHE335E_6MQQK-.[_ *TL=3=^(=-M[*RT
M_38YOLT4XFD:3[Q(/2K4?C.T_MW49F2<6=ZBJ2O#J0,9KAZ*/9QZB]K+H=7J
M6M:3=26ENIO)+:-MTKR-EG]L9Q5N^\7Z=JEE=:?=6KK:A1]E* ;D(]:XFBCV
M4;6#VTKW.F;Q%;#1]'M%CD,EE*7<D<$9SQ5^6_CU7Q;;:AHL5Q),6!F4KP/_
M *U<54]K>W5E(7M9Y(7(P2C8)%/D5[K^KB51VL]M/P.L^(5^DFI16$&%C@7+
M*O3<>37&4Z21Y9"\C%G8Y))R33:<(\L;!4GSRY@HHHJC,**** "BBB@#6\/Z
MY/H6II<Q$F,G$B?WA7MMC>P:C917=LX:*09!';VKY\KM? /B3^SKW^SKE_\
M1K@_(3_ _P#]>N>O2YES+<ZL-6Y7RO8]6HHHKA/2"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#'\-_ZS5?\ K^D_G6]6#X;_ -9JO_7])_.MZJGN13^$****DL**** "
MBBB@ HHHH Q+7_D9]3_W(O\ T&M6L>>TU2#6KJ[M(H9(IE0?.^",#%/\S7O^
M?.U_[^G_  JFC.+MHT:M%97F:]_SYVO_ ']/^%'F:]_SYVO_ ']/^%*P^?R-
M6BLKS->_Y\[7_OZ?\*/,U[_GSM?^_I_PHL'/Y&K165YFO?\ /G:_]_3_ (4>
M9KW_ #YVO_?T_P"%%@Y_(U:*RO,U[_GSM?\ OZ?\*/,U[_GSM?\ OZ?\*+!S
M^1JT5E>9KW_/G:_]_3_A1YFO?\^=K_W]/^%%@Y_(U:*RO,U[_GSM?^_I_P *
M/,U[_GSM?^_I_P *+!S^1JT5E>9KW_/G:_\ ?T_X4>9KW_/G:_\ ?T_X46#G
M\C5HK*\S7O\ GSM?^_I_PH\S7O\ GSM?^_I_PHL'/Y&K165YFO?\^=K_ -_3
M_A1YFO?\^=K_ -_3_A18.?R-6BLKS->_Y\[7_OZ?\*/,U[_GSM?^_I_PHL'/
MY&K165YFO?\ /G:_]_3_ (4>9KW_ #YVO_?T_P"%%@Y_(U:*RO,U[_GSM?\
MOZ?\*/,U[_GSM?\ OZ?\*+!S^1JT5E>9KW_/G:_]_3_A1YFO?\^=K_W]/^%%
M@Y_(U:*RO,U[_GSM?^_I_P */,U[_GSM?^_I_P *+!S^1JT5E>9KW_/G:_\
M?T_X4>9KW_/G:_\ ?T_X46#G\C5HK*\S7O\ GSM?^_I_PJGX@O=4M/#DK&W
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M_O\ '_"CS?$7_/E:?]_C_A1RAS^1LT5C>;XB_P"?*T_[_'_"CS?$7_/E:?\
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M?>__ / 8UN;%_NC\J-B_W1^5 &'_ ,)KIO\ S[W_ /X#&C_A-=-_Y][_ /\
M 8UN;%_NC\J-B_W1^5 &'_PFNF_\^]__ . QH_X373?^?>__ / 8UN;%_NC\
MJ-B_W1^5 &'_ ,)KIO\ S[W_ /X#&C_A-=-_Y][_ /\  8UN;%_NC\J-B_W1
M^5 &'_PFNF_\^]__ . QH_X373?^?>__ / 8UN;%_NC\J-B_W1^5 &'_ ,)K
MIO\ S[W_ /X#&C_A-=-_Y][_ /\  8UN;%_NC\J-B_W1^5 &'_PFNF_\^]__
M . QH_X373?^?>__ / 8UN;%_NC\J-B_W1^5 &'_ ,)KIO\ S[W_ /X#&C_A
M-=-_Y][_ /\  8UN;%_NC\J-B_W1^5 &'_PFNF_\^]__ . QH_X373?^?>__
M / 8UN;%_NC\J-B_W1^5 &'_ ,)KIO\ S[W_ /X#&C_A-=-_Y][_ /\  8UN
M;%_NC\J-B_W1^5 &'_PFNF_\^]__ . QH_X373?^?>__ / 8UN;%_NC\J-B_
MW1^5 &'_ ,)KIO\ S[W_ /X#&C_A-=-_Y][_ /\  8UN;%_NC\J-B_W1^5 &
M'_PFNF_\^]__ . QH_X373?^?>__ / 8UN;%_NC\J-B_W1^5 &'_ ,)KIO\
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M/0[AV_*JR>*+$V%W>2[XX[:9H2",EF!Q@#WH VZ*P++Q3#<WL5K<V5U9//\
MZDSH ']L@]?:M^@ HHHH **** "OGOXCZY_;7BRX"-FWM?W$?IQU/YYKV[Q/
MJHT7PW?7V<,D9"?[QX'ZU\R.Q=V9CDDY)- "4444 %%%% !1110 4444 ;N@
M^+-4T"3%O,7@/WH9.58?2NXL]0\/^+%'DNNFZD>L3GY'/L:\JI02I!!(([BF
MFUL3.$9JS/1]0TJ\TR79<Q%1V8<@_0U2JIH7C^^TZ(6>HQKJ-AT,<OWE'L:Z
MJ+3M*\10&Y\.W8,F,M9S'#K]/6MHU$]SAJ8:4=8ZF!14L]O-:RF*>-HY%ZJP
MQ45:'*%%%% !1110 4444 %(2 ,GI2,X1<FIM*TF^\07HM[6,[<_,Y^ZH]ZQ
MJU5#3J<]:NH-1BKR>R*JF6YE6&VC9W8X 49)KNO#_P .BZI<ZNQ&>1"/ZUUG
MA_PM8:# OEH)+@CYYF')/MZ5NUS<KD[S.G#Y8Y/VF*=WVZ(KV=C;6$(BMH4C
M0=E%6***T/8225D%%%% PHHHH **** "BBB@ HHHH *JWNGVFHP&&Z@21#_>
M%6J*!2BI*S/,O$/PZ>%7N-*)=1R83U_"O/YH9()&CE1D=3@JPP17T;7/^(O"
M5CKT+,4$5T!\LJC^?K4QYJ;YJ;/'Q&6.#]IA79]NC/#J*T=7T:\T:\:WNXBI
M'W6[,/45G5Z-#$1JKL^QRT:ZJ7BU:2W04445N;A1110 4444 %%%% !2@$G
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M4J* .NHKG+GQ9&;6Q.GVS75S>C,46[;C'4D^U96NZ[K#>'M4ADT]K2[A129
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M0!5')[L?4U>KGC&VKW/2P.!5!<\]9O=A1115GH!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9^L:-::U9-;748.1\K8Y4^HKQ;7] NM"OF@G4F,
MG]W)CAA7O-9VM:/;:UI[VMPHY'RMW4^M2T[\T=SSL=@577M*>DUL_P!&?/\
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M)L_^0]??[B?RK6JI;DPV"BBBI*"BBB@ HHHH **** .8T_\ Y'G7?^N<'_H
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M$D^,-=2C)/TK+N+F:ZE,D\C.Y[DU%1344BI2;T"BBBJ)"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#H?!]UY.L>43\LJD?C7?5Y3I\YMM0@F!QL<&O5L
MYP?49KCQ"M*YW865XM!1117.=054U-UCTNZ=TWJL;$KG&1BK=4]6C>;2+N.-
M2SM$P '<XI2V8X[HYB+Q.UE9Z/;66FM*UY&QCC$GW2/4GM5RW\621?VC%JEB
M;:YLHQ*RH^\.IZ8-9NFZ9>QW_AEWMG"V\,@E)'W"1QFK=Y8WQ\4:K<PV@E22
MS1$\P?(Y&<BJEO\ >3';[BQIWB34+J>W:;2@+6X/R2PS"3;_ +PQQ5:V\0VF
MFV>J7*VC[UO#$L:ODRR'&,9Z5C6FF7/]J6<FEZ9=Z=*) ;C+_NMO< 5.^A:C
M+97\D<!\^'4Q=1(W'F 8I?U^*'_7YDFH:GJ=QXDT&*_T\VA,KL"DNY6&WH>!
MS6G/XLN9+JX33-/2XAMF*R2/.$W$=0HQS5&ZNM2UG7M&<:3/;P6\C&1Y,<$C
M^59HT%=+N[V.[T.2_P#,D9X9HSP<]C1_P0.\TC5(=8TZ.\@!"OP5/52.HK(O
M_$E[%X@ETBQTW[3*D:R;C)M4 ^O%7O#5DUAHL43VL=JQ)8Q1]%S7.W.HW&G?
M$"^>&RDND-M'O$?WAZ4/XK MF_ZW&:[KIU3P[*KPO:W=O=1I+$6S@Y['TK<O
M-:U)+PV6FZ6;AHXPSRROL3GL#CDUS=WH^I7>GW]^]HZ37EU&ZP#DJH/>IM2M
M+V77KC^T+.]NK38HME@?"CCG-']?@A_U^)H/XVVZ%]O^PMYR7'V>2#?G#9QP
M>]6+;Q+?#5(++4-+^S?:E)@<2[LD=CQQ7+VFB:C'H4MN=/DC<:FL@C'.$SU^
ME=5K-G<3>(-$FCA9HXF;S&'1>.]"_K[D2^O]=2GX.O=5NM3UA;Q$\I+EAN\P
ML5.!\H&.E;.MZW_9(@BBMVN;NX;;%$#C/N3V%9OAR.ZL=<U>VGM)%CFG,\<_
M\)! &/K4OB2SNQJ.GZK:0&X-J2'B'4J?2CHOD/JPC\43VL=U_;&G/:-!'YFY
M&WHX] <#FJT?B^ZB>WFO]-6"SN'")(LX9D)Z;EQ4&IQZOXJL+VW%H;2U,8\M
M)@-SN#G\JR[?2HYS:6\?A@QW"NOFR3'Y%QU(H6^H/8-0E<P>)RKM@72;>>G2
MO0+'FPM\_P#/-?Y5Q%YI-\UOXA5+5SYUPC1 #[P&.E=Q9JR64"L,,$ (_"A?
M#]WY ]_O)Z*** "BBB@ HHHH S[/_D/7W^XG\JUJR;/_ )#U]_N)_*M:JEN3
M#8****DH**** "BBB@ HHHH YC3_ /D>==_ZYP?^@"NAKGM/_P"1YUW_ *YP
M?^@"NAH *BN8%N;66!CA9$*$_45+10U<#E(O!TBZ7!:OJ+F6TDWVLRK@Q^WO
M5S3_  [-%JRZGJ-\UY<QH8XOEVJ@/7 ]:WZ*/,# \8H9-!9!D$RH,CJ.:6VT
M*9[BVFOKY[A(,-%&5Q@^I]:W2H888 CWI:I3:5D0X)RNS-L-)6S:_P!S^8MW
M,TA!'0$ 8_2L[_A&IUMVLH]2D6Q)_P!5MY ],UT=%"DQN"9R%QILG_"600V4
M[6WDV>%8#(Z]#6B/#8;3[Z*6Y:2YO,>9.1Z=.*W=HW;L#/K2TW-V)5-)W_K:
MQEWNC_;+.TM_-V_9W5\XZXJO/H4RWTUUI]ZUL9_]8NW<"?6MRBES,?)$Q)?#
MHDT06'VJ0R"02^<W)W9SFHCX?NEO!>1:AMN&C"2L4R&QW'I7044<[#V<3FO^
M$4/V*^MS>,WVN1)"S+R"#FM'79[6WT>:.[;"R(448^\<<8K4IKQI( '16P<C
M(S0Y-[C4$MC'\+:>UAHL8DSYLOSN3UYK:HHHE+F=PA'EBD%%%%24%%%% !11
M10 4444 %>4?&>]PFFV(/]Z4C]/Z5ZO7@_Q8NS<>,Y(LY6"-4'Y9- '"T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5T_AC27OKNWMD'[R
M=@"?05SMO%YUPD?J>?I7LWPQT<-+-J;K\J#RX_ZFLJFK43R<Q;K5(86/75^B
M/1-/LHM/L8;6%0$C4 59HHK4]6*459!1110,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "J>J:?%JFFS6DH!61<#V/8U<HH%**DG
M%[,\(BCDTS59K&;@JQ7FM*M3XD:4;748-4B7"R_*Y']X5CP2":%)!W%;8.>]
M-]#YW#IT:D\._L[>A)1117<=84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%%  #@@UZKIDWVC2[67.2T8S]:\JKT/PE,9=!13_ ,LW*_U_K7/B%[MS
MIPK]YHW****XSO"BBFNZQHSN0%49)/:@!U%88\4VFX.;>Y6V+;1<%/D__54E
MUXBM[:_>R6">:=4#A8ESD&JY)=B.>/<V**RX=?LIM.DO271(CM=67Y@?3%0P
M>)();J&"6UN;?SCB)Y5 #'\Z.278?/'N;5%<E8>(6MKS4XIH[JY\NY?[B[A&
ME6]1U3SY-(FLYV$4T^&P<9'H:?([HGVBU.BJA'I,$6LS:FI;SYHUC89XP.E9
MJZY:Z?'>3RR7$B+<^4V_G:3Z>U6K3Q#;W-ZMJ\%Q \@W1F5<!Q[4N1[CYX[,
MUZ*Q)_$UK#-*J07$T<)Q)+&F54UHZ=?Q:E8QW<((CD&1NZTN5I7&I)NQ:HK*
MOM=@L[HVJ0S7,X&YDA7.T>],?Q'9+I;7_P _EHP5T(PRGT(I\KW#GC>US8HK
M&/B.W2V6:2VN4+MMBC*#=)QG@9IJZ]'=QW5OY,]M<I$7"R#!QCJ,4<K#GCW-
MNBLOP]-)<:';2S.SNR\LQR3S6I2DK.PXOF284444AA1110 4444 %%%% &?9
M_P#(>OO]Q/Y5K5DV?_(>OO\ <3^5:U5+<F&P4445)04444 %%%% !1110!S&
MG_\ (\Z[_P!<X/\ T 5T-<]I_P#R/.N_]<X/_0!70T %17$Z6UM).^=D:ECC
MTJ6J.L_\@6\_ZY-_*@"@OBS33Y;-YJQ2<+*4^7/IFK-GKUI>7;6P$D<H3>!(
MN-R^HK O8E_X0_2EV#'FQ<8]ZNZL3%XIL72/>5M)B% ^]C'%;.$;V]?P1@IR
MM=^7XNQ:?Q38*2VV8PAMIF"?+GZU8O-?L[*>*%][/*F] BYW"N,N[U[KP_+N
MO=KLO_'G#%C;ST-;=JJR>(M(8C.+$X/X"FZ:7]>0E5;V_K6QK1^(K*2QN;KY
MU%M_K49<,OX59NM3@M+>">3.R9E5<>IZ5RVH0/->^*(XD)9H82 !UXHU/5[6
M]T_3(+=F=UFCW@*?EQZTE!-JWD-U&D[^9.^HSWOBYK=GNHK>!00J\ G/);VK
M3/BJP!#;9O(+;?.V?)GIUJIO>+Q+JTB1^8RV:D)_>//%<[?7C77AMLWV7*@F
MTABP$YZ'Z4U%2M\B92<6_F=O?:W:6,B1'?+*Z[@D:Y./6LO5_$ZQZ5'<V =B
MTRQM\O*\C(/O5>WN8=+UYKJ])6">V012D9 P.14>KWD=YH4MU#:&*!+N-MX7
M[X##+8I1@DU_74;FW%Z]_P CH[;58;F[%J$=)O*64JPQ@&H9M?L[>.[D<L%M
M9!')QWK);4K6U\4B^EDVVMQ:*(Y<'!()XK(GE%WIVMRJK!)+M"-PQD4*G=_U
MW&ZC7]>5SI)M9AN?L;(]Q;JURB#Y<>9GM]*DF\364,\\ 2:22!BKA$SC'>JV
MOJ -$"C %[%T^AI-#C7^T->8J,FZ89([;12M&S?]=!\TKI=[?J:,FNV,>GQW
MOF%HY>$"C+,?3%,L_$%I>WRV:+*DY4L4=<$ 5RMD#;6VEWTR,;6&>0/@9VY/
M!K4AO[74/'%N]K\RK:N#(!@'D4_9K\R?:/\ (ZRBBBL3H"BBB@ HHHH ****
M %'45\V>-[G[5XRU20'(\]E'T!KZ2+! 7/102:^5]2F-QJ=S,W5Y6)_.@"K1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &EI$6Z1Y,=!@5]
M&^%M._LSP[:6Y&'V;G^IY->'^#K'[7J6GVY&1),"P]0#D_H*^B%4*H4= ,5E
M#639Y.#_ 'N+JUGT]U?+<6BF2DK"[#J%)%>5>&IO&?B:PEO+?64C1)3'M9>>
M/_UUJ>L>L45YS=OX[T&$W<D\&H0)RZ ?-BNBTWQ)'K?A6;4K7*2+&VY3U1@*
M .DHKROPZ?&GB+2EU"#6HXT9F4*R\\'%7;JY\<^'8S=W#PZC;)S(J#Y@* /1
MZ*R?#^NV^OZ5%?6^0&X93U4]Q7/>)/&-S%J8T308?M.I-]]OX8_K0!V]%>>)
MX+\1:@HFU'Q'-'*>2D/ %17-CXO\)K]JMKXZK9IR\3CYL4 >D45SVC^((O%&
M@R3Z=)Y5R5*E6ZQO[UR&O1>-M"TJ;4)=;C>./JJKS0!ZA17G6DV'C74+.UO?
M[;B\J4*Y4KS@]J[]Y!!;M)*P 1<L?I0!-17D=GX[U9O%"7$[D:+-<&%..!^-
M>M*P901T(H =17,>/=3N](\+37=E+Y<RNH#5LZ/-)<Z1:32MN=XE9CZG% %Z
MBF2DB)R#@@$UQW@/5K_7-%NY+RX+RK.R*V.@[4 =I17&IK.H:)JYMM5D,EM*
M?W<V.E2ZU>ZII=S'J%O,;C3VY= .@H,O:JUSK:*I:;J,&I6B7$#[E8<CT-7"
M>]!HFFKH6BN3USQ!.UVNEZ3\]TQ^9QR$KH--AN(+-%NIC--_$QH)4TW9&9XR
MT[^T?#5T@&7C7S%_"O*-)EW0M&>JFO='021LC#(88(KPPPG3_$5W:'@)(R?D
M:(/EK1??0\?,8^SQ-.JNNC-"BBBO4+"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *[7P1+FTNH?[KAOS'_UJXJNI\$28OKF+^_&#^1_^O6597@S
M:@[5$=M1117 >D%4]6@DNM)NH(OOO&0OUJY10!YVD-J=+2TE;4'N.$:V!(&?
M\*W]-MS%XKNLHP"VL2@GZ>M='L3.=JY]<4N!G.!GUK5U+F*HV.+,MU:6NL20
M0DL;KNF<#U JI.YFU'2G6ZN[H+<+N9U(5/PKO]J\\#GKQ2!$'15_*A5+= E2
MOI<Y#3M4@TVZU=+F"4%[ERA"$[_:H8+.>"WT?S(V4M=F3;C[H-=J40]47\J4
M@'&0..E)5+=!^SOU[_B<'<PNT%V#&Q!U5#C'49%;FLQLVMZ1M4\;P2!TXKH-
MJ_W1Z]*" 3D@<4<^W]=+![/?S_SN<=97\>D:=>V-W#)Y^YR $R'!Z<UL>$SG
MPW:'&,@\?B:AFT342TT<.H 6\I).],LH/8&MBQLX["RBM8ON1K@9[TY23CYN
MPHQ:EY*YSZ7"Z+XAOY+R-_+N"'CD5<CITK+N899]*U*[$#K%<W*-&A'.,]<5
MW956^\H/U%&T8Q@8],4E.VHW3O?4YSQ#=7%M_9Z1YBA<GS)U3<4XXQZ5C0;G
MUV9UEN9T:T8"64'YC[5WA4,,$ CW%)L4=%'Y4*=E:P.G=WOV,OPRI7P_:A@0
M=O0CWK6H  & ,"BHD[MLN*Y4D%%%%(H**** "BBB@ HHHH S[/\ Y#U]_N)_
M*M:LFS_Y#U]_N)_*M:JEN3#8****DH**** "BBB@ HHHH YC3_\ D>==_P"N
M<'_H KH:Y[3_ /D>==_ZYP?^@"NAH *" 1@C(HHH ;L4J%VC Z#%*54L&*C(
MZ'%&0>XHR/44 -\F($GRTR>ORBE"*""% (X!QTI20.I%+0 FU02=HR>IQUIH
MAB'2-!W^Z*>"",@YI,@G&10 ;5W%MHR>IQ3?)B&<1)SU^4<TXD#J0*4D#K0
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ME?H:Q[RSGL+I[:Y0QS)PRGM4% &XWB[6GO)[LW>9IXO)D;:/F7TK#/)S110
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M/4+71K0W<R83<%.T<Y)Q2:CJ%KIT$5S.A(DD6-2%R<MTH,72;N[ZF=X=\/\
MV$&[N_WEY)RS'^&MVYMHKJ!H9D#(PP0:D4@J#3LB@TC!15D<*%N_"&IX4/-I
MLS=!SLKMK>9+B%98SE6&13G1'&& (]Z5 %&%  ]J!0AR[;#J\V^*8_>Z>W^R
MP_45Z37FOQ38>=IZ]]K']:SJ_ S@S?\ W27R_,P8?]2GTI],BXA3Z4^O6CLC
MGC\*"NG MM"TBWF-LD]S<#=EQD 5S%=,DUEK6DP6T]R+>X@& S#@BIJ;(VI[
MON)>16VJZ&VHQ0+!-$X5PO0YJO>>&S90[I+R(.<;$)P3FI[NYLM.T;^S;6<3
MO(X:20#@8IFM7EG=:[;2&026ZJH;'ZU"O>RV+E:UY;V&'PV&AD,-[%++&NYD
M7_&DN+>)?"5O,(U$IF(+8YQS6_\ VC9PM.@O8! \9$<:)C'U-<_<W4#>%X;9
M95,RS%BO?'-)2D]_(IQC';S'^%HH9)[IIHED"1;@&&:N6<MEKHGM6LHX954L
MCH,=*I>&+FW@GN1<3+$LD6T,U6[5M-T03W,=Z+F9U*HJC&,TY[O\!4_A7KJ9
M]IH!FMO/N+E+>-GV)N_B-7-*TK[-?7UO=1J[1PDJ2,CZBK5EJ,%WI,$)N((9
M8F);SDW C/:FQZK;MJEZ\ET&0P;$<KC<<>U)RF[H<8P5F4_[/^T:59*?*C$L
MA4/CG\:J1:%,]]=6[N$%NI9W/3%6+N]A_P"$?LXHY09HY"Q4=15[4M9M9-$+
M0./M=RJK,!U %5>2V%:#W[%"#PXTD,32W4<4DW,2-U:F6?AV:Z:X5Y4B,#8?
M=T^M;<6I6UW;6D@NH(6B0!UDC#,,>E41JD$EGJVZX!>4C9D8+?E2YIZ@H4]/
MZZ&?>:)]GLGNH;A)XTDV$K5?4=,;3EA\QP7D3=M'\-:WA-UGDN+"8$PR*'^A
M!K+UR[^V:K,X/R [5^@JDY<W*2U'DYD9U;'AC_D8+;ZG^58];'AC_D8+;ZG^
M55/X613^-'H_>BCO17G'JA112,P52S$ #DDT )Y:$YV+GZ4K(K##*#]16(_B
M_0XV<-?+\AP3M."?8]ZLWVOZ;IQ1;FX =UW!%4LV/7 H TMJ[=NT8],4;0#G
M SZU0BUO39M.:_2[0VR]7]/:H;7Q+I5YYH@N=SQH7*%2&('< ]: -4* 20!D
M]32%$8Y*J3ZD5R^A^-+2^TJ:\O7$(CF*'Y2 !D@?RK53Q'I36;W?VH+"AVEF
M4C)]O6@#4V@XX''2LO4M+GU&[A#W %FC!VBV\L1[TZSUW3]2CF%G= R1J259
M2"OO@U4M/$-I;Z7:S7^H1R-,#ME";0V/:FG9W$TFK&Z   !T%(R*^-R@XZ9%
M9<'B/3+N"XDMKC>8%+.FTA@/I5'P]XKM]5T:6^NG6'RF.\E2% R<=>M(9T1C
M1CED4GU(IU9EAX@TS4IC#;7(:0#.UE*DCU&:B?Q3H\=T;=KQ0X;:3M.T'TST
MH V**YIO%4:^,%T;!\LP[MP0DER?Y8J>SUZW@L#<7^H1R*9VC$@3:!STHZ7
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MF#DL1Z8ZT =%I>O7-Q8ZG:W)3[?8J=SH>'&,JPJKX4N=9O;)=7U*Z M]AVQ
M=0.YI-$L$72M5O8M.-FD\;")6SO9 IP6K2\,V[2>"K:W<%2\!4@CD9H H69U
MGQ*C7T=\UC9,Q$*QCYF /4U!#?Z[8>+;+2;V<36TB.PE P7''7W%/T37H?#E
MB-)U@/;/;Y6.0H2LBYX((JM_:\FL^.-,E@MI5L8XY DSH1O/&<9[4 2I?:[J
MOB+4M-M9_(MH)!F;&2!Z"I[N;5_"YBNKF\-[I[.J3;QAH\G ;Z9-4++7#HWB
MK6C<PR&R>89F12VQL=\=JLZYJT7BNU71M(5YUG=?/GV$)&@8$\GOQ0!H:YK=
MP=0M])T^6.*>9/->9SPB?XU0NYM4T&'[<NK)?0H<S0N1G;W(J+Q+H\5OK=MJ
MEU:275EY(AF$>=T>.C8':J5ROAR\1;?1K"2]NI"!C#A4]2Q- '1ZAK$O]J^'
MQ:R8M[YG+CU&S(K0\27<UAH-S<P-ME0#!_$5A^(;.33DT._AMV>'3I/WL<8R
M0A7&0/:J?B?Q3::IH4MII8ENII,;@L;#8,C.<B@!/'%O?7/AV&Z6]*1'RMT>
MWJQ(YJ[JWV[2M"M?M%U]ID>]B7>R]%)Z4_Q5&[^"H45&+9BX YZBI_&*L^C6
M(12Q%Y 2 ,]Z #4M1O[S5ET?2W6)T0//.1G8#T ]ZC>T\0:0\<\5XVH1;@)8
MG&#CU%17DDOA[Q))JDD,DEA=QJLCQKN,; 8Y'I5F3QA!=R1V^C1O>SNP!PA"
MH.Y)(H CU>\GGU^+3GO6L8# ) Z\%V)(QGVP/SK=TJWN+:W9)[LW//R.>N*R
M]=O='5TM=9B/S)N5S&2OT!'0TSP<SF&]"-,UB)L6K2@Y*X]^<9H Z:O*_B9+
MYFOVD(Z+",_4L:]4KQOQC<?;O&LR@Y6,J@_ <_KFLZFJ2[GDYQ+]PH=VD-48
M0#VI:**]<E!1113 **** "BBB@ HHHH **** "BBB@ HHHH T+36+FRM'MX=
MBA\Y;'S<^]9Y))R>M%%*RW&VVK!6SX57=K\'L"?TK&K?\'+NUT'^[$Q_E4U/
MA95+XT>@4445YQZH5F>(DFD\/7RV^?-,1VXZUIU%<I)+:RI"^R1E(5L9P:4E
M=#6YYSK-WHK?#R*%#%]H"H @'S!\C.:NW%^6\0SPVXL[66*",//<C)<8[#VI
M9_#6JZC&+.YL;"$,X,UW']YP#G@8ZFNPFTC3[ED>XM(970 !F7)XJO,GR/.=
M+%M<^'=72[N66/[9D2QIP#G@X]*U-*O)H?$=E:S/:7XEC8)/"N&08_BQ7:II
MME&DB):Q*DOWU"C#?6DM=+L+%R]K:0Q,>I1<&DOZ^ZPV>;(T$G@AK;*F1=2Q
M(G< R'K70^(XH;;4-#DFC5;!'_><?*&QP373?V1IVZ1OL4.Z1@SG8/F(Z$U8
MFMX;B$PS1))&>JL,BA ]7]YQ>H36EUXNLVTLH^RVE^T-%TV[> ?QK)L(8Y[+
MPBDBAE\R0X/TKT6VTVRLU9;:UBB#<,$7&:$TZRC$(2VB A),>%^Y]*%I_7J#
MU.9FACB\>R+&@4-8G( ZUR\I,G@BTCAE"B'4,W.!G8NXX+#TKU,VL!N?M!B3
MSMNW?CG'I4,>F6,7G>7:Q+YW^LPOW_K2_K\;A_7X6.%6!)M;TYGUF.XD3)5+
M>(9VXZ$BJ4KKI]E<265[;75H)"S6EPG[S.>@[UZ-:Z5864A>VLX8G/4HN#36
MT;37N/M#6,!ESG>4&<TP.7M[F'_A/+2:95@\[35V*W'S;NGUK"$:R^'[6-QE
M6U9LC_@1KTJ;3[2XGBFFMHWEB^X[+ROTI!IMD(Q&+6+8K[P-O ;U^M';^NMP
M_K\+',:Q'%:^+M&>.(+^YDR%&,@#I7-W-^USX7OI(7L;.V??_HX3=*3D]?>O
M3WM8))HYGB1I(P0C$<K]*K?V)IGFM)]@@WOG<=@YS2MI8:=G<Y#16W>(-";.
M<Z=U_&NH\3KN\,ZB,9_<-_*KL=A:0O&\=O&K1KL0A?NCT%3NBR(4=0RL,$'O
M3G[RMZBCI8\]4VM[-X.52DB*CA@.0&"#K5S5;T+XIEMK6.SMI8H1NGN!U'H!
M760Z3I]N8S#9PH8R63:N-I/4BENM+L;V027-I%*Z]&=<D4/5@MCS& S3Z#XB
M$<GG8N$9S&N 5R,X%=>U_P"'Y#I<<44=Q,Q A6(<IQR3710V%I;^9Y-M&GF<
M/M7&[ZU';Z3I]I,9K>SABD/5E4 T <]X&DA%O?0!E$RW+ED[@9KK:KPV%I;W
M$EQ#;QI+)]]U7!;ZU8H#J9]G_P AZ^_W$_E6M639_P#(>OO]Q/Y5K54MR8;!
M1114E!1110 4444 %%%% ',:?_R/.N_]<X/_ $ 5T-<]I_\ R/.N_P#7.#_T
M 5T- !67XCLY=0\.WUK!_K9(R%'J:U**35T-.SN>;:UK27GA.#3(["Y^UHT:
MNAB.$VD9.:+VPCL/%>HSZDU_%!=+&\,MJS8.%P5.*]'\M,YV+^5*55OO*#]1
M3ZW%TL<1I&B07WAO5$BMKF(73ET:X<L[D=&YZ=*JZ+97VOVNIW=U&\4ZVILH
M=XQR!R?Q.*]"  & ,"D  Z #Z4-7N"T/*(+6R&A1Z?<1:N]\%$3V@=@A/3KT
MQWK;N]+FFUR>TAC=-VE"-2<G!],UW>Q=V[:,^N*7 SG SZT/7^O*P+3;^M?^
M >?2:N'\&MH2V%Q_:)A^S^5Y9QNZ9STQWIMM>IX>\8)%>122!-+@B>2-=Q4C
M/\Z]"V+G.T9]<5F)HR+XCGU8R;C+ L/ED<#!)S^M%];_ -;/_,+:6_K='%WM
MO<7NE>(-36VE2&[D3RHV7YF QSBMK6(&:^\+;8F(2<;L+]WY#U]*Z[:N,8&/
M3%& <<#CI0M/P_ 'K^/XG!>(=-N=1\0ZU!;HVZ734"''!(8G&:RDM["XL+:S
M,6KS71*J]LTC!5(]^F*]2P,YP,^M)L4'.T9]<4+3^O,'K_7DO\CEM)MVB\=:
MBQC8(+2)58CCJ>,U@W5M.=%\2[8)#C5/, "G)4,.1ZUZ1@9S@9]:-J\\#GKQ
MUH_K\;A_7X6*NF74=[IT$\08(R# 9<'\JY33[Y?#.L:O%J$$^VYG\^&6.,L'
M!'3CTKM0 !@  >U!56^\H/U%#WN"VL>;2V5W_P (K=7#VSQF\U1;A(L<JI;N
M*]'0[8%)[+3BH(P0,4M'2P;NYYM>:]!KNKRQZH+J+2[:3"6Z0L?.([L?3VKN
M;$6%_!%>P0 !H_+4LFTA?3%7?*C_ .>:_E3@ HP  /:A;6![W*$VAZ9<1QQR
MV4+)&,("O05=ABC@A2&) D:*%51T '04^B@ HHHH ;(GFQ/'_?4K^8KY6O4,
M5[.A&"LA'ZU]6#J*^9O%UM]D\6:G!C 6X;'TS0!BT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!U?A.^^QWUE<$X$,PW'VSS^AKZ+1@Z*PZ
M$9%?+6DR[9FC/1AD5]$^#]1_M+PU:RELNB['^HXK*.DVCR<)^YQE6B^OO+]3
M>J+[/#G/EI_WR*EHK4]8:44K@C(]*-HQCM3J* (EMH5?>L:!CW"\U(5!7!&1
M2T4 -V+LV8&WTI=H P.E+10 T1JOW0!]*8]M"[!GC1F'<BI:* $VC&.U"J%7
M:!@4M% $<D$4N/,C5L>HS2B%%QA0,=..E/HH Q].T9K/4-2N)761+N0.%QTX
M[UJ1P11#$:*H]ABI** $*AA@\BHX[>*(DI&JYZX&*EHH 0J&&#R*C6VA3.V-
M!GKA1S4M% #3&K+M(!'I08U88(!QZTZB@!K(K+M8 CT-,CMXHL^7&JY]!BI:
M* &/#'*,.BL/<9IRJ$&%  ]!2T4 ,FD6&%Y7.%12Q->%QRF^URZNS_&[/^9K
MU/QQJ/\ 9_AFXP</-^[7\>OZ5Y?I46RW,AZN:*<>>M%=M3P\PE[3%4Z2^SJR
M_1117J&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !73>"8\ZG/
M)V6+'YG_ .M7,UV7@>+$5Y+ZE5_+_P#7659V@S6@KU$=;1117 >F%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &?9_P#(>OO]Q/Y5K5DV?_(>OO\ <3^5:U5+<F&P4445)04444 %%%% !111
M0!S&G_\ (\Z[_P!<X/\ T 5T-<]I_P#R/.N_]<X/_0!70T %%%9NOZ@^EZ#>
M7L8R\49*_7I2;L-*[L:5%>=ZQ9ZG8>&(]636;IKB0HTH+_*0Q' ';K1J&L76
MH>([RS=M0%K9JBJMGP2Q&26-/R%YGHE%><3ZMK'_  B-R)7N(IHKM(X9I!AV
M0G@FM&>.^T'6='<:E<7"WDGESI*V5/&<@=J .VHKS!-7O=8DO;MY-45DF=+<
M6O"(%.!GU/K5R2]U?5'\/P3SSV<MP'6?:=I8#O0M0>AZ'4%Y>06%G+=7+[(8
MAN9O05R.LE;.[MK&?6;L0)$3Y4&3*YSU8^E8$MU/J/A7Q):37-T\5G(K0F8X
M?:0.&]N:730:6JN>CMJ42S6L:QS.+D95U3*CZGM5VN(+RZ5<^';>*>9HFC=G
M#.3N^7--TVUU'Q#IL^KOJUS!,7?R$C?"1A3@9'?I3>ER5K8[FBO.8M5U+7YO
M#H6\DMC=02^>8CC=M.,C\JV]!>ZL?%%_I$EW+<V\<2RQF5MQ7/;-.W]>@SJZ
M***0!1110 4444 %%%% !1110 4444 %> ?%"U-MXWNCC"RJL@/KD5[_ %Y!
M\9K+;?:?? </&8R?4@T >64444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!)#(89DD'8U[!\,M9$5[)I[M^[G&^/ZUXW70^'=3DL[B&6-L2P,
M&'N*RJ:-2/*S&+I2ABH_9W]&?2]%4M)U&+5=,@O(CD2+DCT/<5=K5:GIQDI1
M4ELPHHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHK.US5(]'TF>[D(RJX4>I[4-V)G-0BY2V1YS\0]4-_K46G1-E(.N/[QK
M.BC$42H.BC%4+0R7M]+>S'+,Q.3ZFM*M\'#1U'U/GL,W5E+$2^T]/0****[3
MK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[_P=%Y>B%\?ZR4G
M^G]*X"O4-%@^SZ+:1XP=@8_4\USXA^[8Z<*KSN7Z***XSO"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/L_^
M0]??[B?RK6K)L_\ D/7W^XG\JUJJ6Y,-@HHHJ2@HHHH **** "BBB@#F-/\
M^1YUW_KG!_Z *Z&N>T__ )'G7?\ KG!_Z *Z&@ JEJZ12:1=)/$TL1C.Y%ZD
M>U7:*35T-.S/)]0'V[2+6PM=7ENMTJ"*UV891G^+Z5VMWX:F.IOJ.FWS6<\R
M*DPV[E?'0X]:W4M+>.0R)!&KGJP4 U-3$<U)X3\W1&L9+V225YUGDF?G)!ST
MJ_J6BC4+O39S+L^Q2^9C'WN,8K6HH Y=_"EU;S70TS5'M;>Y<N\6W.&/4CTJ
MTGAE(KK2YDN'(L0P^;DOGN36]10M >ISVH>')I];.J65[]GF>,1N"FX$56M_
M!@CM]8AEO7E_M(*79ARK =:ZJBBVE@OK<YV'PU-YFF275[YSV.X9VXW@\8J!
MO"=U"+B"PU62VLIV+-$%SC/7![5U-% &!!X7@M+W2YK>0I%81-$J8^]G'.:F
M?1VBUB]U:.<B2:W$:J%^Z1WK9HH>H(H:+]K_ +(M_MS%KG'SDC!//'Z5?HHH
M8!1110 4444 %%%% !1110 4444 %<'\6K'[3X22X RUO,#^!ZUWE9GB.P&J
M>'+^S(R9(6Q]1S0!\P44YT,;LC#!4X(IM !1110 4444 %%%% !1110 4444
M %%%% !1110 445/9V5S?W"V]I \TK' 5!DT 05L^'M$U35KU186SN!]Y^B@
M>YKKM+\ V6E1K=^)KD;^JV4)RQ_WCVK4N]><P?8].A2RLQP(XA@D>YI-7T)G
M!3BXRV9<\!ZV=+U&31[QL([80D\!O3\:]1KP"Z1@XG0D.ISD=?K7K'@SQ*FN
M::L,S@7L(PX/\0[-6<'ROD9Y6!J/#U'A*G_;K[HZ>BBBM3UPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\I\<:V=9U:/3+1BT,3
M8)'=N]=3XW\3)H^GM:6[C[9.,#'\"^M<1H.G&-#>3#,C],]A64WS/D1Y&-F\
M356$I[;R?EV-M?"Z&Q1M-F$C*HWQGAL]ZQI8I(9"DJ,C#J",5NQRO$X>-BK#
MN#6@;NTU*,1:G""W03H,,*[*=;E5GL=DL)%*T-#CZ*VM0\.SVZ&>T87-OUW)
MU'U%8I!!P>M=<9*2NCDE%Q=F%%%%42%%%% !1110 4444 %%%% !1110 444
M4 %%%% $MK$9[J*(=78"O654(BH.B@"O//"MK]IUN(D96,%S7HAZUQXAZI'=
MA8^ZV%%%%<YU!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!GV?_(>OO\ <3^5:U9-G_R'K[_<3^5:U5+<F&P4
M445)04444 %%%% !1110!S&G_P#(\Z[_ -<X/_0!70USVG_\CSKO_7.#_P!
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M9_\ (>OO]Q/Y5K54MR8;!1114E!1110 4444 %%%% ',:?\ \CSKO_7.#_T
M5T-<]I__ "/.N_\ 7.#_ - %=#0 4444 %%%% &=?Z1%J%_8W;R.KV;ET Z-
MD8YK1HHH **** "BBB@ HHHH *SM'TB+1K>6&&1W$DK2DMV).:T:* "BBB@
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M"NBBB2&,1QJ%4= *<  , 8%+51@HG9A,'##K363W?5A1115G6%%%% !1110
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MZ%::@IETR01R=3 Y_D:YVXM9[24QSQLCCL177"<9;'#.G*&Y%1115D!1110
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M_P! :_\ ^^*/^$K;_H#7_P#WQ74T4 <M_P )6W_0&O\ _OBC_A*V_P"@-?\
M_?%=310!RW_"5M_T!K__ +XH_P"$K;_H#7__ 'Q74T4 <M_PE;?] :__ .^*
M/^$K;_H#7_\ WQ74T4 <M_PE;?\ 0&O_ /OBC_A*V_Z U_\ ]\5U-% '+?\
M"5M_T!K_ /[XH_X2MO\ H#7_ /WQ74T4 <M_PE;?] :__P"^*/\ A*V_Z U_
M_P!\5U-% '+?\)6W_0&O_P#OBC_A*V_Z U__ -\5U-% '+?\)6W_ $!K_P#[
MXH_X2MO^@-?_ /?%=310!RW_  E;?] :_P#^^*/^$K;_ * U_P#]\5U-% '+
M?\)6W_0&O_\ OBC_ (2MO^@-?_\ ?%=310!RW_"5M_T!K_\ [XH_X2MO^@-?
M_P#?%=310!RW_"5M_P! :_\ ^^*/^$K;_H#7_P#WQ74T4 <M_P )6W_0&O\
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M3_9H/^>2?]\T?9H/^>2?]\T 0?V_IG_/R/\ OD_X4?V_IG_/R/\ OD_X5/\
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M^>2?]\T 0?V_IG_/R/\ OD_X4?V_IG_/R/\ OD_X5/\ 9H/^>2?]\T?9H/\
MGDG_ 'S0!!_;^F?\_(_[Y/\ A6+K<]HEO-K&E6UO+>KA9)S'\RKZ\UT/V:#_
M )Y)_P!\TIMX3&\9C78XPPQU% 'C5S=3WDQEN)6D<]2QS4-:WB#1WT?4GBP3
M"WS1MZBLF@ HHHH **** "BBB@ HHHH [*VN+JST:UCO;"._LW'R;1DK[5:7
M3K>U\4Z1+"'19T9C"YSL^4URMEKVH:?%Y4$Y$?93R!4;:Q?/?K>M<,;A/NMZ
M4[ZW%;2QU*7#V6A:K/#@2+=D*V.E6[G4[B.YT385!N0/-.!EOK7$-J5VUO+
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M*C_N+^5'E1_W%_*@!O\ :=I_SU_0T?VG:?\ /7]#3O*C_N+^5'E1_P!Q?RH
M?!=P7)812!BO4>E35G6BA=5N@H &U>GTK1H **** "BBB@ HHHH **** ,6V
M_P"1DU+_ '8__0:U*R[;_D9-2_W8_P#T&M2@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH R]?TA-8TUHL#SD^:)O?TKR>6)X)6BD4JZG!!KVRN,\9>'_ #0=3M4^8?ZU
M1W]Z .#HHHH **** "BBB@ JS96%UJ$QBM8FE<#) ]*K5T_@<9U2X&[;F!N?
M2FA,R;K0=3LX3+<6<B1CJW7%9U=VMQ#I5A?"ZU5;PRJ52(9.#5*:WTC3] L[
MF:S\V>YC8#G@'U_E4C.1HKL)K32=(:SM+BR^T2W"AGD)^[GTIT?A^QL;W4)K
MA#-;VR!TC)ZY]:8'*BQN39&\$1^SAMF_MGTJO79W<MK<>"3):P>0C70R@/ /
MM4-WI%G'XHL+1(0(9$4LOKQ1UM_6P=+G)4Y$:1PB*68\  <FNLCTJPM!J=]/
M!YL5O)LCBSQ1H]QI4WB*QDM;,QLX(9#]U6]1^M"U!Z'-PZ?=SF81PLQA&9!_
M=%5:[98[:[U/6BD1C\N,]#U.>M4_LNFZ-I=G-=6@NIKKD[CPH]J2 Y6BNUB\
M/6">(#$R%K66U,Z*3RM5)K73;[P_=W%O:""2V?:&!^\/>F!RM%%% !1110 4
M444 %=W-_P @#2?^N KA*[N;_D :3_UP% %&BBB@ HHHH **** .BTC/]BS8
MF$)W_?/:HE=_[6M$:\%P-V<CM5"*^1-*EM"A+.V<]J@LIQ;7D4S D(<X%/J'
M0V1I\<US>7,J/(JR$!%ZFH+FPMK:XMY'5Q!+U4]5IL6K1[[A)4?R96W#:<$4
MR2_M'NXG\AC%'V)R6/O270&2ZAIMMI]LS,Q>21OW>.PJW#'LO-..XG*9Y[51
MN=72]MI(KB(EMV8B/X?:E&K1B:T?RVQ NT\]:$#+#VEE>S7440=9TRVXG@T/
M;FZTW3(,XW,P)J'^U;6,3RP0,L\H())X%0C50EO9HB'? Q))Z'-" NSZ3;M'
M,D44J/$,AVZ-7/UL7&IVLD<C)$_FR?WFX7Z5CT@"BBBF 4444 %%%% !1110
M 4444 %7])T\WUV 1^Z3ES_2JD$+W$RQ1C+,<5VMA9I86JQ+][JQ]30!8 "J
M%484# %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$GG&!TKI**7]?<']?>-CC2&)8T&$48 ]!3J** "BBB@ HHHH **** "BBB@
MJGJ>FP:K9/;3J.?NMW4^M7** /'M4TNXTJ\:"=3P?E;LPJC7L&K:3;ZQ:&&8
M ,/N/W!KRW5-+N-)O&@G4C^ZW9A0!1HHHH **** "N]TD7Y\&V_]G.J3><<E
MCCCFN"K;?68_^$7ATZ/>LZ2[RPX&.:.@=3?UF&*^;2;.\DC>]=L2M'Z50G\/
MZ:^IIIEI-(;@.?-8] M8.FW@M=4M[J8LRQOD]S5]-<6#Q,^IQ(3&S'*GJ0:.
MH%TZ+I5\EW#ITDHN;92QWGAP.M1QZ/IECI]K-JCR^9<C*A#C:*D_MG2K!+N;
M3XY3<W2E?GZ(#UID>KZ9?:?:PZFDOF6W"E.C"@!-/T"SN9+RX,LDMG!]W8/F
M>I)_#-N;[3S%(\=K=D@B3[RD=J2Q\06<$EY;^4\-I/C;Y?5:BO-9L'O+0(DT
MMO#]\NW+'UH[!W)=9T*QL[21HX[F*1#@%^5?\:M)X9T]+*%Y%N)#(FXS1<A3
M]*CN_$5BNF3VT#3SF88 EY"4[3O$&F6D<,@-Q&R+AH0<JQH Y*5!',Z*20K$
M D8S3*L7UP+N^GN @02.6"CMFJ]);#>X4444Q!1110 4444 %=W-_P @#2?^
MN KA*[N;_D :3_UP% %&BBB@ HHHH *EMI%BN$=T#J#RI[U%10!T$5QIMO<_
M:HYY!W\H#C-017]O<P7-O<$QK+)O5@.E8U% &O#/IUK?PF,,R*,,Y[GUQ5FY
MU&V:SN(?M#R,_*Y' ]JY^B@#>&K01WEM(I)58?+?CI3+V^A%JR17,DK.<X/
M K$HH TXM8F,T/G$&-&!P!5X7FGPW5S.LKLTZGC'3-<]10!T&VVDT.W%P[(I
M<X8"L_5;N*Y>*.')CB7:">]5&N)6@6$L3&O(%14 %%%% !1110 4444 %%%;
M.CZ.;EA/."(AT']Z@!VBZ0;AQ<3KB)>@/\1KI_8<"D "J%4 *. !2T %%%%
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MW$2Y,D1)QSRU-=OZW:%_7X([:Q\0Z7J5VUK:W0>91NVE2,CU&>M5O^$QT,,
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M@=/K0!B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.X87H:F-C:F[%T;>,W &!)CG%6** *(T730S,+&#+\M\G6K*6L$<S3)$JR,
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M% ' ^(/!SV^^ZTX%XNK1]U^E<>05)!&".U>W5SNN>$K75 TUOB"YZ\?=;ZT
M>945;U#3;K3)S%=1%#V/8_2JE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %=W-_R -)_ZX"N$KNYO^0!I/_7 4 4:*** "BBB@ HHHH ****
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MVRV\EM&T*]$*\"GVMW#>P":!]\9Z-ZU-0!6MM.L[-RUM;1Q,1@E%QD59HHH
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MIRU;^8HZ6^1H>!O^10L/]RLO5_$%_'KUQ9"]CL(X@/*,D>1+^-=!X:TV;2=
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M@CN+A$<C.*?*R>9%VBLB_P!5:&]TQ+=D>&ZD*LW7C':M"*\MYYY(8I [Q_>
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M(B1KMC4*/0"EH B@MH+5-L,:H/7O4M%% !1110 4444 %%%% !1110 4444
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M/ STH MVMK#9PB&! D8Z*.U357FOK:W6$RRA1,VU,_Q&J$6JK#<:@UW=0^1
MP QU3/K0!KT5G1:[IDT,LR7<9CB.';/ I]CJ]AJ)86MRDC+U /- %ZBL/5O$
MMC8VMVL=W%]JBC9E0G/S =*NZ+>27^BV=W+CS)HE=L=,D4+4"_1110!5MO\
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MQ5"7P)I;_P"KDFC_ !S0!YQ17>O\/K?^"^D_%14#_#Z3^"^7\5H XFN[F_Y
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M0H$B0!54= *??Y#9)1112 JVW_(6NO\ =7^5:%9]M_R%KK_=7^5:% !1110
M4444 %%%% !1110!BVW_ ",FI?[L?_H-:E9=M_R,FI?[L?\ Z#6I0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!EWW_(>TG_>D_\ 036U6+??\A[2
M?]Z3_P!!-;5 &;IG_'I_P,_SJY5/3/\ CT_X&?YU<H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH JVW_(6NO]U?Y5H5GVW_(6NO\ =7^5:% !1110
M 4444 %%%% !1110!SCWD=AXBOFF23;(L>TJA(.%JS_;]G_=G_[]FMDJI.2H
M/U%)L3^XOY4 8_\ ;]G_ '9_^_9H_M^S_NS_ /?LUL;$_N+^5&Q/[B_E0!C_
M -OV?]V?_OV:/[?L_P"[/_W[-;&Q/[B_E1L3^XOY4 8_]OV?]V?_ +]FC^W[
M/^[/_P!^S6QL3^XOY4;$_N+^5 &/_;]G_=G_ ._9H_M^S_NS_P#?LUL;$_N+
M^5&Q/[B_E0!C_P!OV?\ =G_[]FC^W[/^[/\ ]^S6QL3^XOY4;$_N+^5 &/\
MV_9_W9_^_9H_M^S_ +L__?LUL;$_N+^5&Q/[B_E0!C_V_9_W9_\ OV:/[?L_
M[L__ '[-;&Q/[B_E1L3^XOY4 8_]OV?]V?\ []FC^W[/^[/_ -^S6QL3^XOY
M4;$_N+^5 &/_ &_9_P!V?_OV:/[?L_[L_P#W[-;&Q/[B_E1L3^XOY4 8_P#;
M]G_=G_[]FC^W[/\ NS_]^S6QL3^XOY4;$_N+^5 &/_;]G_=G_P"_9H_M^S_N
MS_\ ?LUL;$_N+^5&Q/[B_E0!C_V_9_W9_P#OV:/[?L_[L_\ W[-;&Q/[B_E1
ML3^XOY4 8_\ ;]G_ '9_^_9H_M^S_NS_ /?LUL;$_N+^5&Q/[B_E0!C_ -OV
M?]V?_OV:/[?L_P"[/_W[-;&Q/[B_E1L3^XOY4 8_]OV?]V?_ +]FC^W[/^[/
M_P!^S6QL3^XOY4;$_N+^5 &/_;]G_=G_ ._9H_M^S_NS_P#?LUL;$_N+^5&Q
M/[B_E0!C_P!OV?\ =G_[]FC^W[/^[/\ ]^S6QL3^XOY4;$_N+^5 &/\ V_9_
MW9_^_9H_M^S_ +L__?LUL;$_N+^5&Q/[B_E0!C_V_9_W9_\ OV:/[?L_[L__
M '[-;&Q/[B_E1L3^XOY4 8_]OV?]V?\ []FC^W[/^[/_ -^S6QL3^XOY4;$_
MN+^5 &/_ &_9_P!V?_OV:/[?L_[L_P#W[-;&Q/[B_E1L3^XOY4 8_P#;]G_=
MG_[]FC^W[/\ NS_]^S6QL3^XOY4;$_N+^5 &/_;]G_=G_P"_9H_M^S_NS_\
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M_9H_M^S_ +L__?LUL;$_N+^5&Q/[B_E0!SIOH[_7M-\A)<1LY8LA 'RFNDI
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>plx-20200630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20200630"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20200630.xsd" xlink:type="simple"/>
    <context id="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gS8uxFBdfkSX_TQFGXUbNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-19</startDate>
            <endDate>2019-12-19</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0C6K83V4j0Kphnkf8n9mcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IjoXygzFWkGqMriuJJW-Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NOmRUBGMQ0qHujxUMsdUWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6VRfrb4a006C6zwz8zQtcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_w3xlUNxxE0W57aWLj2hlhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fUF3B9mz-0uCzmKZ02-ItQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kfGHTqSzx06Mpo3yF5o4OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bQ8d5NSZLk-awmHoE9teAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D91DMekLyUi786I0a96WxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VL6BuAeE9k-1CymbZrfhIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2iGT9UYX20ufEOy7uLUIZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_vbRY0t2qH0qlCvQizNy7Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7lZ2PehKpES7w0uB9Q2kTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YVr3HQawREa2lJZHx3PH6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LXVbu_pYy0S9ohnZflii4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fnM9Fs8xWUimFQZTDbqXWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_00e2daMkjkeossE65QH8wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uG2XyhIdEaKWq0i_Og6tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Joi_qhyS7EefeW8MDTljgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_QmGZUi6OjUqO1LnkJZCRXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ubU6rEERnEi4sCmFzEPs9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_yM7VN6n3HEqpoGO7RPojOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_b4IHEMa-EkOw9g0xX9vuVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_plx_PfizerMember_MzTzy7EFIEmRNIq4UP5v3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_country_BR_TrfPY3So-kuw0KkLJAQz4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_ObY9WS7lOkC896sj2TQd1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_leyen5aCU02wk6AuAeZjWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_mjHtdYriEEG-CXeWej1g7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CnxupLEavEiCHMgWdkLIPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_plx_PfizerMember_w1KRKtpN60Coy6CM1mW_ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_country_BR_yD1PqwkIzUCdzznvt7waSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2020_To_3_18_2020_twsaV_MqKEyUfAkshadSOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-03-18</startDate>
            <endDate>2020-03-18</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCX0MKCM4Ee34kOUnZ6BZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__6LA1s6dWU-YSFkzfQtBfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PQTvkYR-K0GQcvIHSBU09A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NWcLSQS2Y0abZ9Z36xlHpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_pL8I8jq_hEi_gqPwIAohXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_-Vqrm9TF40e2UHLfW2k7NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_R_GVwE60AEeYABBHU95XbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-18</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_2BE4yI-8FUy-wuebFU1qwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YozhTzDOZUqiiF9r9XEkGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qGcyw11XhEi9-0J_8vb26A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_U3lSq0ip90Kl1sHOY8UG4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZxLgitN4OEGYDuBZoHnVXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_RRB1BC9l90W_DnZi--Mbqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q_06E9Fbq02P0s8c6weMJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_WY_KFkHtI06S0Nse9YgtVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_RgcHJTMxiESAmSco2vlgwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vmg-JoGYmU-PSD4wN2qEbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DJm4hQ_X0kWnko7Ett0rIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyryerKYm0ufav34CwRxYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_srt_ProductOrServiceAxis_plx_BioManguinhosAlfataligliceraseMember_-6BPcOpQpkGF-ZjY7GtFWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:BioManguinhosAlfataligliceraseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_hPUJj7qNDUCmWCpyRrXLFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-18</startDate>
            <endDate>2020-03-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-05</startDate>
            <endDate>2020-07-05</endDate>
        </period>
    </context>
    <context id="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-05</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Sxo21H1-MUWD7YwWykIU8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_WPrxp0I9xU2_fyXrH5jLVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GM0kOY_mhEaJYH7pGa-SUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cV4rpMaJSkOSIB3MCn8lXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_3_16_2020_To_3_16_2020_oczPe0ei5ku15xZwnsPhTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7Z6yJiZE0GhfmBPrBAtlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_7CpUJdJGtEWp1gkOo1-Dkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RbVve-0-m0yDA75z_FJzKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_8_1_2020_HtHclQDk4kyUNEXyTR4Guw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_ckVCq6MfJUie7H_8uVpt2Q_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_IW2DNjztgEK6TAjae8vSVA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_s35AJIzc3UawdPSXsEOiyw_4_1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_Y1o2mvNPzU6u6MJltG02dg_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_e5I4_87RqEuawUA5JIlxig">false</dei:AmendmentFlag>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew"
      decimals="-5"
      id="Hidden_1glMU2yQtkCyCKsj6VV7zw"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">25000000</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_gS8uxFBdfkSX_TQFGXUbNg"
      id="Hidden_aWG3j73WyUuWsRh-fIJdNA">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <dei:DocumentType
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_yTOFm2dzeUeSj-6VKJmmmA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_jtf_MlgNlUmCEIrxVyb0EA">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_XX6pRXZVEE-UkF39ds4erg">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_iEjsTr3hGEmdkkH2PMce8g">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_Qo8RYBBcMUuHEA73j7qw2g">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_nNKQhe0ed0e7xyO7Joqckg">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_WpGeGCjHiEarHfUt-wm6BQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_djvWS5VQ5kCiTQ619cXbsg">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr__u9jdLXT7069IKv_c4tfow">2 Snunit Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_1arZNpZpgkai-RnpkSDKiQ">Science Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_rigEptziSUuDBq4mCnWlwA">POB 455</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_nw0JFT4AP02p9HyuEcm7fg">Carmiel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_K2wMeFoHuU6LrkK-O4U3cQ">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_9Gztz08mkUGjqkOi3Ngx_Q_4_1">2161401</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_jHNG9jBEIEW9BoleMtL-IQ">972-4</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_TxLfrsEcSkOUyuwcvJE8nA">988-9488</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_eC6Fis5PREen6_VfFSKfLg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_SHaf4MX4yE6rXS4TVyEQSw_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_hBYj_iMxS02ZJCTCwoa0Lg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_M2AhJtotDEGPIuDZiTJzLw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_IPhSHfZAWEqybvqIvU2N2A">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_02zBJzqH6EeXGxw6UHYp-Q_1_2">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc__3m25o93yEqeQyyKsQh1fA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tc_mRzKk3ZZuEy0LaTPzg46Eg_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Narr_44myAHaO9UyJCMRS7lTU8w">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_1_2020_HtHclQDk4kyUNEXyTR4Guw"
      decimals="0"
      id="Narr_nsHPCTqGRUWPRcu1NywwGA"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">32442636</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_HLe6VB0I80-ExV6HzL5qQw_6_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_1XQvvLNfuEuRuM9e619WBw_6_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_sns04n-0i0q0svPk5b4S8Q_7_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">30147000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_a4_6hr48ak-ZTeUUCllTOw_8_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5262000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_FUo9PXa7D02KcGIKJY1pmw_8_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_pYg_HspKi0qFSL18naOJ6A_9_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2893000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_maxEuA-3a0iSMNesIdc9Pw_9_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1832000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_qCZihxhwGEq20FyYCkZeeg_10_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">11065000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_cB1BsAOarE-YBTJ7duKu2Q_10_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">8155000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_RPGKz27qeEGg_YAANEH7mA_11_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">54210000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_MulEmMgllUS3Wxcik0hZxw_11_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">32479000</us-gaap:AssetsCurrent>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_Twe2v9UBH06PDE_8XTs_tg_14_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5025000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_7A5AvHxMo0KK3pD1zyuamA_15_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2005000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_rsOhk65AekStjf6MzSi-kw_15_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1963000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_wWSrBkX_GkiwoMVOKEnqVQ_16_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4793000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_psdI0O9UV0q_tfEwx9u67w_16_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5273000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_JI0N8pN-Uk6JBTQuG4YBWQ_17_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5677000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_mBxLrphYBUa8P7Di39BPBA_17_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5677000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_-EpAQJTUjEWjTIdI2Af8OA_18_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">17500000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_aetSJ4uhyE236YW6_SmVxQ_18_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">12913000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_Yyl-hlGf-E-6_x_yJwPkjw_19_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">71710000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_rDaq0_GzRka6v4nmyaX8rg_19_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">45392000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_d51aL7pjpUqItBWvjLhnMQ_25_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">6707000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_AUpJou5aFUGcFwGev6t1mQ_25_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">6495000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_NL5Hp1H0yUCJHmgyJ20LTQ_26_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">11910000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_iKtL5NKdM0mqGMrg2bSnfg_26_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">11905000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_53khd3VOc0OnHy-WMMjTYA_27_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1145000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_Ea_tvjO4DEyRs1b0afl5rA_27_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1139000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_WIH9TIFAS0CRChqKcdd5wg_28_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">18352000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_lNJFrIVf8EKXJvRDWzrXYw_28_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">16335000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_EZ4no7Z9wUGbyyzBwEcUxw_29_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4301000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_lVLPjwAco02eV-r0c26HHQ_29_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4301000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_gcSMAAwNrkKq4uDDgAsIRw_30_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">42415000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_UX-C_LM6J0K-EIxoQ6D9XA_30_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">40175000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_bgUrse6cgkWLDzyzQY2X-A_33_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">52622000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_wX3k0Z09Akaeq21FN7qb0Q_33_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">50957000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_SzreveLBAEGTiNT4v3cPHg_34_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4122000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_pHf77p3HEEi4sStu4Md-7Q_34_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">16980000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_RtR8QQEDPke_PR1KUIEN0A_35_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2665000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_Viix6tMjh0K5Q1X7EnpFxQ_35_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2565000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_fd8f_e291UCYv7ehHcNt9w_36_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4526000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_c7EQkeY1sE6yeA-YXXwAlQ_36_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4528000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_L56IHoulxUy9F8h2zxBFnA_37_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">124000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc__vl_dOiCfUy040txldTjmA_37_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">509000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_emT3w-MErkueD9OJrlCv3g_38_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">64059000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_KjIXEmY6NEC86LGJM9ZY5w_38_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">75539000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_zLkDqLJJMEO6qJP5JwoM7w_39_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">106474000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_6wcrO9Y57U2Zj8lifs_bew_39_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">115714000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_IVlIE1xqNE2q7K54C3lGkQ_43_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-34764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_BvlPfORoY0Oj5mB_d0TCgQ_43_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-70322000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_2balJo3F10iXiuReHfzVXQ_44_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">71710000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_i33o0Ij0Vkmq6Ep7oysaUA_44_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">45392000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_yM7VN6n3HEqpoGO7RPojOQ"
      decimals="-3"
      id="Tc_o1FoUtK_zU6X8L5e7iX1bw_3_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">8679000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_mjHtdYriEEG-CXeWej1g7Q"
      decimals="-3"
      id="Tc_0TjI7N8e30qSytmN7MheBA_3_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">6960000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_QmGZUi6OjUqO1LnkJZCRXg"
      decimals="-3"
      id="Tc_O9UFqPrWrk2eRloN0sh84A_3_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3648000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_ObY9WS7lOkC896sj2TQd1A"
      decimals="-3"
      id="Tc_xBxk0zZ0n0yLGLa_EvLl5g_3_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3430000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_b4IHEMa-EkOw9g0xX9vuVQ"
      decimals="-3"
      id="Tc_Y0omcKFFQEyaC_XHRuG0Jw_4_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">23934000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CnxupLEavEiCHMgWdkLIPw"
      decimals="-3"
      id="Tc_cvbjjOueD066ceZ_j_DtEQ_4_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">15726000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ubU6rEERnEi4sCmFzEPs9A"
      decimals="-3"
      id="Tc_YH9BVnBxykGciXVWgCKgTQ_4_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">7319000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_leyen5aCU02wk6AuAeZjWA"
      decimals="-3"
      id="Tc_zrbEweIGKkCCkqZ4W-w8iA_4_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">8817000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_6N0wQeMDM0WIsVnSYoPI7A_5_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">32613000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_uC8yQPJceUOFhaGWSON05Q_5_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">22686000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_ZobAhpgXrE2U-66sHqDogA_5_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">10967000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_cj3P5JbnEUe_e4I9WodCJw_5_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">12247000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_qawOWwvI4UmeWjc3dPqUeQ_6_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5253000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_DjRQEoCaqkOTz8nvL23dsQ_6_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4740000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_R1MiKoO_0USYxioUGUBvLA_6_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1827000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_3EQdXqrjPE2wXD47URaNdg_6_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2695000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_SGr6NUUCe0C5Bk_s1pDMng_7_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">19526000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_J4RETHFjp0638EmprGXqgw_7_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">25021000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_Ui5GxFKS9E2x7Ltt3u8Mbw_7_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">9186000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_iv2_bzm7606avIFAv9jEDA_7_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">13323000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_u36KAAK2xkWqrWosBzYeJQ_8_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5381000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_hnMVfBeSmU-kdjccWs-nQA_8_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4298000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_HBLGVjxUYE2z0u3vuDZE6w_8_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2194000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_YGB6guIBwUuiEMPH4WOchQ_8_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2068000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_EvrV1osUa0W9m_OSLRlgLg_9_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2453000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_qUjlTwUbmkmHG15LqpieZg_9_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-11373000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_EO2r1jaGsEO2ThEpyxQe0A_9_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-2240000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_-XULAD_Fb0eEguoHuhEF0w_9_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-5839000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_K3htR1Tj4kGXDUXasHn7Vw_10_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">5177000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_2m2s41B_mkSNCBBTOq6iPw_10_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3827000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_usK05MoeAUmWhvJHW_BOtA_10_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1948000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_EoIlOpahxESlhyZX_YeFEw_10_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1907000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_4aENFiYp-06VYdMOY3BldQ_11_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">241000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_F7-meTDb3kyonkGqVtP0Ew_11_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">193000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_sSJ56NB4706Msj1hp-xnJQ_11_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">38000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_hRatgfPYzEuoCHY9IT6dSQ_11_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_cNekAXYebUq1zUVMvO5Ltg_12_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-4936000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_mhLNqWfi1EWHwubpDRYZYw_12_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-3634000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_9j5VLCb1qU2S6-RHPL9JcQ_12_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-1910000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_M1CB2gj0dk2HXUvqFXCP1w_12_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-1904000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_TfR3DfBK90K7L7vfSMMTDQ_13_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_bQd0Zc0XPU61H_x0JM0jNw_13_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-15007000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_s3IHY2E84Uqh-GJUtgmJtQ_13_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-4150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_wSh9Fcb1EkW7AX2S6BGjPw_13_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-7743000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="2"
      id="Tc_y6-tCtrsEEuVu9S8AAoY9w_14_3"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="2"
      id="Tc_RIDnrCEqf0G4xMZrMNSKHA_14_6"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">-1.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="2"
      id="Tc_e4c4FW7Eukmtglu5BFNk4A_14_9"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="2"
      id="Tc_dPghKo-SskCahhJRwTxjcw_14_12"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="0"
      id="Tc_GHidFxu9A0mogDg8Y3BIZQ_15_3"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">19923935</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="0"
      id="Tc_cLSLtadXOEqTSHM2_23nFQ_15_6"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">14838213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="0"
      id="Tc_nrO4cQMnRUqj3HT3V9Urcw_15_9"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">32442636</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="0"
      id="Tc_tIbwDqO1E0WdJ0F2soZB-Q_15_12"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">14838213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZxLgitN4OEGYDuBZoHnVXA"
      decimals="-3"
      id="Tc_EeE-6K-_SESW5-xiJhQxfg_16_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">73000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_RgcHJTMxiESAmSco2vlgwg"
      decimals="-3"
      id="Tc_kqv6uzIi1Ey5FprxClxd7A_16_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qGcyw11XhEi9-0J_8vb26A"
      decimals="-3"
      id="Tc_WlSMvUVBHEycYD-zq58bQw_16_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q_06E9Fbq02P0s8c6weMJg"
      decimals="-3"
      id="Tc_WegpFSIS406CMoEwVP6qJA_16_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_U3lSq0ip90Kl1sHOY8UG4A"
      decimals="-3"
      id="Tc_K5U7vCuU0kyZZtRTXa6SHQ_17_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_WY_KFkHtI06S0Nse9YgtVA"
      decimals="-3"
      id="Tc_wxqwnlxsWE6oQjwmxUjyNA_17_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">87000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_YozhTzDOZUqiiF9r9XEkGA"
      decimals="-3"
      id="Tc_iiLvmh8awkCekx-T4BcjYw_17_9"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_RRB1BC9l90W_DnZi--Mbqg"
      decimals="-3"
      id="Tc_HcH8PP-tXESuCn7gBm6Npg_17_12"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uG2XyhIdEaKWq0i_Og6tQ"
      decimals="0"
      id="Tc_BgiW9FPxW02DMAsP901yug_6_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uG2XyhIdEaKWq0i_Og6tQ"
      decimals="-3"
      id="Tc_KUU4hrParUaoU0Wq1RRk7g_6_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YVr3HQawREa2lJZHx3PH6Q"
      decimals="-3"
      id="Tc_d7T3QGvRukiHq-ANJbXeLg_6_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">269657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7lZ2PehKpES7w0uB9Q2kTQ"
      decimals="-3"
      id="Tc_LGPgncN4CE2n788r7qQ7ow_6_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-322553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_2BE4yI-8FUy-wuebFU1qwQ"
      decimals="-3"
      id="Tc_47XLLqBXv0GBmRpSoFtP2w_6_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-52881000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyryerKYm0ufav34CwRxYA"
      decimals="-3"
      id="Tc_96gQSeEnPEqYQelUAJwD0w_8_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">403000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_Dc6M3fyNeEeMgj_jxwO1vg_8_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">403000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NWcLSQS2Y0abZ9Z36xlHpQ"
      decimals="-3"
      id="Tc_9Xj8gESXSE2V-evOIvOKhg_9_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-15007000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_KSnK6CzLQUmjV4J-pPMMZA_9_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-15007000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ"
      decimals="0"
      id="Tc_iVEqitVQvU-5xqMr6waasw_10_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ"
      decimals="-3"
      id="Tc_Bw6jItEYrEGBajt1KyHECQ_10_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D91DMekLyUi786I0a96WxA"
      decimals="-3"
      id="Tc_YYXHzjDNQ0a7pLFh8hpocg_10_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">270060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bQ8d5NSZLk-awmHoE9teAw"
      decimals="-3"
      id="Tc_3RXcmxP1nUmK6PWJdlNFeg_10_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-337560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw"
      decimals="-3"
      id="Tc_EqsXr3UvTEasUY6X4cSkLQ_10_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-67485000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fnM9Fs8xWUimFQZTDbqXWQ"
      decimals="0"
      id="Tc_P3QDfTMfWES1L14xViYFdA_11_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fnM9Fs8xWUimFQZTDbqXWQ"
      decimals="-3"
      id="Tc_XIUxTxopgUmZDm90nm6Fww_11_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kfGHTqSzx06Mpo3yF5o4OA"
      decimals="-3"
      id="Tc_p2w2gYmyD0C4y0w4uuWzlQ_11_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">270492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fUF3B9mz-0uCzmKZ02-ItQ"
      decimals="-3"
      id="Tc_94ZAyNZQqUyp-12bhM_pTg_11_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-340829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_IFq764MHV0u11oAuPWiUMg_11_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-70322000</us-gaap:StockholdersEquity>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7Z6yJiZE0GhfmBPrBAtlw"
      decimals="0"
      id="Tc_Fr4gczi0IE-okyUw_-7bWg_13_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">17604423</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i7Z6yJiZE0GhfmBPrBAtlw"
      decimals="-3"
      id="Tc_9PKwc6sAFkGX_OgtorTdCA_13_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">18000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q"
      decimals="-3"
      id="Tc_AeHDbaI_C0yQqIAZf5DtHg_13_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">41325000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_CutGlNx2kEGpsToJgXdv6A_13_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">41343000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:ReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q"
      decimals="-3"
      id="Tc_aWo5wtU1SEeGDhhJLmey4w_14_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4000000</plx:ReceivablesFromSaleOfCommonStockAndWarrants>
    <plx:ReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_k7qKh4y1QEGwWG6OMym3sA_14_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4000000</plx:ReceivablesFromSaleOfCommonStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipR9pRO6IkSpA4ZdvfxT8Q"
      decimals="-3"
      id="Tc_Vd3I9AOjS02Css7Kl_gqZQ_15_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">698000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_G0A71PSnqE6oj4GgFEP9uA_15_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">698000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__6LA1s6dWU-YSFkzfQtBfg"
      decimals="-3"
      id="Tc_6wm3BA8XFU6_vLD4nrZJ7Q_16_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_kDwYs7wD00G4Agw82wLqYw_16_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g"
      decimals="0"
      id="Tc_6v7CAO-TVUO21ZSLi16FLg_17_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g"
      decimals="-3"
      id="Tc_wImdQ_0N4UCC936Iyj7U1g_17_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IjoXygzFWkGqMriuJJW-Lw"
      decimals="-3"
      id="Tc_hJ2aDGIj6kKbGiVlVetQFw_17_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">308515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0C6K83V4j0Kphnkf8n9mcw"
      decimals="-3"
      id="Tc_-y7Y5-JJ2U2hzGgePlrz3A_17_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-343312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_FwxZAx_42ESRwHSvVnzODg_17_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-34764000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_00e2daMkjkeossE65QH8wA"
      decimals="0"
      id="Tc_wQKrDYKrC0iNFY-QHlvcXw_18_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_00e2daMkjkeossE65QH8wA"
      decimals="-3"
      id="Tc_1F2yuJcyw0yeEC3lN0Wjaw_18_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2iGT9UYX20ufEOy7uLUIZw"
      decimals="-3"
      id="Tc_QPurUBqOOU6JEc2IK9H9vg_18_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">269947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VL6BuAeE9k-1CymbZrfhIA"
      decimals="-3"
      id="Tc_UvQF1fMGKEyUqJHdJQNZpQ_18_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-329817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_vbRY0t2qH0qlCvQizNy7Ug"
      decimals="-3"
      id="Tc_2zKrSw_U5Uy--o2-Fgu-zg_18_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-59855000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DJm4hQ_X0kWnko7Ett0rIg"
      decimals="-3"
      id="Tc_36EBWWpygkuxICNztiVqeQ_20_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_kmg5NzlAZEe7AuL1UOEZUg_20_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PQTvkYR-K0GQcvIHSBU09A"
      decimals="-3"
      id="Tc_NwgoiTTEXEKXRalqnu-6oA_21_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-7743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="-3"
      id="Tc_Njdz7aaXTUKMgRrrnCnLIw_21_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-7743000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ"
      decimals="0"
      id="Tc_TnOmOEnIYk2Rn7q7Xnj0iw_22_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9myIomEHKkuoaxvpIWf1HQ"
      decimals="-3"
      id="Tc_R1XQ_7FUPUW9do7dqfJyoA_22_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D91DMekLyUi786I0a96WxA"
      decimals="-3"
      id="Tc_6ZcDOPZQgEugMMNHhB7ZHQ_22_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">270060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bQ8d5NSZLk-awmHoE9teAw"
      decimals="-3"
      id="Tc_118WhVkm_k2ZMTrZRl0xkw_22_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-337560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw"
      decimals="-3"
      id="Tc_rTBv8CoxL0Gau0FZUW5O6w_22_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-67485000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LXVbu_pYy0S9ohnZflii4g"
      decimals="0"
      id="Tc_Cw2t2AjstEiMdHc8f0LPHg_23_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LXVbu_pYy0S9ohnZflii4g"
      decimals="-3"
      id="Tc_lUxM971TukSaJ0aTRbqP1A_23_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6VRfrb4a006C6zwz8zQtcg"
      decimals="-3"
      id="Tc_omJLh2NONUKbK2pbvyX8RQ_23_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">308248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NOmRUBGMQ0qHujxUMsdUWw"
      decimals="-3"
      id="Tc_R5D1WW2p30iUg2PfxdFDCg_23_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-339162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_w3xlUNxxE0W57aWLj2hlhw"
      decimals="-3"
      id="Tc_cimR9YQPLE6OhvNNeZiuZg_23_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-30881000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vmg-JoGYmU-PSD4wN2qEbQ"
      decimals="-3"
      id="Tc_E4c2LbxMQkSfpG5IxIY5Bg_25_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">267000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_b3wufFFusUmFpwToW1lXiQ_25_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">267000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCX0MKCM4Ee34kOUnZ6BZw"
      decimals="-3"
      id="Tc_JcL8_fQ_JUaHw1uM3HvZlw_26_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-4150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="-3"
      id="Tc_w-szCl4iBEGBpU26DArnTQ_26_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-4150000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g"
      decimals="0"
      id="Tc_rAT4sKTVtEmVf-XqUEgE6g_27_2"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nL3FDIird0yv1nShw17b3g"
      decimals="-3"
      id="Tc_w9aQCs2sIk2QK2sdhauECA_27_5"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IjoXygzFWkGqMriuJJW-Lw"
      decimals="-3"
      id="Tc_6PZba7x_NUKzTaQOY81Yqg_27_8"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">308515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0C6K83V4j0Kphnkf8n9mcw"
      decimals="-3"
      id="Tc_xk5xFwB0_kWepYmJ4xRavA_27_11"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-343312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_s-Qy9Ou8NU6C8w-gWALIYw_27_14"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-34764000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw"
      decimals="3"
      id="Narr_7WjgQ-TVBkmyWYIerFFV1A"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="3"
      id="Narr_fOLVMAYkF0mcU_7lXGa2Eg"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="0"
      id="Narr_3oLcKUew1EufuoV8mFPLjQ"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw"
      decimals="0"
      id="Narr_G9gi4DchuE-QN00BRHu2bA"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_I209uJsesEK-jHJXsse3eA_4_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_VTa-f4iBdEi8O0Ts31sYvw_4_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-15007000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_Gyk9angNAUC-WaDJ73CIlg_6_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">698000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_m2JkcPSRFUKMRMYk8sNI3A_6_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">403000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_QSYnTIsTHEy2f10owrXmiQ_7_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">710000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_Cs-BPTrZrUKRquR3x3RTlA_7_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">784000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_ZZVpRTiPA0y5FcNS06PdBQ_8_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">250000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_OhbQwFiqNU-As3iQVW1kBw_8_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-150000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_S9jAnfeSh0yheFJsR12gTQ_9_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">107000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_m8ICoPeJakKHpbyXG1b50g_9_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">13000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_kOmAz5MbVkWlIC7F-1fQKA_10_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-22000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_DuaA9HhTXkW7w8CKns3Wug_11_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1665000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_WBV2PPergkaOm-im1aETLw_11_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1435000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_g25DZ9MMYk6WEpXPMMhBIQ_13_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-10841000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_srlGELsm9Uuqb_WCVZEf0A_13_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-442000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_sYf-45RStEuprHFPN-_nRQ_14_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1621000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_LKQKAckbtkaJkGlWqSTzsw_14_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2811000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_FcWLD6iPy0C4J4STr_BQfg_15_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-27000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_GWKlcFpF_E-qbgfO17OfWg_15_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">69000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_vGv0r1nkkE61hQmDxowiIg_16_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2910000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_D8NS9gz2M0iirNIj9jvzEw_16_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-1571000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_SjhVd2Qxx0mwJC5kRHysFw_17_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">309000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_VanhuKtuB0GkMPp34on9Tw_17_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1471000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_9yS2S62DfE-5gAzCfxPixA_18_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-385000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_wPId99l0o0Wuu6Ssy-1Fdw_18_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">56000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_JxJW3bLFrEa2fCOGrCViMA_19_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-14952000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_a-B6vefCmkuhFcc4oP-uKQ_19_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-12446000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_huetaFbNQk6_WKPH5r7BkA_22_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">35000000</plx:IncreaseDecreaseInBankDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_dxpx6ERDQUmPj0iUKAdUAA_23_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">278000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_MGjcBoqX_0KkDBRefdjMtg_23_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">207000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_4rYibeOzg0uZc1JVuIyK4w_24_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">236000</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_WRSb7Ko9ZUeLxZtb6QxKXg_25_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">69000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_uK7AaIGLFEuR6TbuIo8Ueg_25_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">23000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_WdXNlKRIvkCWpTpMQGMI5Q_26_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-35347000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_FO1EE_s3XkaoK_v9D00W2w_26_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-466000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_5MDwYu0LKkSTNd2NHOuTGg_29_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">37343000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_D4wrQplwE0el0GhLmDhGWQ_30_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">37343000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_VYmcDKYeskqPHpuaiVag_A_31_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">7000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_DVFJP75FMUSzrtakkHaP5A_31_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">200000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_N1QB8kqJ6Uu_Aqv8dTKSgQ_32_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-12949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_OhPYqok_CUqO5pD0RTSP-w_32_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">-12712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc__-hQD-kbKUKST433ykfKeQ_33_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2018_2BE4yI-8FUy-wuebFU1qwQ"
      decimals="-3"
      id="Tc_N0yQOpNBCk-KGqFIeK-zdg_33_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">37808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_gT_XeOYvnUObnO8dPwZwWA_34_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2019_jpbBPHbWwkKkTL70hOf1zw"
      decimals="-3"
      id="Tc_C5l1J4pg3USXg21aIhxnHA_34_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">25096000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_MnHmRvjDh0Sd5er98y0iYQ_4_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">50000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="-3"
      id="Tc_HGp_arIGW0q2awzjo8fWdg_4_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">329000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_fs8BfyLriEaEjoHchMH1Bw_5_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">362000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="-3"
      id="Tc_zS5GpQDv5ky064h-c_ETXA_6_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4000000</plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_yrhMO_LrFEyPapvu5P3OrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Protalix BioTherapeutics,&#160;Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix&#160;Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;OPRX-106, the Company&#x2019;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(4)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#x2013; a chemically modified enzyme to treat Gout.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&#x2019;s development and commercialization partner (&#x201c;Chiesi&#x201d;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease under the FDA&#x2019;s Accelerated Approval pathway. On July 28, 2020, the FDA informed Chiesi that the BLA had been filed for review and that the FDA was working on the 74-day letter. In addition, the FDA informed Chiesi that no &#x201c;Refuse To File&#x201d; will be issued for the PRX-102 BLA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On March 18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing &lt;span style="white-space:pre-wrap;"&gt;six months&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; following their issuance for a period of &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;five years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#x2019; terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The net proceeds committed to the Company from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;In July 2020, the Company collected total proceeds of approximately $4.6 million from accounts receivable outstanding at June 30, 2020; approximately $1.6 million in connection with its collaboration with Chiesi and approximately $3.0 million from sales of BioManguinhos alfataliglicerase to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&#160;the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;&lt;span style="-sec-ix-hidden:Hidden_1glMU2yQtkCyCKsj6VV7zw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;million&lt;/span&gt;&lt;/span&gt; in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per&#160;year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per&#160;&lt;span style="white-space:pre-wrap;"&gt;year, and to receive  additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) in accordance with the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#x201c;Pfizer Agreement&#x201d;). In October&#160;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&#160;year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The calculation of diluted LPS does not include 7,812,543 and 18,445,764 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the six months ended June 30, 2019 and 2020, respectively, and 7,805,142 and 25,997,289 shares of Common Stock for the three months ended June 30, 2019 and 2020, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#x2019;s reverse stock split at a ratio of &lt;span style="-sec-ix-hidden:Hidden_aWG3j73WyUuWsRh-fIJdNA"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-ten, effective as of December 19, 2019.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2) the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;e.&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_zk6-HKcyXkGgdP0dT-mliQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Protalix BioTherapeutics,&#160;Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix&#160;Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;OPRX-106, the Company&#x2019;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(4)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#x2013; a chemically modified enzyme to treat Gout.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&#x2019;s development and commercialization partner (&#x201c;Chiesi&#x201d;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease under the FDA&#x2019;s Accelerated Approval pathway. On July 28, 2020, the FDA informed Chiesi that the BLA had been filed for review and that the FDA was working on the 74-day letter. In addition, the FDA informed Chiesi that no &#x201c;Refuse To File&#x201d; will be issued for the PRX-102 BLA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On March 18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing &lt;span style="white-space:pre-wrap;"&gt;six months&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; following their issuance for a period of &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;five years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#x2019; terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The net proceeds committed to the Company from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;In July 2020, the Company collected total proceeds of approximately $4.6 million from accounts receivable outstanding at June 30, 2020; approximately $1.6 million in connection with its collaboration with Chiesi and approximately $3.0 million from sales of BioManguinhos alfataliglicerase to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&#160;the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;&lt;span style="-sec-ix-hidden:Hidden_1glMU2yQtkCyCKsj6VV7zw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;million&lt;/span&gt;&lt;/span&gt; in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per&#160;year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per&#160;&lt;span style="white-space:pre-wrap;"&gt;year, and to receive  additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) in accordance with the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#x201c;Pfizer Agreement&#x201d;). In October&#160;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA"
      decimals="0"
      id="Narr_x3F3deHGHUqKzmrxcoI6dA"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">17604423</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg"
      decimals="3"
      id="Narr_6zLx54aA3Eu7TV98_Zk6sA"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA"
      decimals="3"
      id="Narr_FM6EtmD9lkK811nEHH8_Ww"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">2.485</plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg"
      decimals="0"
      id="Narr_2fFDA5s3MUSkcTvdFoOEmw"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">17604423</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg"
      decimals="2"
      id="Narr_dOQ0bAvn-km3qOCqQy-bOA"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">2.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_DVVkMfC_ZkKZGLIx7OpjsA"
      id="Narr_-e5-iVuh9ES5BDDsoq5otg">P6M</plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_yeMHowxmq0a1DzJlEaTOLg"
      id="Narr_W5fmk2qCMkuxnS0MXVIjgA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_3_18_2020_To_3_18_2020_twsaV_MqKEyUfAkshadSOQ"
      decimals="-5"
      id="Narr_NyopeK6Wg0-f4LGS2iR-Ig"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">41300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromSaleAndCollectionOfReceivables
      contextRef="Duration_7_1_2020_To_7_31_2020_hPUJj7qNDUCmWCpyRrXLFQ"
      decimals="-5"
      id="Narr_YsfEHp7db063bXmJM5CQpw"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4600000</us-gaap:ProceedsFromSaleAndCollectionOfReceivables>
    <plx:TotalProceedsFromAccountsReceivableOutstandingChiesi
      contextRef="Duration_7_1_2020_To_7_31_2020_hPUJj7qNDUCmWCpyRrXLFQ"
      decimals="-5"
      id="Narr_9F323QsRQEaSNYmDTykneQ"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1600000</plx:TotalProceedsFromAccountsReceivableOutstandingChiesi>
    <plx:TotalProceedsFromAccountsReceivableOutstandingFiocruz
      contextRef="Duration_7_1_2020_To_7_31_2020_srt_ProductOrServiceAxis_plx_BioManguinhosAlfataligliceraseMember_-6BPcOpQpkGF-ZjY7GtFWA"
      decimals="-5"
      id="Narr_28Jm5uZBBkSGpvYqlsmvtQ"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3000000.0</plx:TotalProceedsFromAccountsReceivableOutstandingFiocruz>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ"
      decimals="-5"
      id="Narr_Hww1lG__8keU_ftcNTlqfQ"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew"
      decimals="-5"
      id="Narr_7vx4TvIuQEaMAfDzR1PAmw"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew"
      decimals="-5"
      id="Narr_Wt6APVWKL06LMai4qWq0mQ"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3yhwEM6GD0OZGHFnyrvhew"
      decimals="-5"
      id="Narr_VLfEkt_aeUi1jbLCPXZ9Gg"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ"
      decimals="-5"
      id="Narr_iUkPD3sv4kyJXIqXBiifqA"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ"
      decimals="-5"
      id="Narr_33heOCz9Kku3UZySwet47w"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_USeqfupNQU-q_z6axdyDSQ"
      decimals="-5"
      id="Narr_xXRJtjaqI0itpx_7cJMP4g"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GM0kOY_mhEaJYH7pGa-SUg"
      decimals="2"
      id="Narr_vCa3xoe1CU6Y3v2bviDKPA"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cV4rpMaJSkOSIB3MCn8lXw"
      decimals="2"
      id="Narr_DOHjea3cFUK1DbcvC7rafA"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Sxo21H1-MUWD7YwWykIU8Q"
      decimals="2"
      id="Narr_GvZtySasHkipJIHAXgXfZw"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_WPrxp0I9xU2_fyXrH5jLVA"
      decimals="2"
      id="Narr_9Rihp4q_wkGGY5JejMCSQA"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_7CpUJdJGtEWp1gkOo1-Dkg"
      decimals="2"
      id="Narr_PH3Rzv_Gg0mLFqo6KblN7g"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_ScJ2WMKRL0mRVJFmBEecwg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&#160;year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_7cmmcAUhNkSCflGe9zDEtw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The calculation of diluted LPS does not include 7,812,543 and 18,445,764 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the six months ended June 30, 2019 and 2020, respectively, and 7,805,142 and 25,997,289 shares of Common Stock for the three months ended June 30, 2019 and 2020, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#x2019;s reverse stock split at a ratio of &lt;span style="-sec-ix-hidden:Hidden_aWG3j73WyUuWsRh-fIJdNA"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-ten, effective as of December 19, 2019.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_6_30_2019_us1bN0rKhkSC9MVXA3EO1w"
      decimals="0"
      id="Narr_a6pqRSj9lkuDGUop-GhCOw"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">7812543</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      decimals="0"
      id="Narr_MGTQypRsiUOR7nHay4lkuw"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">18445764</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2019_To_6_30_2019_jIWaHndiTESYGWrX-I0Jhg"
      decimals="0"
      id="Narr_poagBYGCwkuZFiAnzuTYvQ"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">7805142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ"
      decimals="0"
      id="Narr_0x4LkikptkyHioPAsB1pdA"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">25997289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_9TNA6kp_T0W8_0pU_UuFGg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2) the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_ZA-J0t5TB0-gl3sM848Cag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;e.&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_JOZuFmGdxkyQTDpWJ1NC6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Inventories at June 30, 2020 and December&#160;31, 2019 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,902&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 552&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,603&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_82QTYnFHsUG-9knzOPy7kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Inventories at June 30, 2020 and December&#160;31, 2019 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,902&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 552&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,603&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_-2lRnp42nU6F3wE3MX2S3Q_3_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3902000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_L2pko-4eQU-JOT2_PyWP8Q_3_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3607000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_lqW08dZew0ycVyGtpTpOzA_4_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">560000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_yNiDTfxuK0S5EHvzdxYPLg_4_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">552000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_hek_wMxb7k-7898tCy4qiw_5_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">6603000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_ecGbIEPNs0OiPQAUoelcHg_5_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">3996000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw"
      decimals="-3"
      id="Tc_9QXdcoXSVUmaDebvg2K8Mw_6_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">11065000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_sVVIB1asJ06gOBmXTx1kyg"
      decimals="-3"
      id="Tc_IJFOCpssuESi401n3fLDTQ_6_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">8155000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_jMiD2EFpnUaWVJtwnnBzCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT (Continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.3pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;As of June 30, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;The fair value of the $57.9&#160;million aggregate principal amount of the Company&#x2019;s outstanding 7.50% convertible promissory notes due November 2021 (the &#x201c;2021 Notes&#x201d;) as of June 30, 2020 is approximately $62.2&#160;million based on a Level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June 30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 107.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_R_GVwE60AEeYABBHU95XbQ"
      decimals="-5"
      id="Narr_JvxT1sySYEGghxr7IaKFNA"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">57900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_-Vqrm9TF40e2UHLfW2k7NA"
      decimals="4"
      id="Narr_vcbdxbT0EUaT2nbQZLkNYQ"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_R_GVwE60AEeYABBHU95XbQ"
      decimals="-5"
      id="Narr_WvBLZQZDIkak4YDtclE9Ew"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">62200000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_pL8I8jq_hEi_gqPwIAohXw"
      id="Tb_IoYL9kE8vE2Y7zrvXaK01w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June 30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 107.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Joi_qhyS7EefeW8MDTljgw"
      decimals="2"
      id="Tc_QOGcGRlKmkitBcJ7rDPgeg_2_2"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">3.79</us-gaap:SharePrice>
    <plx:FairValueAssumptionsTerm
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg"
      id="Tc_XtrCszAw-UqzXrAl4lRgXQ_3_2">P1Y4M17D</plx:FairValueAssumptionsTerm>
    <plx:FairValueAssumptionsRiskFreeInterestRates
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg"
      decimals="4"
      id="Tc_YDl92K5T9kaRI_bFeHJlvQ_4_2"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.0016</plx:FairValueAssumptionsRiskFreeInterestRates>
    <plx:FairValueAssumptionsExpectedVolatilityRates
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg"
      decimals="4"
      id="Tc_YnOcKylfAEqvuizGpIW-9w_5_2"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">1.0787</plx:FairValueAssumptionsExpectedVolatilityRates>
    <plx:FairValueAssumptionsExpectedDividendRates
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BTm2jYrDokuFuwbQOVVqcg"
      decimals="4"
      id="Tc_500Mv8Jx-ky4kEFSgmnYDQ_6_2"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.1287</plx:FairValueAssumptionsExpectedDividendRates>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_VdPnePiut0azwhOTtEdG8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES (Continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;During the six months ended June 30, 2020, the Company recorded revenue in the amount of $6.7 million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;On March 16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#x201c;Kirin&#x201d;) to evaluate the production of a novel complex protein utilizing ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, the Company&#x2019;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0 million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <plx:SupplementaryIncomeStatementInformationTableTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb__R5cjI0fTUOQ02GwdQnpvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,735&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_plx_PfizerMember_MzTzy7EFIEmRNIq4UP5v3w"
      decimals="-3"
      id="Tc_oVqk338hA0KBtLJtmzoF4Q_3_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2679000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_plx_PfizerMember_w1KRKtpN60Coy6CM1mW_ow"
      decimals="-3"
      id="Tc_1TMfvn_JDEq-Wmd00iW3mg_3_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">2735000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_StatementGeographicalAxis_country_BR_TrfPY3So-kuw0KkLJAQz4A"
      decimals="-3"
      id="Tc_g4MqE1y02ECQdsGhbdxQyw_4_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_6_30_2019_srt_StatementGeographicalAxis_country_BR_yD1PqwkIzUCdzznvt7waSA"
      decimals="-3"
      id="Tc_psqc0bd1iUaE8WrUclMtxQ_4_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">4225000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_yM7VN6n3HEqpoGO7RPojOQ"
      decimals="-3"
      id="Tc_bO44unSX6kmWi-_K4bFS4w_5_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">8679000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_mjHtdYriEEG-CXeWej1g7Q"
      decimals="-3"
      id="Tc_6o3dcnZpN02rrXi62ycaxQ_5_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">6960000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_b4IHEMa-EkOw9g0xX9vuVQ"
      decimals="-3"
      id="Tc_eNdTzr3Y-UCaAcuv9UKIhQ_6_3"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">23934000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_6_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CnxupLEavEiCHMgWdkLIPw"
      decimals="-3"
      id="Tc_TnUCritni0Kkhomi17Pf6Q_6_6"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">15726000</us-gaap:Revenues>
    <plx:ChangeInEstimateOfTotalCostsExpectedToBeIncurred
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_RbVve-0-m0yDA75z_FJzKw"
      decimals="-5"
      id="Narr_zZrzFtov30iybxPtwKPFJA"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">6700000</plx:ChangeInEstimateOfTotalCostsExpectedToBeIncurred>
    <plx:NonRefundablePayment
      contextRef="Duration_3_16_2020_To_3_16_2020_oczPe0ei5ku15xZwnsPhTQ"
      decimals="-5"
      id="Narr_H-7Wvbn2tUuHa0dRx8bA2g"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1000000.0</plx:NonRefundablePayment>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_a8t9JYdSIEWR3SoTtSCAYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On June 17, 2020, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 196,995 shares of Common Stock to the Company&#x2019;s Sr. Vice President and Chief Development Officer under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The options have an exercise price equal to $3.59 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the Sr. Vice President and Chief Development Officer are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company&#x2019;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#x2019;s Sr. Vice President and Chief Development Officer to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.5 million based on the following weighted average assumptions: share price equal to $3.59; dividend yield of 0% for all years; expected volatility of 80.43%; risk-free interest rate of 0.59%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;On June 17, 2020, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 760,311 shares of Common Stock, in the aggregate, to certain of the Company&#x2019;s employees under the Plan. The options granted have an exercise price equal to $3.66 per share and vest over a four-year period in 16 equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.9 million based on the following weighted average assumptions: share price equal to $3.66; dividend yield of 0% for all years; expected volatility of 80.49%; risk-free interest rate of 0.45%; and expected life of six years.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      id="Narr__c6YMLwRVU-d3r21YwLmew">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      decimals="0"
      id="Narr_eWvZzfcB90yR9VEImfcXig"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">196995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA"
      decimals="2"
      id="Narr_mC4FH-KumEyvo2MsZfKf6w"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      id="Narr_uWSrdCLBrUaAShjPco6ZJA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      decimals="INF"
      id="Narr_FEm2AzXTREuT3fVspTit-w"
      unitRef="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA"
      decimals="-5"
      id="Narr_cPupUzcWHEC0NJnIRA4t7g"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">500000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1tfrA-f7D0Ky4aYBCnJrlA"
      decimals="2"
      id="Narr_QV6Qrw8k9EudKYwFX7sP2A"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      decimals="2"
      id="Narr_N-VRNeK28Uuzy9SWI84Z4A"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      decimals="4"
      id="Narr_0mNT8fMjV0a3g89n2TadfA"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.8043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      decimals="4"
      id="Narr_fCZHI5xLmkCaRRH2yEs9sw"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_j69VsB_N-Uui2hyj8CVKlA"
      id="Narr_cPzeGgypskWle0GlzCMNvg">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      id="Narr_dsd66gD5bk6TZV6stjhsrg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      decimals="0"
      id="Narr_brz9SFQf_EO_V78osa0FPg"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">760311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog"
      decimals="2"
      id="Narr_rU1LxlxB5EWJZfedJxX5Gw"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      id="Narr_kehIwRs3EUiX7uI5fTBJNQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      decimals="INF"
      id="Narr_3IvkRzgK3EKBna7rzzcUsA"
      unitRef="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog"
      decimals="-5"
      id="Narr_aNRIAdljqU2znHzOXHqvAQ"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">1900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_PWjQoNK-KkCYuAYU30ACog"
      decimals="2"
      id="Narr_LhOgxXeqZUGtvZK6wrj7aQ"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      decimals="2"
      id="Narr_9CgSoOQgiUSfgJSlIEGYsw"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      decimals="4"
      id="Narr_xsWFaRsX1kiQvWG6avCZhg"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.8049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      decimals="4"
      id="Narr_hrIGzFrImEmxZyh2by8taQ"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.0045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw"
      id="Narr_4vS6TTljGEa9PllyEveycQ">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw"
      id="Tb_ey-Fhz3sOkiXLWa270xwLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On July 5, 2020, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 129,771 shares of Common Stock to the Company&#x2019;s new Vice President, Research and Development under the Plan. The options have an exercise price equal to $3.73 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the Vice President, Research and Development is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $329,000 based on the following weighted average assumptions: share price equal to $3.73; dividend yield of 0% for all years; expected volatility of 80.60%; risk-free interest rate of 0.395%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;In accordance with ASC 855 &#x201c;Subsequent Events&#x201d; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      id="Narr_9TudnAcswkuevEObysHXhQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      decimals="0"
      id="Narr_1YIw3wS2t0u20xbeF6_Exg"
      unitRef="Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA">129771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q"
      decimals="2"
      id="Narr_gpcAcjjO7UKz3rwKCFUq5w"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      id="Narr_-e5WpTQo9UGnVV8vh9SIWw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      decimals="INF"
      id="Narr_IVGvtkUWBUaKkUd5KdR4KQ"
      unitRef="Unit_Standard_item_wze8_4GJek-5zeZcRZvdoA">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q"
      decimals="0"
      id="Narr_Efa-smEr0UOlmwTcK36ZgA"
      unitRef="Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg">329000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_J-W9I1Ux10qoLgfeHT8k-Q"
      decimals="2"
      id="Narr_5bBYTTIWRE6BXAsxd6hd1w"
      unitRef="Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      decimals="2"
      id="Narr_8QPUgARR0kOSia7npedpLA"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      decimals="4"
      id="Narr_lRDnD4b6N0WeotpJ6bQryw"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.8060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      decimals="5"
      id="Narr_CA1FJJG8z0OqY72CpudFuA"
      unitRef="Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg">0.00395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA"
      id="Narr_0i2sP1AnyUe2txsYbn7nKg">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389343276024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Snunit Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">POB 455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmiel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2161401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972-4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">988-9488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,442,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389343324696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,843<span></span>
</td>
<td class="nump">$ 17,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">30,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">5,262<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">11,065<span></span>
</td>
<td class="nump">8,155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">54,210<span></span>
</td>
<td class="nump">32,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Long-term bank deposits</a></td>
<td class="nump">5,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,793<span></span>
</td>
<td class="nump">5,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,677<span></span>
</td>
<td class="nump">5,677<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">12,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">71,710<span></span>
</td>
<td class="nump">45,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">6,707<span></span>
</td>
<td class="nump">6,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">11,910<span></span>
</td>
<td class="nump">11,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">18,352<span></span>
</td>
<td class="nump">16,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,415<span></span>
</td>
<td class="nump">40,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">52,622<span></span>
</td>
<td class="nump">50,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">4,122<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="nump">4,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">64,059<span></span>
</td>
<td class="nump">75,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">106,474<span></span>
</td>
<td class="nump">115,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(34,764)<span></span>
</td>
<td class="num">(70,322)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 71,710<span></span>
</td>
<td class="nump">$ 45,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments, and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389349736152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="nump">$ 10,967<span></span>
</td>
<td class="nump">$ 12,247<span></span>
</td>
<td class="nump">$ 32,613<span></span>
</td>
<td class="nump">$ 22,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="num">(1,827)<span></span>
</td>
<td class="num">(2,695)<span></span>
</td>
<td class="num">(5,253)<span></span>
</td>
<td class="num">(4,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net (1)</a></td>
<td class="num">(9,186)<span></span>
</td>
<td class="num">(13,323)<span></span>
</td>
<td class="num">(19,526)<span></span>
</td>
<td class="num">(25,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses (2)</a></td>
<td class="num">(2,194)<span></span>
</td>
<td class="num">(2,068)<span></span>
</td>
<td class="num">(5,381)<span></span>
</td>
<td class="num">(4,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(2,240)<span></span>
</td>
<td class="num">(5,839)<span></span>
</td>
<td class="nump">2,453<span></span>
</td>
<td class="num">(11,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Financial expenses</a></td>
<td class="num">(1,948)<span></span>
</td>
<td class="num">(1,907)<span></span>
</td>
<td class="num">(5,177)<span></span>
</td>
<td class="num">(3,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Financial income</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="num">(1,910)<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
<td class="num">(4,936)<span></span>
</td>
<td class="num">(3,634)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">$ (4,150)<span></span>
</td>
<td class="num">$ (7,743)<span></span>
</td>
<td class="num">$ (2,483)<span></span>
</td>
<td class="num">$ (15,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share of common stock - Basic and diluted</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares of common stock used in computing loss per share - basic and diluted</a></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">19,923,935<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="nump">$ 3,648<span></span>
</td>
<td class="nump">$ 3,430<span></span>
</td>
<td class="nump">$ 8,679<span></span>
</td>
<td class="nump">$ 6,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="nump">$ 7,319<span></span>
</td>
<td class="nump">$ 8,817<span></span>
</td>
<td class="nump">$ 23,934<span></span>
</td>
<td class="nump">$ 15,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389355861432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389347801032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">$ (30,881)<span></span>
</td>
<td class="num">$ (59,855)<span></span>
</td>
<td class="num">$ (70,322)<span></span>
</td>
<td class="num">$ (52,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants', window );">Note receivable from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">(4,150)<span></span>
</td>
<td class="num">(7,743)<span></span>
</td>
<td class="num">(2,483)<span></span>
</td>
<td class="num">(15,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(34,764)<span></span>
</td>
<td class="num">(67,485)<span></span>
</td>
<td class="num">(34,764)<span></span>
</td>
<td class="num">(67,485)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares', window );">Issuance of common stock and warrants, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">32,442,636<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 308,248<span></span>
</td>
<td class="nump">$ 269,947<span></span>
</td>
<td class="nump">$ 270,492<span></span>
</td>
<td class="nump">$ 269,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants', window );">Note receivable from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">308,515<span></span>
</td>
<td class="nump">270,060<span></span>
</td>
<td class="nump">308,515<span></span>
</td>
<td class="nump">270,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(339,162)<span></span>
</td>
<td class="num">(329,817)<span></span>
</td>
<td class="num">(340,829)<span></span>
</td>
<td class="num">(322,553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">(4,150)<span></span>
</td>
<td class="num">(7,743)<span></span>
</td>
<td class="num">(2,483)<span></span>
</td>
<td class="num">(15,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (343,312)<span></span>
</td>
<td class="num">$ (337,560)<span></span>
</td>
<td class="num">$ (343,312)<span></span>
</td>
<td class="num">$ (337,560)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables from sale of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReceivablesFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346130456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389274139272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,483)<span></span>
</td>
<td class="num">$ (15,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
<td class="num">(250)<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss on amounts funded in respect of employee rights upon retirement</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability (including non-current portion)</a></td>
<td class="num">(10,841)<span></span>
</td>
<td class="num">(442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(1,621)<span></span>
</td>
<td class="num">(2,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(2,910)<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accruals</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase (decrease) in other long term liabilities</a></td>
<td class="num">(385)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,952)<span></span>
</td>
<td class="num">(12,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Increase in bank deposits (including long-term deposits)</a></td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in restricted deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(35,347)<span></span>
</td>
<td class="num">(466)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">37,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">37,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(12,949)<span></span>
</td>
<td class="num">(12,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">17,792<span></span>
</td>
<td class="nump">37,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">4,843<span></span>
</td>
<td class="nump">25,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Note receivable from issuance of common stock and warrants</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note receivable from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346211896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Protalix BioTherapeutics,&#160;Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix&#160;Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">OPRX-106, the Company&#8217;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&#8217;s development and commercialization partner (&#8220;Chiesi&#8221;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease under the FDA&#8217;s Accelerated Approval pathway. On July 28, 2020, the FDA informed Chiesi that the BLA had been filed for review and that the FDA was working on the 74-day letter. In addition, the FDA informed Chiesi that no &#8220;Refuse To File&#8221; will be issued for the PRX-102 BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On March 18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing <span style="white-space:pre-wrap;">six months</span><span style="white-space:pre-wrap;"> following their issuance for a period of </span><span style="white-space:pre-wrap;">five years</span><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The net proceeds committed to the Company from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">In July 2020, the Company collected total proceeds of approximately $4.6 million from accounts receivable outstanding at June 30, 2020; approximately $1.6 million in connection with its collaboration with Chiesi and approximately $3.0 million from sales of BioManguinhos alfataliglicerase to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&#160;the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;<span style="-sec-ix-hidden:Hidden_1glMU2yQtkCyCKsj6VV7zw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">million</span></span> in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per&#160;year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per&#160;<span style="white-space:pre-wrap;">year, and to receive  additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#8220;Pfizer Agreement&#8221;). In October&#160;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The calculation of diluted LPS does not include 7,812,543 and 18,445,764 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the six months ended June 30, 2019 and 2020, respectively, and 7,805,142 and 25,997,289 shares of Common Stock for the three months ended June 30, 2019 and 2020, respectively, because their effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#8217;s reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_aWG3j73WyUuWsRh-fIJdNA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one</span></span>-for-ten, effective as of December 19, 2019.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2) the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">e.</b><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389347762248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Inventories at June 30, 2020 and December&#160;31, 2019 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,902</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,607</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 552</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,603</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,996</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,155</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346253224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">As of June 30, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $57.9&#160;million aggregate principal amount of the Company&#8217;s outstanding 7.50% convertible promissory notes due November 2021 (the &#8220;2021 Notes&#8221;) as of June 30, 2020 is approximately $62.2&#160;million based on a Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June 30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346263000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,735</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,960</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,726</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">During the six months ended June 30, 2020, the Company recorded revenue in the amount of $6.7 million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On March 16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) to evaluate the production of a novel complex protein utilizing ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, the Company&#8217;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0 million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346314568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On June 17, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 196,995 shares of Common Stock to the Company&#8217;s Sr. Vice President and Chief Development Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The options have an exercise price equal to $3.59 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the Sr. Vice President and Chief Development Officer are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President and Chief Development Officer to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.5 million based on the following weighted average assumptions: share price equal to $3.59; dividend yield of 0% for all years; expected volatility of 80.43%; risk-free interest rate of 0.59%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On June 17, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 760,311 shares of Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Plan. The options granted have an exercise price equal to $3.66 per share and vest over a four-year period in 16 equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.9 million based on the following weighted average assumptions: share price equal to $3.66; dividend yield of 0% for all years; expected volatility of 80.49%; risk-free interest rate of 0.45%; and expected life of six years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346396184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July 5, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 129,771 shares of Common Stock to the Company&#8217;s new Vice President, Research and Development under the Plan. The options have an exercise price equal to $3.73 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the Vice President, Research and Development is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $329,000 based on the following weighted average assumptions: share price equal to $3.73; dividend yield of 0% for all years; expected volatility of 80.60%; risk-free interest rate of 0.395%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In accordance with ASC 855 &#8220;Subsequent Events&#8221; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389355473224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Protalix BioTherapeutics,&#160;Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix&#160;Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">OPRX-106, the Company&#8217;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&#8217;s development and commercialization partner (&#8220;Chiesi&#8221;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease under the FDA&#8217;s Accelerated Approval pathway. On July 28, 2020, the FDA informed Chiesi that the BLA had been filed for review and that the FDA was working on the 74-day letter. In addition, the FDA informed Chiesi that no &#8220;Refuse To File&#8221; will be issued for the PRX-102 BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On March 18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing <span style="white-space:pre-wrap;">six months</span><span style="white-space:pre-wrap;"> following their issuance for a period of </span><span style="white-space:pre-wrap;">five years</span><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The net proceeds committed to the Company from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">In July 2020, the Company collected total proceeds of approximately $4.6 million from accounts receivable outstanding at June 30, 2020; approximately $1.6 million in connection with its collaboration with Chiesi and approximately $3.0 million from sales of BioManguinhos alfataliglicerase to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&#160;the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;<span style="-sec-ix-hidden:Hidden_1glMU2yQtkCyCKsj6VV7zw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">million</span></span> in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per&#160;year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per&#160;<span style="white-space:pre-wrap;">year, and to receive  additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#8220;Pfizer Agreement&#8221;). In October&#160;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The calculation of diluted LPS does not include 7,812,543 and 18,445,764 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the six months ended June 30, 2019 and 2020, respectively, and 7,805,142 and 25,997,289 shares of Common Stock for the three months ended June 30, 2019 and 2020, respectively, because their effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#8217;s reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_aWG3j73WyUuWsRh-fIJdNA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one</span></span>-for-ten, effective as of December 19, 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2) the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">e.</b><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346398680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Inventories at June 30, 2020 and December&#160;31, 2019 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,902</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,607</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 552</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,603</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,996</p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,155</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389347605896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member', window );">Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June 30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389346277336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,735</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,960</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,726</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental income statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryIncomeStatementInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389272669896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 18, 2020</div></th>
<th class="th"><div>Dec. 19, 2019</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,997,289<span></span>
</td>
<td class="nump">7,805,142<span></span>
</td>
<td class="nump">18,445,764<span></span>
</td>
<td class="nump">7,812,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables', window );">Total proceeds from accounts receivable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TotalProceedsFromAccountsReceivableOutstandingChiesi', window );">Total proceeds from accounts receivable outstanding - Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=plx_BioManguinhosAlfataligliceraseMember', window );">Bio Manguinhos Alfataliglicerase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz', window );">Total proceeds from accounts receivable outstanding - Fiocruz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 2.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants', window );">Exercise of warrants, commencement period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share price at which the new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TotalProceedsFromAccountsReceivableOutstandingChiesi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total proceeds from accounts receivable outstanding - Chiesi.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TotalProceedsFromAccountsReceivableOutstandingChiesi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total proceeds from accounts receivable outstanding - Fiocruz</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the proceeds from sale and collection of receivables during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_BioManguinhosAlfataligliceraseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_BioManguinhosAlfataligliceraseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389355077720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,902<span></span>
</td>
<td class="nump">$ 3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,603<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 11,065<span></span>
</td>
<td class="nump">$ 8,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389351569272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsTerm', window );">Expected term</a></td>
<td class="text">1 year 4 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsRiskFreeInterestRates', window );">Risk free rate</a></td>
<td class="nump">0.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedVolatilityRates', window );">Volatility</a></td>
<td class="nump">107.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedDividendRates', window );">Yield</a></td>
<td class="nump">12.87%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedDividendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedDividendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedVolatilityRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedVolatilityRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsRiskFreeInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsRiskFreeInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389351244344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Additional Information (Details) - Seven Point Five Percentage Convertible Notes [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 62.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 57.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389343333752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Company's disaggregation of revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,967<span></span>
</td>
<td class="nump">$ 12,247<span></span>
</td>
<td class="nump">$ 32,613<span></span>
</td>
<td class="nump">$ 22,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NonRefundablePayment', window );">Non refundable payments not yet recognized to revenues</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=plx_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
<td class="nump">2,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred', window );">Revenue recognized due to change in estimate of total costs expected to be incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,648<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
<td class="nump">8,679<span></span>
</td>
<td class="nump">6,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,319<span></span>
</td>
<td class="nump">$ 8,817<span></span>
</td>
<td class="nump">$ 23,934<span></span>
</td>
<td class="nump">$ 15,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the revenue recognized due to a change in estimate of total costs expected to be incured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NonRefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non refundable payment not yet recognized to revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NonRefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389343343992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Certain employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">760,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">80.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember', window );">Sr. Vice President And Chief Development Officer [Member] | Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">196,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">80.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389272565544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - New Vice President Research And Development [Member] - Subsequent Event [Member] - Non-employees<br></strong></div></th>
<th class="th">
<div>Jul. 05, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">129,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="nump">$ 329,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">80.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.395%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_VicePresidentResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_VicePresidentResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ME9.Q1JSN].;D^ 9WY[=4AXW[>2Y<[A/%J$JO=W%G'@-2D&-%K&IT3VH$SLY
MZ^20T!A0=G::$-\L?_/SPN)I<3X[SDXEK?+S_'#W(S/^E9"(KR'4ONS#5%/Y
M>6E^H^4N.W)\E%K+.+O<<A9P93Z ]VLI]?'&%%"<6H_^ U!+ P04    " ""
M. I1*)3F H,%  !)%@  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;)U8
M;7/:.!#^*QJF'^YFFJ(7O^ ,888 O=*A)!/(W=Q'QXC@J6U1623-OS_)N#98
M+Z'W);'P[OK9U>IYUAZ^,OZ]W%$JP,\\*\J;WDZ(_76_7R8[FL?E)[:GA;RS
M93R/A5SRYWZYYS3>5$YYUL<0!OT\3HO>:%C]=L]'0W8065K0>P[*0Y['_.V6
M9NSUIH=ZOWYX2)]W0OW0'PWW\3-=4?&XO^=RU6^B;-*<%F7*"L#I]J8W1M<3
M@I5#9?%W2E_+DVN@4GEB[+M:S#<W/:@0T8PF0H6(Y;\7.J%9IB))'#_JH+WF
MF<KQ]/I7],]5\C*9I[BD$Y;]DV[$[J8WZ($-W<:'3#RPUR^T3LA7\1*6E=5?
M\'JT#4@/)(=2L+QVE@CRM#C^CW_6A3AQ0)[% =<.^%('4CN0*M$CLBJM:2SB
MT9"S5\"5M8RF+JK:5-XRF[10V[@27-Y-I9\83>Z6T]ER-9L">;6Z6\RGX[5<
MW(X7X^5D!E9?9K/U"ER!Q]44_/'A3_ !I 58[]BAC(M-.>P+B4%%ZB?U\VZ/
MS\.6YWT]%)\ @1\!AA@:W"=N]RE-I#M2[B@Z=^_+S)OT<9,^KN(16_J/#P^S
MY1J,5RN9Y[4C(FDBDBJB9XL8ESL@:P,2=4%_'-*7.*.%,-;J&"JH0JD#]S+R
M!AX9]E].*Z(;H3",<&-U!M-K8'I.F*L=X^)*4)[+4U!\EYV_9V5J1GF,Y)\
M(!!YH1F WP#PG0#&2<(.LBR2"Q(J:_244=EF:QYOJ F#KV'P<8 [E=*-O!!"
M,\Z@P1DX<=Z)'>4@+DMJ+DZ@/1,/HNX6ZD9H0"P[&#; 0B>P>?$BVXKQE!IQ
MA?HC$0S\#C#=:H!\WPQLT  ;.(&MF8@SR5V<2WR.R@WT+?4P@AV$NA7!7AB9
M(48-Q,AY[)=WRZO+CSZ"+9E"9^H+5CQ?>*CJ2&?I0VPI/3JA<^1$\/D@:5EQ
M-*?E7DHE8%M \WW&WB@%7&E:"0[[2H)%RJD49&%$A_2VAK#;/08K% 7$DD/+
MR0@[<[CG<DKAXJVB4<6@>P7S(RBH&2LV''OM"!JL?!S:L+9LC]QT?R>1QB(M
MGD%&Y31Q++$J^D$N[+U?1SU#$X1A%_,[5N>86^I';NX_'M""%5?O'U*DDS\*
M?=@]I28S'"%;>5N10&Z5.$)UP-,I/T2A1B(&,\\G-@U%K3:@P,DCC8CMX[=*
MP53'QDG"#W%6.BFE97GDIGFK(B*=NX,0:BUDL/(B&\VT%(_<'%^IHA&5SM<(
M1?J&&,V@#5?+ZRCZK>.8I?%3FJ7"(I)UM',8GD9S)BMBD2#<B@5VB\6$%8++
MUYBR0?EFPHAUH9##@]^=?4QF 2&6BN)64+!;4"09YVE9,OXF&4,8.Q'K,N#)
M";$+\!VK<WPG [Q;+,ZGC7?V&QND GNHN^$F,RAISX*U%0M,G'2QN%O^!=:S
MAV]@,1_?SA?S]7SFG#QPR^G8S>FRF5ZD9J:*A-0^F=/765I-T5HK&<Q@Y%MT
M![=DCMUD?FG#&\@:Z2!U*Q1$ \NTCUM*Q^YY?_$+&M@R_G]&)VQX(PBTP=MD
MY0>V#FO5 KO5XC?Y#^OJX,F.Z&(U6@TL6%L-P1=H",CDR RJD?D]K ;)P%X7
MJN&E MJ8NE45[%:5(\=<CE37B\"#?M3%JIN%OF_3%=+J"G'K2HW6C9$8Y (&
M7M@MJ,D.^2'R+"A;72%N79F,[^?K\0),9Y_GD_EL.?G7"%,7C2OBA8$&TV 7
M0H(M$QYIY85<(B\GQ51O(6J^3^)]JFYMZ#9-4EHD1BZKHY]^O#'-IP8STWS:
M/_G.ISZR?HOY<UI(.J5;Z0<_A3)_?OQN>5P(MJ\^_3TQ(5A>7>ZHG">Y,I#W
MMTQ*1;U07Q.;K\>C_P!02P,$%     @ @C@*4:8+TJ 3!0  XQ(  !@   !X
M;"]W;W)K<VAE971S+W-H965T,RYX;6RE6-MNXS80_17"6!19((E$ZIXZ!N)+
MVA2Y(<YV'XH^*#9C"Y%$5Z2=].\[E!39IL9:MWVQ)/K,#,\A.1RR_RZ*-[GD
M7)&/+,WE96^IU.K"LN1LR;-8GHL5S^&?5U%DL8+/8F')5<'C>6F4I1:S;=_*
MXB3O#?IEVV,QZ(NU2I.</Q9$KK,L+OX>\E2\7_9H[[/A*5DLE6ZP!OU5O.!3
MKKZM'@OXLAHO\R3CN4Q$3@K^>MF[HA<3&FB#$O%[PM_ESCO15%Z$>-,?-_/+
MGJU[Q%,^4]I%#(\-'_$TU9Z@'W_53GM-3&VX^_[I_;HD#V1>8LE'(OV>S-7R
MLA?VR)R_QNM4/8GW7WE-R-/^9B*5Y2]YK[%VC\S64HFL-H8>9$E>/>./6H@=
M _"#&[#:@)D&[@$#IS9PCHW@U@;NL1&\VJ"D;E7<2^'&L8H'_4*\DT*CP9M^
M*=4OK4&O)-<39:H*^#<!.S48/=R/)_?3R9C V_3A]F9\]0P?TV=XW$WNGZ?D
MX9H\/$Z>KIYO $#.R+?IF)Q\^4J^D"0GSTNQEG$^EWU+06^T3VM61QY6D=F!
MR ZY$[E:2C+)YWR.V(^[[?T.>PM4:*1@GU(,6:?#W];Y.7'L4\)L9B/]&1UM
M3B.,SO^+/OG/T??$<)IYX93^W /^GH6*4_+$-SQ?<VQP*W._--?9:#.@=N0'
M?6NS*QF"8LPU4.,VRF$^=?91DS:*,3_T&]0>3[?AZ7;R' FIB'@E"R'FDDB1
M8C-Q6/GP=D*?T9"99!$4\R//((N@/.:99!&4&[@V3M9KR'J=9)^XY'$Q6Q)8
ML9!--[!-K"#I*\(_8..17)Z2'/:F$_H5$\%K=RFB._I7(B HZCC,X#?&8)''
M#&\3!,8\FU%<![_1P>_480K[4I(O3LF"Y[R >:[UB.>07A.IBEAO78TDY(2A
M:OA(SVCD&FI@*-L/#3$0E.>$U- "0;DL"G$I@D:*H%.*AQ77A/,%9/.9R#@Y
M2864*., X<)VIF3%&$%YH1,9C-LHYK;6 .**4B=P<,9APSCL9'R=Y'$^2V#4
M/X<8(QMB\],U!FZ$HFPSO2$HCP8&:H*@G-T<LT<V:LA&1Y*MAA>C&K4".R9/
M!&)P;".8:T[@-H9&!P:3VMOZQ?Z7PUDF,;0>L;'AHN8,QF&VL;3'&,R-'#.#
M83#'=]P#O'?J-MK)^QX2M5ZJ! X+1"TY@86<"'3WJCWY>SVE7HLW @L"UQQI
M#,;<T%R\& QBV@<F-&5;XJR3^*TF#62)7,8%UWLW3.P,SAQ0*\_>H$ =QC*9
M55M<DJX56EL.ZR#!;O?L<[/F&.$PCYF:X-Z8J0D"H^?V@=V,;FLUVEVL?2^/
M0QSVL UD\P4G^3I[ 85 FU(DV5)I+0$-]3LTKM9E^D_W93W3QZ\C9'3:F8&Y
M+O/-=3!"D!1F3<A,S<<8,HJ8$SF>J><1/O<EW9:%M+LN_*6L!_^XXUK(/SL*
M:KHMOFAW]?7#DKJVWZN#_=:>@Z%<QS9%;*-"/XA, =LH/_(/5)ET6U[1[OKJ
M-IGI3%Q.GJ>?XFSU,YPH>;&!YN,TW58OM+M\^;&F08MAX-#(U+2-"D-J[N,(
M2L]*UQ2U#:->P,R#BK5S:,]XL2AO2R2LR'6NJG-:T]K<R%R5]Q!&^Y!>C"C2
M/M8W..4EP=9]=?US%Q>+))<DY:\0RCX/8!H4U8U*]:'$JKPR>!%*B:Q\7?)X
MS@L-@/]?A5"?'SI <Z\U^ =02P,$%     @ @C@*46[<?<82 P  80D  !@
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M042Y$H#O.P:&.3VH"<K+K*O_ %!+ P04    " "". I118<!6]02  "3-@
M&    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;+U;;5/;R);^*UW<V2E298QM
M(&2&)%4."1EF\T(%<G>_MJ6VW1-)K:N6,,ZOO\\YW2VUC"!L=G:_ );5I\_K
M<UZZ>;DQU3>[5JH6=WE6V%=[Z[HN?S\\M,E:Y=*.3:D*?+,T52YK?*Q6A[:L
ME$QY49X=SB:3YX>YU,7>ZY?\[*IZ_=(T=:8+=54)V^2YK+9O5&8VK_:F>^'!
M%[U:U_3@\/7+4J[4M:J_EE<5/AVV5%*=J\)J4XA*+5_MS:>_OSFF]_F%?VJU
ML='?@B19&/.-/ERFK_8FQ)#*5%(3!8E?M^I<91D1 AO_\C3WVBUI8?QWH'[!
MLD.6A;3JW&3_I=-Z_6KOQ9Y(U5(V6?W%;/Y07IX3HI>8S/)/L7'O'LWV1-+8
MVN1^,3C(=>%^RSNOAVC!B\D#"V9^P8SY=ALQEV]E+5^_K,Q&5/0VJ-$?+"JO
M!G.Z(*-<UQ6^U5A7O[Z^?/_I\N+R?/[I1LS/SS]__71S^>F]N/K\X?+\\MWU
MR\,:F]"KAXDG^,81G#U \+GX:(IZ;<6[(E5I?_TAF&LYG 4.W\P>)?AG4XS%
MT60D9I/9Y!%Z1ZW$1TSOZ.^0N+?#<;O#,>]P_/?I]'&"GS[?O!-3<2!^0%G(
ML7BO"E7)3%Q5II:9OA-OM+E9XU&IFEHG=B0NBV0L]N$X'!FW*MO"Y^JUT+5%
M;"ZL3K6LM,*;]5J)7__Q8C:;G)V;O)3%EC]-SYX)6:2\8+,&G>V!V10JW5G=
M<O"A3L>\H.-I_,\=%GJ;74=TPHXC(2LE%MJ4:XEH3%@:R)DP8WA1+ WB!5P@
MUHE6JD#7E "0FC?'B[FJ$@T&ODM&!+,$K.#Q0A<2+]6=ED0)3I4N+$=\2S)2
MPO3TS-);)7BL@68D&V'+NSL(,3T]/@N_;H;7I4U2BU*7BFR-0*\J\ E+Z"+)
MFI34)W-3K(0AKD0" 70J:V5_%_O39Z)4JZ;0*YE!36!0R&PI1\)4XNK+?Q],
M)S.L'A*GHP-E52Q2#22O64?0QH5<0))46P6B1*."SD=B!9<B*MG6&FMR*!VO
MF"I5U9G8G\$7,IV:JKC/R'1"1&(ME1EI.H&B>JI?-[DLQ%ME[K:57IBB23)B
M04R9UMM/^!M;'3T3GYV ST>#]C#D^*"G#VX^7;1:[H3>K'4"/X=5H8Q5\!#8
M5UHLX^7PY10VN545/292NEAF$AFK-N"_4U=CB40GCV4BHI!U0UPDLK1-UNE9
MW2%G6O(E;XLS=LK]XV=>52?#(G4;''0D8M5=O7N_S2!<*KY6" @H;?]K1<)^
MOF/?>,9!-9UB/T$9G8(&?I:;5"\U5JGB^S:''Q@GFWB/S#T6GQ<U$CI)B%3]
M#=;'7[($Z[<R<V@!5DH$+RT$OP/*AKO1%XEIBAJ:@]93A5(B95\;CB>YT)FN
MMT13YV6F6-'T8J$22$X.5,'S,V<+6ZO2XL&_&DW&PB+#7 .&8.7 K1W'(4C\
M%:;&*FE-(1<9<:Y2G;A](#LTJR@6\)'\F>!)UX 7Z*00'^56S%ZX5-2S%SZ8
ME>)89>V<K[%$B_>964!A7PBZWKJPHL@6"%X../_:18=H6ER/R_%\/.P-/\:T
M4E8U$H#8#[C-.T0@"O&;(B%]@3X .]>6"RSCI3MUTA%WDG)'9E;(&N*#3E")
M*3$ORPPNQ'OMO_DP?\:> U)?Q]=C<6%,RHR]K9J5F*<H6+2M*_]ZA/ 7;^=M
M*J$0&0*T88R2*>HMB F;%)1_2-L]W()R@4R\T._"JILG"")5<:3,@R>#S'HC
MMVS;/YMLU[A8#S>FRA>+O*WJM72^ N'%6J; $E6(I<[P"C%<J5NJ14D)[:M$
M9P-XH *5(LF[_^GQ00J59ZJN535&7H9PJ29=_6#[P@0]?E%+Y#QQ8\0%./ J
MA5* KPN$H+6-9XOH^>1 G'MOKA HTR%_YK0*Q@@$$2'ZEB(:6)2H8 =*_N1^
MD 5%:O*-)=[(J@(H618F,47A:V^V$@?8<JDJJ*"_F>=S>CIZ/CD>'<^.8$,$
M.ER'8=@BXR._NZ"\%Q,Q$R/R?P'+-DK\,AE/)E-X5N4(]/SOW"VZID51<-0D
M;0.MD!]![$1%Z['_+[/Q\8N3GJCD_^T2V9D0WA7)TXD0[\P;%L@-%,/MCFZ?
MH^?=U@["VAV)&;\&"*8<"A0)>99%<96[^GN)ZLILZ"'DUA4K62+RV1TD$=<(
M5FRV1+836R4KK*E,[HHGLC=9V2^BT,:JA-&<$U]3E<:&(K''6I))0 HG%_@\
MP7--_H0^+F7;]U9X,PI8.O=0C6*#TDFB5.JLJ^O:X7OL,RVK][US Z]Q^'^G
MD;>IP/WE>#H^0O^491Q=<HG]@*:4LCBUI;=4T8"J4I;-Z^HN96NFD+:.2XF<
M@-"YN,.,@>#API:9K@EF@C2$7SM\C9\'MIQ(7L>4V!(%R<C 2$NVIL1*K-;8
M%25CZ(C.=BE.(XKZ?A2ZN,TRN3 >E^.$1:+OT#L:3_H<6IDY5T9V^"B+5:.+
MM;$,V53=KY ?@+.6:XH+@+'\]1^SH^D9?LY.SXSX;#<R2XTXKYKO;9JZT";!
MYSA/P9?R$/-O*OD=I0$>?G0994O?_*%D!M;CN(Y>-'\$:F/QY 9J_]R0?P.-
MGA%"?DYJLX ?3'\C92.>!YH:KSDX'H.5+K@B$N_N4,A;"JV0.NGEZP;Y<ROF
MJTHY7^V!DJ/T[N[@ZW7W2ILG$7(4C%QRN4JVQ\R*XLG%26M,>&O@(O-<</0C
M/;BZSK)O(3"#IK^B,@&1ZYJ:#:(5EQAJ,$]'V?.(U?1B5TT_J9O8,0?T-*BD
MW=J4E@UV?H,5AR[N*V&,CU10* F-AQPT:"F?]-NO>]\]W.WZM]M7HY;7?Y7+
ME'-+4R( "ZI^MJXT-CN*YM1Q$@4LP?K(\64\HJ@X17E*',Y-R<4\39=TWG#L
M_7+Z?-)1&P7]R!5X74$Y_"0JR?LU*:T#@AJ@5=@G*)/+.H)\VF4!L-W1;*>,
M75_BV@;=8K-$;=X0T..S7SQHTP+("V-V5:&,:*, _LM["D"+NP>$C"I)/784
MQS?OV]4&@_4JH6/@=I"V$]EIJ7!&Z*EDV*]:/]#]=B>7WZ!%S:$5&W)Z\A_T
M]1%^^4*-4BK#]L@W85$5*G/*-YR:BJ*!U3R^/X(+(TKL(:.[B.(BWO> E@-Y
M0*Z_0:CCR?]&J*'X?J(PUYIJ)]JW[8,7VU"F(YXY\S4^\[$[P%%<<^"@%AMB
MP=42,%KY&9P' />LA3!JG%$$5"E7:VWI?!_*R8\<>YU/][%VH>H-<3 PBG-\
MQ+#J']W#5*YT0B8$O)\,CO;<XEVDESEU_.E3F8_9F?NE#[$UD _C&LR:C/W)
M+^?A)I?QW@?Z-5!"+68/)7:W;;NHP6SR+E,T'1N+N>46/(0-N5V_-F1A736+
MA&V7GK>*3@\XX7I2Q.>EK:3*(BD@)LK!E1_-+!L:H[4+=4UK7 44!]]#BARU
MNK%D-UUGCJ\(4-',*A1#'@DY4FU)H;+PHZWIQ,5CJ(K%BB<>,"I]ZT49.?-S
M?#KV( C5Z/T>\!YQ8J0E3 Q4BE#4\A>!-5]](,>X1G9ZU-=WWR-#D4'4;E2R
M+FB^L14WP13#A9EG^H%JP]>NSD'NP<!81+6M&^GY)/+4&II[L;5$[#":6+TJ
MT%TEDN?%"SI6:_.+<ZZ#IJ1)4,A5;19F)8X\N, 8H0X)JB+ 8JN32[&'(EWI
M@K;OBO!."RBK34T::'N3D-5I#1_:$:'=5I_;['H->Z.W0G DKN+F]29 PE-:
M"Z_V+F1W&71>VXZ*_$:\>.&G2G ,MN&/]HL":S$6;Z35;#T:R(*VDY9Z5](M
M"TKB-(6$T],>E.W)C?DO(!-/2%-TW@4PGBHE2ZFHS75]HP3#8S- "[ORO001
M=^9H4Q-=4KI;N;,@\O>$BAJW]GZ9'Q+1^_G\JC>6TQ0\.H\8=?,H%GA,,[6>
M)VT%^CH:K_I3C!A*HH5L%KRFHLR/U$B[N[AW*7M(.YR+>)!4 @,=]J(8E*M@
M<&PHT[\:6SME[O,8LZ"=^<2AJ;B)YRF]>M:F?3#0C9C=?&0I==5MW &B;;+:
MMLD@*,A-4VQP"-#K[.:5@43YN>0* PP\3H?'**3'P)3FDZ&4!Z^W:I<9G@GF
MDL" \9(G#X$R)PEJ WZR"[[A.?C/N;)=FR:C"2G-VU,_C?BK*7:&@A'I'Q#T
MWCMW#O)%E:;BPP0ZH$<N.OC/5FR26+B\]Q9*S*EV.9IR@D O[\:UOGX+D=;R
MPZ/L:W(6GORSNZ)E70,@^.TP,M\=*+K'7=ETXZH%!*TS&Q(C1ZR[;0&;W>.L
MJQEI5'9+:@ACKJ"D0;TPHN('J6XL4%I^,-9&HTL"K(3E2'76$)FL_T) @ ]7
MU]T1;^78;WSIFNI;S3!/A3>O]PK<\-4'&O?=PK^AHZ)AJ>"FCX]N=V:A=:47
M3<T3+S]X"'/=-8HY5=G>((PLS3VYBQFO;IDEU(QZ: C20BQ $QB)P>ET]&(Z
M&YT<'[%B4#T<'Y^,3I\?/S2LY423,;+'?!C7+/H"Q4((CK^')KY%^Q7/5DE8
M3M=P?FC/>L;C#=PW-9=%#C5Y0!F]T8Y?@_='8V 7 ]'($%Y&Z]W4TD]*_%""
MGD,KDY/1]'CFWCH9_?;;Z6CVXK>'!&H/:=;(NC^SZ4(EDLXPW)1:+9?4,V\"
M</ 1+)L1KW<AU=2MC1?W?+OU3_+OWAD%'<*X],"GJ'5E.D[:DO,^EO/L9)DI
M?TJXZ\94BE:0P.UARTS7[BB!FPLV)Q0!#_WB:E8^OT41QQ*\8X$)'OZ40#7D
MGVD8HO7:AM1P_IYWB?Z:S"^KE.(HY8K0'1W=(#<FXCD=DH<-&44(U"N9A$.S
M<[Y<1%$5@G]^?4[+.@!S/81_3.>6B2?ABPY_08GZOCMMJ78IZ#+)6A6_NWD,
M.B'MQHBN<_*K.3>Z-II*$C<X\W#33?MA!RH9O&-T3B/, J69]".:WMP=':>F
M V:]W'IL  >1H5RO1+.KJBU84W .2*C%RI#5X0165;<H_&Q;*+KF@*J$H"K/
M&\-YQ$XWN=ME*U6N,%;^1!,DI4N#[M GA-$3F!CM*M/&,S>Z@U,S7^Z*#C56
M4/3"P6HXD>QR7I:%XXI -AJ$M)VUKMM#Q;95=+,REQ4?89^V#&MC50:G\"[4
M1H<[1*(0J=*N8.T&.@]PV.OYN @*JGN0X0>,Z/"X[<[=EH"*[#[+TXAK=S:B
MLLP5X3P]LKV[!S[LORO;=J_]54Y[[A32H"1DX=$D<4BU7"!H*G_RY494U$KU
M%9MTL<W"^"LM6\3T;+R#"KL#UQ[+Y%P^HN@\K]Z8![4&7L.Y0T=+AG-(?W&)
MV(XG0 2Q? K-^!W=;FC]AV_)S)ZU/@\]T??#7$2AO6QX.MQ-BO&P?Q6D#<GH
MI#[PUK_-X8OM'W#:5;ON=DX8.M!%H4P]Q+'EN:+7G+^=LD#?MD3(M<5?8(NX
M0>)_&D-.VB=H&&I: QD!W02Q[J0G;3'YWJT=WZ+[FBZM&J_7(8V3;T96,_W3
M@G!%)Z;5':*T9E*Y]==Q=D#1*JZM*7D')V688[VY$]Q'O#5&T;'XV&.[W:@T
MMCX8X+EMT;ASBW3DF^9*9=UTX7_L]3_?JPVDEHU+$/C 5QGIP/_.=UL=CA(G
MMV@T_86"^*O]!$*K1[BNE,X7#2H@COG[=<,C>:67BT+XM(#M@)C'*HB/V[83
M#U9KXC,FU *.IBLD6I]KB9C$7;-T5RR\MQ(4TD$0+>(;1WSN-:R)/GR$NP'V
M(;VY&X*T<PXG@@-\(T?-@2O4K<QS=\P?I@/!(^_;+Z1#3AUI5V,-)G<9SP=]
M92IY"),T.7=&M]U8U^5E\F+6S5A<H?*M_%$A[^=F%5&Z&):U7^\T--N,V?BK
M25?AP+)?"#GFW:T_:A<?X)UO]'D^PE%,G(D#8D8W6)Z >V[:R=ZV#4#AGOEW
M1GW9^80]V#2.YZ?MQQ/NSHR<Q2FY=WZ2$-C4YH!^MXYRT]=L.JS9X!"]I.8H
MVFXHY& 3ZFNX4N#0L+"@76X##U&V'\;.G?HA.DS^L0KXTK";)KB,-_I9K1SM
ML/'E5YF79V^[K7K?_A\:R"?P_P=O' M%0B?^HKB[,]<;_!IWM].57I?^6 2]
MI,?@BW9T--A%OC'XU=(MAE_Z6J;N/$#RT2CUO:GRK-]Q)[6BN[M25RQ>;E!Z
M<K'-&-@-KZ2URE7H,MQ^[]PTH2NYOH=G"N%BV$:L&NW&WGYRS!>WO=(BW.+K
M$A$?DFI07H=E,G/'9;;;V6,Y'QAS1]0EF$3:M5A2"1L;J)TF.:;=P(K;J'[$
MAKZ=#SQ:YM5PTT_#$2X8"CH'IXDP3=Q!*.'2R5W=^L&,=,P3R<G1V= _LAQ&
M_R@$1UWQOT-9=T?;_<]0^[3]CZNY^T>C[G7W[UH?9;6BL[A,+;%T,CX]V7/]
M=?A0FY+_[6AA:D0%_[E6$O%/+^#[I3%U^$ ;M/^']OK?4$L#!!0    ( ((X
M"E'G\4P:A0(  .4%   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULI51M
M;]HP$/XKIVR:-HF1-Z"T Z324I5)?1'TY;-)CL1J8C/;-.V_W]F! .I::=N7
MV'>^Y[GG'-\-*JF>=(YHX*4LA!YZN3&K$]_728XETVVY0D$G2ZE*9LA4F:]7
M"EGJ0&7A1T'0\TO&A3<:.-^M&@WDVA1<X*T"O2Y+IE['6,AJZ(7>UC'C66ZL
MPQ\-5BS#.9K[U:TBRV]84EZBT%P*4+@<>J?AR;ACXUW  \=*[^W!5K*0\LD:
MTW3H!580%I@8R\!H><8S+ I+1#)^;3B])J4%[N^W[!>N=JIEP32>R>*1IR8?
M>GT/4ERR=6%FLKK$33U=RY?(0KLO5'5L&'N0K+61Y09,"DHNZI6];.YA#] /
MW@%$&T#D=->)G,IS9MAHH&0%RD83F]VX4AV:Q'%A?\K<*#KEA#.CZ?7#Y/KN
M9C:=S >^(4+K]I,->%R#HW? /;B2PN0:)B+%]!#ODY!&3;15,XX^)/RY%FV(
M@Q9$011\P!<WU<6.+_[;Z@[8.@U;Q[%U_NVN/@9?W]Q-((+OL,<"4_&,PDC%
M40,S0.5C4SXPD<(Y)E@N4$$<6F]X#(FDAM &4Y!+,#G"4A;465QD)_#E4S\*
MXA__O38Z#M)_A?OVO TIY6-* Q>47JXUR=3?&JA3OC-(\(Q5]& -*LX*W1Q]
MAKAU'$0'=B\X@D?J84N]4C)3J'> ;B]XH[/;C>"""T[//X5,RG07WB.V^ V
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MZ!W;C8&E)*E(X<F<DSGLO&L6Y5-UY$.JC;[ J>[!&5TD;T@(@6@0%2(FTO$
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MU#Y. ]#U**D-JU:^?>?*TC#PVX*F+VH70.=+I>S6< F:>3[Z"U!+ P04
M" "". I1LW?-XOD"  !;!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6R-56UOVC 0_BNG3)M::2(AM(5U@$0[IG4:4P5MIVG:!Y-<B%6_9+93VG^_
MLQ-2)K5H7[!]OGONN2>^8[S5YMZ6B X>I5!V$I7.5>=Q;+,2);,]7:&BFT(;
MR1P=S2:VE4&6AR IXC1)SF+)N(JFXV"[-M.QKIW@"J\-V%I*9IXN4.CM).I'
M.\.2;TKG#?%T7+$-KM#=5M>&3G&'DG.)RG*MP& QB6;]\XL3[Q\<[CAN[=X>
M?"5KK>_]X2J?1(DGA (SYQ$8+0]XB4)X(*+QI\6,NI0^<'^_0_\<:J=:ULSB
MI18_>.[*232*(,>"U<(M]?8+MO6<>KQ,"QM^8=OXG@XCR&KKM&R#B8'DJEG9
M8ZO#7L H>24@;0/2P+M)%%A^8HY-QT9OP7AO0O.;4&J()G)<^8^R<H9N.<6Y
MZ>?9U1+N9M]NY["8SU:WR_EB_OT&CF[86J ]'L>.DGC7.&L!+QK ]!7 ,UAH
MY4H+<Y5C_F]\3.0ZANF.X45Z$/!KK7HP2-Y#FJ3) ;Q!5_$@X)V\@O==.[0>
MK ^_%BC7:'X?0#WI4$\.HJZH6_):(.@"!&=K+KA[@DS+2BM4+KR<'.@9<D5&
M!%951K.L?$G@PYEN2H1+PF7J":@/*V8(F,$#$S4+#YT8./(I&#?!BCM+&_7N
MS2CM#S]:H!ZUCJF<JTVC1R/-$8-O^( "!L^@Q\"LAZ&/@=W'Z('GLI_"(JB
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M,^R@%5V3-)"7_.X#+6[(4_9\'B397W17K+4ZR$\3R<,"# Q"%N7_R7T1B H
MNPT NP#8;0%. 7#: MP"X+8%> 7 :POH%X!^6\"@  S: H8%8-@6,"H H[8
M;#UDSFH-*9.=;[I\EV1;[)1(<GPH^!T2:CW84P?9/LWPL+-8I$IJ*05\R@ G
MCY?S]^?SV7PR/K]"X\GDXOK\:G[^'BTN/L\G\^D2O3ZEDK @>8/>HNOE*7K]
MZ@UZA7HHV1)!$\0B=!TQF1S 13@^8T$ A9(<]B1P4QYZ?L'C).=A-_ X(Z*+
M\/  V99MU< G9O@I]0$^4G \JH&?FN$?TZ"+'-SH?=H";CN9]V$-?&:&7_BR
M)#^H@;]O <_)8Z\&_F$7^0C@5N.]SUO#:R/_\?]Y__33WGM0"64YV&4YV)D]
MIZD<V"9B:^:32**Q[_,TDBS:H 4/F,]@OW_]#  TES1,_C:X<TIW3N;.;7 W
MX6$(?64IN?_M "V(0%S &9%TA;Z0(*5H0>&"JK6ZQ.;&AYEQU3MOCZVN9>'#
MWFTU?ZU6?6RUZM.N58^BX)91<(U1&$.05RQ(57-%2^JG@DD5[.F]'Z0K",5:
M\!!!K.(40J,:,5^C*1$1I";1$3I XU EK"Y2.0&OPMOV1J.!/1P]"=;SA8.A
MY6'7?A*NY^OPT'6]0=]]$K$Z@]CV7*<^9EX9,\\8LW.8MF+!?4I721Z?6+!;
MV#@H#HA/8>BIB\-);G148>/B;@.5?DFE;Z1RQ24)GI A>>TD,'7Y%'C=!!3!
M0)=($JT@:W4*W7].K=NO9S8HF0U^-3-H<Y,M;#Y61S'WIKJVSGH3QV')<6CD
M>,(X.B/1)F71EB=H'*RAC0=L X)#!<R*Z.L9#6^H,,G-J/0UVH>Z84L/%]9O
M2,",<5^D/VK;>.ZO7\E P^[%E0D(&TDNBL)9/!1.FY!CW5'P7EH*UCT%_\ZF
M<H)?I/%8BSPVJ_QYJF*JI/MA=DR2%"B]AKDQO_*FEDZ-T@[ZENO:38G7$HK-
M&KI(A;]5)0;2Z=.,R(H' 1$)BH%I1JJ>D_<L1';7'7H-A+208K.2ZA#=$2&(
M*I*60>J_-$A:0K%90Z?W5/BL#%*5VPL"EOL8/ J8TZ"<6$LG-FMGR:W"Z@#Y
ML/]I5)0R\&)\5<O);+N/H(CD-C&5I-9=/#+K(!5AE60M'[,)#WVG$&C3C*ME
MV3;+\B6]I0+"EBB)0$D<,(F$FJSJ'KQVV,)OUUR\Q9:)F)9BVRS%8\B9&O@6
M:_8#-M1X(^AC14;_HH50387=(]4YK[;0)&,*HZ.?H'GD<Q%SD<^(%<B)(#]8
MT$;6[<J#PEYDW=:R;N^2=:BTF^SN8$P>JXVTR8.CTAFEX!,Z* S-,8T2.%$"
MGS&"&H%59%.G]N]W.,66TOX_3#>@&X!M;@#Y7(6NES5Y-3G0>FY[>TF)UFO;
MK-?7,4PTX.R<1X*NTVB5#3-P]G8BZ(K)['1!OA=9>AAWZEXP%)ZJ@XW=T$]L
MK=VV6;O'*R !M0 S6/YHE"@V&:LK#@]4H +H%#9/P..,XH0GM=HT+?P\>GZR
M&MAI];;-"GM&[EF8AF@*:9)!OA\NUL\)::YJ;OD+5+"6XO#Y<#[H-H50*[=M
MEMUG(2PC.(.I:NS#GKXMJ5_231H0R<5W-(925(.8:E" /6,!!;6-:'UX1\^2
M#]V[GKJC5=XQ*[.IWD 4SUB4A;]%"3I:P!V\E_<G6H8=VSS#%=5U$2'U2+PD
M$&>SY$UW6,3>#L5S*F]W=DCVC@P4!= F UIE'7<O&="JZ^R8HG\B V:+[JZ>
MXVB%=LP*761@>O_BMN-HE74&>XFX%D['+)R_KNW,"D]MVHZC-=-YH6;^9-N9
M%7Z\%NQ<+8NN619_:=N9%<X>/7DU*+>K5=3=,0;OH>G,"@Z/7J4T-757Z[%K
M5L\=!?>RON-JI76=?=2@6WEE;1YF7ZYZLQT6=_8=5TNR:Q;0%DEHWWI<+;9N
M?R])T,KKFN?;GTF"V:+3F(1>Y3M6]6.#,R(V+$I00-=@R>H.("4B__X^/Y$\
MSKYVO>%2\C [W%*RHD(M@,_7G,N'$_5-;ODKBN/_ %!+ P04    " "". I1
MD=U^K%H"   6!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R-55U/
MVS 4_2M6Q -(6_/5!(K22*,%#:2QJBWP;)K;QL*Q,]MMX-_/=D(4VK3;2^)K
MWW-\SG5\DU1<O,D<0*'W@C(Y=G*ERFO7E:L<"BP'O 2F5]9<%%CI4&Q<60K
MF045U T\+W8+3)B3)G9N)M*$;Q4E#&8"R6U18/%Q Y178\=W/B?F9),K,^&F
M28DWL #U5,Z$CMR6)2,%,$DX0P+68^>'?SV)3;Y->"90R<X8&2>OG+^9X#X;
M.YX1!!16RC!@_=K!!"@U1%K&GX;3:;<TP.[XD_W.>M=>7K&$":<O)%/YV+ER
M4 9KO*5JSJN?T/B)#-^*4VF?J*ISAY<.6FVEXD4#U@H*PNHW?F_JT 'XPR.
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M1E8=L)IH4;BNLQ;:]# WS,Q/ Z4-,/L;8?I!/;$)FM_0Z"]02P,$%     @
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MWUH474UO99#*RXE9*;+S5VZW]L%#[1SL_5K9/[HVW! V3VC\&U!+ P04
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M<RWW#GYX\#\XM J06,:EAM3+S8)W\*.%_^S0*J"5.#2G<+IG3DHOF9SS2)$
M9IC*K7<PLTP.'Y,'+6)[X#<16HO0WBZ ^2!-!WP_$T(_/9@SQ.P(N/\+4$L#
M!!0    ( ((X"E$:VHM?C ,  "<,   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;,57;6\:.1#^*Z-53VJEA'TA0*@ "0*Y]G1-.6CHAU,_&'8 *][U
MUC80I/[XCKVPH==E\RF7+UZ_S(R?9SP>SW9V4CWH-:*!QT2DNNNMC<G>^[Y>
MK#%ANB8S3&EE*57"# W5RM>90A8[I43X41 T_83QU.MUW-Q8]3IR8P1/<:Q
M;Y*$J?T A=QUO= [3DSX:FWLA-_K9&R%4S3WV5C1R"^LQ#S!5'.9@L)EU^N'
M[P=A9!6<Q(SC3I_TP5*92_E@!Q_CKA=81"AP8:P)1I\MWJ 0UA+A^'XPZA5[
M6L73_M'ZK2-/9.9,XXT47WELUEWOVH,8EVPCS$3N/N"!4,/:6TBA70N[@VS@
MP6*CC4P.RH0@X6G^98\'1YPH7(5G%**#@G.$GV_D4 Z98;V.DCM05IJLV8ZC
MZK0)'$_MJ4R-HE5.>J8WO1],1__<C^Z^P&A&[13>#M$P+O0[N(0[\NJ,+Q#&
M"C6/,34P08U,+=;03V,8XI;.-4OLPK^?,)FC^D9JT\U<X_>-G1UM_[-V)]-+
M3#(A]XBZXQOB8)'XBP/>08XW.H/WKXVH0="X@"B(@OOI$-Z^><<-)F_ ![UF
M!#-O?[7LDU<*UT2%:R*W5?V<:WYC\3=)P$?:37^KL%\O[->=_:MS]BW02QM2
M,=S(A.Z99BY2^TJQ=(7.J_,]G,J-V=Y-]W=,Q1<P>LRXRI7&J+B,RQQ:C2(,
M8$\'6N6PJX+0U4L3^IQ9!7T!?Y*&T<"/Q.R,U!I^0-GYYD1S= V'SF:C;2^,
MVJU6V/&W):P:!:O&_\9J](AJP36;"[R KRYCD'1_BXHRX''5WC9[YW[ 4U"7
MT<UAMT[HUFNM>CG99D&V^=)DW0=FJ U/5Q5A60WDZMFH;!646I66[C8V]8!<
M EUF)H :95")/0770CE&-JQL$BF#V?H]J)KE/KXN %T_[V,85/MX</#Q0>X7
M'^>7 RC?(]PRKF#&Q,;%2QF!'$SS-$RB=A $Y23:!8GV2P?*"?2^IJK@Z9)D
M]&23_)!O[9L3PX28EE&KAAC4@N"/B@ *@Z<W,GAULC,IR*;@9G^6[C,HKX-:
MLYKP25$0OA;A"=</<*N0'M*4KB&EB?-\JT$&M7J[4<GWZ:4/HU<_X"^H2A/,
M,]":YQ.A?U+VV1+Z$U,KGFH0N"130:U%64OE56D^,#)SE>!<&JHK77=-E3PJ
M*T#K2RG-<6"+R^+?H/<34$L#!!0    ( ((X"E$<UN 22 (  +@+   -
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ @C@*44DF6CS" @  M!
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ @C@*49E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "". I1O]HN^&<%  #!%@  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ @C@*42B4Y@*#!0  218  !@
M             ("!JPT  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( ((X"E&F"]*@$P4  .,2   8              " @603  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "". I1;MQ]QA(#  !A
M"0  &               @(&M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ @C@*40>-Y09#!0  S1<  !@              ("!]1L
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ((X"E$^- K9
M3@(  ($%   8              " @6XA  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " "". I12?4V$BD'  #8&@  &
M@('R(P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ @C@*
M446' 5O4$@  DS8  !@              ("!42L  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( ((X"E'G\4P:A0(  .4%   8
M      " @5L^  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M" "". I1:/\+E,D%  #P#0  &0              @($600  >&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ((X"E$,1N/FA0,  +\'   9
M              " @19'  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!
M A0#%     @ @C@*46 07$JS!   S@P  !D              ("!TDH  'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "". I1E:JTQ&\$
M  "9"0  &0              @(&\3P  >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;%!+ 0(4 Q0    ( ((X"E%_HC;@(1,  (0X   9              "
M@6)4  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ @C@*
M4=&TO@J- @  VP4  !D              ("!NF<  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " "". I1LW?-XOD"  !;!@  &0
M        @(%^:@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( ((X"E'MVDUXH@(  /T%   9              " @:YM  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ @C@*46:Y7'\6!P  42$
M !D              ("!AW   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " "". I1D=U^K%H"   6!@  &0              @('4=P
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ((X"E%,9)7@
MKP(  )(&   9              " @65Z  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ @C@*47_:HOAN @  3@4  !D
M ("!2WT  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " ""
M. I12;?1J7<#  #""P  &0              @('P?P  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ((X"E%>G&$H8P0   X6   9
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "". I1K^R3I3@!   ?#P
M&@              @ %&D@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "". I1_M]0Z&\!   6$   $P              @ &VDP
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     (  @ )<(  !6E0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>84</ContextCount>
  <ElementCount>221</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails</Role>
      <ShortName>REVENUES - Company's disaggregation of revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20200630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="plx-20200630x10q.htm">plx-20200630x10q.htm</File>
    <File>plx-20200630.xsd</File>
    <File>plx-20200630_cal.xml</File>
    <File>plx-20200630_def.xml</File>
    <File>plx-20200630_lab.xml</File>
    <File>plx-20200630_pre.xml</File>
    <File>plx-20200630xex10d1.htm</File>
    <File>plx-20200630xex31d1.htm</File>
    <File>plx-20200630xex31d2.htm</File>
    <File>plx-20200630xex32d1.htm</File>
    <File>plx-20200630xex32d2.htm</File>
    <File>plx-20200630xex4d8.htm</File>
    <File>plx-20200630xex4d9.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20200630x10q005.jpg</File>
    <File>plx-20200630x10q006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20200630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 84,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20200630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20200630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 243,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 1,
    "http://www.protalix.com/20200630": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 7
   },
   "keyCustom": 31,
   "keyStandard": 190,
   "memberCustom": 11,
   "memberStandard": 15,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_pL8I8jq_hEi_gqPwIAohXw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_pL8I8jq_hEi_gqPwIAohXw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:SupplementaryIncomeStatementInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:SupplementaryIncomeStatementInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw",
      "decimals": "-3",
      "lang": null,
      "name": "plx:ShortTermBankDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Joi_qhyS7EefeW8MDTljgw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
     "shortName": "FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Joi_qhyS7EefeW8MDTljgw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_-Vqrm9TF40e2UHLfW2k7NA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_-Vqrm9TF40e2UHLfW2k7NA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_uTImVlXSPEe6oQWxFX8pvg",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
     "shortName": "REVENUES - Company's disaggregation of revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_3_16_2020_To_3_16_2020_oczPe0ei5ku15xZwnsPhTQ",
      "decimals": "-5",
      "lang": null,
      "name": "plx:NonRefundablePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_idcM82ErL0yG_oTjpfKYxw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yF_gdaORCk2yDlonAtg-gA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_4_1_2020_To_6_30_2020_Xjqezyv4fUiL-743qSl6cQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qGcyw11XhEi9-0J_8vb26A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qGcyw11XhEi9-0J_8vb26A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_3_31_2020_w3xlUNxxE0W57aWLj2hlhw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_3_31_2020_w3xlUNxxE0W57aWLj2hlhw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_aKY9zNNBgEyMqABVXQfyTA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "As_Of_6_30_2020_4YUuR9d8A0ad4Yvu-S-ejw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_wdJQp314EE-mC1bdQL70VA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_t7LLVj1CP0a5hheY3eTuXg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2020_rcq6133SzEanNr_erSphHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 26,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "B [R]",
        "terseLabel": "Brazil [Member]"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement [Member]",
        "terseLabel": "Amended Pfizer Agreement [Member]"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_BioManguinhosAlfataligliceraseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for the product, BioManguinhos alfataliglicerase.",
        "label": "Bio Manguinhos Alfataliglicerase [Member]",
        "terseLabel": "Bio Manguinhos Alfataliglicerase [Member]"
       }
      }
     },
     "localname": "BioManguinhosAlfataligliceraseMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount represents the revenue recognized due to a change in estimate of total costs expected to be incured.",
        "label": "Change In Estimate Of Total Costs Expected To Be Incurred",
        "terseLabel": "Revenue recognized due to change in estimate of total costs expected to be incurred"
       }
      }
     },
     "localname": "ChangeInEstimateOfTotalCostsExpectedToBeIncurred",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chiesi Ex U S Agreement [Member]",
        "terseLabel": "Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chiesi U S Agreement [Member]",
        "terseLabel": "Chiesi US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_FairValueAssumptionsExpectedDividendRates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).",
        "label": "Fair Value Assumptions Expected Dividend Rates",
        "verboseLabel": "Yield"
       }
      }
     },
     "localname": "FairValueAssumptionsExpectedDividendRates",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_FairValueAssumptionsExpectedVolatilityRates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.",
        "label": "Fair Value Assumptions Expected Volatility Rates",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "FairValueAssumptionsExpectedVolatilityRates",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_FairValueAssumptionsRiskFreeInterestRates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk-free interest rate assumption used in valuing an instrument.",
        "label": "Fair Value Assumptions Risk Free Interest Rates",
        "verboseLabel": "Risk free rate"
       }
      }
     },
     "localname": "FairValueAssumptionsRiskFreeInterestRates",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_FairValueAssumptionsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Fair Value Assumptions Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "FairValueAssumptionsTerm",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Increase in bank deposits (including long-term deposits)"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, in shares.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, value.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_NonRefundablePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of non refundable payment not yet recognized to revenues.",
        "label": "Non Refundable Payment",
        "terseLabel": "Non refundable payments not yet recognized to revenues"
       }
      }
     },
     "localname": "NonRefundablePayment",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Note receivable from issuance of common stock and warrants, net of issuance cost.",
        "label": "Note Receivable from Issuance of Common Stock and Warrants, Net of Issuance Cost",
        "terseLabel": "Note receivable from issuance of common stock and warrants"
       }
      }
     },
     "localname": "NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_Notes2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Notes2021 [Member]",
        "terseLabel": "Notes 2021 [Member]"
       }
      }
     },
     "localname": "Notes2021Member",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer [Member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants, Net Of Issuance Cost",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation [Member]",
        "terseLabel": "Protalix Bio Therapeutics Incorporation [Member]"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ReceivablesFromSaleOfCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivables from sale of common stock and warrants.",
        "label": "Receivables From Sale of Common Stock And Warrants",
        "negatedLabel": "Note receivable from issuance of common stock and warrants"
       }
      }
     },
     "localname": "ReceivablesFromSaleOfCommonStockAndWarrants",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Senior Vice President and Chief Development Officer.",
        "label": "Senior Vice President And Chief Development Officer [Member]",
        "terseLabel": "Sr. Vice President And Chief Development Officer [Member]"
       }
      }
     },
     "localname": "SeniorVicePresidentAndChiefDevelopmentOfficerMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Seven Point Five Percentage Convertible Note [Member]",
        "terseLabel": "Seven Point Five Percentage Convertible Notes [Member]"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNoteMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Seven Point Five Percentage Convertible Notes [Member]",
        "terseLabel": "2021 Notes [Member]"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share price at which the new stock issued during the period.",
        "label": "Stock Issued During Period, Issue Price Per Share, New Issues",
        "verboseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodIssuePricePerShareNewIssues",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "plx_SupplementaryIncomeStatementInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The tabular disclosure for supplemental income statements.",
        "label": "Supplementary Income Statement Information [Table Text Block]",
        "verboseLabel": "Schedule of Company's disaggregation of revenues"
       }
      }
     },
     "localname": "SupplementaryIncomeStatementInformationTableTextBlock",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_TotalProceedsFromAccountsReceivableOutstandingChiesi": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total proceeds from accounts receivable outstanding - Chiesi.",
        "label": "Total Proceeds from Accounts Receivable Outstanding - Chiesi",
        "terseLabel": "Total proceeds from accounts receivable outstanding - Chiesi"
       }
      }
     },
     "localname": "TotalProceedsFromAccountsReceivableOutstandingChiesi",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total proceeds from accounts receivable outstanding - Fiocruz",
        "label": "Total Proceeds from Accounts Receivable Outstanding - Fiocruz",
        "terseLabel": "Total proceeds from accounts receivable outstanding - Fiocruz"
       }
      }
     },
     "localname": "TotalProceedsFromAccountsReceivableOutstandingFiocruz",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_UpfrontNonrefundableNonCreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non-Creditable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNonCreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_VicePresidentResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for vice president research and development.",
        "label": "Vice President Research And Development [Member]",
        "terseLabel": "New Vice President Research And Development [Member]"
       }
      }
     },
     "localname": "VicePresidentResearchAndDevelopmentMember",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants And Rights, Commencement Period For Exercise Of Warrants",
        "verboseLabel": "Exercise of warrants, commencement period"
       }
      }
     },
     "localname": "WarrantsAndRightsCommencementPeriodForExerciseOfWarrants",
     "nsuri": "http://www.protalix.com/20200630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r83",
      "r104",
      "r106",
      "r168",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r84",
      "r104",
      "r107",
      "r170",
      "r171",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r85",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r5",
      "r36"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r5",
      "r36"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r25",
      "r86",
      "r87",
      "r105"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r116",
      "r118",
      "r132",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r118",
      "r128",
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r52",
      "r65",
      "r144"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r155",
      "r163"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r47"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r35",
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r143"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r96",
      "r159",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r102",
      "r103",
      "r105"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r102",
      "r103",
      "r105"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r156",
      "r157",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r97",
      "r157",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r17",
      "r109",
      "r110",
      "r111",
      "r154",
      "r162"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r65",
      "r93"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "Loss per share of common stock - Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r76",
      "r77",
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of liability component based on income approach"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r136",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r136",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r66",
      "r140",
      "r141",
      "r142"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial expenses (income), net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r115",
      "r117",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Increase (decrease) in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRestrictedCash": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.",
        "label": "Increase (Decrease) in Restricted Cash.",
        "negatedLabel": "Increase in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r45",
      "r90"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r30",
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments, and noncurrent assets classified as other.",
        "label": "Long-term Bank Deposits",
        "terseLabel": "Long-term bank deposits"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r158",
      "r164"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities net of capital deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES NET OF CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License And Service [Member]",
        "terseLabel": "License and R&amp;D Services [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r48",
      "r49",
      "r51",
      "r66",
      "r77",
      "r160",
      "r167"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss for the period",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Financial expenses"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Financial income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r58",
      "r60",
      "r73"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22",
      "r108",
      "r109",
      "r110",
      "r111"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Net proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndCollectionOfReceivables": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the proceeds from sale and collection of receivables during the period.",
        "label": "Proceeds from Sale and Collection of Receivables",
        "verboseLabel": "Total proceeds from accounts receivable outstanding"
       }
      }
     },
     "localname": "ProceedsFromSaleAndCollectionOfReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r94",
      "r165"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r134",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses, net (1)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r79",
      "r80",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "Total Revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r6",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r119",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r54",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "Selling, general and administrative expenses (2)"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r117",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share Based Payment Arrangement Employee [Member]",
        "terseLabel": "Certain employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r115",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share Based Payment Arrangement Nonemployee [Member]",
        "terseLabel": "Non-employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Stock price (USD)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r123",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r98",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r26",
      "r27",
      "r88"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Term of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average number of shares of common stock used in computing loss per share - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=SL116886442-113899"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4549-113899"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r174": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r175": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r176": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r177": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r178": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r179": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001104659-20-092375-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-092375-xbrl.zip
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MRZ-$L$4-9KY)]L=$S#:=-];UP!"F=WXH4X94?F_#(MYAB@@BU1 2;_GZOEE
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M^4KH][[C]F4L'<'1FF?.<$I@JN[WWN.!] :S!9K]3L@L'<71FF=.<4I@\OO
MP_K#F_U_OO[Z?U!+ P04    " "". I1^W(Q,AX5  #N1P$ %    '!L>"TR
M,#(P,#8S,%]D968N>&UL[5U?<^(ZLG_?JOL=?+,/>^X# 4(R(5,SNT4(F4-M
M EE@9G:?IAQ;@':,S9'L3#B?_DJR#39(QO\M$M>IFD-L6>KN7UMJ=;=;G_[Q
MNC*4%X PM,S/9^WSUID"3,W2H;GX?.;@AHHU",_^\??_^<NG_VTT_GT[>5!T
M2W-6P+05#0'5!KKR"]I+96:MUZJI/ *$H&$HMPCJ"Z H-^<?SJ\O6^WS3O?F
MLJ,T&EY/MRHF3UJFPKJ\.&]O[_2]7BWSH])MMEO-B]9%2[GY>'7SL7VM]!ZW
M#1\)E7-XM*4!S9_/9#2%<&KBSV=+VUY_;#9__?IU_OJ,C',++<B#K4[3;WCF
MMOSXBF&H]:^.W[;=_/?CPU1;@I7:@":V55/;/46[X3W7OKFY:;*[VZ9D>-W>
MM@U2<]5T;Y*F&'[$;*@'2U-M!M-1%A1A"_I7PV_6H)<:[8M&IWW^BO4S(BY%
M^80L TS 7&&T?K0W:_#Y#,/5VJ \LFM+!.9ALN<J?F:#$)59J.J:#-:^:0+#
MQO0*[1$WZ*5&J^T-]E< ]-690F]]G0RWO1UT1!LT:=OFX-4&)H;/!AB81 $1
M$\8#Q#8^4YK)2%\;KPVJ+*T/G18C9FH3G:-*W;=,G8P"=/(#6P;4J2YN[^+Q
M?+SV1L:'Q%-QKY%EJP9\/=>LE4M\NKZKX.A)1>32$MA04XTBV=L;J#Q>^TO5
M7  \-/OJ&A)&[L <:I#,>)O\V8T:*RO'=Q!KAH4=!.Y5B+ZIA@,>@4K_IH//
M5/*2Q-;/>'WE1_$4+DPR<6NJ:?<TS7),FRPV3T2"1#CX#M@J-%+0'J_78N7^
M -5G:$![T[=6:\LD5[ZKF#72V7HW-H=D;5V!WIIPHFK+U,SF.GBQ,NGI.J3O
MO&H,S;F%5FP"R)7QZ!'RXVX"7H#I $SEJYJ;*;FC+A8(+-B X[E_/S5SB0?(
M\9VT+>WG#*DF5C4V0Z=_#X4]Y4BM\XS!'P[!?O!"Y]KTQ(HZ\FA5D>:3Z_T,
M]KZUK*!I-W6X:GIMFJIAG,4UG_9---_RH[;9%>.;]9:-(/*;FDZ6V=#!7'4,
M.T?R.'WG1JRU4J%9#*U>UQE)9;TT5F#U#%">=(;[S4;DDM"#-.<9-+;LYT@J
MM_=L!)N6W<OU#?([],@B>@I-Z.X>S)]>EW3DK+N0(,& MM.!OKT*;3K [G$E
M\+QRQP GNV<*.$Y :9Y;CACDM^B$K#24;1?D=W\\NAN,IH,[^FLZ?AC>]6;D
MC^F,_.]Q,)I-E?&],GX:3'JS(6G@[C()<X:EA88TZ/[60FDWF?3*_A[3N_QC
M2RZS9OT1#/49&,S+P6W4S$XH1G: 2/+7/H'DTH\G9.F.9H_1%* 7J('>*\1[
M)(J;;8G<J4H/A<DEKY7?G?>&I9PS+*0#]/FL[?<V1]9*+#Z/!"N*>@<36JRU
M:[V5+G'<,W6/''P76FH.Q<YK6Y#L#Q<ION"/Z<Z>Z'D<G++\?WSH7'<N/ERU
M.E<?KJ[:W6[KL@Q(?!NG($RX7.4/4^(9U"/X,63I[$V@>VV*PB)L&QW%0:QE
M% P![1)(_($03%;N'?61LA>V+A6%BXPH"+F0 (_M^D9,,3 D/_<7Z:B&!:'
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M#H*X[^@R'^L0$ MG&<^2:FB<0EI=G+&8I!1!$L3"6MUE@.J4A-^W'X45=#&
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M^W3+3_/&I49M_K0%9SR*I/6H6H11J%*;'P(<PI%*3G4<"]E>XHS,-.#!SN
M@9^0K;_3M?@EW= HHF[ZL<7C=B.!="[40\S*05 '?/LG/YV9:YYNS-AL_ZG?
M5"\]F4B;;5^_M@';/T=H9ST['E!#HD3]V]AIC/IJ2PFC!Y5UW&+!"J?:CA=
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M%J8S@U2 63W>T/+0?,:%0Y-/Y&X4FMN/>1/>C]37V5=SC97"8NFLAO&JUDH
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MZ4/$ONWV%S4SVNX44*RU+YO2ZX\.GSE@7CD(LA,2L'FFH,Q5%7Y:Y_3)7C0
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MXE@NO4?/I8';QZW4<,?E5*2"F;B4"N+H'(J$._6RU4V!XW3/LG<\OGU)\_S
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M_'4/P#Z[!W12;H.4&X$7/\J V=-XO"7RA;>%G2FMZR55)UU[ 9TG=*=\+&\
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M9('C[C"&9CW]^YJUQ?[-_L7^@!LW?_M_4$L#!!0    ( ((X"E&X1I#^0B<
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MF25()PJ8B:J:;T^@9EU3A]5"FF>>8V>SO1\B%=)$)58EZ3N]29NZ=URH9QT
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M@V)%U'+_0(&F7P0HUGV$2L;_$L>D8U$_ZJVE*B#.@-@.9BZIJMP*D'0QJ4S
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MH4CNI0>L2VQ^\*C@G Z*027D?RV0OMTW>D\C'A5%W]X7/5@E?#+YJUTJ2MH
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MK0X?MH #JAF;IF&Z ;\-UB /^O!<-Z]^;XL<[N??OPX^X_>V<?=-^76HWY.
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M_D'9KZ?\HX7_+%,=39)[H[;CN7W+L'V\)<^,]TY[#@WXB2V?V-$3^$/13YC
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MXB5?/[AI/T^G_3Y1JL]$JCP38J1%E%MZ_U"J <-D&<:O&RT"N-/Z2%AUN29
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M]]D\#Y,POD72H @G$4Z^Q,]QD=*XI,7]YA$OYHBME#-80ZR7CDHT]!,9X.*
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M&Q$*6*LRT0C M*'FP+A-*#F1"([O@M&Z!3^<^Z@-DOD\Y .!B*+^_GB@!R<
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MMT[))4O(>_[ 60'B//+PGBF.E>9VE$:U34@1U SOJQ";_-YR/:G/"\M;I.'
M[*!9I)A'0Y";D 0,GQ@^?Q!\OJX71UC;VZ[Y-:_M/??VPH3[,[*,7<N+<RVO
M#_R_W>$\LC641;URK\42.J<\_#Q+&<L&EHW79*.AZ*-8"0L'%HY#+K:J^C/?
M5-YHHHX%Y.*]C.LCR6F<DW.0!/LFV#?Y<;Z)Z-FJ0?Q)_84WD=-9&6>LN?<=
MXH-%!XO.%SQ?9:Y[UW- A(7GDH0GIXUU5?>P\)Q&>,Y<Q/O(PM.V([AS4[;_
MV4X;L3-PW<Y V'(^/,>TQQA<OT]5+CBA ^=O7(Z88,VY)LW!J5 72R2L2EB5
ML"IA5<+'A#=U3'@9JH2#!Y<?/#A"?O]1K\O=3C0-=1QR<;#@$Y%8BOIJ*)8A
M$8%N1WJXF>U;WKO!V"_U./]^H/TM5,DHIF*I&J%X1%FQ?,59$]0= ?N.':O3
M^RVB[;%H<.K8[/N=-]\DRD?;<J*F)JX<C,K->9QB>#XVRU+#4;.:)&%CWOW>
M=YPK"V-863Z.6M^EGCK9;9MS\0L?8!ML)&=;L"_0LWYW8>8R2@#8]+0C_0+=
M6T]+(UZI=!>D+@L3UFON][0C/]'2+MQ7!-]SX=H 9W9-Z\A=T[K,1.^F\XU5
MEZ1S-<YMI$EJ[<.>#?0?_U#,72J>NJ.I^($.F]^N7[>[BQV=5M\<AO@M+/K?
M[Q:5;P\YG >&/MI_\PP8]*F^FNC14[!VS7'#F1QHG5F1)&;J-!1'4FR)["ZH
M5LM(0A1* !2*-L[$Z(/1!Z//#:#/4Y4#>%.G9&TRVK;]QSM.O-A4@A:OT&9Y
M4%S%&T7VFY%HE&S'FX5ERS?TXB+&U<O#GE:%2)3ZXQ^:3=^QB22&(PQ'&(X^
MVG#\;3@Z=C?RW\2CEN8INJ4!T\>Q -6VK<:3YH!N:-/*G!>3 >EGTDW::!\9
MB%YM*UXM-":66F>R/&TE4RDGN6@F[0"VRJ/^^"=.TW>)1-0_>_4R L:D<V#2
MF2MMG!N3OOD@Z]HPB<[PS+H42^6E=2SPM6%>HA;!J>"$2?:JU46FMR0+F5EK
M+MIYKT$C.&'^^"=!WZ52U'MH<G&G=;\E_]FI8DW FT:^ ^9$>%,-4&\5 UZQ
M-X5=CG5[1&C62!L19=_2PM!JG-RTP(:QYE_'.[DYK^ERM/([)Z]G^0&5/_]%
MS\O=+V\C6^IDXGUV(SOB\Q^]-!@65BRL6%BQL&)AQ<)Z99F>)Q36,_NU'Q36
MVTD&0@D-L:'B:C 5;#;7+%=!'OI-I_J\+K!7D\ES>E3Z$7'.<Y/F8LV.JSE.
MN6;N8\7 BG$YML^Q,QMROH-L"YF24=@^+;=MF97C9/C+,?,<JFMGK3F5_HST
MQ\HRSF2#UJK/??D\@!L]^*X'Y^2V[5?>C"PI9$AE]^RHE@86X0*6BYJSU%6M
M@:+?+4VU)Q9Z2D<Q?>W H4*:G31%C;<:_*+?U$R)*P<Y,I!3,&N"(0^ECV)@
MPL!TE<!T 4</6%-N_\C^%)IR:>&+DV_AU+!..I6I(6;3M4Z/B_,"%5S3MIM3
MV5I\O*YKO%:;/,@/JT"@EA.P[<*S_+?WW:L[PZ]K'F':K@L9@@[IPZ-Y?.Y^
M21=CKR#Z?'-;WI=LP#-??SWA81+6!JP-6!LN11MPSA96#ZP>1TEB/GJ>\E$C
MGJ_<I*AWU:K8%.D^J0P'Z4&<79G%^==3GX%34+)4>Z95@6?P5M9SNO>0FO!B
M3^3I3DQ;"J6E4)E.Y#2Z1$$E[D@R>JWK+PPA1\OW^!D0 @,J&$).%G'YL/97
M1*O"9A^K36GVT&'*L7FC5AMP4/N9CVC_[230?+B:SN&;#KBJSJFJZCQ'D3A
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M.[[.)VQ&^.88\)P.Z$E_MLZ1669-!HSO=Q_-)L2/30R82=,81#"(W!:(7$2
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MW,7<48F#I;4PBEU(62V,8KAAQ27& #\,0$',?<R:C)[A"YFY1+,YSK':301
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M&ULZ9FIC[U?XK>U'R [>?F:[*&KVR]%,!:H6?/:SIR*NP.K&W\:2%]H6?V(
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MUFU' 9X66D<!J"(\^)0L1P/$V*_*^ 1?@T%GWFKK#8Y<)_)J7239QB@#"^_
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MIX7QYJ#4FF2A,A_8H'.^PJ6+TW;/Z":#5+9BN?&N/X%M!& @XHYE#_6(Q@"
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M8_BTH)1 J\<'QH_BNIKG$O;04W0K;-6N;6J#0+X0%G@G)+"">K>;D .$^<0
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M:6"+(V$G"H#[]Z\+ZN$3"6H;5T(1VF^WPL.42JB03XY5Z&\!542Q"T"HN0;
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MB2,HAU4R5J-\1'L2-0.($NRX((5]AX],'U\I?ZMNI20*04(KTDEDHAF1&[(
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M^55R4:(]>L'"XVWB&O1 20QY>K5S/FM5\\V6==G<V/C:;52^]1*MS+.5%SC
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M@\FR!]DU'V2QE7S^8%K?O<O>S,LWK>W.8.1>;HG.[H7B<SGLOTDS715JR+.
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M)Y'^YO>O[<K=_NAF4S\]_5J<MX)&,".M95'* (6@ZAZQ$<?NJ[2Q]IG\Y C
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MRSX[^'UJ)'[+2,YO?I>?U@*>H[V^54!)O<"MOIX-1BT_WSUR1K,S8Z]4_3[
M[&[06)=UY_DU@DG_>O+Z593,2F_C\NRL?7':JFY\:P9W9G5H%AY2,E<:U%IK
M'K]6;*U^<MP=-$]/\S=''5NON6/+'.]_S'*$-6E]A)#02T)\SNF6NU7N50_S
M%Y8W&>]6>R?^?$8AOB5]#]XIQ+<F*X6LGI.P\\Z1QLUF87MW=Z=^GS^ZO:P5
M-\>AN1TBQ\J5EH"E_$BH<4T9'RWBF;>+P7&AZ<Z[5G%R%USVW)J[]_Y5$@A[
M:"",JNZ"IDXQKV9G4ZM7*A+I)MYUC<./ O8F60POL"E--'OEXQ8]#L_Y7C@8
MQJ:J0%<T$:F=C&#JY4B_!GL:)F)CC;SL:!B I0&F!%71FTD[&7YJ.*%)=K(^
MT5Q/6-B+<R#WMV<(>%%Z>N:%#D+'WH8V#"_@ Z4'P(S X!0LTN=.^(E8-8P]
M=O0Y?FE]>=FQJ@"=RX*<"J+V<L3 I5C!SXQRZT3,5_E"KU\KURI7^7Y=ORKG
M&^95KU$J7/5+E7ZQ856L6@%QC0DI^Q?#@2^N<>#7./ OPH'_4<QPOE-M8!S%
M ]W56=P$"$49$FHM* !-5W?F@1UX_6UQK=XF02+_O#0.G"OCAE/"QL./JGU.
MQKZ5I4XG__FGF-.T>*E1H#->,BD]<M&X]]L1B]V4_E()XQ8ZC E\-!8NWF %
M621BD^PD=R7:LB= /@9\>^F%6C 4$D8W4ZXS,[E875FL%_J*3#$2"_;C!7O1
M@K6)-[!(ZI'P3OY>$:(X@)!C3XA;^231*3SD>A-$OY&BUG(":S:TI&2$:6_#
M]0%Q]X\@BT<WII#/GM ;T!T.<VVZ+CH'3ZVQYT_0R?C"P?;(M,?IHA(E,..W
M+(-TP^>.4RI@)E"AD=,ZWBCRLMLNJY"<UN.B!U_Z^@4:T9(SS&AC';&R0T?'
MB >="9S;6$0"<,F(A,V['$S01!S,:0WX50^=]U80B.-VU$-R!QEY" '^ !70
MK.-Y-TA1JK8$KQ0ZR\C270(9AQ5U!)!ZL=:4"X2/0A_("\9K&H0W76B42BKD
M(4<SHI\66DM^VKH36._Q&.7D&.* U ?E4E)SQPI!GSYDJX=)/*/U+,>V^D&&
M;&M7!#]\N7\V;PA?,@)SSFD7B-D<!LJ!^41BG.S%(1BAX((18QOV&$L3I6HK
MOJ'73A<^EN&9A<]ISNE/#=U=^$CT5UC\'!A&^D-:\L*G"(R5^@CI:N$SC_9+
M=Q:^ #W87ISLV/>NEZR!65GZ4\3=7O@,'Y2?(?&0S86'-1[Z8#\1+08V<&.X
MK?:(CX1":]9<4+R\)X;0\L7=&$5"(T/Q-=X7#A62S6KWYX_<"R )^1O6_]$=
M^,@UZB4B>-2:0N^#\JW[/5P,8L('3(=\(XY]>XJ35V[&/OQGP/P#K'/@)?$5
M:53(D@FLQZ: J_1<X"+BL.AUS!GZ#DX,MV5J6[, =U#,0UI8<_KY2#>M!28D
M ,^%:80#QG)  )^C-<B7?V9Q7M%$O['(PNHY<E$P5#CFX*./,.MV +]QT7KR
M\&><<J2-0=H8Y%ZEARGF*QXGGH9'_. FX#OD:L5\X<>&[1OA"!YR":\=E6LE
M$.HJV/OQ0, !:#,\7QV3HJEL%J+]BY-T8WY@BG=F@!T9UIC@Y.'B(6T(N]$4
M25?Z> RK)&W1T6<YE&*/G:I"62-J#6 '-WP2H2N"Q41!1*C$%31#!VY&)ZX;
MDY#:RK,V &.8=K]/8'FP$7"(0#'4PY1VEL]:/BSZ(3"N/5P_X&^FUIL+_>3A
M.</_B3'H_EH8[8'K U/Q_$#AY1PA#ZP)C@94Q[LC> ,ZRK1M_HUD$1]1#<BH
M"DJ4%_'ZR9U$DQ.I$&)^U%#D99,KYG/X@Y5HN*T[';N)1)SE(2(52@E(Z7!"
MU T*H^:(;B83+Y-4?O^FN5.+N\BNYI:'8%,[^CBP_I;_>*%S9.G"$NT'%..6
M? ,XB:RCS[UP\G??OK-,U=R5ECEK^\E6QOR8<*&EVSX^.NOT+-.=5= $Q?8J
M#W>)K"\T?OSO_S6JM<:7]#Q2W2%56SKIOG@/RUH2%+,X_&M[J\F=/)!\,&UG
MS ).L%:2.'B/FC*C!ZBKJ:3F'Y]^RQ;RQ3AO'Z2!K@TL5SR+?%+(*M$PY#;$
M*(V"RTF_0'6#[*DX.T?> &#;(YMT?J'4QE-G*F^%/EAFL,\'*+!1E=>:, -C
M'BO!!\U,_ IL1 *;@GHO& S %^>8NC3TA *!LD;=#5_4(J!8!5J^L4B:JAL$
M8K=O.]R!AG0GMBCY;:)G$(@26!CN11#[]Q:Z3ZYOZ+_\A@IV'P0>*(9X@:*+
M)7M-^7!IIK8?DC%LZ:C] =EM'IVWM[(H1>'0R/V9$0H9DK-NPGX&F&8&VH<N
M=%AI]F90TS4<V\7]CAHV4::<_'"""LZ:;M=T^R#=]G7;0947[1"P)^=Q &<T
M0B6?K '/%[W2..##7/*9Q*>2,U@"I)B3$IU2BQ4?Q]]: -H/62E4@R$BNBB8
M2+B L6'CM& "?FA/<(I?0,M"\1!8EDNFYV0ND*2_P+K0@0$VFYR]Z5'2I_P>
M\S[Q8X:HML&&09^2R5T6TU<)9JF++G4>=M! X0C/T4]@C!%*,GC:=C'%'TT_
MU/A908:_)Z&0G6C0P='V/!WM?;0R2>-C2UZ^$KNM>4 BB;>B$>2Y]@3-:MX'
M!,O&I$%*1Q731H'&AAZP%+%#. OX7"XW"!&.CS82&X^1/>()V]9*3F3-1M9L
MY*4*JNI^7Z2E6'<-PC$9BJ)V5/H%#$>W1^S^XML,E&LAP>K&7/C<]8G@0VD]
M+1Z<G"JDW5H!^1\D#+U4:^D!-+OA:Z9AV[34IU@7#-V("QE#'5-.8//@/AOK
M2[&^%$_HA!S 9.Z*]"J2/V0H9!SZ 0@QHG3AH#<TW0$"<RGNN::P-84]A\+8
M9B<70*PI8(3(=EEYL^.<)=FPE;I6:X[-M46!2*V,#/C#RTX+6X'YL+6NMK^_
M&=GEB6\RPDM,K'*&U;(C='8M>[&-'4 >?O&:U->D_C)FJFK%%/&B3_DISPV&
M]C@.]!.5]+"$C<P-L,)!%^F%I*&3-NU/7+"VUT2X)L(?(,(;)=HE.E5+7%[R
M+8838G=D6WHN;202%:>-2#\D*9TV_*@'?!UMRS51KHGR^40I'#A2]/;FVK;M
M&7YXC[$Z3?='4L)O^/J]C4]I!][73"RC(["6.'ZM$C':;(XPPRQCZ,(6#.;<
MT@LCJ_K MT3J0>S[$?%M&765KDUA:V&<,&1'"?D]G<"3$53AD$KY<+AMN7S1
M(]?C5\NJ+:VS:M=9M2O-JET+D+4 >5RKL:C3)+)OQS:PK"/FO"PS.KIO> >@
M\70[3>P)G2.;4'XJT>&6(#F(8"U1("9(81B@KW&^V5KG69/L0R2+!&I:8\P,
MHFB%JZ;B<8J6[9M9M.GFG'X(A\'N9,N?VH:(59$B8Z]];&M2>SRT(:/O?2"Z
M&$4'_B0TRXF D(&EBR#H7^@1DYHQ?M:;1VDRF*:[)KDUR;W4K2N,+J1!/QQ$
M82_X]K@/+_37!+4FJ!<1E%HTLI#UCEPO*H?@;!"?4MXC:"TU]DJ!K'6^W)HB
MGTV1,6U)NG%L:7$0M7):.1,NJ6T&9[;(7!?-04E,WTFZMMT@]$D!-#P&6%I3
MX)H"']/KQEX@B_F1D&RWCS1&9*9:$%'=+9:YN&IB")9(.5@;$S(E@Q5"! QO
MCDM#XP( 3C'NX;_Q)7(X(E=*VXIY:B"9JH$5*-)<,? O1&6<:Q8FO!GR5X]/
M!*/ P419TEH!7=^-%WF$N!@5RU>TH:4[DZ&!M2N./@-&[8>.)4OM*#.?- KA
MMT?4)N#-"'O# :ZH(IHR$C\0$>;7-/B1:##FST &IAWXX5A-/U9J^LV0G(<3
MR_<]3,O#FC][RD4AC"\[8B":OF,GBZE3E7J4*9AX$^/'1F\B96-9\4E&F&B]
MP#9MW8\^@?T),<&9=1?X%\H:.2]*2@@#H#T+$Q*$,RJ=FY!1$A?LJ17E*62D
M,W9IWK46 '4@MLY#UVMYO(48<13I>=<.**<6!LLB]"(%6"N&K5@+JG\YDQ!M
MR[DDM"X[U,P09=_U4.\R96*Q!QJ2]-I=ZI:C?84#<S/:\3"WE4/V@8YABTK#
MX5J^I)-$)JX<H$XY/!G1+B>G77J!-1YJG:$.8M.V'/E*WYI0D@@5'R/D@@S.
MR3FT*.J"H[YN)G);"I6H%O;#R-KU/?HE[Q$8%B-/RL86IF-H&S[FT3>=4>(R
M=?Q<BFJ)5C>'MM5/(-$?84Z_!4]OP?_3*%K?]D&&7WL$('/L>UC3?:?M3\P<
MZI2R3!VFF"]CF-$&&J(J?A+F'<NU0<G<@JN%947T5O0.^/AU^A[AESW+T$><
M-BA^FW[J6#@H$@#Z+KZ_NKY2ZROUZ)4"LBR6'KA.B*J(N!^F1DE!Y,#";@R:
MZ\&AVJ(DR_)'6C"TK%2DG:$=]1AUDP+G"%<5CJ@90B:";)0H,5P'$],P1^*E
M8]>^CW*KJ#:\D(]P&*(:,OHRQ$NJ@_I+4[&QF"Z)P"3*6Q]3/M>VW?INT-VH
MJTT%$=. 8<0L%A6!'=>3;>PWB2 E<,%2XM1-M.2BNDBZ,=MZ#XA5$"6/AW>N
M1Y6B"%$PF7##A@,=)E3C"<6/($" 26\3-9M1\5D$PP"29>;YA (C^C[4RED3
M1G,L&!OD&L+&"MR$)U;J>A'\B]5'")LS3]N&&4@ &"I:ZTE\UV@3Y*; )GUP
MDZ^) +42,!9K0'20]0+HA3BD+ ^AQC2DRCI4!T]^?42A2I?(#GQ]Q'A5C'.E
MT<B,06=,XO3_,9C@"%2TK#@W+F1&JSDVSN7'OE2X/7^@NX)51J7-HG<'+!HV
M2W,\0T0CEOB_<&2&O6#M0\!L9);62%+*+)8Q$B$J>$4Q+(!.^CX75$LH :(W
M!R\@^RO(C%88_V*NL/PEW!S7M$:V(5%HC)!\'HK'+\ZEP>D/O6",F#O47*>/
MKY3== CI(".SO4!$3*)D,7$!(J<ZHV+AAIEA,(&[.@AM!ECN>XPK MK7DEIL
M>0GHZN+A%)**JSA#H ,LV'S@#'F3">M*]AW2S6N8!^^4V*#(!?10.2O^S$7K
MBTI9/9#HA(9,L()<K4WN)O3ABW+6OE*^C5G/,-X([H^HHO6$%P?=^@,?PQ.B
ML)NT<'%*]$.&; &JB #(" ?%XC@OU2/T0Y^"%>K"!'4* ,"5("2U70HP>Y@_
M*$'BQH3WB<FM$0X&K0+I!"^2 ZS"9XLV.F];'0<=R5Z?3AS1Y/T0?6W"6D&F
MK"$?%B"/A/89N^#0J\VD29Z^F0=ZEMTG"&X8M(< >T!Y<M-=ZOQ%. $"CSU
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M:97HM[9$4:6,0W/SEE$/<9XF!#$%E!2WG4%8[ F80L@70$L,?<[Y",( 6_T
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M*7E6A#5HLEZ4AAGU!G679W-QUWF9%!H7\2<TFY76-KPB+N6-1I:/^4Q1'N0
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MJ//D3HFBV.W-N0[<<\"GO,IYX%2M*4D;[,$SX&-%MP ?[&,D-8/25^TKU$J
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MX4WV$RTL0!*C/YY$R8Q2X0*P/[#]Q,[MQO>(Q'CA3/C#M0>@/0#M 6@/0'L
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MU^#N#L'=3[ZU]KH[W[K[W'/NW??'_7&KG]$]GYJCJL8[YCMJCIHU^W7^=1V
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M9C>EKL\T8O43N^&T"W#YU^(\1NJ7]8?633?$FDY]%NUA[%?1XU)7<XHZW$W
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M&F6R,'W[N8%&O)V%,_)CQD;)7U7Y,<H(Q"S$_QA/7N2!]UO[4YU=2;2N3M)
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M<N ( D #L>"2!EO +H+B1WK!@2Y:X:#YC7PX"9N0/ME!Q(Z?%4Q&X*$5Z[G
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M-LYT=_HOK&Z-#/2>N57*FF_;%6 D$;E&ZSQ=]H2=SQDP 76S=Q9=JZOF8-[
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MQ!F@LI<D<JKNCY6/]]A&H>X/-2.?DH;M3YX(-%[M1DG$ND>I/\ZE+"V?!JY
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M/OS)E<BMP%2A%B.27&3]O=2,26Z('6I<D2EB]E*2*G8:VG/PV# C[X[Z\9?
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MC!$:FFOH:K>/=FP6$&N8^FO;J#2EN]GR[]93LBRQ[&F[_>,BL:;P&*M-"*\
MLGPQ[E'#H7G43[^J\-[O.MN5$8A<G*&+H*JMIRIL2:I,8$9/EK..GR"X9XQT
MG>O_.">=%^EBBFP_5>T5X(K,R#],Z2V+QE[V;V*J3W>!95OD2FA7%2DSYGVY
MD):@MU$!NJ:$)%\'(\!8^3\C^NOVA:@U[;\"JD5^E!"3']"V +88WIT&]!5*
M+.L_(USFSFRV&1/IM,=6%325:DK$7@K@/,R)&WOO=H\L(R3FHFK1@Z)K%EQF
M?H 7IO+ZOYZ23+GITRQ!]BU5M=;:#^UU# >%4]QHJ]^9R\(^,R-?'/$<V,9A
MU;XCA>3)9ZV4ME$T$^W0..SHEQC5''+*I_O6OR0P@6^<)(M8O=[)/TKF-C1T
MUT^KSB.LYM3-%$A:8VL24EH"HQTXV+S]#Y)>1AA9EI]CHTNBC[29-.<7-;".
MVC$<S)O;&B])ZVD0,LJ\T;PRNFE2'G.B[\U$TKS-?0@U;*S)N>E6<WY/-DVH
M?WLMI,9M^*#VF7=9+X96BY#6HK:$H-?H M;_MM=:EIXK.<%]AH_+35=R) FL
M4-:32T0;\0Z38Q0/XX_]GE(F9ME<URF/0(>J@O_9_@ZG)A+..[^?G*"$*:#U
MM8*N:DRU3B:5P==5X"P[G P-9=B FTRY!I:&.N/Z[QE[E7=1.MXDT!N\5;85
MY;,TKSHK\)5E9HX*E,-NL'H?T\BA5^[8<3&CU<TN26+XA=2A3TE-E-!A/8WS
M</#XY./C4TP+E/K5*#R)1@-^/.%F?6BL:O-2/%IU8D* "2_9J./Y$7XBIM%S
M9@(.GTKZ--3(\IW-S>[]Z?&6+(QDK8P254D&/J1)87<A5<%9BIA/&E%(TELQ
M@:DS-]$#F0<[>1]$57MTM.'BY(.J^E6$AEY?&1XVUN^KJ(+%%ANU+&0X/(N\
M+JU(FRUB\D-2V.J,.+Q])O%1^T3!Y)("PX#I,*:T7$_8Q>2X?$):A',0I  #
M#!@_J^4XD'?#JX3')Z1KWLR@6RE]88V< "BQ85R75 J4T 4NO7V<&TF(#X0J
M[:V%U)S+YR(O$0OU\- 2 [K.\7*=C0:==O&B>,;)(EU+<CO,ZD$EC3MK#K&0
MV%'E28GWKP!EG1P>_%_HZA$Q("?@3N5$;L(D!UWEXA?4  %EN 9!@4B 5%(H
MJE-@AXRC;N,XLNX:X1X8C@UY1*S?>[)N#D>KULN^8WG(O<0W\YE9I'-8)-:]
M3X>Z5D=11M B@#_)JVSG;?\@K%E"21-^!6);V(5U8#]I.[?/C, @K=+;88H4
M6_@#Q$-)<8]2*WR5S]Z!RS)M9N+E?@PP'@;-WPXG]:D6S-!U598UPOD,):.T
M66=,8BS8%5&>F6&T4X_XS<NVG?M1 7L?A:0G"P^]PY>4S%V<H'R839"_;T$'
M"-&N&NK\8N.=]V3JJ[6M@XWZ]79RNW+LW62#V\RQVRC>B3'V^X"3B.LW];7:
MI>0,;->,WV*C9@9[ 6Y)WJ--"^.TM'(3Y7*?]=.;?82NOW^8C;U7;&< S@^B
MY6HZR\(Z;205GNJ35_G9"AY9Z+0[0QGR=EYE8@A.LVP3,.+N#S0W%4CBR=81
MU/]X>?H0$%/LQUPI<WQ2;H+":V9ZB; ^JYBW44+75G^IGOWA%PI,@! #3/@Y
M12@;# F(X9L. 5\_=>Y9=%B%\ )ZLAO\YK*]<,*,@:><YC1+V?+N6O90R;.-
MUD^N5F!YY/JRB3+>5) HSK>/\<I5;Y=H."O1%IOD6UF'4-2</*A'*<X([X&=
M?4E:[Q=G+"YLASD^#PQ;3I8NZ*44TGY9'K"G]"M@"1!!!BS-O*E.GU'<?VI(
M@A*8 SIE'RPFIKL1ZLH*!D77\)S/7B_CNS=18<-9^!8ZS4\)\E([(*[EF@D]
M-ZX01Y6=BI*N?>.J<79M]GS;-I:%6^OC;3G;+%'Y,E*C)Y"@STT(-:_.W48%
MJ:W3&[59&FFXZ+ON7]D+TL/1&=R$#]F<J8Z#^LTVA!0;%VF$\(_*G &W%1_N
M/&G3^U4?.4VDDK*.]3'"6H2<+#<?41S?,6\$7)>W=Y%3V=$>ADW &5,27G%!
M31_IVHU@'UB_W</@?4)SG3C07 \!.[PCO0"-UKT"L QL'&S$/^_(-IB6:?"G
MYXFL-"3!7L$'"!PK/HK5M> ,;)1KN*,59);Z##^R6"JP2UY*C-=-/VCA 1,Z
MF^B"DODO1^GBC73>[B@_34*[B)(5W. 'YRSF5ND&Q[P"L.=4-D"S+;493D-]
M&UH'8>O7S.$)-?76"*R-O6Y&&&GI76>0IQN*!\1,]+[_U6MX)4;+XG96IX+A
MQ%M$IF$U^N-1_MN&#@_[=7D,EZ/2C6G6%VK.!D@3LQ+H$40R S2M_$4'1A?(
M]:\ 1XVA1F;NB.Q3W*XPAESE/[<0M0+N!EX!O<;%_G.:%9\J4,[MGL&>$+4H
M R$S9L9A!$KP3B]S+QFOEO4[XH>-$ZYC[O?H,Q']&8Y]69,D+_1.KX#TZQH'
MGSR# _<;Y_D6IRJ/<-N6D\$MWE.=>E5M-&=@(-&6HZ-$%,95N:&2GT":S:<M
M32&1OG>"[MZN);<)G7AI)5D*JHL?>6-=[C8K/#O+VFM*(T<J"%?9-5P6BXR6
M]<8+Q)RK.3 ':W>\2DK0+>GVS14U9>,\G>V:RB""N/'WLP:O@%-3+XA9SH>"
M?7'3>_47LC3:F>,$$@'-#[.>J5RW-WMI$T-#0ITVCI.I:KAU*59]]4FC=U_$
M7HZB?T[%]).W5TMUX;YMVTYG2DAF/ ?$^7_^)J*1?Q]\C6A.7PR5D:.VHU_H
M.YZR[8'_B=+'CVD7NL49D>PSWJ0G]RY?;;YF$R/^\Q+DHQEZ2,NLSI#^BN2<
MZ\=92(B]\IW[AKD]OJ*8B!P5'/[I-#@:S'#2(K[1N /_L&C*)>&\5 W*@-3%
M,3C1D 89M!#<Q&DOZ=DMOF=$1 (4E3[+": P1CAWK.9@(\\E/N30/I".G#-&
M?OER3).19Y'"#"VLPW$WV_H\FAJL.LN#VF^-OC J]"3B2;UV(WF0CH9OPI<2
M[J9!_6;ER$ X:+-YA;J+67L]:-@P[_-@N;=S1S4K@2#.@:;=U5&MQ@_A?<*/
M)Q0^RY],LAI9OF:M''H?;R^R3]N=:B)$X%O%0)/ % @QC\3I-1^_]VE.)I<U
M@ST>'T)"R#S6:QKMX7X06>C&)(CQ;Y%Y!1S-"9%6"X:3.MLJ%\3_8IJNJ"R=
M^'GG3%W/$4+AUEC@&:>_G$ 6K'W68_F"=9T0)4N[?;M; ^Q?\WT%B&G<2$[W
M644$\O%15GW Z:?5K-L93\FU#N-%\^T^(RD!$K[E($TG6KK8S6WP6R2/I7\6
MEO._8AIZ>*=]Q3+VJ"AN&?+BEN4]S)V01[/WD63^D0TX/LXCY/_Y%9!<\G"]
MN> I-7C[Z4+]8NY@M7&_SDM_O\3OK>U KT*-PP"[ ZK0O";<]C%PJ*5\4F9\
M&&<.;!%9F%(F#*WH+EYS86,<YF7^)=<L8CNC+\&+C\Y859;'V5S2OPJ3?T3V
MB2D_R&GOKG5['+:>Z3F7C53&@JG-\&;GJXM.&WY-'(O_J.6W(K2 <J2GXFF#
M3=*AR7>"N@OGP/&?ZOA[0S^#;IV5/YEE'&@)2IO2C8>RZIA]0^>U["PTFRJ'
MBZPK2+%'/G$6'&OD*B 8?Z-NUF@2ZLO]E?A[:TYXQ1S-PZRZ_^&)TF-=<[[V
M,%K"B#6M VV!"Y/P)PV$A_A[3<J(4I?R_0N9_:W5@H2+7&2;XT26>40[D56;
MR:IX<KQV!_?2NS*SB[*A:NY9D_<-0(LYQ@TT<4\F,>_9[SJI._<19\NO@'/*
MZ5"1+O\$%R=AB^^O@*IG2="=\P=/%U6A^HP=;<?4VH+GC"/9$DG<O!(ZB&EX
M]RO@PRN@L,AN"=_HC.,I4@P!Q>4DX%-VP6<GF[;39V828F[ON6[F;RU')6X(
M(_.DZ?,5,A6L=_HBF^;>\Z^ Q(\6K5*M_!30@HMK)+_3S;IW?]NF (GAC<WO
M19J][V;JIDY3OV:1L';/L&%L!T%%;!8S0LP;.:W?[%1-2>(Z]E3UA'W+02YF
M!V1G39V\K!1TNA(X@#_7/ZAH<TW5\%-/R6:/XJK(&/\7_Z:#=:G2)OO<B>Q5
M;B0?LV)$!+:(4\CE(<2;5AR*D1EQS)(%[L+TCY-=G5DWZ=_*DF":26X&" 2#
M&4R,:0L;QF'G>'+TQZ8,.\T#>R]WL3K*>=3NLO*3]<<+FC\4['UP9CH)/I<7
M;W8))V)!.,?F  -.-RI#C48;3+D*:!/W,>H<M68S' @,M<5#*V'\O9OT_"D\
M#7=N4*Y1ES^"RQ]H ;(L(5GH%@X<'CS>@.&JVK9P18O&"XM@7L:HD,IR$FT,
MX"KQDL)[[FQR4#.Q>0^Q4AR=K*5+G+1<URQ7F8T,\2*SXT0E23T8\"D(]2'7
M@24A$?:;N#P]7ZF?DEC@V*HVD*S4H!H+@=F +41-==*6E64G,D?Y2[Z?#8@$
M;MHT??.4<\Q4Q-.5"ZJS&_A]L=9_X?-&#&7H\)5-9WJ_"CG_XUN1EB32:-U?
MHU^XLPED.A(R4M69NMA"SP?8RVYL]]9PH8:MFEB+N"$EO?#S^J3LIC^UY#?L
MJ$E"KP7TOF%EJ@-"R)3*U,[L'C-(#RTD+I-W:"U;W?@+ P6Z75!(+-R7J"O$
M14E7R]91B/+UOK$9H,KI69PF'>BD0R=D2$^7T4*MXY ^@(^ H$<4'Z)$;HV$
M'#ZTJPKA,X.9R%0>3GUYIH%+4JB?88 3RMITD$^).L*O0?R=E>D,<?V=O2\D
MVNECN_(6GA/^GK(=1C9'JIM6N+4DJ*H1'$#%F\T'_+A]G!NS+T_A/\& OJJI
M?/ F"Y_ID@/1V]QK%"VS1_/M2VNGGG9+\634H)!\3Y!>0T3=+W<'AM@;W^[,
M\B"-6;MX_Q3;JM/''F]EN%/T \UC(CWW4 T"U)S,0E8S3[='$CY5/BHOCMJ;
MTF?T$]PH'5NS)2(RPFN@HS1=4JCK[0\DW?7 @LD  3]Y69GO*[D7E!%.A")L
M6_HW)04V!#S<4[*T8L@6=#!SLTUHJIN'0DRO@&,2=AP&J.U9V3:"Q!M CM1$
M#P_\@S(\6E\TZF?\#9Q1!('X0%#$.8KAVW/=)3Z/^\IJ\L#FQZ*<Y+0SYU9V
MT'B==61]8=PH#I<9MU8; TS#67J:4^&=,(/]*8P2;LK%UWP!B\853;KV#.4P
ML6K+H4(R=*;HK[[O[6C7[-I(\'G-['. .=XFID[<LFLOA0\_$80<N+Q!UDY#
M>V.0[Y%?4U-GOW!7ZAT2S#6EV!$XM-]:GLR]X\ZL?P@DVK1T^Q^$O6547.W2
MY]U(< D6'$*0X 1W"QXL:.-NW8V[!@@0W-U)<!K71@,$=W=W=]?)F7GG6>>>
M]\P\'ZX/>ZW]8<NZJGY5==6_4JMB]=&E:)H\&Q?(1^1LP\7>U>FZXRGYERX.
MU5WR,O*J@D^";D#.B_UQV#5+.'7U-Z5S>4U-E6_[/@PYF@ZI76S4.^\=;Y^U
M[N$B9@^AD=8!C%= \6"=R*RP"<S;\!_?[@B6]FMX?ZAP':I?DKNO> &IK&FC
M>SR_XL)KV!N>E6=M:D0K3>MOP\L0;_VEQRYOJ6FVZ/"KQZ3.+\47)K_&+2ZS
M+N3:+-F21.IT-[ *9K,8)W<NIJ5'\#6RL9D-][NV,C?1Z.%'"GD&H52$@\D=
MMV5>7K^K%599USPUZ?)II'<Z9-OQ')GT>M+#L7;]Q4@J#V(2DUP1AL@ 4E(V
MK@UG"D)5F<L0HH+%1G&[A(U:9ZLA.@-']## GFWIT$Q2Q^\@!WW1 )ONULP^
MA%*_E^\E,LB9$ JQC08N6<E/7P 'JQ-^W/]>)_E/BPFO6\?[(2EB;-%/[Y.M
M$E]94]3FB_#6@\9G)0Y52?7O&7J&:EF50<='QJ'GC?@(8552!% W-XXO QU2
M^*I$_P#(T6\<KX#848V_(?VPX6?@J &7Z+GVP>_K>6@RX5EN(?HY)Z/:7PY>
M%+*7$'T)4JJ;HB))L'& \\#++>X0U2D]4HR$75F^N&B3H5_SETNN"E3-':V=
M>";.0&TJ0/RMV#@A)\%V3J?229I.7M;+V*>$AV'=528/K*H<=R^TQ/"%DQ68
M]56D-Q9HJQ) 3;TZO!-310-,4@K"2A.I@]B0^?'@0[U'P<(0(Y9.63VSJ%P6
M?8($1ZU#SDYTE A'/O)H@L&#<'S>2I^LK1%$!:?GR8!NFGP4K]$B_2]V8\5.
M8.86)Q0.6S94(6P3Q@SW=^.?^NFWY7JA%GGG^E.58 &IZ]\KJ3R[%+]?FJ*(
M]0VT6LHBZ\P69!0H(#_W8N/<Z)H3,C74L=O2?;\PV](&*S9%\L)7?W>X*FE*
MF&N6CS".;2>[ 6CL_6(">=ZWTY"]&&Y* )L(KF0@ZZNX5%FH)W-!/\@C3Y"8
M\EHFHF#?7_C;M*6!$<"D^V\ZRD3>J2RK1#?$+XF';3CQOD'6G/T7W8I<,YEH
MF6F-W> VPFD2C; Y:=/W)TX9%1-U'R:X9:VG,4ID]?.V+A]F-<K ;_<>]'M^
M,EL?HITPYL:K/XF6B6\(X[)(TT>(][\AVD74G.$0>I$G+F.+SG(B(K;6C-P-
M29@31[3"-S4V741X!93IKE WJ)D= 6ZY=VYQ>)/PW _FGJ2<II5V:H^-'Z+R
M+A:[R/LMM1Y>?@]I$)7_D7<:<7__34C%,?S&:MNU0ZQ4E.VELHC%--(BF>:L
MT?IAK%;"LV9<2- 1^$><LW,+;61JY+!W]%9*>3UI-4=:2<1$F5)'T9+2UAM[
MG:#Z3B%KA[;_TV+_*T!/*\JKB@CZG?IC4.V32]1^M*'^M#]TA>O<P\A87)W2
MG[LP;Z6N.W+Z1SON\CMUZ\O,7NZPQ$6>NCA*-YL;W>[Z5+T^M5^Q2VGA/<,8
M["#-"502&L4<AEUNX8@)>>>%H#_$0B$-N%X9&4#^34R+DTWM.HPUUFG[''M,
MT\\OPXVV>J=#<;S.AO0@)>HHR1#3X,/;2.O]6Q(S3[)^^Z_+_(((CIX1&H*@
MK>POL"2UQC;Q[!$HJ-[D]&NT+T[/SZ47828,15X-:8:Y$DV@]8_MO+K:N@:'
M'['5,CE]7*/(Y=P@6^T$&=R,K<N95*B!3_G!BK41)QFV];0H5N:MTRL YIMI
M,PQ.<R;_[=KOXC'Y@DM\$O!RW-@NE W.I1VJ440<<&U&B'#=@:Y>%@\KB6GR
MI3\6^68R#-?W$D'I(/LZ 0LK+:%[X]C=LJ4QX5M+#OWF+W7</Q<&E#UF[]6-
MC#]2'E=<YP\M2&S7D&-\J5I<<P,WVM&-(JV2-R*X(5Z7#';9^^AD!;(%L#W;
MKPYI7A%':E1A!]-(G]7G?DP"()S\)51>%1MOG=XQR_AA@[/SWH ZA /EJ](4
M]NV_?P[NI<Z%/ [_76D#_GZ]VHUS.WRIE!../_!H\+893WV#LBG]!>$9;/7U
M7G;U> 8UC<O3M_,> >P6AF=WTNM]6Z%:P7AGX+OAXBZZGWQ=H5'Q.;K=?OKN
M>QA]F<(_>MVJO/]:IO<RKP!OS6E@2V6X:J"N8F9$>P9)DZ-*6CPGE)"/K[P@
M^=^2DM DUV)S$$&M]CQ)$/&ORO26=!E)O A5LRL5*;G_2(R\1NG\?L2TV 3;
M'2T2$$O[!YL,IN_M@;TBUP>\\FT3&OW$GSF8^J]$49975E>$!%J/F*.^27_$
MAXLN- !YTB:GN^6C1^I(TXE_N*:9'H1='<+2B*_ZRH;\V'&B4LN]#$CJHXN5
M&FQN0J8V74=DH22V4) +0YQ<9$T] <9JMQAQPPO.V'%_&I^%)K*@?Y$+"Z,=
MC0%(H'30AHA8OY<14CC-PLKB7&Q7SIKD+)X9>YDV5-4\86L#5]TFE3G+L? ;
M'R[]7<.&<HUDO>>OX9H[3Y+Y\1:IC4=7MT1-.X6&+S[UX85RR9,A%DQ)&OP+
MTP8KF#HCQ[^R!U&6.1S2 *T>&W;$RQC<"72TNVA+,YY/XK/,_=]/QM>EUU,)
M^:"X[?7^6VF6?P,)-\AM4<%04CJ18)_XX8@5@M+L!MN/]S7J3;4PD,QY]36X
MPLG#B"7;$-82?)Q?12:[%#)JJI4\\]NX0=M"-D]3+\A\7^\DUP6Q?D7O'8*O
M8-AM#M:D>+;T&/=X::^#\$1_DKE4'^+,W[C_%1#B?-,T.:]!L<:'8=_Q+7&C
MR6>FV#HJ9OAC4DNBVD1MF9!NT4+1N\L!<F5^+K@KK)^_=%DC)O07>^8:.A*B
M[BKHS]R"6ZY@D&NS!NW0!1F^4L%HXD.=>")#328D:5.Z)E(VHB40>)9^YE:R
MR)!:"$^,I*$IX>VPC1U8VXC#6O]/F2=M?E;\N]"FLRU6C(!# QN;<Y*9=;$I
M;]ZW&OP8 3_+0MIH[DRL\KY[05*25#E[%;XBFQ85)!KG_JB:?YOPU.)"5UUV
M%2Z8R7H%SJ@N/YX[5FB:]>8MV<<)89.41T>ZO^MA7&XK_ 7F ;+K@L=:XJ6J
MQ,& G=H[%L3/*_TS^,M^$Q1$FC^@J*^ P&C9*(80=]E^8>R)JHJGCR6M:5*@
M:KN,MQJ/FFV%!6"FLKWJIO@M/ZP57P' H9 \04(2WI?+6/O0F.:F%X+(;V5<
MKN,,5%O^GB2SYW29F"OQ3O9]JF8*P85[#T).I)!Y=)XY(& ,F="M8$5'[-N0
M ;>P?F,IINW(O2US5[S,+D[F\"3!2:2-[?FQ^]N N;!BA]S]!NN"C9&/C)\X
M!+XB9[F[R8WG57K8U3 @9^8B<+-,:-\;E7KYP33$]YC<>M3V%Y"#6]I#[8CM
M^0AV?Y^E@ [AD@!TWU$UMGW%NP%2Y5H=;A52^."27^<Q&5Y3:4>75@]EK1$=
M(CVRJ_[].CLNRD3,;I'>-NE'OZTMHY1/-3#=NCGO8M#3G>$FM]&4P8"])_T"
MT&0WHB?M5LP?_D&R*VXW)0X==_)<C<L9?O@:-].T2Z@=@6+-44-5$&H[=1VP
M9>HTULGTVPZ\TS9"CQ7"Y-5A^AM8%B3UW?2O8&<3Z5V^?;WIT2X&!2S:R2D,
M2I91S=OR=X]JS6U?&SR6(VRO"UN2G<J@WG&TE9UL>M&>@-:2 TZPV[ODG_.)
M[A\IG18:G*/?O@*,4A./L_Y&H"#/XU(4UFM,@QMY=YL/H8:D,?9(@E-QBRMZ
M!GI_, +ZHBG MG\C3VVVJU903MK"OBD[SW&IAZDNRI"YWBVYE$=F3Q378X6(
M7LAGCU@ARP"@M;>B!^;2)^T^UC33SJK'MBFX%6KHJ$/\0%ICX1+1CG=V\A!\
MHQ<VOHX>\S&7R8JSH![>5-A$Y529K84RJSF='%P[%]SQ.R*(.=\F?+TU$O4W
M]F%S4/]+,.'CK[ICD4T?*_CA?S_Y]Y^64Q9/[.88<6Q8YF:,@SZY4QO7#^VK
M=UJYEC9KZ](0:]'SO]^6*/V16+<**ZF[=M!1CB9G:[JIN(")+M6V%,4HX/W?
MBR>%$&_ZOP ;]P\;W^9Q_O,5$#;YOQA4 NA_-^)%U*(&+0K*@X&4M$?1?%HA
MZ;@5^';!KO'\CQ!MUE(3<\V+Z6PG9X1L'2V2D=6OH8'UVZ&B5-%#Y*(A#?A3
M<1<[ [AK*=,I.+= ,C4U:?];N9O*.(188D9?O9FW$^">"YONI<,C%_EP?2PY
MJJK O%)'C4](7FL.VC$>L:OE]PJ%[[?\1!,5"PR6YMP-? [(AOD1W!\;R4MX
M] REYP^CM]4B$M/DEDH%-&U[<_:]N#'Y#BBLM-]_E_2^):H03%MPWZZ#);O+
M^ ]X?J)J%+FN6P_/?]2[<4QB5R;-Q;Z\+FV57MF9N>&C6ZXR]67&:U?+0"M6
M' CSD579+E(Y?]=?.XKMX15GR!TCN^IL%'6M-\K25L$\J_31'NFY+$;:7JQ,
M<\*.[<@YL>]3:?D73GO^M1G$,9^L$UT/-_-OFKV/TWD5@[C4D.K5D#"A0R%W
MK3RXS:^"IHUEI$S3C3+15O#NLW:S!$!5+5V)D%])CX+'@LT!0 J^:9MR? ](
M'4_L4\G#4E82\SS-L"M95VD!CT34YRWL,^Y]"EQLT#J42+^!(,2U]Z_GT*N+
M6R+S63O"]M4YX=+6VQL'S-ND($Z(G9KTE&T(&IG56"6I4T-.MBC!A3_!E5*?
MJNN#J.I-7']%&,WR,[,UAN<& XT>@PT\GQGJ.85X<XV008@-A=RMM1]V#3=H
M/:R)WT8IO[^M^-2&)\,4F9-9;8I<^!Z8?QA_-/DTZF#@PMWGP:J1@!=L-#AY
MNC5+*V%E;6EX/PC9NC?SZTOM^;9'.0*]?U1][CG*D&ZDS-27DSS3/4*@,R.R
M=5]@)$UT+V6MJ8WFBL"1TQGR46KN=,R^D_DP:CV5EGO2[/325^0,@G?WI$.O
M)2"#"Y/O8;'?G=,<7./PQ1DXH/F=VK!]?S<Z-?,CR#M\0UZVG(1;?M"W)H.A
MC[K RZFCB+5L>'BSISQLZ2W11MGBG%S>89JID(.M/(C.C>R9B43N4BZMOUP]
M/&VH<C\F4F!"(Z%<Q[(7\UA+A":I1]OFE&YR6YN(/MRLQ<@S0KUB1U_Y(G)"
MMBS:T4G-/5@%-FEMPZ*Y0N?V%5W6/PQG7TVJP>M(7S)><VG/6Q0C;23<A3P/
M3(,1V>!FK5*$<A5"/1GP"LCC1.!DF\T77T</K!H_+8]3C* FE;VF?H)\\*#P
MV(A=JJGJ_WBH$A(7M1@5YKAJ4GHW7+Z4B/#==X7K%?!F28;@>;PY)#LAI-//
MD7.5JU]D.^458/H*L. V[9 M@\*,LV,F I[7G8!Y7Z?>Y![@)B9).2X5B_LK
M.,^CT4G8\U/JZ)MA'Q^V8/%.R?JZD7G)"CH]3*E[5O7*_K(B=!T3W86])*Q,
M8M_,/DP>\\>*'C9<X0\O*;Z<O=3&C17"UE_**:%J*4%G-J?%R/=39B\[%#Y6
M"?YK@S5+N_>S4@A9%9\+?MR=^1P\5+V8U/S4R\L^HSS4Y/I!W=E =FWZ=(#B
MCGUM>*BA_EXKPH+X&_09W.E@1T3N_>>9L<FT/_[@]TPV\?.2Z7/%6;DS>%3A
M3@?_D'>XQ19GTZ[><Q8*C'EBZ#\G.#_>\CV:/IS>5[G#Z0!N_&5(S8)_@.37
MI94_QD0PF$G5#^+W%@6EA@2^?3BO@%4"YXU\[G>6FK9O'?6Q!A8V!)NM3JCX
MHZ26"A?"<M=/[PF/? _C7@&,3*A0N=P"[#2&&J4P^F+Z_Q3O6P=;6SMD8,S0
M>%8'VU2^V8U#UIEIH=%6$.^8LX=$G+W96HC,?%CNH[,J,"J+^N['LP,A'7^)
M-ZO(VH:(^&*Z6YP^NV9E."*Q&[B4NV=W+[B%EL?1&5;:,KT#^FL >[ZQ-$12
MJ-<WDC93MAZ+4=39_+**^;,M15+BIM97[J1]I[M>9B+!R*FKH#QT3F;1Z(OM
MK6EC!Q2 [+WH_:&J],31/&VC9BFHH,AJ\D+RCH@7(Z=(/9N5'U^;+US^4GW-
MK"M8=/[QS_3YFT 'TH(P]Q%-V1&4$GOW-F(J.JV=,#'4]UC3)I/=-TZZI?.-
MD42;K/0(43,BZ <U,L35T[J.V>E.%!"LR_7":*Y[R?J&;^X1WBVST(IP%HU)
M0F3,L88OXS96?RC39AVX++-JX;8G[M0,LQ;@O, C*UK+T:? -+"$9M5O6(1V
MY0_>!5URIGT&;[V0#K>??:,$VPM9=6B@Y,I!$KND.Q'E BN$_@D?2>(;[2'T
M+/N"BKV"AXMSYMQ*H],.6D^T!^E>K;.AI//H&EW".5[OW'+& [GU>/I4EC49
M,EL &N!^M4N'(OWG(I,^.R1)U%Z3AG=!/D<<)S+ZW'8+.$$2'/A$7JI'7)ZK
M3=XX<I*8[' 6W\%+[YU_T;\G\14Y2!Q133_%>$KO)QG :SJI83HG-8YA/(D]
M.U/FR_&U75"2@$A1W**^P.>6DP.&V17BB3HH9N7!BF0?>[.HUX(?'S&;"U.1
M 6XLC^=FQ+0@ZG9=;(/8>?7S!.I.T[/@>E2-$V=^_H;'P#=5915]9TI,[A33
MH(H//^R8OXN=BE&XN_@8]BLSZM[E?40CY"N/8\.Y^R-7HT)Q;X; /(F16/%5
MT5)YLNNKP=YYESH@+V<7OU](;=V]/.]101L4O,R4!K@4M O]QH@R9B@=W].%
MI-HJY14<S(W*382KE497S<XZ')QH[8CI\3O$11_I1>M7]2)YU<?AA>Q/Y;GK
MF66MP8$GMD8KDO'\<-'&$WZ"A=2'^PJCR 3]>H>$MO>!'%$IW9H"Y47LM=D#
M?HS>YK'49]0G&C0PLIN*K!/GYF>VS]%JCZJD\DF+VP']O65>HV'.C]FX=YH/
MZ-]7F]6H1+^<W]F6GG)5%2Z54XE]CG^B^8K,^! !3%<]D4.4'Y<15P!9YU"5
MF25&_X3R\GP@B#=3I*$^Z2,L^[!/*/4S:69&#3^["]@*T(!,.3/./&5O=(M5
M*_]^)L.)ZFS2K4"'W#PX&0@WA<A\C!(KM]!FA5M"XNQ1_XH8Y]/8F,0A)6=I
M4\1C,,"[E,N,;*P1)U@L_D=TL!^I.1II_[=5%0RFW6<#,TX#Y*YY.11#\'J]
MM?P*^?AVJNM"7@9+EC\0HC8#$!97FEX!:" [T(9\DNA!*BJESJY+7TNKM 4S
M/"=9&J ASV#@Y5U+9;/?0$BG[*!+;^%$J0Y=Z :Y*F(8JC5:=W^$D2WYI8I6
MB^IBU]IIE.BUGYO.2AK$_%,?2Q(3JAKX2T"<#R9 .6_>7=NY>5!1VBJO>:N;
MBD\TTDG :V'/+=R!IF,=UZ'V<5:NV%US 8)>4;W(FR)FQK]31?B'RF! $$:#
MTF6G)D8IZ6[9I6/04"CQG.E8G?B56$;ENKQD\H1W!A:->.>F<':=FRF"]S95
MXNTRI+Z&7_IA[$W:?]?4$O8_\YGJ=<$;@_=7SP0%#3;E6JP^)>N$#/2_&!4_
M8RGG)&A 4 V\4,R=DLP0_[>2D_VO, :,?R1*=RN(>BHV;52^\VBNG1!]%+F^
M8O&^WQ2V>* D!E?VBDS)A0#@M$Q8!LKMQ 6;B49-?843S*1/'WOV!(TT='T$
MCEU0LF2)U2GDRA"*P80+P$R"KK#SOA4CS(@(++%2F!TKJ89_FN5'X47NP4(.
M =QD)IGB%1 F],XZA83H*88(R1ZUUX I)8THIT69XX2'FNRC,+2RUJSQK'O>
M#)T^,'*P8U\/[_W+N$34X5/Q1H9M9FA.9IK"TMG$8EN)@B-NA]96A,H&_? 0
M#[#Q(_UXF[(!%J,H1L[+[,?,'!$'W;36[U+KH[24O@G=4X^>W^I4;HNM%%H7
M@GDA;HY))!JURD%Q( 3/,R>MIN;3Z9/T[-8HWY6R3!XI+:Y"$_C\Q1^B&L-&
MX+A0%])&N#X+&M]5=?5O6S*4H;FV3^T+^DLX:R:TWE[36A52/?%@F" VL<C2
M*^#+R"2JT7F-;VF#\6B=%>B,9D&!'<^?F"S:<]:)$TR#Z8#7J!H!Z[@E*A]5
MHA,D"@118S8BLB$U8G+@B517KME(=GP<LR38%[ VF>DAPM\V%<L5^5XLJ9@1
M5<8.0V>=4?LN4B<C5?^HN)G;-4+\S=RPS'F%EO%-4]#:;D[I*>9P0Q>>#0 S
MCV1B ==@QL1U4M=;J0@F] A,5P@+=QRO%&VR%\G;O0>6WD7N9$O!HC \\K_I
MS4894'>X@8EE^__ NXLTWI::(PZH5M9W2=,XLF\=\U.>I!4Z<579$&'DV5K?
M[I0SL<V=#, C!#0(;;T"8M7+$]:W$/QQ_>\R9I1X0O/TMW\N@B;K>K['):#'
MB*B,.<FQ#S;F2OZ]TY',_]:WC'O$+/Y0IR)P^,3XP&[; )E<>E(?J]B&_OO!
M'5ZCJ2Q^UF /)'.*)@3,L/-=1=O-?Z7)\.TJ!T@>/A+*6>X+E];)NC0T#;W(
MN"[(Y2[KPLV,W"YW_*INP)-1WVSSX3.K4-^?M>CD;&/5.5#U@?)V+B-FLYSI
MH=I=&BIR.)>7H =/3#$.HP=UJR+R1T+' YJ\4IW*H%? .AE,M1B=LXAISF&B
M)#]RLH749#G"L13;\\!;!61G:M%/YDME)(O\N\Q1M&F56,Y<K8>0FR^(PBQE
MSTEGSRPI6<'F9K%/ Y_I;2N6I_K*V^_NW$ 0E?,;V2VO:>GF1FTJ65LSG*?&
M/Z8?5YI^!\?Y6DDYLVZOC),5"8,F55QXR982.:.GQR)=S^LYC9M,PTIZE'F(
MT;)AG-W6X(>(FX7N(Y78:,YM87O&DD->R0\U# ,,_2K="E.VUZR\U<360?JZ
MR'8I0UA_]Z-8=YPFFO*0H ]$:>3&(U-3#HDX5:S]BB#+,M$T!AHCL1G% #*F
M.Q'L3_GS[L.WP*N\%.LSF]&4/(1%H>N"?@=!"6)0'C_R^VQ/^9KH-U^PG9XA
M8)X]<]6-?28[E[5428>USON8Z!9I"/>[41 Z\WS?0< 3>#70/&IF6>CIGA#E
M''9]57KSM1I&CABHH3Z.IY I*:(;S1[2MVNC])V\TN_T%>!]O5/R_GGR%=#Z
MS+C<\B:0U3W"+/YN!K6\I_1*.8C]%="U<2*&-8D$)_P"OBZY4 Z*]UAYW_S>
M1MP:ONCX$E@VFRN_Q@?V%O_+F('_"+Y5IIUOIH[:!J+>UB#$ XMP:13*J-_H
M_XEST'BW<1*:H!ZO.C<QR8(9E6X''B+J\I<CWX/2'^P1$W'$_D.]*XP^[]-_
M:INISXTMU-NL2%H=:)E<>]Y*?B<P, !C<%QZF"U8*7\DGBTPI;ZJ$+C3SA=)
MM2M#HBE-QABP0L"]['J@[1[)_>N$A#:&M[,.($,+NL.B*K65R5Y4L*6XZ"]#
MLT:<=Y=J%!:CJV09E_J8484VG#ISRX!1A!U^;!W [W5THFS]*5N6 IR5O Q.
M+/:5FB<5H?"-9J0L*69#C/TQKTGG,H-=A;;?'-K9='+R=KTZPRVI%5GRP8"W
M<F+T"#JW>M/;82X-*"J.(8M5O65Z9T'#,X7&-Y!G26GC?L$F8/JR3Z6NH%!4
MBFUOF?[8B3G$MR984&X[V!-PDRG'<LH5\FZ,N1D/Y'SB \'^TB)WO"@YC2X9
M(1NEM[:[4MN"Z5H_XT7,:^0?L*]#P7$VY/G#ENL>QT*49R6%"^X/A,3VY]JQ
MXH?&5EY4$0SO*YUP PBPN2H$WC1^QRG+29,[<;IBMRY=([#4M5VF>0KKVN!A
M KT^Z8(SA.H5 (Q_&$.2:G$#%>OI"QWC0V[5A$M U_PK*\(U ^A?\/T@F'8K
M7DD@RO=D"#J>$:N6E5&RLSN(W[C@?MNX%/<*'VG:7M!8(]V B]TVGKV4$ZF9
MD93@D+G[!XO!=CSO8Z>U+@**R_A=B#9K%,^27?DL;!W$2'2"(^MT Q\)NM=D
MM\CBZ'&6="7(SCN8SWG9&)_']<JV%TBWS?SDWY(K>KD%B+7>@=R8)$.J BY,
MRP".#MX*R8H+QG6D_JAM3>3R&_D[R>"XQ$LW4_]%[IV'Y1:'(9JY8K((OBMN
MU8O[\G6K+3TX/^PR@&L;U?G4PN;"T+D-2NL[*.@6%\Q)+).8^)@_;+3_E>@7
M9Q\J1O-7->O:_<W4PCC^33%YI+U:N*JB V5(45U++.N50544IN?OSF7)U3V.
M3FD"HDL#9;M\O5+7M*Y"EW@]1,%&NE;*M7UQ\V+XQ:]Z;:,*%GZ"LW62MNIJ
MWD6O )@HXV^J"#\=2<HSQA"B:+G<5T!;$$#3-6RA9P,H9HHBST"&8Z#BX+$.
M63S3'!#Z0?.+3>=:^!O$2HC?>T*9I#@DXH1@34=P_T&SH"E\A(1H.B+SS L-
M<-5?-XJJO=]A.9$;"K\+80.OG[3(04KZ6*X@UMJ2B^%%CW4&AIAW\1NH CF!
MBW-L;W.]FWO+P.YV[4T50;EMC2TX*#0+/]4#5OQPZF"GSOT;;CZ%6[3)9$"N
M&1VLP$-&.-=7@!?$N;]"?+:%S:<TY7>-#E$LOCDI@+WBT[GRCU.1U900W,^?
M]K#QX2A#3UBB8WW>E'0(LLY*[4E)K$>R/JKX[U0VLG/4>Y<^'W1/81XL]MZD
M+/*ON94IHQEF<JK_V-%>8(Y!^XJ<MW^#-- )";^-,-B%YQ;R-W JT>EPHZFN
MJ>&/1\>-DJV0.!?B>04L\MSV:2O4OP+XD -Z=3:.V&R<([]ABH\-PM>+4[\G
M >1Z$-1GC6*F]<5XB,5L(F9=Z:Z(LR:25\9FR8@V1U?:Z5Q5D-SY*OU]\JUS
MI62.GG&)4&H5?SW;]/R]I!?B2EB<"??G>Y2_W[4"Y+*!B:S;X&&K:?4)#L.1
M79\GU:'(_;O\L*IPNI&U-&F^ Y#)!3I4Q9'BW7*9W7JJVT;1E"2,Y)Y(9N.3
M%Q4XAMQDY>F7M4#0Q-YMWR<BYCFK;)H9G:USAHUA2"RD8DXV(6"TR>HN,GUZ
M0Y,8+U(+9_O?'==LS"9[!?2UK%Z/0PI*;BNEA'/SBLIA(T06M?FL<L6NG&58
MGK;"(U[_U>.CREA"KP&@WWO#HI>Y:*&B*??_:U*LR!"R1WZB6VA\!10<&\K,
MCHCP_06'6> KH'RGL<H03>#3*AY'[?S+,!GNM8JC!+8&E:,H8]C!ZE'6^T]8
MH4STQ;5S<5KKETH?=",G*&_$$*<<5U*O7P%U@7K]#-:?^G8:-?<.Y)UFN>35
MG'X-X\8V;K3WWY3#FS,4EY"9:R%$ZYP8Q<F<374R,Z7XD\J(YML'OWS6>P6,
M*A\JX[_@6P;K9F('$=I,#[68ZUJ-SI1"=&"/G#W09J]:FT5$M*%)\T?NB(FH
M@FUI7X%P30D"&*LTYF#E+:+F^.^JL5#MJ:G@+Q(\2=B&K(=ND]O<PXU(VBAO
MJCE'9YK*4'+&R\D8>HZV;LLU@!RQQ\\@95E)ZG,.'UZD@]4H!9MGB*E2N$VQ
MYF;0$Q9?Z3''?/?5%R2TGF4(1#EHNQF9ID):N&:B+HS3>O_*?4._FL*,$<Y.
MY^!XR<,TK7VRM).^OVSO+2*T,B(:I]?+<>;7C+JDYO.:>3_U A143[>JD;1-
MWO"I!UM<-YF>*!K\_0TZ%9?^0E?04AQ1"!W,QTTY29QFO-BR=QFAXA5@T%Q\
M-@"AV/DD3H @-.$J.\%WZX RN/FX<M4_E]@0@;F8_$9TN6S828'A?>/W3\<9
M OX+C8?U%R?K8ARJN$.]JW4\Y:5<1R.GRK&&DM)2:+D(5L?#'-8><9LSO\;T
MS<Y:F&$=PFUUW.WP<B@GX&]]+I_,&N3+'/FRWW.6>UWM5!Q>A+*45JXWX-X_
M[)3\B87J*WE*$!M?]XB668))XX&39?-]XG81KJ,$8<# R*9?RY&/^[<,'$4.
M#8G<DSI6$X<4;+73Y&@=UC]''Q6\@!]OM,,KDA!SRD4DLB?+G&<-/B9+M-97
M_> !V:(%C*()D&B938 2=35+K>YZ%,>/R3G3-O&S19@?@6H;'F[2/I5,R<BW
MX]\(1B->J.I)URAS]C>_-FO-ATB]"268=P?^X0 !3^V3X7(9?AAZ;GD+B\8Z
M;O*QMGQSV2-AZ8CWC!ZI[>QA,2PF"I43=!9:["HF<?]^)>F^.CI3\SM,]&&G
MSLE L&[P\A6@B*DZ.I1]/0Q!B]:T>_.+19M,'OG9Q6Z+@77C;2K\<X_1X-6'
M=%O[F:?+7<I]53V.ME1T7Y)FJ@<LF4NH(2HF6#/F98/M5ODR;XI#Z.^&57G:
M2WZ6-#RAW &Y& A1R,!>7.JP"K@]\9G3!\ZV6P**8BAGLK^ELVE%-^VZ/XD5
MQ:.O6PG/^>HT_#4U3*B7$3\19^IXS"0<T=V'8AOXOKX"."G^P)<K; [61@F%
MG,E2%,X4H7)":NW;C#=G_35_85*WBP;AT3P"!;@M<YYH5%V\&C8IQ"C+/(\]
M*#ME+KG#+R/@T/Q$2:X'KJR>4-:+S__B%]-G^']6N%4=?K6)MC&!JZ\?Y4Z=
M:]XTV<7 VH=!4ODJ/.;ZO$IRKKPMPB/^IJ\ O>1[%=6],3E([H(XQW$L-5SP
MSU^5Q:7SDXHZ:,_A4RI2XO^YPOUE%,11N$(O]@1-/7-FL<M=DOIPG"!H9_CE
MP*(W[IZ/5%DD<<A=WR;!,-WK1PJA8&J41PYVRI-6H/O,C8MB^$ZET/5.S2"G
M@5AZY3;L0RNPRQ,IJ;]D92F1IL8&<-G44MW3/:M>:]*=//H566W&3UA-X2RJ
MHN).DY]:G,P_Y+Z'%VVCC@5;;:Q\AK3V<?A):*,MKLFB\FP+3XJ8CJ_C8LIE
MH\50&U+\LW7*/#+"]FYI66W!CT_N.!#ZH6'([U*#"S:SJNJN=G)-D/\*8*83
MN58:%V_U\&WN!G@&!]!HA%DF ,+''F<-A?/;2ED4:W_P+Y^S3B[ ]/%K/6U[
M^):<PDZ%WI"0?];\)DOV%5EX\YA"'VE>.S1I0KQVZS+M4K<96E]G5<:\%3>)
M3"OEY=N=$RP>;C]P4O&F::J@,A-WQ -7I(![BP0P,'%UG_]&AT=JN?%" .V@
MXOCXI#1IF4:L0QQY\E!_N&_"^9E)"53:,.R!8F$\-YNQW-$"9L(WIY5Y;#^3
MR0?8@E[(=6.M]L9J^V\S*%L8O#T*]A\,TNW>E(\*-\8@K,!&CR'''#<HQ[=L
M"6(F D[ZA&&V'UK&?Z6#'I7/JW*P1 @N3:C$UF;;[A@) M:E#OND)X(BW<G]
MF,R.L&FN*NS.EJ)> <C7"#O&KJ912V/(J>YI*P>G7^HSUW$6&X>LE>DJ29TE
M!AD? 8]=0(BOJ4,Q)$TJC-TH)AC%DY= 6:?&BBI%GH)H ([H*@>#H#5E_@/-
M:=!Q@[].TL)R]TB"]35I;]0*>T*GBZA.&LOGN4^A-@EL@ C7:^C#DX!%H3G$
M)G^)D4LL58Y<.1^@X8NOG?D.DYLMY0^9_\WQ5?GCNAD#5'N9Z"1]@%6VEV#S
M.%]0;)B9$0GE#=].J^]:EW7]I+EK$1'UTE=D'[:@H[Q[LR2WZS^Q&JL=#SK=
MU)1UMFBR785I2TD;Z/84&\ZA/GJ;W'B' F;&*:N+]?A/S3V*  ^W&X25/8&$
MTII^?.LY3*I[L0JN2:D63^?Z[YJF7(NI:+NND['1 ZT]G<?*@=SS4_#8*9TM
M!L(V7,]HG7L+TI)._*M1<EQP<RN0A?+JF1M7>>&L+51<F7:^4X6JR6MY5%O:
M*1=#OBJBR.T^HG*!Q0WS"6R6GX:QH6%2E!R[958@L8,T_^;8U.FQ>M13,4)O
M>2B8I. G6=+LJ1T9 JF)+2I!GQYXH3[7B?.'&8UQQBU!H]NW^IK.8FO'"9M%
M=>[T#$,/)'8L+"*V+X#1<9OR!6UNP4+>M[I;!(>CX+3/M_OHS$R_1Q"W3!&X
M(=+3QU=S%>_CV'@XFL,>IEX!"^\NZUIF;E0_MQDMPYQSL)I[V.@A-)$ N^J(
M%XU=WJ2'R*3O;X9T3>(^BY^&G7H;"DV 71D^'-N])S">)/#?0(>$+Y,3Z/HF
M+574 5Q6B&&XWO33: QHH>W"V#.-F+K N(U5Q="K1_?M4+XXSBFO68UUJX+P
M=:QZ"CK<-^LH%0)CILE F&SB9PZ?'=,P@+X:,(W8(]H=M2X, Z#<"KFST*T?
MR\-9\J<X.C8>UC]7RH38V#%_8DQ)1JQ^!>#T<H]:D21FUB5VJ0WL26P+L^^+
MD;\" H^_36^$4#6Y.'\E1K:'K-8NA6CA99!9M%F?'1_JNH]T'BS_":V$W53D
MU?YY+!Q%%A9% [3^=W-6M VHID;B\X7;HX?ZT2,VR\#_IK8GS:B!:\$7RC>1
MD'1#"1)=L/GK<I8/,SS5IY7_B^\T^G44<9#="SK_SR(-TZXH*8,OZ<% 3IPE
M'\&5N??Y)DB5C0B\P9E*XM38*ASD9-*&[VR\G,Z.ED=B',6/SIY\FY7:OJ;I
MZ=M[)'JJ/DYYA?JOPE>1^L8-Y2TTND1@9NA:UC(.DTSVESAQ"!,'5H9;N0!
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M+,78Z[3]XTWH"-.TC9"\2]'>H0-4C[FR\1Z.>*?&MJY9>S/QS0$#-1P/&N#
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MJD,\3]D*B;'7>NL#WD!QU3=K6RJPYS\ )6-5+[P!^..'J6?!A"'Q)0)1$Z^
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MJ:$--]3[DRM-(/]F>TW/$_Z\>>>]=LC3#-SD'C'#O,5B]5:CU@F90'</10?
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MW*SBFX)/S#0;*/VJ"^57,A5/6;"U4S95)2LAKX6LQ&TS@#/R6(]ITCQF]Y5
MFA15M.BV2<VY2+93*_/B;P<4B)L>C7Z75UNDO-]EJ870%O+#H5D!AU<R)U5+
MS@S))BE=G:C^GRNNZ2)OJY0SHU@B]0$Y42Z*W2JIP'C,2G+5=^7MRIH9:318
M:PUP&,O<<VUTXIO^Y"ORS<N0%?EZ3C@X.2.YQKH,%7\&=K6WQ/IT&3$R?_+,
MU6HOHC3I-J-YE#O@&:25HXI8[?B.;)H]^MRVU;7S,/B(8-](A)>9"ZW("<="
M+DR47Z]'(5U5AR[LOO$1GU&B29E=#L8D_3K?4;EO;ME,UE<V7"U\\GW-HW="
M/GD9EXS(//(&56OM['5I#O$,IKQRW6A,[:E1]]7+Q&W?U?A\B/RQ,&&&[3!^
M$-WZ8&'S1KQ#6GG E!FIA:M'^NO"N<^W8(9NHX<*_CA5#6;,'7?^LJT$H4TU
MRZF4->E[Z@9!UC>X-&7+?)5E7/L%>D&VX$*,&)ZW7NN_!\9Y'/4XW0X_T!(V
MY: [JY:,<10X[P8,C(<4M1A%W48_',QE2LBVLY',,T@8ZBC;R_$YR9C>E"TO
M+(MN&_0%39$ML <M#([*%-.$&$:Z(,#)$MUGT+2FR'S9&C>\0FA48"*C!;1*
MDYGX6S6S47*7#BKV4?YT+RI8L4REK!R=93.\W;,DRIGK9 H?V5@1;Q$P17PB
MAV8#M1,VU<&THY(M+J=7U14##B<S+MT<":,>=RBG$$4QHF0:-ZVXMW4)'DO6
MGE,*BTSVYG%Z??8>=2O]_<UIFD+>B]I0$["3-S!@5NB1KNFN-/<S4*#-LKI
MS!^X8W9' %O1#:FM*O@3I-#<HD>UR8#IC[,I;&+OK"=T$_:SW3^IF]*G2#,9
M,:7W&/A9VG+I!MLYKG'?"Q=\7!QA"!4&UA"V$<PJQM/._$9#!Y6O]6[C4\3:
MF!SJ!^G2!$%DVV7+!&WQY7Y+2TRXNRST"_6":8O)_KV+4RP/0O^N52)ZEH+_
M.E?=%5W,9<R^H147I=M079+[F'@D$:PX9E(8BG>\(5.@7)O76WI$6WIDMW W
M2)BL4J".!G<L:7B24_))QTJK]C\G2?K7.!]Q+V/3.041 QWB8DZ/^T;-*ZT?
MDB"G8NVE]$7!1+W'$\6H/X<[65_5+_RN*=97UYDV!**J:GLF:1'2.S+X:JHA
M^[L"K-A'ZXCV?_*9H$\4^D":L&HF[>A^T$Y,C+3.E=\KV\3>?32+))H 41R[
M;5<'BNV<3:@!L3PK#(Q$+<Z="W$SI.K<(\/TX]]J; 9&CA-]^"%4BC!Y>8JZ
MKBN5.,)>9+D$%RWKMS%LU#*>&'K!_^I8KU*Y+-+$$&R:8<LL83NBGP0W6!/Z
M#'!B#<Y5E2<-G?:]8HII7,'J_<DL6CQ8CDSH=<4)-R)(OHZDW(*05S YMSJ4
MZU5;+E.\L27.]@,[/[]7N'^-(^<50%V/LR$+UI2A8>!G_0L'\(;W@4X'^^?E
M:0:@SYM;P#$GZ;+15?^6J_0>_KS[_1 V9EWB^<E>M24\+E@]XK-SS/S@(5OS
MRG><T4:M,XSZ4B7O:V):(MJ^;U>5F59+6^<T/JO2-Q>'H@09;CO+9P(X2"1:
M7#7>50W'?X7%;-O?QS1&%M?*.G5Y-5*H,*OX=K$*#0#<UDDZ0AA[&\Q(H2NP
MYDO2.CT#@349K-A6F4/=[([M'-5.-9-IC9,(/ZS:#XPH)P(QM A-N1K-C3D"
MWHK17:%D:IWBGQ&&9Q[1'>*M:_LJ(B0[CTORN9J>Z!J=FX#D0CUYZ)EI1TR)
M/H?(4_F5#!TF4FB&Y^_LA]?43JZ.X:8CF+:-I8DNJ\U/]F13Q%5X4'\I I@#
M_$!O([9#[QP6H ((.0PV_<+DTQ0-<[;+"]3V'YO8;R@=M35B-\R_+W(GR))[
M:>!&O$YTF;K&T^=V79FR!NRW$W'2M;,8=;(SXR%28!W; \-Z"=*:&L(Q5[.J
M;7"[EW_#=IM@IO6R8\3YL=9S?UY,J6'$NBF>HPR-BH)F7Q2_I+]9)S2?ZE+#
MF.]Z0SS*O)48066Q$5V?Y?@=18CJ2;,*PY3Y//-JY6B/#&DO&Y#D+;2]ZTR7
MA:FOM<"%!@R('*3_H)O^+K D08A^,HH&^L>U=*4;LHVT(U>SV8!:HR<LQ3<\
M8?<'1R"R3;8*<QEH:I]NA^^0=CH!\ #-E2C-C^>_S<3_Y6NM:*.<<#H<5[W
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M2GGZ_)ACCS<E!\RV8AJ/ NU8&O-Z.OJ+#-873N]%WI":-;M><.RQ[>%/*>F
M3J+]G(E7;>.'81]V1F%$<-]!>>B>5Z9@-S M97:\A/#4!A)$7=$LIH2^P;:I
M I#HN$5R60![@NU:516"E83>L9H/#B*0AI?NPDZILF_J^"?LR#TY O&<LY1?
MM;@&)\@LR%"%RW$0\DB5IAI$=5/?"^;C-WWDO<V$%>*XW[!8I])A.:Y<0(%4
MDZS"286*+7HX B98[/Q-VD2_I7R]"0 S]>WW.GQL@@IAKW0*K?2N0D*TPK?"
MVV)5/B.=<[V.-7.TV$O_*K,6(!-TLO)G/I*74CX3N@/@K//I.@D(>+2$;U@.
M:)RW0YST"?^IN7*:X>/5BTO'B"F^@EKJMPF?UP4K;F]KB9<K;Y<KE7TB<Y:E
M2GX\*KUA&W@'YE9'65KM-_D-F>9/Z*F6YNAK13:)L<.4^J7(U?@GB2'24X&%
M+-KL2):WN"E=0&O_=QPTH)Y&Z)LT=C)E/3K_PBAWH$Q(+WUK\W@WSXVWNNLW
M%Y[&S!';AA&:$'?>;I+5>8OYA659?;/4G4_4(N**NO,@T_99ZD!&SZC7JY?#
M7.F.D/75$<K*<$B_KMTD=U:&GFB=ZS3QUCW1DS7S9M?1W1S,AI71@=,2)C@&
M579PE+&%\$>/_]%+$*70]U[PMDP,KH\;()K",N>)SD2H4;:$'V^MR5E01&!_
MW<(V6E+:FT/'= 718E*3YCQ7J!P[<'"<8&>B=@5JG.='58TDS[\%@"C..%O=
M4IU!3)$RN.\&R#O?.CG1/G4!&)\!H)YK,>ZA==U!\M,6M[*CQC>G\GE2LA3W
MPVL5]+Z8GN^@,FL+.Q UDSZZ)W5ON5IO*ZH4&?+@3H :'^\-)YF95%>:33.)
M8X* C2F:@\?^W/QP8[#G>]- K6#_M*56[M?6#-',P,QH"4IZ7:GR$J$!*=O3
MD_4E.Q5:V ^F9-M4WNX[5\@TZK); 1=><!E"D:F9=MO\<@D$*&L!65D9BS[+
M0P\:M-Y11<3Z(DGV3[W*[C/?K)M60DE[?/=U#"2(_9P[Z=DI#:PZ*XNRJ/6]
M"HJ#H^]GY\_1&[,_HP?QE>'I9WY^D;2B\:ZGK:",(1G;9.3)V-8QK#.S2!W[
MT795O0FUL8>SO,XHL'Y_N^XENXO6A5]=G-#1N%JF<V=K]B?F "CT^L"#DFTX
M,JZOT73_(D)-T.NA&3-\+*W#XTYCLLV,.;]05Z<7:X2L>]6!7N:((F9H3,9$
MVZ<*BD"T6:(G41MOL<G"H%"'6;&Z-AXR6H80=<5EZY$P>S2MF^2(EI!69/(,
M8,Q\K!FL[=K :PW7G@3E03TVSHM"?B!4B[VN)(8_ 5%Q+H#7W]A1L;CND+9V
MN,6J^%JMA88,+F(>'CD-[$EC-:,3@99%X?;V!U1A@@K/ ./H&L.LLN1"'D0?
MZ*IHR4"A-0-&+H@F9<3$P6VD+276"H%B,2.0F%0+Q,595M@,]!/PEJM);'9S
MC-7!>08LQOD9I)N_?>>;7B,\K6-^+QN#MUB&5Z7'H1&I<J'^I3"#(BRZ%;Q7
M[</B2EDCDHH%L=.1C%B!FXMR/;(Q$)^EJK.),&L,7!V5PJ3(@COPGB&\0@;F
MJ^BY;<X:S%6-?] =0*$(4?I)Z*2HE]BOC-UTS\B^.N*(FU&:+>Z5H=6P/ZLQ
M;R=CP+S+J76[]]'!63N%7[@$@DH8Z;&18=J <_%I*J!GF RF^=1IXO;4*;EP
M)@D%.F*WP^0YV#U%C9)32SF_'<!N4T,%//<LMU&,APEY)]1JI^T_SH'LJ=E2
M+HI2#$M"&%D!5\4_K%I'N?.OL:(BH0$TX\OB)EG>?WT>0F?6#AM0'D,87DBD
MP[R5*40<7@\L\OL [+-Q91IH_S9FBS7RP;6/"%[(.GV6"[>YX;PRK]F;Y@>!
M9UMPEN%>#+W V@>5.=C3KDLHWUX,;V&$ =DKVP1%(<E\)S_,]^B]J'P%+5IH
M,PQ;>P@=3,5=;+.,Z_)T$&B&T(YJL9#SY[F&S,@.*3Y5RRCM$63*9\ '$]+1
M>HS82D%N6<[W(UALGJ W6:7#OY9.+PL-#G<)_ S(+VR*S_78CN4'$R9G1J,7
M V"-7(HJ3,QXZY\LK$B-R<\2M0CLPVJJ)-/BR;^@SX[V /V+',%+B[;%'0V?
MP&\LX,YGQ@8WCKP)N+Y9.7%LOE'IGV)JGQG9?9."*6QN,OU6!]?@"V(54_*H
M(B']+=!)*R>-*_YM6"/M<3#X"V7HMM*K-AEM401$NYL)[<[ZQ494=XOS A+C
M]W:Q\]*ZS1T$H4$U/N(PJYL1(A6=M>Z ILZWB%=E.V>4&L<[;TRS"T5GV=^?
MGVFC;K0]+AXU_>YO?E=.CHSZ3NQ$458D],2D/4?KZ+@Z^( O>?36 N]!DDDZ
M?Q;UCX$BSTSV[_#Q(.)N_/(][6#)DI':6J\5U95 SX>R&:L=3@ZC\X^L:4]B
M_LAXF[4?85>A(&JZC8"/M3[U#-LMRU)6S>8C0%RF!W7$?:)!F,=Q]D,77]@H
M(>^3JY]6*TX*B=V-6(>4:@TUU)=D5G7N00!D:A)B.]X6M=()RK^(\CK38VXV
MX;I.8_JYTBX3?4'D@$Z,-%?DHXJ2+M.071"JQ"PKQ5K<5 R-(92"@@:PW7T*
M*<$]>CA'EAG1U1\F6I):?59-**JL#736Y/,[&AL"!1+?J=M><MH8PG9L[-])
M,QT E6R8ZF5"MMA-T) ,(%1=X9LM">Q,-$ KV?>3TJ-^W1I"S6$L0)7&''F/
MC6B3!#ZE++V8C:CY0P%T<P9Y7[9^9-";[[,59MFBW7C'4OGYUJ3O!SC#)2LW
ME[Z7*\4F;=VIJO9/<Q026J7,_S!>?7^>J%[%^6A.*./22R9O>5[LL&1NH.#&
MA;E/4/]=HF@X#E6K"'&2<)<>0YJDX77(Z1_9/'0GQ?8"0G/Z\^NIO+MYRZNE
MO3/T!G3$A>E,3TI3QYO:*-(]^<< ASN]QWIVBC''W7[G^)[AJ1T%;OZU]1+B
M_ID>._+&!$I3WR'/P;?[\@:'TUZXY&=$]L[V1$W.?<0]*U@QPF=W;J5#X'P^
MOSJE;<9BFM1OMIMU1K]/(-?1PMI,FYC 40)MA8'(LQ&2Y/S'"/=GP)N':P\E
MOA.%H-TMPOJ'LL-'GY"2JPMFQ4W:!$],!NV]&&I4RE)VK&> 3LQ6__7T&'D1
M^QB1R*&I+J KS"M0 -U$R3N-,>4UV),G0@^J<+75\26SC^?+JIYM0V,K+GJ+
M/,,[Y1PH\;ZU  6D;:Z@$;:BW)/P+K_30&*]@O2=#G,)5<3DGY\78VY#)8O8
M]D>TR[*U#FT$+(PA>,1LNK$/Y*V%5F>X"2)-Z>#1E:Z=>#C'6SC%]3MDG>64
M4T%YUL96:(.L? #^F^^]H66J_;C*!XNTU_6CD2@B*2VWO+LI%Z*MB?>?1"E0
MZ3^1OVH]/O*E7\O)]F!AL:.)X>3H+H5O<A =8)(NN3KG MF3M]7%G'"$9[O#
M>Z-,!/5_697'DY>/K1]=P?3MHA/9T.!L^S_:^\JHN)HNW298T. 6W-U=$B2-
M!G=W=[?@@4#CFI>&X!K<&@]. \&E<7>W "'83=[W^V;RWKEKYLY=L];\N/.C
MUNI59U?5WD\]?6J?<VKO0F'[)EA>W.E*++W@#JL[8KTJDW4L?]8)&6_DB1CT
M(*N9FS+;TYIXITBCHY\Q1V]*6T3C(O.UU?59O;/HF[0DA0RA%:(,AV2XGXYI
M*31WA2.BPD$V?BQNW<(Y(P9YS+A0=5I4[+-A1I]/7GJAF5GJ#B7S]4L;QWB%
M# %RVCB6=,J(2=\%7APNI1#945OC7A?.]_KZ(RX7,CL.$D-5[3+F!<L2[MZT
M(8"T97,# 1<N7:VS)1MO5P=_=1?'T$&\6L=.A+6PE8CC![\H&B6V0);9J9WX
MT5@K6VW3TWIWL+XQOH0;6P%_,A2QQT%.O^A4?FB"]ZYUD8U_#Z'7;8DG<_/4
MFJAL/\^PZL.WK]2X(XWIY,H9,<_<0?C]D_39?2IO2(#UGX[3E#E&52^2,[4N
M/@V]*!EQ(5171HI9\,#1^PIH[FX*RKR_[5_5.\W?X"/O#O^,JT4&Q%/'^D<<
M1,?6KR@6T,)G<$1F2V'CO.$0DHD;B[R:*MAAM-Z@M*FRJ.JW=]ME7@31YN88
MGVM,<<(1;O*:=_[*F8#PKSD3N,5L!L@.,TR=>5MB&F=Q9%C5$C+T$34\.C^W
MQ'SE:D\4J -V^M(MUH?,J2!K#<0,#7_6]46X+MY"W=[D7+;#?JCU0G68..\
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MJ@V+PY?2ETI]EGI52)?I8Y88)=IG(H%4=Z_R\N[5:N"F X-QO?E=UN/,Z%)
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M+;9VH5&>?07/]2C+B(T%M)L(F-?21/B8T&!7Q>EO\\F+5D<>].+U0D'6Z.F
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MW#EF^0WX^CVK%QQS/U<-ND<-;=&9@DEA6\A:!N\!4X7C"=>N%.D?^^T2?0I
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M$32QDB77>4F3VQQLU$WQ(K0J/;Q:F#?3>['E%35\>*JRIK^_+?OO++H_1M/
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MLROCJ\IM<9LUDWYNX#G] S!Z LRCP#7=&*=HT8C?5>5%:;)ZP\4)G@!7W4^
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MW8=DDNR[0_:+(A\MZ82!AKTG@&N^N%]J\:TS7!%C_-$UY<^,/[[919LEDN?
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M:B^.OKK_B.!WCBDO[K^K JO*Y]8>NI*%J!I:6)^)GKUGJ\C][E6I,7<5VV=
MOHOF$+_$<?4G;%='D,L (S^\Z"[3%^_3M-9T52*)WH+YN/&"6%SY#YYT)3N;
M-.__6JK\C_!21.O^GDNAN7UQQY/1R,XQ[3=W;"0%M*4?$G8-3-D=PO'/S+"$
M53X!-&O@4U.57QJ/+KX7'5GB=5D] 5#%:J\B]9X QR+P#X'7?SS&&&/[*[NN
MIYVG#KGZ!&.O#;\Y.V&.-WXQFXU]47_X_4RSXFZGSB1_8%KZ!1QNG4\X((A^
M^8NA,EC71GH=+7()0\:602US.UZNOT^):KC[0 PU:+J/C]>/;MYV;NK\MF"D
MFWI+IE6V])$I;2S8/7=%^]!AS<BHO2W0@,YV=U28U%B]_M'8FIQRGJZYII5#
M^5V]D^QKVT&KC<R3T\,[U#DCQV+GJ@6;M]9 CO:1;W9N+Z7J0T\(M8#7L2F6
ME</N/,,10OV:Y]GH^32!QYJFT_8TP1^;DJ$?K*]HQ)()A' OQPOIKL"]S_RJ
M]DSL7B'B4A?H,=)H_H?W.4^ JKY96W^UR %W_+PQ3U93R)NWG/>9*]Z7X+@-
MD-3Z9(6M/<O9]A, _VB30G>$;<Y05(<^R SO5YI,3(G""=(6#K06N\?_5A$S
MK">[NN()\.4:ZHEXD0NR>+2'B]_8WRT]C#TLR[D\ >II6<PY3K',S3-<*J5Z
MLYA3A45$KJMP<UB.2AYPJ%C$-1&;]@UJ**@0I_%V>.=NE-?/OB0GI&<*J7 -
MXU AS-11)-YLQ'3..^P_NED:66X4)-^1Z(VBE1-D/RI^1*98HH2!;$Y.2$CD
M[2I):3F8/ILM "E\?5;I9[A+6"I.5&UWL'_1UB2^0K'SFMN-N-R_4D8W7%RZ
MX"H>X9H)SO!+% O]#7%[)[7Y:G'=.YKW'#KEAH;7%\$;[V69$36;VJ9J;5VB
M#S5D%C>-_25K%\\.<72$6M^H0'7!,74\<U=KZ'5R-)*"&0DQS%)]::[SWWA>
M-M0W+I*GM3X,XSR:/0%<<&94NDEPGL.,IL9R^B1RS>[<3 6-U&5S%:QSFT42
M"^D7*;ANU)I,)7\M/JSOBN0 ^M$Q[USNX72G2!1,F4078B:4&(! Z5X>,W68
MUG]=^K+B#-IO.E$:AUH?Y>2!FP7U#'H"T'P:'U#17Q1Y2.9[O_CN!*>)T&P/
MV5E-SZ.&_.!5%?=A*VVSD'&R!8GV-0I*\%6%7C3]P?TZ!%*O*I81J#\X4M,]
M3*&;;V]=;&2P#^NVJ%#F'*G<V+#&HQ[T^X2AV7Z(5CB6==A?CC?[TPUJN[*L
M!6[P-$5$];X2X&%=BS")/)J$0O4-EO49?L3) *A\/SE&;$,\P!NS[(5R/$J"
M3P#'A6M/\^R)K.69E*'IQ?U:4 ,PTH'Z"1 [^C$LZNXMA-DT:]<B_V"_O)LF
MG#Y(+ML\[F/3.^NT@6;DN*U\:98;G QI="F6M4>;$=B7M,A!#S:+YK1)\Q=0
MO<*^*(XQ:^$/"3H>89_FA+\Q-'PC%D "-:>(G"F=?&U)SCFSS0W=KS+.&M&S
M6*%5?R,GPA%3/^J/G[_<3;::Z6Z)-VH;:IUH:[9 2O[ZIL+7S?L4S]J]1D=;
M+GDRQ-P3-W]$8OA%W>_ZZ2J[+U1!H]I9)N]:P7U32)%D?_BY60USK@4MSDRR
M59IKZZ?9*LE7)>,%C1G%U$!"O:M,30;OX!>:02:DZM5:OQ/&7@0(S9ZB2= "
M[]8]4OE6:M2ZHF)M=G^WS[@\XJC5US<T*1:V6GX^KPL?/FC^G:9X^01XSKFI
M4TNW56ZYMB#/(H/%QY(XQ!%DPDW^WS";IK.71<EI[8L$G"P$0F0Z=4'^+2+,
MZ7'$OO;2640\WOV*L:NC+B0VYBYH2^>EIV [XD&C%ZMJ1BIJ^29_0KTB_.<W
MOG96]>W;^NB1-L[-W1#[KI09."+5ED!W+S9:!+>%I9%B^<(>FC*#]$MMRSY-
MQL"39J?W*/,BF- '86MWOX#PS@*X:[NV*,D30*?LN8&ZS!YK+"MNQH6_S8MX
MI_C7E,O!ZK]E^=S?+D<^ 23 NB.0)T!<]G//Z\3^B RQKJ5J7,7]&D)D"KCB
MAJ17C7RW2E&3?YN$YRGIF&7-.N)%HRA A L4>&SVO+Z<KOBB)H._3\ERBXH)
MUIB!E+>NH=DHD5*O'BP^E*;X?\HHI5 %'BV23Y*]*2[2.Y@+@FYQQ'IUCC@.
M"> Y ,H >\C,F8(KLX60I-(@)O8=I26?G]15I;0:WSU")1N_+W?%K>A]L(#&
M-NM[$Y,2OU05(KD,29)#"E#^F 7YU;NA6%/(5NAL6HI4EH>GPSFV&\ 1\RXK
MU[-DM'QOW_MS-:+HMGF"P_[$_;3&RE'?0;D!68"%J8/$H#YY(F0TVHY,D%5M
MW5;<ZN2#OW^8V8"\R+O'Y'*?Z<2.N@_A ^8ZZPE>QF["KH5#QTZ)L\>/]F:?
MOW/&BU/&S5@6.I=6'7#U7B_YLO^L60F0@I^%E>BK4P 5=:[*?QP[TF+1?HUW
M>B!_=2Q+@VG50L;#/10LX+I9)<*<9?1V31JO?64U@[HVHRP4VR)!Y#5AQ4V3
M7'H?YS!%)F'2IQ['+,9K^Y+VLCTW7ZM*-R6[8U?"RR5FNJ1?M2-HHB]BO=+&
M#9-!S/-IP_VS^3]6"<>.!QL8'<PTJ2_Y&"M=#ENBP?U52T<T$20IKPKI1IE$
M\W'W7,&2%^HM$$AM=#Q4/)9F..;5\:"N *&W7.9+O!#,<"D//UM)N:!?.+A6
M=0_&FWA5MC3#UJ3Q);(6Z%UN!1MSFVK*IC;,68+7N4YV=-/UZR+@5CR6*9.,
MF%:9=YX0T+XAX9'+KF4\!PWW'VEELW\P-T]"I)W+-^1E4DJ46$L4TVG"HD0E
M[H@)^@@FP)!?)UG4=4T6*AL?:W$FJOM%Y=&@'_9*T=YMTJ)?#A]J-PH6%<US
M%<9D$#-Z#7,=8<)/21]!))ISY'?C<NVA*U%Y1XBO["J$/H=W5R=]J'1+7.-X
MA>+U&R9PJ#W7\FMB)KE7K4Z;-@FM;^@^J6;&%X1EA^UMB[?^53+T*K2K[VXB
M9T'P&^N;&<Z,]<!!0R_59O>7RYR> Z"(67L+XD_57_*T=1C0:$X%1#<@U&T<
MA[R*WDBFFT=?CM\U4VF0)_[A[KR"]$)!]H?>9'AX/_U[E%U@D",MU70\D8]=
M<L 95F7'#2:ZMM#Y3Z%,M/%4O/L%"^^],=45%X=$"CX%1<V*\)Z 1HTX-V:/
M"]$UXV*\W%&:*@R\?"7%WEK'+7GZZ7&L9T3=[48H\*4P+D_%<DRK:J/H=;8T
M97(O(:4).3?(>O*>V*U[@,D8U&.U:O029:3B*Z-GM1VDW[ R1ROQF5[AJJJI
M_%]^\*>R8J"W*/FY)94JRMTLZE$$%#\#I]3K;^;>0P<_ 41H?_MIS.@M?)N)
M$J5W^RC)]-FX3"@AHJ_SS"[.Y+OE10%%+X48V+,CO^I -Y^B7K]A^@&MZZ&<
M$Z)QGY'0WUD;,ZYR&^C.IC6"%^+?YLGS<^7@YJ9"=^- =MQT5B$"@ML@L*WF
MM!)(>_6\ T7U_/4;L$8?@R< -3SP"6!X%:+7P?:\ _F+/]<^7@ZWDP5^1*2N
MN*H&,E1_J2T1IW1H;(>.BF=(M58S-S$LE2AEW<:";VG_A!A/RO>+C*@Y+F:E
M%STH!7VDS[<Q$UD5E=TV<,NNM$[+"[9V)\D^20C^ PQ2WTR6RQ"V&^K-50_6
M5L0D: C[P*&N=^"+)>UQG;!YK/<)FO"^Y:L_>J:_X,EE+.D^<:GVJA1( $[D
MA7,$RG*QQ*DD#%<>VB_),0Z00"+_ZIY7P_<_;6W><V5=JNM,RJ&/O-Y[G8."
ME56?+IM3@$U##SL SI SZM XA[B:1<&<Q=]T719T7>)&LMC) =5D53 5QJKG
MCB$8,N<C-!?0:BW:V!_9"H!)U^6OB*$#")<5T312WFBCD4OE12TMZ4%''"%D
M + C-0$CF6),>9:TIF)S3#XWYHN"5X%?5XVW[LP@ /U_L$^R?.G^$*$=%8#)
M#::F0EC1R$KE_P5@!+@ U"9U+ T@Q$O[1N>+)A?R0X.&V;J Z2X4?MPF\J2D
MG$-KL+6C(:XV>E27C!%#D.PE6,9"FN4G[INMC>B 7VV3^:US+*XX5%KU:\_Z
M+7/H:@/,\'3/X6BLHJ!YA\D/(<-J EW'\D5K_:7[L%7I&POQA3&Y<1M HQR
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MTUU-E<05(MJZ49OE0,S>@4"%R5/1>0)@8JKS;+E7DG.8?__*/,VS[%9Y28]
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MJPOE+-9YTH<$11@T=.T$K]0.(_.$PCQ>THV-H*1"I;7\1U> RPFWMAWT U[
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ME<BV4(JM*G;0 P!FV7)^3W\*V2DX$!?ZP?"O*JE@2?\]K%,!^>^@L-5/Z\M
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MT^%">A\^ (Z(8!M=R*V[_.F6><HX@,$#H!V4^P 8>50@2!02H66."=_-A0?
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M/M-!8TQ_V^-W Q\,[YI/#)?BH1E]^J^_-=J0?E6I/$K3U=BU).1!S*-*^?6
MZ1P;^ZI<,GHW=T>R6-9'4K"[L3 6-_OU%^K:W#]:>-P2EH-GWF)?&R=H9QQQ
M%&:"W]Z_5"Q,>A-Q"-T*3,TBV>$DQW*X7Z?HKL^'[C-VRI.FO9H/H&.#.9+Q
MW@N S"?E'(-R211@O+_QE2MGAT#OP6X(GC>%95WBFF09?]<Y7[Z@T.=0<XOW
M%4 A=+>=;S(78)]JA#ZEU6<ME!>IB,GF"5CNO)3X<.))59AH8Z)NG67FPOU$
M0JIDM^,!\"JD4'MG3\+]=<2NCEGP'= @O;59$X,9_7K#H$]P(:Y!>ZY$]I37
M[MHHYN)WGNML)N/,]*RZ*%5U(+7(C+AZ)GCT E=*XZ]C-^W_.O92N+!]D13Z
MG#0?][/0 H$E^!E# >.GP4:QH^UEM=KQ7\YDO^7TVAN1YL;^$N'*QL[<'SI0
MU<:J1JY"VE5YSYBZ4-6$O2KRD3Y5K!NYUP65/9TFX=@( YTTF]"C'49)M;%2
M=E!W3<// DKGAH_G!"FZ85B?+4M&R@<DZ@O<JBR HPKB!'6U?^>AXO='H>>
M9+G9*L#2.(^M?GAO9R\#;N :UA:95W8^ZQ(97KS]JVM*>Q]HV:&:E5\FK'6V
M0H'4;7"UJ)"B34*7%%<AU/MG3AC>!EF?]<<@K3YA=JM,/G&BEPKU+3%>)S%;
M6>EW'W+D&!,Z]=@BVJ783^:^&,?-3)_33#HI* L_SJ#U'R>%FHX"'P (=EBU
M4<*/X[.2%]5>K.X7,J8?97'E(F$J1D-XFI_6DP1(P-B:C-_/VL&,@UYZQ]1*
M1P^ GW03^_O6J>PH6$N;U^.U>Q[.J$O&,/H?58E5CZS4LN1"_\744%$PJA]U
MSRBFS#U>\O,!D"IS5S P7QN?_8@V I">D@\ [Q>1KR5$>DM91JWOWB(I@G2^
M[M#6([XE_@Y"HZ^V/ A;(9VG;K^(9L>=_W6 (+7]N)S(YI)J,9M.$2SN<.H6
MHP#^PB017UK0C^DNS=(?LJ-%0+9 U50[<2[-64F(R($^NR!FR[&_###,>=1+
MC WDIH[CX.6S")SY[06\"9*#9TD':Z@U(O3,K)>_4^.RK%<TC.MBY":+QS$0
M=&YW=6)%WWF(]RR:F&D+)IYCL67C[+P'_:H^%KKPB<J"Q"?I[9=L16'PH)K5
M0:P9]>IKI];'STEQ0 [Y-(K1MJI*5TK5U2CIF15>DL4IF%*@J1^#8H5[:"6R
MC(+8>+H=GA:$!;G>\:0=U<2$,M-6QL^)EL8U T:W\TM4.[K>U%RJ:3F=:?%I
MZ- E9O>@U!)M9#T ?M0H>*I.9HT-6(!]8>XM/'J'SWJ^ G8KQ>U.+!%A(^'%
M+]/#BG,JV1@LT)])$5L9031]W\S+;,ZI6_1QQ&*)?3D--.M1S/S.N\.87'=L
M; KKW+X8<G;T^(2O5;U*+B4X%5>R6]_AYJD<)", 85X6IQ->RQ";UR+WSO=X
M.GG 4"+E)>EJE+=]46I!5A_7Z1G/RHS/<AF"HVKEI5P,M[.4!U9U%?N 4"-Y
M*VX"Q$8)\R34&09>HQ7DE/(?$[84ZKG9CGB_SZA(_7)7][E.GPL+E\^T85;N
MZBSXONTNOPSO7U1;FMD#X-WNX27>M6J5\<P#H-?C]KX3J0)1 ?8%M8GC*\?^
MW5UU)/&]B^ ]O'<,>  ($PRZ)2R'UE\TV.=#;CII>1!JW"5I_YTIKR=1)1]L
M>65!+S8*=()%?M%7Y/(+78NYMUS(Q)A@_DY,1]A**:9JGL?BL:))84 ;H.,F
MU*$Z(4+]OE&!:I\'A;XTQ\4E%6>,Z0#7K=CH]/6Z1EW;!:2IZ#MGZ*MDQ8G:
M8I7)["0@VX:T>6<,DW$FQ49CC7+2R@.@0Y9B5S%U[[ONM(0J]_6FW[1:B9(7
M='--U[O02F68"K%YB])9HU83^0U6<S'Z>_TS$%JX5'"6?71?!BN^DXC6DL)R
M5<-2T+'SL /5?<C6SZ>>D\=_]1T[ARL_/AAE.6Z2Q2:ON;[&EDNVFK.,,=3&
MQT%RC1'W9F57_JBKM;9N,O4Z\J BG"TJ8R1]AQ$FC)+^-,;0[*!4<%) Q-S>
M18'/K>AS9/>LFNS;<J6V_%)KLP3%8X<>O!C@;XR>!3ZYKP?5?N%H^/K&R:\\
MQH"^E)W4><M7%)Z<I79.Y!C YC%;&WQQ1]Z.A%]QPJUHUU,,UK3-QV2[J#43
M3##F7_8.V(,+"W';LWA$B-JS+DYU7'5=?NNY'(=&'#'8(?SX64[4!B*W!E\/
MFV[<N#+%ECJXWXGUKBC@LE)QQX5"H@F4KTO:61G?1XT[B_OBXYX]HCK[*.Y^
MJ+:L?NI;O<^2AHO77OKFLZ)BG/0P)7-$%@!';N0&687-LIMW3>%N;6)Z05(U
MZ6%]/HG[3'2BU_4+FAUV#I]XO%O5+;I34=%N".?\9H]3\.L2/KQ%CBT182+
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M<L%>)>.GXU1Z_"Z"I<=A%D^-X\K/ZB_90UL])C+16-5!5#$&!Y4)-2':GX,
MH8FA;JA_>:K]X_;^3O0&T\BO+N-/30GM_\WPB^P4>/[*8)'Y=P7@YS^+>/4'
M_Z3Q60+R@8R2. -4H(](/V\1E$N7WHJQ<J%N#PA$T42J+Q\SR,WH6QE,UUJX
MH3_DNO$<-#"\TJB84+_8G+71G]OV?)5DX<9%]XFZGW4_066"+0_4>=F,V*U)
M[#=G7E_=&JF<:#ZO$H\8[7.F#H?294VI:*<SIKASJ<)/?ZYS4 :355I'=!AL
M)Q'[M+6D@.L2C).I;0/3UV#%'QIHU3:\GCEWGTYJ\N%%6+_=UNE^@1\KC2UB
MT# ZEKB?8Y:?[2]Y<#W#9G'P#>"\F_37TGGW >M^DE_;WG:9 ,/A1;/Q&-)$
MM"3-SUBI\#4ZKB2"VD2>ALUT.]/XV9Y822:*GZ\.4GR'( (A&LIZEF W+1O+
M0EU^"B\D<MTMHHO+HKVHALC=7L7?:8LCU%5#Y ]#O2()2#UYPH\E[I%3'?04
MIC:@MI&B@OT[/SW4V:O'VB< U>_&IH _6"R=!ZKM"+VJGNK+Z^9U+.)E%Q3H
M>JEK'$"\W1["7WE30CA'NIZIN00?9@<*YYD9WG9],JT7R85=FERVR&A(.=!I
M-#\#7&<-];I4<--VA5"&]PL9W<E6:,/8 <@^\=3CFS/#3T%3/"%BX5\- 24^
M,1-CVII)JM8B5,DY,2T#($)]Q$YVR&QPJ;Z9S[/EROVGA-T:BJHG+@^TAP?#
M+]DY+99(-1K61.B-4MF0AHBAQ"M=?BJ+_D+XF^;U#8EN_%:D%;=Q*O_FE@1O
MS)*<<](%9Z/W7?KHPYY'BQG5K9;@\Q^T.W>1XL3X<'S30%!%&&0N2D7Q3*6,
MK&H];7N8"G5Y]I4ES[FWK ?#B;1+,+YI/7.]-14>4/Z2=-*H[7NT3N8,2<WB
M4XB2D!2C8V!1S=>N)!R:)D:=>7_ H<V,-]/*=C49P]M"7@YT6&MKP:@6S?&>
M&([L;7.'*4/7N]LK[AWP-WO>X6'F*HS-1<;\(WOJYT^U]/I//0J0^9^1*D9^
M8UY%A,SL"DF.O9'UB9R)9:XIF/&/@_B!D8Q6DK?4\36TSD!U@9VT /OK3+.U
MQR]^QK!-]_ITLO92#6'XH^79[7:UWVLC:UE6N]=55:3)9FM4TYKIWU+(,[[@
M;<7;'?VTL,UPY50ULD[2#=RTPA@;0P;XXNT4U9?T&F?UK>9YS=?C#2=E]AC#
MWF$KAW-/Y% _,+&N;MH4*<3U#6_5<^/A3J@RJMJ+98<RAOSO='<!"N0%#X'>
M>.4!QICK*1]#M8)A4,UK6F024N(+VRWD"?.Z$Q18_4)0PNI?U'P8C*0^L6 "
M._PU[EEJ*[]%1%@"5M:,V(2QKD4 !3^V(<ROQD--(K<W*4\$=72V+^&Z-O)3
M,161['0+5!/IDTY+W;%2#SGX1<:@,ML<[,J<(XR"?'3SG0:S?;='(C>H _2X
MCX;:IT.&J,0MD;>WFQ@RR!.@'CN$)=1^RD_45YSX!/!@GSMDMEJDGF MJ+6J
MSF2QP^QGYGS#\P1H8N_6A)Z@YZ=:%.M#<H[T.K%[RN.8OQ/V>&IRYR<[/Q19
MT";E&^S 0A#J!A[W[!V0E&[Q<U@2[F/:O*_![&!L7O+/A'D/OO1^4YMRA=:>
MOWI#N C+S\\L%<K:<AL3@A>_?QVR&ED=2&8MPU$8AZV2F#-11_$I=H%1V(=4
M&AHF:GYY23OFCM@C-86;>K"W4]UH6HYJ 1N;(X\D8Y\ @S'I1#E"I)=<?NV(
M33!N67"$@& ? LH]GK!Z9'8EV[V<%\$/&ABSRU+UGYC2U/!4=<2];L/CR3AM
MRXJ/EQ6S%33A*N?Z4X+.A?-62V_9TDD86*/G9)IDKK[G8:[^9DE]K"4JVRM0
M/]XO/FZ&+#1/6#%+506F]\)JV;@A<FSHB:EYJ<&1'T:8RROX]S'XN8<6MF\3
M%C/\?"\CXPP-I/< Z\6!B_D3$#:SJ3+1:N8C.P@//52; H5OB\O/*(#BXCH%
M<PW40##WV+'HI.^3+LN[A9[FX#499H^]A*Z*RB()O..=C?])"FRD=A5RU&_.
M#RGLS0+:N=Q0.1:5!K /XPC[)DS:\+CAN =^3.'3R0E)'?PRYGXD\=BR#MQ[
M #-<"UQI-$Q<!#5]/(W="#[Z4*'V]?1K9$(59,]OAO)U=JU-:F/P'*[8FLCZ
M)5[J2M]A*7C(<-9+#I^_@+-7]#A:C/!VHH6ZJI$X,J-X5LP.O>C]*IE\AKP
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M'1Z_4_*6)X"C:(*-!M#IR^^_4@[_/4TZ:4_&,T0>;GP"Z"\_ 4:17+A'K)X
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M\'L8%]GC=D' ZS[^W#XZ(EP R* ;&IY>@+M$^S[M8]K%C0S7JMBN6!XU1C4
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M2%<8]DO-WPO^[$/NC3YK%WE>K4DWD4M3\S2(<5("[ U2Y/G)'*Z*Z3G'PWW
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MLDCR0X'S8ZRT9PE:Z%MAHT5'SV_P)$/6*A!SSCXTZ0"=0+'1'?FD-/6U2?I
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MU"G\Z=165"^IL/X\,-9>TB9O5F=\#O3:<ISF'V*R^E)@X1P]IN?V@XMVV+D
M?&]3>")P>#R<S9XQSWM:4C&M*W'2Y'I2(MWX-N@N9U3],(P2%XQ6^D'\2,GW
MM+8P)R]*6,W&BS<P05XV-)(00^QS($1_TE[B.E_/1GO_("\4J\'KZX0G@H&I
M@%*&G<F'F8Y@#AV>,IZXB5 ]"&O/I3C-4*YJP[F%?HSD9,#T&2':^+8()5;_
MEO$*T:"-OQ85']Y4S1/@^[J OJ,46=>@6) Q:0%IG $N#W[BHT4<B-@C362R
MYP@B8Y^[<QE'!-E?"96<3!#C0AAQ)Y:5:CY'B%>H9=41_)JR9]WTW.4*6U_2
MGAA(MP36Q[^=#$4L^G\1Q#\Z)5SPW.&L[ DPQ2=ZCF" #L!+6A7D!V-B+.FV
M/T)E^U1V;51#%0W0!07301 ;.8\5/JZ^?59?> 1Q V$DCA41?_9EAR FWB[G
MKJ(?+@&0I).EA ># $F):>R^>MB5;4->0^_HF=0K0[IAO5BYEM%&[O;JLI R
M8P(E ^*5 <&8L?H=6/$V5&OVH:S #4S2+3";2N\6[H1,=\)7+O&7XQ # #$3
M<4=2JXX%DSX WF>ILG.%97WDC?OQ\NOT>V&!\U[/N4;89JI^.HQP@==*@IN.
M#OFOXHH&<]#PV]4D1/ZV$0BFT=Z?MNJYVZE'A"V8]<H]\2SVM+Z?Y4_?D0T/
M"Y(&"V'VQ5209SKY28"4!V[L2]ARR'J$&QZ5Z' SJO&6H+2/HTY(#N5UI(]V
M?]W B\Z-F+9V.E$( ?P) !^Y[YC5NUT@-3AH[CY,6$57!.7)VJTK,_(8)?OW
M\D$@QJ]LCE!!(3_D>O;9%FXPC>3WH&7L7Z,45/P=V];R4)4[CY'+UZ[3"'ZX
MS/V2Z1*8P-^>RQO_]+[W93 =46EN[>^ZW] J=NLS ^SBRR$J)%7A6^-FX#^F
M1-N-_->'28S?GB&77ZRW]FU4I[J&]>J&$4Z_JP[1^+%6M,8=" ;QCWD#H6\P
MN)4_  IH)#%D()[2KYR_9NCRE MA>)[ H_9.ZOR,@D(;S";<&EQPN@BIWK69
M/;.$^/&CI$Z!GG+\K)=W=A9G*XE\ \@O7=9@C9\ A "$ _'_F40>TRM@MC<5
M:.;V!'@-F>R<$S(_4]?[%D9:G'C(-#9Z\%5NOWHU,_PM.U &^.IP*]709M2F
MH:EB-V"7A756@:9!HG>8JI%"V?K05BKH'LNP'8"0<SI1"7KOPZ[E7?@$V$IY
M5%]^$0X 7&:!/GO-9_%\S]>7(76:D>@G['C1C&003+\<]#[DA70HGKH+P 7W
M]A]>A0B5=*DXO0\73#>A-[H7:%I5681,[RD@/MH"H3>IW? ETQ/S@E<?\%<J
MSH< QO^)O^SDM=+=OAM<Z^6RY(=YGZJ1;9OMZL_;I0)8,48L5AP'R3G"A*9:
M8R*8$W[53=PV#+8-K+VWD4ST.SQ1=&_NTLQTV<J;6M4\L^^$^$<2,Z[ZBBPA
MRMI64DP!',+TL^R1$[OT+VB@04:>/5^C')HF@L3UL?Y*TL]KO#_SM1:69(F(
MF,>""Q@C+E\ ^#!$@5!_6T00?7=BU*5'X DWJ4')TK(DQ*W^]-))'+?NC$JS
MMW"(/HB \!/[>&3\+3TBA=)8RLBGB3(:< SK.@8!&=^1;DP[KB16=N$E81%]
MYDM&PL^GC'P'JS]B8XJWRE[]-2I*,*%0: 0H2^$@XI7GB@SW\\O'B2L/WF'M
MB$=H?_9WW%/*]B?N*VW4?B&,SB'HGCV21%SF\X^>46A.X0),F(XI3H7B00!,
M\>=9<%CA$QIJ\:FK=DT%]3*T3+&6C9PTBF[:3-P[/B^OQ;7Y&C(F[^'4R=ZM
M5M*.BFTM!WF990&YYYA!C9!0A^$XGE+LG4#E ZZ*85;FOXUH45S^>58T0F<6
M1I'\!-C3XC1(^KK:I15[FV T\&S9=#1= [DSRU7(0+@J^LCY_WEZSO]SE^*X
MFG:MA2))F8N&/1PGTO(/GJIVG?*'/0EX6Y[=Z05?5GY<F,+M4E8E(NC93J.[
M')#MJJV)N^%9JX(#O" QW9EB1DC&RPHBF@C1]Q[I(5(>7;?0BN=3&-&7<$B9
MPE0=291+Z"KA3EMM$7DG#G=Q(T[H[EB4VQB.A:J?I'V=]1>T9AK$T6J&4S<W
M>G!+F2;#YG6/?^ N6TS<3O:S@7U4[D5?GHU8L+2!,ZQFM3'.6<2W/<G$/3R0
M@M)JM=@J"8,W[<7U(RLUAP]G>WS,]\5B<#;$XYC2+DQVM+$7E NOM;H2X_07
MA#2=F"3,^7QR,4CF4@RXB'5+TB-GXX'<I3:DPZS2&I,<.;M>&K.KJ -Y^M>N
MBPR;EBF\%FCKAS?.BN,@,,7;G:K=HQ+]=G:W4VS>#FG<95.W'<4=)TVH8 K3
ML/$DF,77'B.H*79Z09PMW9AOH7J-ZA32C'18ZJWBEROGQC+4Y,A<D:SGJ'\Y
M).AG&"C00)\=_?<E^E_-';D;50VTYI43SEQ<B;@78_@$,!0_21D 769X(V,2
MA6>HH@,\S/Z[GO_2L"7?!YM&NW+O4Z#5Q.#MIWC5'FZ1K-U.14Q)KBPH 05_
MF$54,*,1>H7^R8^0/:TB;% -9A2U\)/V89-2A8$):PPX4/LB/X;%"F,Z:MEH
M%.WTR*NHZOU5!X#^/XVMHL^NJAE2%::02S^4X"@)(B^H09].'I)@59TA=S[!
M5.>]G=!U48P/+!-MLA&@[U)AQ AE5V=!2ZJ%+0XZ#7:MWZ; (,<.8Q,^RNF=
MO)JJ7< #8>$7H?1EXZ7_[L5,K<<NAH8_C"CV:.AN_>27F2:XM$5&LF=EPLF^
M1DV<Z5]_/YS>Z2@9WKC]K]"J_S\S#/X5W9A8%B.7:T!]PE5!.+QNF/N\#1FX
M7;CV1^@FD.>JP_10#0SU(+#,T"ES(FF_L!T#R%)POD#JK@#H3&>$@U&!YU"K
M5S)*=P$(=%_GH,;Z'^R]=5!<S;HO/%@('A(@. D6G""#.\$#!)=!@NO@3I!
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MH3.I.;ML$XJ_''1ECC%"LY W!55(,U=\_M2EI/;M0M<I5X_8>U50A3J>Q:E
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M!O&LS+R!DRKH.A.L#>DX>'9VM?.<V*O.;^FS'J:@X<HLSSA'&%[%>A ^G9(
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MA>\U7UXYY?HP\N;U@FU=1MSM26E:^HHWK6,]Z/,K!"?*#_;N7F>W]@4L*3A
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M("7>0QC";."%JQ2YB<UG<_J?Z9&8BD&6YWSDFFFM7;P?:(]DJ]^M,@TX/:T
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M941?&U5;<(\HE#B)*R.1+G17CB>PL+=X.S%A0>$KN&U$H+$7O8C@83IC.ES
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M3C3;TG,Y-VUQSOW8=)/%5(P3?V$@K9B;+7?4YYDCCFL'!)%A_S@;-V1HIBI
MM#43$2KK(> )P2V?S7+%1.^[%XR_-V#'JR=@QQ.P8U?#Z*N!7MV!"BD&>(A(
MN-BC*K81Q(2\ &G\$\4G;0A;3/R^(),>O<:'M"UWK1>(KN<@>(=%J8K?F?'2
M#/K2[IF\9>_F1T_/_KVG9W5]+VE:LJB=+MRQPO4Z-J L\2JW$MBWU[057.EU
M\&W4;M+7N,D^E>T>#P.'Q:1A=';I0UX!&:2;;+N&*FC(>P1_*R%+>G>IIK^T
M[&/\!-75(I;J>Z2D2E_D2(8]&VYR"*\)=\?.)(8$^H\<*T2_NEBN5Y%05^"
MVPXRLK<G7% Q<Q\0JY_[7D4.$1[6D)_?UB6V \*S?U&[;>HEA %[JK"5%'12
ML(PC\<]89I]P+N25PYJ]J]^(6UY3N"A334KD3C99%ULSS*)3WR/59UH2BX$O
M:'.!W.E(L<3(X,.*]NF ;$0_HR='>E.]]S-WVZX17^#(]:O<=JSV^K??B>)"
MK'U,;&^MT+1BC2HW1,,ZU,$6FN[]V:G#!0Q<S*#@2:8&HX7]N;E>/_IQ7Z,J
MGR\*^']L_/E8[<>[-5JYAX/SKFGJ&X5A1'R:#4;+7=JC\,*3NIK)EL(.3E6+
MAP!I[.+@%"H)IIH\Y<%,LH-4YS;==L:"P?5RA=X=J) -2/Y<:,'1E&+SA@A9
M0]B4+U*=QHVX1YWXVT50$_,_SAX?1#>WW!P*;A -24467\2FALAY2B(>U#DL
MMBO!"\N?'"CI@.O?KNQ)'TK/X<U4=S4JS[)F<#ILN?)ZW[IW!T%?$JXE+1>&
M";RA$X9JM5='[8? ] \S[?;D#[P"OSR/E0T<7L2W3[?I*8FN7F "2^2+=:8:
M/QL/X=UOW6%:OS;NCD%:W98P+A%F@I_SB0WJ8<6F59E DSF)_H"FZ;9*&>U[
MQF12\U=O(WJ>'#:)UNT@:?HX#9#!OHA6&DN/CH>VSIL[G ;".ZLWEE?4O47#
MU^U#-IP2HK0W^@($OG"P;_KXHEZ78,[DU#$9.W#.YU8\BS7MVO](S;C@O:O(
M2(+4/_GOMJ='['X7#9I'%;="JSH_X-3V)$T%'E.I49.ODA,6G0\\7H%:89;A
MGA^EN6/)P%"#9)Q=+WR'KC&9(-KZ4V0C([Z27KUCZI-RVS)G@+A:!\V?>D@0
M67X9);%G#/%!UN)!RJ"PNLU+38(KGGX8NX4S>S69 $X0<\R*^,FX8]7D[8%@
MLFRW+!X>\L/@([!_'VEET&-LS_3?JAD?ZR3H1G) AI;).3P8;>V 7[#Y>>F8
M<:G#C._,0@WZ*E8</-841YHF_8K\U->AGUJF$EO?OO4<I;I?+<]3F3F&$-\N
M9C9;-^T-&NI>'Z2[8E%V/QT\U#YV*8T N;9>:X?4P4@;3B_\^)P.HVHR?8>]
M)+O%8<["*>IU,+MRC??-[;^YA<5E.[$U:T;I8HRD@4GK0G43B!4V-Z_NU\18
M:)@W*[#L5NF9*&FT1N$^#)7?6\+_JZ>$_U/"_\M*GYN('Y<.C*1SKPH"2//P
MG&Q.,!%)5B!G#NDGT JM:S$5=0_ 7J0D1V=+!Y!Z76H:/5L_RSJ*,:3VLU_7
M^;FC6!^R"4PQW8P\#\2#QU'BQD:H+8,=Q:!\C_H Q;HW#_2V?5O)'Y-0N(M!
MM)K/SX-JNP6(FW,T8VQ1H3#+XW^)*\#^I-<5U:L4C1+#W$# 'QX&_&R0I.<N
M8O<9@J#5Z\[-_["H[MY8W*]=BKMUT,49RSX9W<>+C<14V,!CX?"!BD^OZOI%
MI@[86+#B]\.RU)^2;7RF,S( ,39O8_#Z%(N?8\N6.:P;C^<&QIXUB\CEHUUH
MP\-\!]Q^#JH0$PEO>F[W\'GHJ^+3G/6*=V?:DUKBSXE0%#K0N<5>8"U-#J^$
MP6QRL,DN%]9!W ;8(2_&V<4487WW@L)I$<@U&-ZA+R@D?Y[8CTZ4Y?Q#,QNN
M8W[N%J/9XGB070F>A%Z:/:<];M^P9K?)C_=PY;)R80R"<V.B"XT5&ZY01]I'
M&8KPAW)N+VE;41X!%1B5&[H#[M*_\)6&(BLDU;4,ZFG\IE3DB&&)6][6A??]
MJ<+0U\QW%!M-G?B.8W1S:KY3&JX<5TB'N2?^=5,7+8 ?2]V5H%FD\R::J,^H
M=TK6(@6]E%_BL\"&A<U/J@BDDJE:$_A*&1C*364N6XE^82]MY$^T-2;4'$ ,
MB8(H%F;KIHG77^) Z;U:%Q6:E5FQQ.<12>BY=<9$#[3KHG/,"R:G $%<(%"
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M3L%R$+ZH*/9.7(U6==->Y'Y"+M!_87QA0>J I==*4*_-);IC:Z7P(E4K)9_
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M,MFT#.BB[9LY_GH.NZ.0S%IQP[%NU8(&YE88^5<:1*VO84?NFW6>T%#[&%R
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MI@WLPV'W\'C-,+ZMYUZJ\F]>N5>Y3O\/4$L#!!0    ( ((X"E%J58/6:@@
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MUJ: ];+CS)7= (GCHA[:)$L5K/N1%BF+*"VJ%!7'_>MW)"7/SE:L[>*E*&K
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MJ2OXU635M7PPWZR4=#DLA-)!:M?:0XQW*Z:%*+&?8K724"<2BP.UXHJHQY=
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MLC32;7%X/9GME,D9UR>!HEN0OT:A%Y/ZVM@ARBHTY%GT9@J@$>)0U[SJD5>
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MQ:1176##O$Y1=A57,]\.;D.EC2RSJMQ#7T?FZ4,9^(WBD.RD#&.07BG9Q!M
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MB%ICH]S3.JG;)[O9U \WKRHI!^4,5(O9DWO8SZFFLB>8;.=PE9B/L"7$;+Y
MBQ=$]UV:9.SEV^3-9NA^%56]"MWCHE)0:H(8Z+1>N%(,P_C*<Y(85@>7:W%B
M#B]295](E38\BKY,IY1P&U7/*JS-K.4@JOJC#7F8V  .],HC;11OSBK6_M(-
MCLL-*>K:*R2XEP>T0D@CV\?46_@1FM'5IF]R!+%IU.CN2 [OJAS*>2),-^&"
MFJ\C!C Q(RZ(7"3H&+TYG[>7$FUYI/\I"[F&VU[6%6Z;3Z+F3T%,U3V@?/ZL
M<+>C9[C;,]QM,W"W$J>_L42Y2+S.Z[%4JCDQ*MW&^:,A9R_RIN:,6F@X!RPX
M_?<1K:2+#"@.3(<N4,X&:X++\K!4] ?WK3UDMM,MY(P&1Z96+LR?GL>8;]W!
MW9IJ+O08W[<[9QBJ;7WXT#KM/;*G^,8)+]0#=?JJ=/(8MDL'VN#S9J@!@.<&
M!'7^&A0Z)EBCV)HM%(>2R9.-#SB[?;<6? MWNW/>:S\^."6?6Y,Y$&O%\A)!
M+";,0MU\(D'\DZ0(#WDON5'G]K+ &GXVQOW\<UU/H=L,@07+/KK3.V!,9FWL
M7 G?#[U! H(ET+Z1.885,58J'EL72R=W&I64)=98Y@!2( :*KK(SD+>DJ>_S
MAFZ9/2^JKED]1\'-0[4/B&:G\8XY_(6G>YIN4.4C0'V)79AT_5'](;-F+L?W
M311%)BBJV%OB6+WFY_8?XGW[O/>IU6U>M*Z <B\;HMTY?9"<R(*1#O8B;)B3
MPB4_Q.?T_KN%+7CWH;@,@3=2<9F"; 3JN\2SS&#G+KSX^R..XV+W?%>\CWZ(
MHY<O'_&UIUX\5C(0AP>O#H[V#PR(\>&ZW.>BZH,1"\?B[>M#,.G?OGGS]NC-
MVW?]^/=FFH;'XG2DY%!\L-F1<VZ(\QB#*R!BJ.%D @HRL6VMD+V'ML:_U.W3
M"$\=01_8UM&U/K.6/3FZO]I^HG":%B$MZ"A+I4^R81\Y+XO#&F*.V!8%*5V;
MG_Z<Z$-'W7.VM+S*A:RO&'C#[>PC73_'4_+M=9S+TCV[TAP[3LNDN$NG.<++
MMS4*V._(8N2>M,5PMZ+FQ6W\.[UVMR6:'[NM%I9H;LQT6 /N[08BL7 OR!)0
M^P$%-DD[\[&XY0A7A05L.2:W@ VS0!N9V"1+^M() KG]JS"1>BW-J6]DQ)@H
MHE.9&7N!QB)JOFQ4T(*52)<)1!$,JC#E,A)0B&;.XIKAORMS"D)MT)@Z9W('
M436T(>2"Q45='?'MZ-R6JW8J4B(7)3EDU44LW6@XI^><_TI<7FKB5JZ;ON]4
M_'S26\0@[0[B9SJMRTOQ#2R5UOD'9)'J:>SVA,QR'+;8,P1LSB1UO%@2;$]*
M^#PIV^W.49LG,@R*':5<NZP#A!QH&T1!X$T2>6Q^<%^=;PQO)[8P*$;ZZ)/"
MEKLTP->0'*:8:N#-HDS?Y,;8!%''/W[CR"?,,(WA?]_.<4$4]L5?W<71+S8+
M]0"+_W[&3LQ>ZB\[Q*/7-JRI8Z@'DQ\(V <Q:(*OCSJ'M:*/R\_WY?[\^5)'
MMHD7PT;_)'/>(UI\LO3XP'OIT"[&QS=,N!UO+%=F/R3'GV-+GDGM4>?30VCF
MKTY.>Z1Y3?;HB0SO%QT&F?4'^RNZE//:[#IH_[PO>"'C1+_$$:$6,M.=1_L]
ME7Z.>)HRSE!Y<0X;R,%D#LB"Z\^&#=VJFTOK!G@F8[((BL.'_17'M%U&HPUO
M?:V&7.>U?>2VW2@YE6783VGN960(!9Q43"#L6&*Q)3YKY-'!O=$$SX/'T"=!
M-:(^ [DI^'.CNQ.:]N*VG(I]+ Y[5=:!"W]R-SSA,J,*-&F%U:NL1;G.D;<%
M?3R=R&KHV$-BO%X$5W/!DR\'9B!Q">*5U+K G!1#C_[_,CPR''_1=6$E4'U4
M[N!9'OB02S>=D7,$L>+%VE<6HX9 T\JGN/2<T-SNG\+96619;\0@$U5\SW+H
MLF>OXZ?7W08N%0*'%Q%#"U^S[NCQ40] 8,_HL@JZ[.4SNNP97;89=-E<.JV-
M"_-]AZL)AEMQS7]\:K]O]QC7_#"IZ-JIN7MV9['V\$.N^#J/L#6]:A8ML;OT
MTQE]9IA&?_ RWD<0PN%BY^&8TQL&T=00COF=/-%CEIQ36+);)9H6U?1B<ZG7
M!TLK2^4C"S?GPLF*B'+]]WT%?I[7?+4U7S'6^?A1MX4PQYKSWXZM)/IU@XE/
M>;\6.J(/XV[^*CL'MNF39+,SC2Q%8?=S<%=_J6=6;2+:O;=OWY[0-!?V =2]
MD [V#RU<9^O4FRAL+OX1NY.9C[?%GJAYW&J#>OOZ\,7M@^J L58SL.*>/4N0
M7V:"3WXK%Q%KTQY4U+$G.1E.XL; _D\B;9YU^:_ B;_4SBU4Y^X15#\'B_V+
M_XA__:LA\(>?:">>>>A7Y*&++!Z,L-WE!1VA-S''^_P<[/3K[MDSM_VL.[>(
MV[XB["&\IL,3DV<6>SH3>V:QGVGG%M9__9@HC?U!+OLYF.P6L_!IXS8V.XP'
M3=,MS,$5R.(.(*RCET\,A/7 N.R#IPBLJJDR715N_LMLXXKRWYGX$RCI6!Q7
M;GYIK:,0#GX:W?W+;=E9L]>JB?O_*56B<R$B81X4K%@+3WQ4*.$=..$98_B,
M,?PS8@S?;Q!CZ*N8F]L=QVGP='"%C[0#%]WS/_[YR'V>GLKR+ZVPN#J-*YJX
M)8<N0**&(5AT)50<RYN(3WF;Q-&/F>D08N  >:50<RQ#7Y^ V95TZKN?][UZ
MKR)X6>Q-9 9F4-(0[7"PVQ"'^_NOQ&4:#;[C!UC)=6/[J\, ]".W\/FX7H?[
M=KV6)B(@!G@>T<+"M:#G'YQL4X>VFRCE[BY)]7"A\MDZ)KFL#Y5RUQ-/-("'
MC*7$.*/%MB8X83RR37*#07>5TLHJW77Z3OW5*JM@SKR'F= D3.LW6 Z$);IE
M9>7YE*N^J/OWR N&YDMGC<KG/_&AR=ANR:,6R@MNY;55H1IG8]/AJ7!0(;:R
M<M?^EG$6*R)-LQGGH!%/3*(I(PH\,#7B4%;XP<.W!D$TQ7CRDXO./+* F5,3
M>Q7288M$ZE-D(E\.5>ATSAHPWHD/IR10>);8K]T3:''EQ]*C$V:]9!"KOM2M
MB>38;>"JZQ5K1)W=YB3?Y^3V;4;*@JT.(GIQX3 _;L9HA (W#9MB5WP\YB_5
MI_R9HR6PQ^+,4#B>0(!G-AI)XAP.ZC2A5'1+Z.&!WWAV:7$DU%(^/R OR2N&
M=?-Y(]'FO*Q1:&PNP6O5IZ@W]*)0#RM>M'16VUB]?B%<<9)/@3XN+@(,T8\&
M&570.CWQZ5BYO#N6\P500'SM]LZ:>T2Y<XESPC<G7+&,6A\HYR6)3!,NK*:I
ME%KSZT]KWD(+ZDYG6_?\RD\1-7/3#3H'V.H.OK>[@_WG[#!! _ '\$/=V>VV
MYK=!@@^T+IVWBL?@Z-MUE7E^BER@OLOM1CZLX5#YWHWB\VY-QZSEMS7O.TI4
M8@@>/ICEI%?3Q)2.E4C$F&=7('?F;^P(B,WV^*A3/""!&J\F*C:'8_M 31%P
M=CNT3:+M*?9UQV%0*S09@GIUS[&WG?5!V2Z2_;>*!*LK70)&V8!OH(-B%J]Y
MWL45C]KB;MC<\XMN(MF5>M]Q.HOX1PVKB]E 0T3!YM")W?F9: U>9>HD0!W$
M]+ ;<X:HDGG;@>P$K 1N'3,&G>N 764-/R8PDY@/'ZU3O*:=W216-P0CPL?U
M S5P>2\ [;V33=S.>$S7SMHDV_G#8)GTH>4XB7X<>6!M5$9JQ$<-.^OND_I4
M:'VBLST%NDS03,5)%M_H$]CYG%ANIUGS8CJS(HJO07W]QPHIX%>C_)S362JR
MK':]EQ%EU<<]:">\G\-.T9T?+\C!08*Z,,S>-,SN=(_6G17RWLQ3Y>,1S[ 9
MW$$51%["9\K&,E!T;(YU'&QS#_O)=>0%B3Y)!P](+S3+>-X;O3?L?/(N@'F/
MS3S@/SXN0)_Z2WZ9%P<J9V8\$BX;YTVX/4OX*"&],/$&AJ-.;4.*4QA ' 4/
M=5CCO B"+=-^\7+WZ&5U7=R()CYL4R&=1QOYKU[QF9?E8/YG8Z6'U7I#C#/O
M/WJ0N<3W]U[LF2_WXO3A\W+?\W(_4_?]+?<JQ7Y/ 0%QAYCYFBMV+S+@%Y_\
MGY<RUN2?S: R5CP"96$28 6HS3.3_'K;_S/!=IYA,'>#P=P5\W(3*?\VR,M>
M/_)G\,\H'0>__S]02P,$%     @ @C@*49(,U?;V*0  )/X  !8   !P;'@M
M,C R,# V,S!X97@T9#DN:'1M[5UY<]I*MO\J_3)O9NPJO,;9[+Q4$9LD3#G8
M _CFWK^F!&I $R$Q6HR93__.TMUJ+6# "W:N;]TD-D)2+V<_OW/ZX__L[#2"
MD1/TI2N^=;^?"S?LIV,9)*(?22>!3Z=>,A+=<#)Q O%=1I'G^^)SY+E#*<2'
MW7>[^[MOWN_L?/H(3SI5MX3!L7B_=["_=[A_N"_V/QR_>7]\="3JW\765?=T
MF[Y]=G':_>.RP2^]O/I\WCP5KW;V]GZ\/MW;.^N>\86CW?T#T8V<(/82+PP<
M?V^OT7HE7HV29'*\MS>=3G>GKW?#:+C7;>^-DK%_M.>'82QWW<1]]>DC?@)_
M2\?]]'$L$T?T1TX4R^3_7EUUO^R\AV\D7N++3Q_W]+_\W5[HSCY]=+UK$2<S
M7_[?J[$3#;U@)PDGQZ_W)\D)W+D'EPO?N=F9>FXR.C[8W__KR<1Q72\8[OAR
MD!P?[1Z]RSZ*O.'(?!;RU(XCZ3N)=RWQV=93^[YTHN->F(Q.BB^HNG.B[QN$
M0;(S<,:>/SO^>]<;RUBTY%2TP[$3_+W&G\"_L8R\P=]/Z-NQ]U\)CX;I)?(F
MV7%\;P@/Q[&>\/R/X9K /^_Y7WQA+_?"J:2I]4+?Y8>XLA]&#@TS#5P9^5X@
MBU=V^J$?1L=_V:?_X*&-FY'7\Q+8_0\?]WJPU),'F%@?B%Q&ULP>:C87E]WF
M14O4O[8;C>^-5O<1IT2;=;#_L+NUU>G66V?U]MGV/<^L,(]W9AK=D1>+BPF.
M1M2'D90DL."SL>-*X<0B'(A_J?_PAYKZ36PE(RG^]I?WAX?[)PO6XM4G\U2<
M$MUP<+)=$[V9< )7]&0RE3(0"Q]QV;[HUL^;OXO/S8ONMT:[?MFXZC9/.S71
M;)WNXG-K @12&$W4P@HOT+^!#*7U%SA>WYG2C/#G3@(7\9<SX/FI$\GEIW2:
MO2D_*9P1/F00^GXX!?DDY'CBAS,I]5NM6Y=_'^^/E/;+CA^$.A83]JM/K?KW
MQO%CT>;"D33/GL8X?@ ]-NI BCB:X@Z/'2](X$],>U\'+G"!'I%*VC).B#@O
MHS !D7,C/GMA=R0C9R+3Q.O'0-M!?[<F#O?WWP*MAOV?^ &P$6@G<>D[00VY
M<^S,@(6$HYX\B,*Q2&"6(@GI7^:+R0S);SKR^B-D[1'<V$.FFT3AM8?WX;=A
M@)K.V%!)4#1D,@%'/0BC<0P_ 7\E<A@YOI@X42)@V!)>L#0]X_!M6C[!AS_M
MG<0U<R6HA#'(<61R)\DO&>P"+$B0T/Z*D"5J)GEPRKC,DS0"PRF6(@;S2<85
M8@$7Y>#=20S[-A[#,V+:^PKQ 1_!ZHMKQT^EN.K\K]C?W0<33SJPRTMO18>&
M42W%S-QP\@X2 E%*G,(+:*XU^+GW;]E/\&,'C%F\"]<HIF?TP\ ELRI&4@5;
M$>D'",L+LB7![\%%0XE(2EZPNW%B:%W\J G4-8TO%^T&JQB/%*-:"!@T2_GX
M821Q8; 'NW_[R\';_9.[_WV+IFW4OW\^;P@P0\19XTNSU42+J_,0AI8'S!$D
MQZ_?+I[WNC/O(HF!%S7N^2P.\^(,B#,&3R5-Y%R!=I]4N,J,#]><\57@RQA$
M"C!7-/5 QKAR0-**F:HF^L[$0V7S7V1D8M,T-I=1(@$+CQS0+\B>8^D$:,$X
M<3_R>D9)C&WVO<\5RCEYM$3VFNTL7K1UEVQ%]OC:KK>ZXN*+8$=D<VQQ>">V
MR"DVV'RPQ4F>QR5# '\)TG$/M!BH&_ZX(,H?U&VMXPK3&).PQJI-.2OR1D9]
M+W:0NX%Y0W$@MF#(VX(T&BBQ(=I="?#SC/A=*=!+K7\O(Z\/6G@B^][  ^I^
ME)GD%.9<93E?4RYQR_TKT%6H<ET^[-I$ATJ6'#)C99WF7+L$C%TB52^.P?1!
MN<$1+6U4T5*%3-/V94V_>)VDI)#_2;UD1J^#1ZKE'J1)&I'.N'8B+TQC@69W
MXJDGPU)X8*RDCA^3#5X>(%@*L"4A4*;K@?24]#&+5V-#;FJ'7J^Y0W48?#=*
MXP0VZ&#_T*SE%(.88/R.I$],E.!WR+LW7W<FD] CRQ@^7G*UR"Z<H%D(MX'1
M'*>XE[ E'> >_ *.0?%TU[D1%Q$H#XR]&CZ)4M"&-1')8>K3J^"7, *VY5V$
M1_>EFR*YP(_CU!^2.X94(=ELWUK*?LZ&8QO1F]K=HS5W]P<Z?+ 6$R6;*G:Z
M5O )6&\X_9]!./6E.Y0Q\^M([L4C8F*:L <NBG(G)9OY,=$-[)VU=C6,V/@I
M&@#T[3!-A.^-P5JA;Y#<FTVDK82TMY5MF)&00 _>>.)[?4?Q^X1^489@YK]L
M:I?>K"LEJW:%W7J6+I836G ]86WV0ERB&2O(&/VUL,\YAH@E*=PTR30K+3:M
M517;J^>Q%%5B-Y)]Z2&_@I*+0;+"4O@S*Q:&+P?E&R"I -L;:Y3W&%U$6QMG
MU&%T-T4]S$RK)J#4JI$\@<N""70C7>C) &QB8PT8:L;K--<);&[HTG4,HS@X
M*] 1$0LO6_@L[6)_@W]P^I?T:#(9\5OZ#MB_1.[$$Z<OCR>1W)E&S@3N,I)$
MB"8/5@T$K9F8!ERY+Z"X@C !ZYT, EIS<()B&/04N#,.Y;6,:KE%LF]7\:1$
M99]@^BVP:2KI#G<!MLGI@^GCDN2]G<V!X7#JF[*9WZ[)=\OL5U&"XL*7UZUD
M "Z0B,"UACZ9Z'%C8PD_P,9&TI=HQW+(CY1N]2OQRYT"@Q*?X^MM7G>J;K;D
M!J6OP(")P/H!<J87(^<%:(@&:N2D/Y$0+(E>JQ#IM2K:J69YH=[?"P,PQ73<
M+%*!,;+%R"!4(F#N>%(PXGR5!DC8H=GRMM4'D]B$Z//\FO$_2]3"%KGP#/60
MWV2<X'UG#L84C,W"SHNV.3C*-4@C$ISE,"+'&2D?J1/&-J^R>8JS);%?TR:K
MNFYBAYDE54--'*>#@=?W=!@7%D?&L1/-C%S$[\/"#C.AKT=D'HE:->SYWM#1
MAE^>X*V[C'I@N@,1U@H3_'Z<P 5<(WRGTP/C#H8WH-VEVV,'5+1%W&&_#\LH
MP$S3-^4WAP59#!3$KRUMD6(<- !F0NT"ODW>3&002S-0G!Q&A$AK]<F4@6TC
M$C?ZIA=&@21#%9ZE+%F]2@\@V.X4#UG7RE\U7-AH-R_.LH#(B?BMT>DV6U\W
M%AAY?:? "/IF+ :JLJ),"1B61QH12H2>J33B5_8V-Q4=8>N7?$L:D)+O#CR1
M91W^VKB9>,KOHF%OD;3A(*%E<KW9/0""!ZMM&UTFMJG)&DJ4M9F1/G*2IP2R
M>7N<\]BRH$5!J"_XDAVJ?4PKW4KPOUX[F-%9I.(S0]9$TXBLKF6<J(PX4)C,
MQ;=83Y((#"M438[@]!X>[F^YV_D7IAP?5@F,+$R\ 9I=VGC.S32?IK(LJ5.X
MT0M2#-5T9'2-D;VBA8^DBN%#RQ>TG_V &2<;-&(;DME=AW 12:0'[G(R.QYY
M+A"H\@'V7Y]4ZA;0V!/?F1T',+L3W(&=$2_<JB-88Y;[RX^W!.W*@; ("08_
M)^&8P6 6)NLA$%B50"5[15::%?\]BO3-/:?_<QB%P!,%ZK?FG+^@M@SW/[>%
M54NC/K(P<.H3&P)7!-=-G*'<Z8$W]W/'&<#4CQU_ZLQBM<X?#G;WW_[UI$=A
M,86'VR^ YGXA*-X:%E6&SELWLK:B1?6]T?T&%A6F7T\O6F><?44#J_%[HWW:
M[#0V9ED=K6U9=:IR'DH^YU5]K9SNR 5W:\5 A?9?W:)!CK\/V5%UQ#3RDD0&
MZ#^C:E#CL*+0Y$>1!X((%WKW6(++ZEH8&PO]41'&7EJA-;3'W:+!K!H.TO$^
MX[@;]T0.!K#(Z%R:@!OY^Y/$^'1J_A7#!\L.H_ 3\+/ZWL3QX19P&#&-!J;'
M>.($'D][<38-%G&0JK!0,--?PD1R++; X(-']=! 5.@5NK!-<;QI(<IO$LQ"
MH%VN!LYSY2CAK)";5"&.HE=:M%<Y0M:3A,W3Q(,QML DBO3[@13D,*3X11G7
M->-$.<P4M# N5"7T*IZ!5SZ&07"P/$>@?<<*M0(7[&% 0 _2!9NZC]%3L*10
M,\"MH%B&N6  CYHVM@][$-?47=E3BZ_4#\G\;1Z?H2$7V9#YSI4^"-^(=A%&
M6B#;C0;RCM:VS)>6'AZ&2S$EY7!8C3:6@UT$$*G8;> =]('"*D>KIC^'.2+[
M%.(^L3;ZT0E0 ,%\?KL4*GMX&_U$?$SU.]9_I YY?=Q+/]7NY8DC$!9 F/Q
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M8S X?C0'-:>(1AMT3!O: LX_7+>7B"WS+IP&&+E/$;7GN"";\;F8.XE \(I
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M 1FI\@\3JZ?X?L&5(Y,D#4S+-0<=!R)1S41TKS5]>VW@*V,$KRI5GEM?-IR
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M7,=G#E!=:C+1L095!>3XJ=,(]8=6#(7?PPW&ESD/HXAUU3Y2KI:6^M[I[:S
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ML?_I_P%02P$"% ,4    " "". I11\?@M1T,  #W8@  $
M@ $     <&QX+3(P,C P-C,P+GAS9%!+ 0(4 Q0    ( ((X"E'.$2%ZA@D
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M              "  :V-  !P;'@M,C R,# V,S!X,3!Q+FAT;5!+ 0(4 Q0
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M;'@M,C R,# V,S!X97@S,60R+FAT;5!+ 0(4 Q0    ( ((X"E'6E#+3=04
M #D7   7              "  ?XU! !P;'@M,C R,# V,S!X97@S,F0Q+FAT
M;5!+ 0(4 Q0    ( ((X"E%DE;C/>@4  %,7   7              "  :@[
M! !P;'@M,C R,# V,S!X97@S,F0R+FAT;5!+ 0(4 Q0    ( ((X"E&^EOR&
MEBL  ! - 0 6              "  5=!! !P;'@M,C R,# V,S!X97@T9#@N
M:'1M4$L! A0#%     @ @C@*49(,U?;V*0  )/X  !8              ( !
M(6T$ '!L>"TR,#(P,#8S,'AE>#1D.2YH=&U02P4&      \ #P#S P  2Y<$
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
